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Abstract 
Parkinson's disease (PD) is a debilitating neurodegenerative disorder that affects I in 
100 people over the age of 65 in Europe. Current treatment of PD is focused on 
dopamine replacement through the use of levodopa (L-DOPA) and doparnine agonists, 
which provide effective management of parkinsonian motor symptoms in early stages of 
the disease. However, the long-term use of these agents is associated with debilitating 
side effects and importantly, these treatments do nothing to halt the relentless 
progression of the associated nigral cell loss. Thus, there is an unmet clinical need for 
novel pharmacological agents that can provide both symptomatic and a disease 
modifying, neuroprotective effect in PD. Substantial evidence exists to demonstrate that 
in response to doparnine depletion in PD glutamatergic pathways in the basal ganglia, 
particularly from the subthalamic and pedunculopontine nuclei (STN and PPN), are 
hyperactive which may contribute to the development of PD motor symptoms. 
Importantly, reciprocal connections between the STN, PPN and substantia nigra pars 
compacta (SNc) raise the possibility that glutamate hyperactivity in the BG may also 
contribute to disease progression through the process of excitotoxicity. Thus, agents that 
pharmacologically modulate glutamate transmission may be of benefit as a treatment for 
PD. To this end, substantial evidence exists to demonstrate that selective ligands acting 
at metabotropic glutamate receptors (mGluR) are anti-parkinsonian in experimental 
models of PD. Herein, it is now reported that selective ligands of mGluR also provide 
significant neuroprotection of the nigrostriatal system against 6-OHDA toxicity in vivo, 
in a concentration-dependent and receptor-mediated fashion. Furthermore, these ligands 
are effective neuroprotective agents when administered to animals already undergoing 
nigrostriatal degeneration. Moreover, when administered in combination these drugs 
result in enhanced neuroprotection of the nigrostriatal system. Thus, selective mGluR 
ligands may represent a novel, non-dopaminergic treatment for PD which has both a 
symptomatic and a neuroprotective effect. 
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1.1 Parkinson's disease 
Parkinson's disease (PD) was first described in 1817 as Paralysis agitans in "An Essay 
on the Shaking Palsy" by Dr James Parkinson, who defined the condition as 
"Involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported; with a propensity to bend the trunk forwards, and to pass 
ftom a walking to a running pace: the senses and intellect being uninjured". 
Subsequently the principle brain lesion in PD was identified as a degeneration of the 
doparninergic (DA) neurones in the substantia nigra pars compacta (SNc; Greenfield 
and Bosanquet, 1953). Subsequently, it was discovered that the brains of PD were 
deficient in doparnine (DA) in the corpus striaturn (Homykiewicz, 1962). Thus, a 
textbook definition of PD is given as "a progressive neurodegenerative disorder 
characterised clinically by the cardinal symptoms of muscle rigidity, bradykinesia 
(akinesia) and rest tremor, due to the depletion of DA in the corpus striaturn as a result 
of the degeneration of the DA neurones of the SNC (Zigmond et al, 1999) 
1.2 Neuropathological features of PD 
1.2.1 Neuropathology of idiopathic PD 
The pathological hallmarks of PD, which are depicted in Figure 1.1, are a loss of the 
neuromelanin positive DA neurones of the SNc and other sub-cortical nuclei (Marsden, 
1983), coupled with the presence of intraneuronal proteinaceous cytoplasmic inclusions 
termed Lewy Bodies (Wakabayashi et al, 2006). Formation of LBs is considered to be a 
marker for neurodegeneration since post-mortem studies of PD patients have revealed 
that all idiopathic PD patients have LBs and that significant loss of neurones is evident 
in the preferred sites for LBs (Jellinger, 1987). 
1.2. LI Lewy Body pathology in PD 
Lewy Bodies (LBs) may be single or multiple, spherical or elongated and possess a 
dense core surrounded by a peripheral halo as shown in Figure I. I. LBs are found 
within the perikarya of neurones or within neurites in axons, these are defined as Lewy 
Neurites (LNs) (Bethlem et al, 1960). Morphologically, LBs are comprised of two 
types, the classical (brainstem) type and the cortical type (Takahashi and Wakabayashi, 
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200 1) and are composed of several proteins, including neurofilament proteins, ubiquitin, 
(x-synuclein (Spillantini et al, 1997) and cc-synuclein-interacting proteins including 
synphilin- I and other ubiquitin-like proteins, such as torsinA (Wakabayashi et al, 2000; 
Mori et al, 2003; McNaught et al, 2004b). In PD, LBs are found in several brain areas 
including the substantia nigra (SN), locus coeruleus (LC), hypothalamus, nucleus 
basalis of Myenert and in the cerebral cortex, (Takahashi and Wakabayashi, 2001). LBs 
are however not confined to the CNS and have been observed in the autonomic nervous 
system both centrally and in the periphery (Iwanaga et al, 1999). 
LB inclusions may also form in glial cells, known as glial cell inclusions (GCIs), 
which have been observed in the midbrain of PD patients (Wakabayashi et al, 1998; 
Mochizuki et al, 2002) and are immunoreactive for (x-synuclein (Arai et al, 1999; 
Wakabayashi et al, 2000). Interestingly, GCIs increase in number as the disease 
progresses (Wakabayashi et al, 2000) and GCIs may be observed in other brain regions 
outside the midbrain (Piao et al, 2000). These findings suggest that the 
pathophysiological processes underlying neuronal degeneration in PD may also equally 
affect glial cells (Stefanova et al, 2001; Uryu et al, 2006). In support of this hypothesis, 
GCls in oligodendrocytes are the main pathological hallmark of multiple system 
atrophy (MSA) a disease which has clinical features of Parkinsonism (Kato et al, 1991). 
These findings suggest glial cells may also have an important role in the pathology and 
pathogenesis of PD (Croisier and Graeber, 2006; Miller et al, 2006). 
1.2.1.2 Neuronal lesions of the dopaminergic nigrostriatal system in PD 
In addition distinct neuronal lesions are observed in the I'D brain, with the primary 
lesion in the nigrostriatal DA system (Jellinger, 1987; 1990; 1991; Braak et al, 1996) 
indeed,, the classical neuropathological finding of PD is the loss of the neuromelanin 
containing neurones leading to depigmentation of the SNc as shown in Figure 1.1 
(Marsden, 1983). In the midbrain, DA neurones are distributed into three cell groups, 
A8 (retrorubral area), A9 (SNc) and AlO (ventral tegmental area, VTA) (Pearson et al, 
1983) 
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Figure 1.1 Neuropathological hallmarks of Parkinson's disease 
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A and B: Substantia nigra (arrows) from a control case, note the darkened, 
pigmented nuclei. C and D: Substantia nigra (arrows) from a PD case, note 
the depigmented substantia nigra, indicative of nigral cell loss. E: Brain 
areas affected in the neuropathology of PD. F: Histological section from the 
substantia nigra of a PD case, illustrating a dopaminergic neurone 
containing Lewy Bodies (black arrows). Images kindly provided by UK-PDS 
Tissue Bank, Charing Cross Hospital, Imperial College, London. 
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Axons project from the cell bodies of neurones in the SNC (A9) along the medial 
forebrain bundle (MFB) to terminate in the dorsal striaturn, thus forming the 
nigrostriatal pathway. The striaturn itself is divided into dorsal (caudate nucleus and 
putamen) and ventral (nucleus accumbens) parts, segregated anatomically by the 
internal capsule (Fitzgerald and Folan-Curran, 2002). In contrast, axons of neurones in 
the A8 cell group project to the ventrocaudal putamen, whilst those in the VTA (AlO) 
project to the medial frontal and anterior cingulate cortices, nucleus accumbens and 
limbic system (Pearson et al, 1983). In PD, extensive cell loss is observed in the SNc, 
whilst the VTA is affected to a much lesser extent (Graybiel et al, 1990; Jellinger, 
1990). It is not clear why DA neurones in the VTA are less susceptible to degeneration 
in PD, one possibility may lie in the expression of different proteins in these neurones. 
Interestingly, neurones in the VTA strongly express the calcium binding protein 
calbindin D28K (Damier et al, 1999a), whereas the neurones in the more susceptible 
areas of the SNc express this protein at much lower levels (Damier et al, 1999b). 
Because of the nature of the topographic projections of these DA cell groups, the DA 
pathway to the putamen is more heavily damaged than the corresponding pathway to the 
caudate nucleus and nucleus accumbens (Dauer and Przedborski, 2003). This results in 
dramatic dennervation and DA depletion in the dorsal areas of the striatum, whereas 
dennervation is milder in the nucleus accumbens (Dauer and Przedborski, 2003). Based 
on these findings, it is generally assumed that the pathology of PD begins with neuronal 
loss in the SNc and the subsequent destruction of the nigrostriatal pathway accounts for 
most of the motor symptoms observed in the disease (Langston, 2006). 
1.2.1.3 Non-dopaminergic neuropathology in PD 
Previously, it was thought that the neuropathology of PD was characterised solely by 
the lesions of the DA nigrostriatal system. However, there is substantial evidence to 
suggest that there is also extensive non-dopaminergic neuropathology in PD 
(Hornykiewicz and Kish, 1987). Indeed, neuronal loss and LB pathology have been 
observed in the noradrenergic LC (Jellinger, 1987) as well as the serotonergic dorsal 
raphe nucleus, and the adrenergic neurones of the medulla oblongata (Malessa et al, 
1990). Furthermore, neuronal loss is also observed in the cholinergic nucleus basalis of 
Myenert (Whitehouse et al, 1983), the pedunculopontine nucleus (PPN) (Zweig et al, 
1989) and the dorsal vagal nucleus (Gai et al, 1992). Moreover, peptidergic neurones in 
the brainstern and y-amino-butyric acid (GABA)-ergic neurones in the cerebellum also 
appear to be affected in PD (Halliday et al, 1990a, b). Interestingly, LB pathology and 
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cell loss has also been observed in the olfactory bulb and the anterior olfactory nucleus 
(Braak et al, 2003,2004). 
Interestingly, whilst the clinical and pathological features of neurodegenerative 
diseases are distinct for the most part, in some groups of patients there is considerable 
overlap. Indeed, patients with Alzheimer's disease (AD) and PD may have overlapping 
neuropathology such as LB formation and nigral lesions in AD cases, whilst amyloid 
plaques and neurofibrillary tangles in the cortex have been observed in PD cases (Forno 
et al, 1992). 
1.3 Clinical diagnosis of Parkinson's disease 
Parkinsonism is defined clinically by the classic triad of motor symptoms namely, 
bradykinesia (akinesia), muscle rigidity and rest tremor (Tolosa et al, 2006; Muller et al. 
2006). Thus, the criterion for a clinical diagnosis of PD is based on the presence of 
akinesia and/or one of the other cardinal symptoms (Gibb and Lees, 1989; Hughes et al, 
2001). Clinically, any disease which results in striatal DA deficiency or direct striatal 
damage may lead to Parkinsonism, thus final diagnosis of PD is only made when other 
possible causes of Parkinsonism, or "Parkinson Plus syndromes" including progressive 
supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal 
degeneration (CBD) have been excluded (Lang and Lozano, 1998a; Dauer and 
Przedborski, 2003). However, PD is the most common cause of Parkinsonism, 
accounting for about -80% of cases (Hughes et al, 1992). Asymmetric symptom onset 
and good response of symptoms to the doparnimetic drug levodopa (L-DOPA) are 
considered to be supportive of a correct diagnosis (Hughes et al, 2001; deLau and 
Breteler, 2006). Importantly, these clinical criteria at best lead to a diagnosis of probable 
PD, whilst direct confirmation of such diagnosis must generally be made post-mortem 
(Klockgether T, 2004; Tolosa et al, 2006). Indeed, in the absence of a biological marker 
of PD, a reliable and easy applicable diagnostic test is not yet available (Sethi, 2002; 
Dorsey et al, 2006). 
1.4 Clinical features of idiopathic PD 
1.4.1 Motor symptoms 
Parkinsonian motor symptoms manifest when a critical threshold of nigrostriatal 
degeneration is reached, prior to which inbuilt compensatory mechanisms appear to 
compensate for the underlying neuronal loss, which is often described as the 
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"presymptomatic phase" of PD (Zigmond et al, 1984; Berzard et alý 2001; 2003; Pifl et 
al, 2006). In principle, this functional compensation in the partially dennervated 
striaturn could be achieved by several mechanisms, including upregulation of DA 
turnover in the remaining nigral neurones (Melamed et al, 1982; Zigmond et al, 1984; 
Hornykiewicz et al, 1998; Pifl et al. 2006). This critical threshold is suggested to be 
reached when 70-80% of DA axon terminals in the corpus striatum and approximately 
50-60% of nigral DA neurones have been destroyed (Bernheimer et al, 1973; Foley and 
Riederer, 1999). These observations are supported by sequential imaging of PD patients 
using positron emission topography (PET) or single photon emission topography 
(SPECT), which demonstrates asymmetric loss of DA or dopamine transporter (DAT) 
in the putamen using radioactive tracers such 18 -Fluorodopa (Wilson et al, 1996; 
Antonini et al, 2002; Brooks, 2004). Imaging studies suggest the preclinical period of 
PD extends for approximately 6 years and the greatest rate of decline is observed in the 
early phases of the disease (Hilker et al, 2005b). Thus, when PD patients first present 
motor symptoms and are clinically diagnosed, a significant amount of nigrostriatal 
neurodegeneration has already occurred (Schapira, 2006). Each of the primary motor 
symptoms is reviewed in brief below. 
1.4. LI Bradykinesia (akinesia) 
I VrIk Akinesia is perhaps the most important symptom in terms of contribution to patient 
disability. Defined literally as "absence of movement", akinesia refers to the slowness 
and/or lack of movement characteristic in Parkinsonism (Schwab et al, 1959; Imai et al, 
1996). In real terms, bradykinesia is perhaps a more realistic description, since few or 
no PD patients experience a situation where the initiation of movement is impossible 
(Klockgether, 2004). Bradykinesia affects all voluntary and involuntary movements, 
and automatic habitual movements such as arm swinging, blinking or swallowing may 
be strongly reduced. Often PD patients also have less expressive mobility of the face 
and use few gestures (Narabayashi et al, 1980). As the disease progresses, fine 
movements also become affected and a bradykinetic gait becomes apparent, 
characterised by slow, small, shuffling steps, which may also manifest as difficulty in 
rotating the trunk (Marsden, 1984). Although slowness is a characteristic feature of 
movement in PD patients, they may also display abnormal high frequency movements, 
such as festination, a gait characterised by rapid, small steps, which may result in 
forward falls (Klockgether, 2004). Clinical observation suggests that bradykinesia may 
result from impairments in the preparation or programming and execution of movement, 
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which in PD patients may also lead to the appearance of freezing, where patients are 
completely unable to walk for a short period (Achiron et al, 1993) 
1.4.1.2 Muscle rigidity 
Clinically, muscular rigidity is defined as the increased resistance of a joint to a passive 
movement, which is constant throughout the range of movement and often termed "lead 
pipe rigidity (Fitzgerald and Folan-Curran, 2002). In PD patients, where muscular 
rigidity is often accompanied by rest tremor, a characteristic "cogwheel-like rigidity" 
may be observed (Klockgether, 2004). Muscular rigidity appears to affect all of the 
somatic musculature simultaneously, but a predilection for rigidity in flexor muscles is 
observed, giving rise to the classic stooped posture of PD patients. Muscle rigidity may 
be caused by an abnormal response to the shortening of the antagonist muscle. In 
normal muscle, antagonist muscle activity is suppressed in response to stretching. In 
contrast, in parkinsonian subjects electromyo graphic (EMG) recordings show that 
antagonist muscles undergo an exaggerated EMG response leading to constant joint 
torque independent of position and hence, rigidity (Xia and Rymer, 2004). Interestingly, 
this appears to be under the control of the DA nigrostriatal system since dopamimetic 
therapy effectively reduces muscle rigidity and blocks the enhanced antagonist muscle 
response (Klockgether, 2004). 
1.4.1.3 Resting tremor 
Tremor is probably the most conspicuous motor symptom of PD, which occurs at rest, 
primarily in the upper limbs, but may also affect the legs and the head (Jankovic and 
Fahn, 1980; DeLong, 1983; Marsden, 1984). Resting tremor occurs at a frequency of 4- 
7 Hz with a characteristic "pill-rolling" motion and is suppressed by voluntary 
movement or outstretching of the arms. Thus, resting tremor is not necessarily 
disabling, but may cause psychological suffering to PD patients since it stigmatises 
them as suffering from Parkinsonism, which may lead to anxiety and/or depression 
(Lang and Lozano 1998a). PD patients may also experience action or postural tremor 
(Hallet, 1998) and often patients complain of "tremulous feelings" in limbs before the 
actual appearance of tremor (Grosset and Lees, 2005). Parkinsonian tremor is thought to 
occur by alternate activation of agonist and antagonist muscles (Boose et al, 1996) and 
is associated with rhythmic bursting activity of neurones and interneurons in the 
striatum, pallidurn (globus pallidus), the ventral lateral nucleus of the thalamus (VLN) 
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and in anterior horn cells of the spinal cord, although the cerebellum may also be 
involved (Fitzgerald and Folan-Curran, 2002; Klockgether, 2004). 
1.4.1.4 Impairment ofpostural reflexes 
In addition, as the disease progresses PD patients also experience impairment of 
postural reflexes (Traub et al, 1980; Bloem, 1992; Grill et al, 1999; Stack et al, 2005). 
Thus, patients may lose balance easily and fall stiffly in response to a mild accidental 
push, leading to injury, especially in older patients (Grimbergen et al, 2004; 
Michalowska et al, 2005). This is primarily caused by an impairment of the anticipatory 
postural adjustments, whereby a push to the upper trunk which would normally elicit 
contraction of lower limb muscles to maintain equilibrium and prevent falling does not 
occur (Grill et al, 1999; Adkin et al, 2003). 
1.4.2 Non-motor symptoms 
Asi e rom the classical motor symptoms, it is noteworthy that PD patients suffer 
additionally from a spectrum of non-motor symptoms, a summary of which is shown in 
Table 1.1. It is suggested that these non-motor symptoms are primarily due to non-DA 
neuronal dysfunction/degeneration, indeed non-motor symptoms in PD may be 
accounted for by neurodegeneration in brain areas other than the SNc, for example 
olfactory dysfunction correlates with an observation of LB pathology in the olfactory 
system in post-mortem tissue from I'D patients with very early stage disease (Braak et 
al, 2003). Additionally, degeneration of the LC and raphe nucleus and cortical 
pathology may correlate with the appearance of depression and dementia in PD patients 
(Braak et al, 2004; 2006). However, to date, the neuroanatomical and neurochemical 
substrates are not yet fully elucidated thus, the pathophysiology of PD non-motor 
symptoms remains enigmatic (Chaudhuri et al, 2006). 
Non-motor symptoms correlate well with the progression of PD and indeed, 
advancing patient age, although interestingly some non-motor symptoms may manifest 
early in the disease course before the appearance of the cardinal motor symptoms, in 
particular, constipation, olfactory dysfunction and mood or sleep disorders, including 
REM sleep behaviour disorder (RBD) (Doty et al, 1992; Ferini-Strambini et al, 2005; 
Borek et al, 2006). This is relevant since a greater understanding of non-motor 
symptoms that may precede the development of Parkinsonism may aid future clinical 
diagnosis of PD before the onset of motor symptoms. This could be particularly 
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important in the context of the apparent long preclincal phase of the disease, such that if 
one were able to diagnose prospective PD patients earlier, it may be possible to begin 
effective treatments with a still relatively intact nigrostriatal system that could act as a 
substrate for functional recovery (Chaudhuri et al, 2006). 
Neuro- Sleep Autonomic GI Sensory Other 
psychiatric disorders 
Depression, anxiety, Restless leg Bladder Dribbling of Pain Fatigue 
apathy movement disturbances saliva 
Anhedonia REM sleep disorder Sweating Ageusia Parasthesia Diplopia 
Excessive Orthostatic Dysphagia and 
Loss of Blurred 
Attention deficit daytime hypotension choking 
Olfactory 
vision 
sleepiness Function 
Falls andlor 
Hallucinations, Vivid pain due to Reflex vomiting Seborrhoea illusion, delusions dreaming orthostatic 
hypotension 
Dementia Insomnia 
Sexual Nausea Weight loss dysfunction 
Obsessional andlor Sleep Dry eyes Constipation Weight gain 
repetitive behaviour apnoea 
Faecal 
Confusion incontinence 
Delirium 
r Panic attacks 
Table 1.1 Summary of the non-motor symptoms of PD (GI, Gastrointestinal; 
adaptedftom Chaudhuri et al, (2006) Lancet Neurol; 5(3): 235-45) 
Importantly, non-motor symptoms also drastically affect patient quality of life. 
Indeed, non-motor symptoms such as falls, hallucinations and dementia are major 
sources of hospitalisation or institutionalisation of PD patients (Schrag, 2006). Recent 
evidence also suggests that non-motor symptoms such as balance difficulties, sleep 
disturbance and neuropyschiatric problems such as confusion or memory loss were 
rated as the most disabling symptoms of the disease by PD patients (Chuadhuri et al, 
2005). Furthermore, some studies have suggested that depression in PD patients is 
associated with a rapid deterioration in cognitive and motor function, perhaps 
indicative 
of more severe brainstern degeneration (Klockgether, 2004; Braak et al, 
2006). 
Moreover, dementia complicates the course of PD in many patients and frequently leads 
to nursing home care (Schrag et al, 2000). Clinical evidence also suggests that the 
classical DA treatments for PD are not helpful in treating many of the non-motor 
symptoms of the disease, (see section 1.7). Taken together, 
it is apparent that the non- 
motor symptoms of PD must be considered alongside the classical motor symptoms 
in 
-30- 
terms of patient care and the development of novel treatment strategies for PD 
(Schapira, 2005; Chaudhuri et al, 2006). 
1.5 Pathophysiology of the Basal Ganglia in Parkinson's disease 
In the mammalian central nervous system (CNS), the initiation and execution of smooth 
movement is regulated through a group of sub-cortical nuclei, collectively known as the 
basal ganglia (or basal nuclei; Zigmond et al, 1999). Therefore, the role and function of 
the basal ganglia (13G) in the normal brain and how its function is altered by DA 
deficiency leading to movement disorders including PD, has been extensively 
researched (Marsden, 1982; Marsden and Obeso, 1994; Obeso et al, 2000). In the late 
1980's several groups proposed a model to explain the functional organisation of the 
BG and how DA deficiency may lead to the appearance of PD motor symptoms based 
on electrophysiological observations in primates rendered parkinsonian by intoxication 
with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) which 
induces a selective loss of DA neurones in the SNc and produces a parkinsonian 
syndrome comparable to that observed in humans (Crossman, 1987b; Albin et al, 1989; 
DeLong, 1990). This model has helped to provide much of our current understanding of 
the pathophysiological process underlying PD motor symptoms (Lange et al, 1997). The 
organisation of the motor loop and the pathophysiological changes that occur between 
the normal and Parkinsonian brain as suggested by this model is illustrated in Figure 
1.2A and B. 
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Figure 1.2 Schematic of the classical model of Basal ganglia function in the 
normal (A) and Parkinsonian (B) state 
Blue arrows indicate inhibitory projections and red arrows excitatory 
projections. Thickness of arrows indicates the degree of activation of each 
projection. Note that the striatum communicates with the BG output nuclei (GPi, 
SNr) through a monosynaptic direct pathway and a polysynaptic indirect 
pathway, with synaptic connections in the GPe and STN, suggesting neuronal 
activity occurs through parallel neuronal circuits in the BG motor loop. 
Doparnine from the nigrostriatal projection controls the balance of activity 
between these pathway by promoting direct pathway activity and inhibiting 
indirect pathway activity. In the Parkinsonian state, destruction of the 
nigrostriatal pathway results in striatal doparnine depletion and disinhibition of 
the indirect pathway. This results in inhibition of the GPe, leading to STN 
hyperactivity and increased excitation of neurones in the BG output nuclei, 
resulting in overinhibition of thalarno-cortical and brain stem motor centres, 
resulting in Parkinsonism. Note that there is also increase excitatory drive from 
the STN, but also the PPN (not shown) in the Parkinsonian state which may 
exacerbate nigral degeneration through excitotoxicity. SNc, substantia nigra 
pars compacta; SNr, substantia nigra pars reticulata; GPeli, globus pallidus 
externallinternal segment; STN, subthalamic nucleus; PPN, pedunculopontine 
nucleus; VL, ventrolateral thalamic nuclei. 
Adaptedftom Obeso et al, (2000) Trends Neurosci, 23(10) S8-19 
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-32- 
1.5.1 The classical model of the BG motor loop in the normal state 
The BG are a complex interconnected network of sub-cortical nuclei, which form 
parallel loops that integrate the primary motor and somatosensory areas of the cerebral 
cortex with the basal ganglia nuclei and the thalamus, forming cortico-BG-thalamo- 
cortical loops (Albin et al, 1989; DeLong, 1990). The BG appears to be comprised of 
four such loops (1) motor loop, concerned with learned movements, (2) cognitive loop, 
concerned with movement intentions, (3) limbic loop, concerned with emotions 
pertaining to movement and (4) an occuolornotor loop, concerned with the control of 
voluntary eye saccade movements (Fitzgerald and Folan-Curren, 2002). In addition, the 
BG is closely interconnected with brainstern nuclei such as the LC, raphe nucleus and 
the reticular formation (Obeso et al, 2002). The motor loop has received most research 
attention since this is the loop most directly related to the pathophysiology of movement 
disorders (Obeso et al, 2000). The BG motor loop itself consists of the striaturn, the 
subthalarnic nucleus (STN), the globus pallidus (internal and external segment, GN and 
GPe, respectively) and the substantia nigra which is divided into the pars compacta and 
pars reticulata (SNc and SNr respectively; Fitzgerald and Folan-Curren, 2002) 
In the motor loop, cortical motor areas project in a somatotropic fashion to the 
dorsolateral putamen where they form glutamatergic excitatory synapses with striatal 
medium spiny neurones (MSNs) which are GABAergic, thus forming the primary input 
into the motor loop, the corticostriatal pathway (Albin et al, 1989; Alexander et al, 
1990). Thus, information is summated and integrated in the putamen before passed 
through the BG nuclei, which occurs through two distinct parallel neuronal pathways. 
These arise from different subpopulations of MSNs in the putamen, which connect the 
striaturn to the primary output nuclei of the BG, the GPi and SNr, which are also 
GABAergic (Lange et al, 1997). These pathways are referred to as the direct and 
indirect pathways, respectively (Albin et al, 1989; DeLong, 1990). The direct pathway 
is monosynaptic and projects directly from the putamen to the GPi and SNr originating 
from MSNs that express DA DI-like receptors and co-express the neuropeptides 
substance P and dynorphin and provides a direct inhibitory influence on GPi/SNr 
neurones. By contrast, the indirect pathway is polysynaptic and connects the putamen to 
the GPi/SNr via synaptic connections passing through the GPe and STN respectively 
(Albin et al, 1989; DeLong, 1990). The indirect pathway arises from MSNs in the 
putamen, which expresses both the DA D2-like receptors and the neuropeptide 
enkephalin (ENK; Obeso et al, 2000). In this pathway, the projection from the putamen 
to the GPe and from the GPe to the STN is GABAergic and inhibitory (Albin et al, 
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1989; DeLong, 1990). In contrast, STN neurones are glutamatergic, thus the connection 
between the STN and the GPi/SNr is excitatory (Albin et al, 1989; DeLong, 1990). 
Activation of the indirect pathway therefore results in inhibition of the GPe, leading to 
disinhibition of the STN and excitation of the GPi/SNr (Albin et al, 1989; DeLong, 
1990). Therefore, a balance between the opposing effects of the inhibitory influence of 
the direct pathway and the excitatory influence of the indirect pathway control the 
output of the BG (Obeso et al, 2000). The output nuclei of the BG project to the VLN 
and other brain stem nuclei, such as the superior colliculus, which in turn Project, back 
to the supplementary motor area (SMA) in the cerebral cortex involved in motor 
control/activity (Albin et al, 1989; Alexander et al, 1990). 
Evidence to support this model comes from functional studies in primates, 
which demonstrate that facilitation of movement is associated with pauses in neuronal 
activity of GPi/SNr neurones (Chevalier and Deniau, 1990), suggesting that activation 
of neurones in the direct and indirect pathways facilitate and suppress motor activity 
respectively (Chevalier and Deniau, 1990). This indicates that these pathways have 
opposing effects on the surnmated output of the BG (DeLong, 1990; Alexander and 
Crutcher, 1990). Importantly, The classical model of BG function states that DA 
released in the striaturn from the axon terminals of the nigrostriatal pathway is critically 
responsible for controlling the balance of activity between the two pathways by an 
action on either D, or 132-like receptors on the different subpopulations of MSNs in the 
putamen (Cepeda et al, 1992; Gerfen et al, 1990). 
1.5.2 The classical model of the BG motor loop in the Parkinsonian state 
In contrast, in the parkinsonian state the essential pathophysiological change that occurs 
is hyperactivity of the GPi/SNr output nuclei, leading to excessive inhibition of 
thalarno-cortical and brainstern motor systems, which may result in the appearance of 
PD motor symptoms, particularly akinesia (Albin et al, 1989; DeLong, 1990; Obeso et 
al, 1997). The model predicts this is due to the reduced activation of DA receptors in the 
striaturn due to the degeneration of the nigrostriatal system, leading to reduced 
inhibition of neurones in the indirect pathway and decreased activation of the direct 
pathway (Penney and Young, 1986). Increased activity through the indirect pathway 
leads to inhibition of the GPe, resulting in disinhibition of the STN, which is able to 
discharge strongly causing the subsequent hyperactivity of the GPi/SNr, which is also 
promoted by reduced inhibitory transmission through the striatonigral 
direct pathway 
(Obeso et al, 2000). The net result is hyperactivity of BG output nuclei leading to 
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reductions in thal amo -cortical transmission and the appearance of some Parkinsonian 
motor symptoms (Obeso et al, 2000). In support of this idea, lesions of the DA system 
in both rodents and primates lead to increases in DA D2-like receptor expression and 
preproenkephalin mRNA levels increase in striatal MSNs of the indirect pathway, 
whereas in contrast, expression of DA DI-like receptor, substance P and dynorphin 
mRNA decreases in striatal MSNs of the direct pathway (Gerfen et al, 1991; Engber et 
al, 1991; Herrero et al, 1995). Considerable evidence also exists to support the 
hypothesis that hyperactivity of the STN and pallidal output to the thalamus contribute 
to the development of PD motor symptoms. Indeed, metabolic studies indicate that 
uptake of 2-deoxyglucose (2-DG); a measure of the activity of synaptic afferents, is 
decreased in the STN of MPTP-intoxicated primates, suggestive of reduced inhibition 
from the GPe (Mitchell et al, 1989). Similarly, in situ hybridisation data reveals 
increases in cytochrome oxidase I (CO-1) mRNA, a key enzyme in the mitochondrial 
respiratory chain involved in cellular metabolism and adenosine triphosphate (ATP) 
production, in both the STN, GN and SNr in MPTP-treated primates (Vila et al, 1997) 
and 6-hydroxydopamine (6-OHDA) lesioned rodents (Armentero et al, 2005; Oueslati et 
al, 2005). In support of this method, levels of CO-I activity, protein and mRNA 
expression have been previously demonstrated to be responsive to altered neuronal 
activity (Wong-Riley and Carroll, 1984; Hevner and Wong-Rilley 1991) Furthermore, 
in situ hybridisation data also revealed that glutamic acid decarboxylase (GAD) mRNA 
is increased in the both the GPi and SNr of MPTP-treated primates, indicative of 
increased GABA synthesis (Vila et al, 1996). These findings are supported by 
electrophysiological data obtained from MPTP-treated primates which suggested 
increased firing rates in the STN and GPi, but reduced firing rate in the GPe, consistent 
with reduced inhibition from the GPe and hyperactive STN and GPi output (Bergman et 
al, 1994; Vila et al, 2000; Benazzouz et al, 2000). A switch in firing mode from the 
classic spike firing pattern, to an irregular bursting activity of STN neurons is also 
observed in both rats (Hollerman and Grace, 1992; Hassani et al, 1996; Benazzouz et al, 
2000) and in primates (Miller and DeLong, 1988; Wichmann and DeLong, 1993; 
Bergman et al, 1994). Importantly, chemical lesion of the STN in MPTP-treated 
primates and 6-OHDA lesioned rats improves parkinsonian-like motor symptoms and 
leads to decreased neuronal activity in the GPi/SNr (Guridi et al, 1996; Piallat et al, 
1996; Nakao et al, 1999; Phillips et al, 1998; Carvalho and Nikkhah, 2001). Similarly, 
deep brain stimulation (DBS) of the STN or the GPi in PD patients results in marked 
improvements in clinical rating scores of motor disability (Limousin et al, 1995; 1996; 
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Lozano, 200 1) and appears to activate cortical motor areas as demonstrated by PET 
imaging (Brooks and Samuel, 2000) in PD patients undergoing DBS of the GPi (Fukuda 
et al, 2001) or STN (Hilker et al, 2002). 
1.5.4 A reappraisal of the pathophysiology of in Parkinson's disease 
1.5.4.1 Criticisms of the classical model of basal gangliafunction 
Although the classical model of BG function serves as an excellent starting point, recent 
research suggests that the organization of the BG is much more elaborate and 
complicated (Obeso et al, 2000; 2002). Indeed, the notion that DA has selective effects 
on separate populations of MSNs in the putamen is challenged by findings which show 
these neurones often co-express both DA D, and D2-like receptors (Aizman et al, 2000). 
Instead, DA in the BG is suggested to act primarily to modulate the interaction between 
glutamate and DA receptors in the striaturn, rather than act directly to excite or inhibit 
MSNs in the putamen (Morari et al, 1998; Chase and Oh 2000). The classical model 
also does not account for the evidence that indicates that extrastriatal regions are also 
innervated by DA neurones from the SNc, including the GPe, GPi, SNr and STN (Joel 
and Weiner, 2000; Smith and Kieval, 2002). Moreover, the model does not address the 
putative importance of other brain nuclei such as the PPN and the 
centromedian/parafasicular nucleus of the thalamus (CM-Pf), which are both intimately 
associated with BG function by virtue of reciprocal connections to both the STN and 
SNc respectively (Parent, 1990; Parent and Hazrati, 1995a; b; Parent et al, 2000). 
Additionally, although the classical model has proved uniquely predictive of BG 
targets for neurosurgery in PD (such as the STN or GPi) it does not fully explain the 
pathopysiological basis of the motor disorders observed in PD (Obeso et al, 2000). 
Indeed, experimental evidence exists that disagrees with the proposed origin of 
increased in STN activity in the classical model (Levy et al, 1997). In reality, the current 
chain of events that leads to STN and GPi/SNr overactivity is not yet firmly established 
(Bezard et al, 1999; Vila et al, 2000). Studies in both MPTP-treated primates and PD 
patients suggest that parkinsonian conditions reduce the rate of neuronal firing in the 
GPe, compared to the GPi, in line with the classical model (Filion and Tremblay, 1991 a; 
Lozano AM, 2000; Filion, 2000). However, at the same time, metabolic studies have 
shown that the level of CO-I mRNA is increased in the GPe in MPTP-treated primates 
(Vila et al, 1997) and 6-OHDA lesioned rodents (Vila et al, 2000). Similarly, GAD 
mRNA expression is increased in the GPe of rats with 6-OHDA lesions and is normal 
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in MPTP-primates (Herrero et al, 1995). Additionally, biochemical metabolic data and 
electrophysiological recordings after lesioning of the GPe suggest that STN 
hyperactivity may not be induced solely by hypoactivity of GPe neurones (Hassani et al, 
1996; Herrero et al, 1996; Vila et al, 1997; Orieux et al, 2000a, b). Furthermore, it 
appears that STN hyperactivity occurs before significant striatal DA depletion in 6- 
OHDA lesioned rats, suggesting this is a very early event in the pathophysiology of PD 
(Vila et al, 2000). 
Taken together, these data suggest that in fact, the origin of STN hyperactivity 
cannot solely be explained by reductions in inhibitory tone from the GPe in contrast to 
the predictions of the classical model (Obeso et al, 2004). Importantly, the proposed 
changes in the direct pathway caused by DA depletion in the classical model have been 
relatively sparsely studied and remain to be confirmed electrophysiologically, although 
several studies have reported increased activity of unidentified striatal MSNs in 6- 
OHDA lesioned rodents (Kish et al, 1999; Chen et al, 2001; Tseng et al, 2001) 
suggesting an imbalance in striatal output. 
1.5.4.2 Stabilising internalfeedback loops exist within the BG 
Interestingly, reciprocal connections between BG nuclei may form "internal" or 
"closed" loops providing positive or negative feedback between nuclei, thus regulating 
their activity (Obeso et al, 2002; Breit et al, 2004; 2005). As our understanding of the 
connectivity and interactions in the BG increases, several such circuits have been 
identified which are illustrated in Figure 1.3 (Obeso et al, 2002). Among these are: 1) 
the CM-Pf - thalamic nuclei - striatum - GPi - CM-Pf circuit which appears to act as a 
positive feedback loop leading to increased neuronal activity (Mengual et al, 1999); 2) 
the CM-Pf - STN - GPi - CM-Pf circuit, which in contrast appears to be a negative 
feedback loop, resulting in decreased neuronal activity (Fenelon et al, 1990); 3) the 
STN-GPe-STN circuit which appears to be an excitatory-inhibitory loop (Plenz and 
Kitai, 1998; Ryan and Clark 1992); 4) the STN- GPe/GPi dual projection which is 
"open" but may allow the STN to induce excitation and inhibition of the same GPi 
neurones (Joel and Weiner, 1997) and 5) the primary motor cortex (area 4) - STN - GPi 
- motor thalamus (VLN) - area 4 loop, which appears to provide inhibitory feedback 
signalling to the motor cortex and may be involved in the termination of movement 
(Obeso et al, 2002). In support of this concept, anatomical data reveal that the STN 
receives monoaminergic inputs from the dorsal raphe nuclei (Lavoie and Parent, 1990) 
and the SNc (Hassani et al, 1997) and glutamatergic inputs from the pedunculopontine 
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nucleus (PPN, Lavoie and Parent 1994; Bevan and Bolam, 1995), as well as the CM-Pf 
(Feger et al, 1994-, Mouroux et al, 1995) and from layer V of the motor, anterior and 
cingulate cerebral cortices (Orieux et al, 2000b). Of all these, interrelationships between 
the STN and GPe could be the most important, as neuronal firing in each nucleus is 
rapidly mirrored by a reciprocal firing in the other, forming an excitatory-inhibitory 
loop as described above (Ryan and Clark, 1992). Thus, normal activity in one could 
maintain normal activity in the other, whereas in the Parkinsonian state the STN and 
GPe may both be affected causing a loss of this equilibrium (Obeso et al, 2000). 
Importantly, the classical model does not describe the existence of such internal 
feedback loops, which may act to stabilize neural transmission with the BG motor 
circuit. Indeed, the development of the classical model was largely based on 
measurements of the change in neuronal firing rate, suggesting that information is 
processed in a sequential linear fashion (Obeso et al, 2000), whilst in reality this 
explanation is perhaps too simplistic. 
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Figure 1.3 Modern view of the motor circuit in the basal ganglia 
Somatotropically organised parallel projections form "closed loops" (black 
arrows) between the motor cortex, the basal ganglia and the motor cortex. 
In addition,, horizontal loops provide "internal" stabilisation of basal 
ganglia nuclei activity. The centromedian-parafasicular nucleus of the 
thalamus (CM-[Pf) forms a CM/Pf-putamen-GPi-CM/Pf positive feedback 
loop (blue arrows) and a CMIPf-STN-GPi-CMIPf negative feedback loop 
(red arrows). The STN controls GPi activity through a direct STN-GPi 
monosynaptic excitatory connection and an STN-GPe-GPi excitatory- 
inhibitory loop (green arrows). The GPe in turn exerts a reciprocal 
inhibitory effect on the STN. Doparninergic modulation of the putamen, 
STN, Gpi, Gpe, and SMA cortex is indicated by pink arrows, the 
nigrostriatal projection is indicated by the thicker pink arrow. A positive 
feedback loop also exists between the SNc, STN and PPN in the 
brainstem, but this is not shown for simplicity. 
Gpeli, globus pallidus externallinternal segment; SNc, substantia nigra 
pars compacta; SAM supplementary motor area; STN, subthalamic 
nucleus; VL, ventrolateral nucleus of the the thalamus 
Adaptedftom Obeso et al, (2000) Trends Neurosci, 23(10) S8-19 
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1.5.4.3 The role qf the Pedunculopontine nucleus in PD pathophysiology 
In addition, the classical model does not consider the potential role of the PPN in PD 
pathophysiology. The PPN, a rostral brainstern structure establishes reciprocal 
connections with the BG and increasing evidence suggests this reciprocal relationship is 
crucial for the normal functioning of the BG and PPN. Indeed, electrical stimulation of 
the PPN elicits locomotion (Garcia-Rill et al, 1987), leading to the suggestion that the 
PPN is an important relay nucleus between the BG and the spinal cord (Takakuski et al, 
2004). However, recent evidence suggests the PPN is more than a simple relay and 
plays additional roles in reward and learning (Inglis et al, 2000; 2001), sleep-wake 
cycles (Mena-Segovia et al, 2002) suggesting that the PPN shares functions traditionally 
associated with the BG (Mena-Segovia et al, 2004). 
The PPN is comprised of both cholinergic and glutarnatergic neurones 
(Sugimoto and Hattori, 1984). Furthermore, the BG and the PPN are highly 
interconnected, with reciprocal connections between the PPN, striatum, SNc, SNr, GPi 
and STN (Lavoie and Parent, 1994). Indeed, The PPN receives GABAergic input from 
the SNr and putamen (Winn et al, 1997; Grofova and Zhou, 1998) which inhibits 
cholinergic and glutamatergic output from the PPN (Kang and Kitai, 1990; Saitoh et al, 
2003). Additionally the PPN receives excitatory glutarnatergic inputs from the STN and 
the frontal cortex which are critical for the regulation of PPN activity (Granata and 
Kitai, 1989; 1991; Matsumura et al, 2000). Additionally, the PPN send excitatory 
afferents to the SNc (Charara et al, 1996; Kitai et al, 1999), the STN (Lavoie and Parent, 
1994; Bevan and Bolam, 1995), SNr (Rohrbacher et al, 2000), the GPi (Lavoie and 
Parent, 1994), the striaturn (Parent et al, 1983) and the thalamus (Pare et al, 1988). 
By virtue of these reciprocal connections, one might predict from the classical 
model of BG function that in I'D disruption of these inputs could alter PPN activity 
(Pahapill and Lozano, 2000). Indeed, one may predict an increased inhibitory input to 
the PPN from the SNr, but also increased excitatory drive from the STN under 
parkinsonian conditions (Mena-Segovia et al, 2004). In support of this, lesions of the 
STN in DA depleted rats result in PPN hypoactivity (Breit et al, 2001; 2005). 
Additionally, in response to DA dennervatiOn induced by 6-OHDA, metabolic and 
electrophysiological data demonstrate PPN neurones become hyperactive, which these 
data suggest is probably due to STN hyperactivity (Orieux et al, 2000a; Breit et al, 
2001; Jeon et al, 2003) 
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Therefore, under parkinsonian conditions increased inhibition of PPN neurones, 
which as the PPN is thought to facilitate movement may result in akinesia (Mena- 
Segovia et al, 2004). In support of this, pharmacological blockade of the inhibitory 
input to the PPN by microinjection of bicuculline, a GABAA receptor antagonist into the 
PPN reverses akinesia in MPTP-intoxicated primates (Nandi et al, 2002). The 
importance of the PPN is further highlighted by pathological changes which occur in 
these nuclei in PD (Hirsch et al, 1987; Zweig et al, 1989). Interestingly, lesions of the 
PPN lead to an increase in both STN and SNr activity, similar to that observed 
following 6-OHDA lesions of the nigrostriatal system (Breit et al, 2005). Thus it 
appears that PPN as well as nigrostriatal lesions induce motor dysfunction (Breit et al, 
2005). Indeed, PPN lesions induced a decrease in the activity of SNc neurones and 
appeared to produce akinetic symptoms in these animals (Breit et al, 2005). Thus, it is 
suggested that lesioning of the PPN results in decreased SNc activity, leading to an 
upward cascade of functional changes in the BG propagating through the indirect 
pathway, resulting in decreased thalamo-cortical feedback and akinesia (Breit et al, 
2005). 
These findings suggest the possibility of an additional feedback loop within the 
BG centred on the triad of the STN, PPN and SNc (Breit et al, 2005) form a negative 
feedback loop that may act to provide functional compensation in the BG in the initial 
stages of neurode generation thereby preventing deleterious increases in STN activity 
(Breit et al, 2005). In this respect it is noteworthy that high-frequency stimulation of the 
PPN alleviates akinesia in MPTP-treated primates (Jenkinson et al, 2004; 2005). Taken 
together, it may be concluded that the PPN may also contribute to the generation of 
STN hyperactivity in PD. 
1.5.4.4 Importance of reciprocal connections between the SNc and STN 
In further support of the idea that the PPN, STN and SNc form a negative feedback 
loop, it has been suggested that reductions in somatodendritically released DA from 
nigral DA neurones produces STN hyperactivity by virtue of a loss of the negative 
modulatory effect of DA on STN activity (Obeso et al, 2000). Indeed, the STN and SNc 
are reciprocally connected, as the STN receives DA innervation from the SNc (Hassani 
et al, 1997), whilst the STN sends glutarnatergic projections to the SNc (Kita and Kitai, 
1987; Smith et al, 1990; Iribe et al, 1999). Furthermore, STN neurones express both DA 
D, and D2-like receptors (Cossette et al, 1999), whilst DA nigral neurones express both 
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inotropic and metabotropic glutamate receptors (Testa et al, 1994; 1998; Christoffersen 
and Meltzer, 1995; Kosinski et al, 1998; 1999). Moreover, direct injection of DA 
agonists into the STN modifies the firing patterns of STN neurones (Hassani and Feger, 
1999) and there is considerable evidence to suggest that glutamate promotes firing of 
nigral DA neurones, although this could also be regulated through the PPN (Morari et 
al, 1998). Microdialysis studies confirm the hypothesis that the SNc may directly 
influence STN activity and suggest that activation of D, or D2-like DA receptors on 
STN neurones has differential effects in a manner analogous to that proposed to occur in 
the striaturn by the classical model of BG function (Albin et al, 1989). Indeed, perfusion 
of the DA 132-like receptor antagonist raclopride into the STN prolongs carbachol 
induced- increases in glutamate release from STN neurones, leading to increased 
concentrations of glutamate in the SNc, which was attenuated by perfusion of quinpirole 
a DA D2-like receptor agonist (Hatzipetros and Yammamoto, 2006). In contrast, 
injection of the DA DI-like receptor antagonist R-(+)-8-chloro-2,3,4,5-tetrahydro-3- 
methyl-5-phenyl-IH-3- benzazepine-7-ol (SCH-23390) did not alter carbachol-induced 
increases in glutamate release, although it did appear to alter basal glutamate 
concentrations (Hatzipetros and Yammamoto, 2006). Perfusion of the GABAAreceptor 
antagonist bicuculline into the SNc also prolonged the carbachol-induced glutamate 
release similar to raclopride (Hatzipetros and Yammamoto, 2006). 
Taken together, these findings suggest that somatodendritically released DA 
from the SNc appears to activate DA D2-like heteroreceptors on STN axon terminals, 
leading to reductions in stimulated glutamate release, whilst activation of DA DI-like 
receptors appears to preferentially regulate basal glutarnate release (Hatzipetros and 
Yammamoto, 2006). It is noteworthy that carbachol, a cholinergic agonist stimulates 
glutamate release from the STN, perhaps further emphasising the key role of the 
cholinergic projections from the PPN in the regulation of STN activity. 
Taken together, these data suggest that under parkinsonian conditions, STN 
hyperactivity may also be the result of a loss of PPN-mediated excitation of nigral DA 
neurones resulting in decreased somatodendritic DA release and subsequent STN 
hyperactivity (Obeso et al, 2002). Therefore, these mechanisms may also contribute to 
the development of STN/GPi hyperactivity alongside reductions in GPe activity alone 
due to nigrostriatal degeneration and increased indirect pathway activity (Obeso et al, 
2000). 
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1.5.4.5 Excitatory prqj . ections ftom the STN or PPN may contribute to 
neurodegeneration of the nigral DA neurones through excitotoxic mechanisms 
Additionally, the classical model also does not account for the possibility that increases 
in glutamate transmission from the hyperactive STN or PPN in the Parkinsonian. state, 
may exacerbate nigral degeneration through secondary glutamate excitotoxicity 
(Rodriquez et al, 1998; Greenamyre, 2001; Blandini et al, 2001). In support of this 
concept, destruction of the STN by chemical lesioning results in neuroprotection of the 
nigrostriatal system in 6-OHDA-lesioned rodents (Piallat et al, 1996; Nakao et al, 1998; 
Carvalho and Nikkhah, 2001). Similar destruction of the PPN results in robust 
neuroprotection of the nigrostriatal system in MPTP-intoxicated primates (Takada et al, 
2000), suggesting that removal of increased excitatory drive from these structures in 
DA-depleted animals reduces nigrostriatal damage, thereby implicating glutamate 
excitotoxicity in the pathogenesis of PD (Rodriquez et al, 1998). Interestingly, PPN 
neurones also degenerate in PD (Zweig et al, 1989). This raises the question as to 
whether the degeneration of these two nuclei (PPN and SNc) is independent or 
simultaneous due to the strong excitatory drive both structures receive from the STN 
and/or frontal cortex, which is amplified in the parkinsonian. BG (Breit et al, 2005). 
Importantly, taking into account the negative feedback interactions between 
these nuclei and the generalised increase in indirect pathway neurotransmission 
observed in the parkinsonian BG, it may be predicted that degeneration of the SNc 
and/or PPN would lead to the generation of vicious feed-forward loop, whereby 
neuronal degeneration in these structures and STN or cortical hyperactivity are self- 
sustaining, thereby further worsening neurodegeneration in the SNc and/or PPN, which 
may have important implications in the pathogenesis and potentially progression of 
idiopathic PD. 
Taken together, it is clear that BG function is highly complex and further work 
is still needed to elucidate how pathophysiological changes in the BG motor loop lead to 
the appearance of PD motor and indeed, non-motor symptoms. Furthermore, to 
elucidate if altered BG nuclei activity, particularly from the STN or PPN leads to 
secondary enhancement of nigrostriatal degeneration. Importantly, the findings 
discussed in the proceeding sections highlight the probable significance of non-DA 
projections in the development of both PD symptoms and possibly neurodegeneration, 
particularly with respect to the STN and the PPN, thereby strongly implicating altered 
glutamate neurotransmission as a significant downstream consequence of nigrostriatal 
degeneration, which may directly contribute to PD pathophysiology. 
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1.6 Epidemiology and Etiology of Parkinson's disease 
Parkinson's disease (PD) is the second most common neurodegenerative disorder after 
AD, with a lifetime risk of I in 40-50 (Schapira, 2006). The etiology of PD is not yet 
elucidated, but both genetic and environmental factors have been implicated and are 
discussed below. 
1.6.1 Prevalence of Parkinson's disease 
Epidemiological studies suggest that the prevalence of idiopathic PD is estimated at 
0.3% of the general population and 1% of people aged over 60 (Nussbaum and Ellis, 
2003). Limited evidence suggests the disease may be less common among non- 
caucasians, which may be interesting in terms of exposure to different environmental 
factors or different susceptibility genes (deLau and Beretler, 2006). Clearly however, 
the primary risk factor for sporadic PD is ageing, since the disease is rare before 50 
years of age whilst the prevalence of PD increases with age to up to 4% in the highest 
age groups (75-80 years of age; de Rijk et al, 1997; 2000). Interestingly, some studies 
have also reported a higher prevalence of PD in males compared to females (Schrag et 
al, 2000; Swerdlow et al, 2001). This has been suggested to be due to a potential 
neuroprotective effect of estrogens, but this remains controversial (Gillies et al, 2004). 
1.6.2 Incidence of Parkinson's disease 
Standardised incidence rates of PD are given as approximately 8-18 per 100,000 person 
years (Rajput et al, 1984; MacDonald et al, 2000). In support of ageing as the primary 
risk factor for I'D the incidence of PD is I in 1000 people below the age of 50, but the 
incidence increases dramatically over the age of 60 to approximately I in 100 people 
(deLau and Beretler, 2006). Additionally, in support of the increased prevalence of PD 
in men, several groups have found higher incidence of PD among males compared to 
females (Gilles et al, 2004). 
1.6.3 Environmental risk factors for sporadic PD 
The most convincing evidence that environmental factors may be involved in the 
development of I'D relates to the discovery of the MPTP neurotoxin (Langston et al, 
1983). Indeed, drug addicts exposed to MPTP, a by-product of an illicit synthetic 
meperidine derivative, developed clinical symptoms and neuropathology remarkably 
similar to idiopathic I'D (Langston et al, 1983). In the brain, MPTP is readily converted 
-44- 
in astrocytes to the pyridinium ion MPP+, catalysed by monoamine oxidase type-B 
(MAO-B). The MPP + ion is then taken up by DA neurons via the DAT and causes 
profound inhibition of mitochondrial complex I leading to neuronal death (Blum et al, 
200 1). This led to the hypothesis that exposure to an environmental toxin may be related 
to the risk of developing PD. However to date, no MPTP-like toxin or factor has been 
identified in PD patients (Blum et al, 2001). 
Since this initial discovery, many epidemiological studies have attempted to 
examine the association between environmental factors and the risk of developing PD 
(Schapira, 2006). These have suggested that rural residency appears to increase the risk 
of PD (Rajput et al, 1986; 1988). Since rural residency is often associated with fanning 
and pesticide use, it is interesting that increased incidence of PD is observed in people 
with agricultural occupations (Gorrell et al, 1996) and exposure to herbicides or 
pesticides (Semchuk, 1992; Giasson and Lee, 2000; Priyadarshi et al, 2000). Indeed, 
exposure to organochloride pesticides has been identified as a risk factor for I'D 
(Fleming et al, 1994; Seidler et al, 1996). The drinking of well-water has also been 
investigated as an additional rural factor (Tanner et al, 1996). 
Additionally, chronic exposure of rodents to the pesticide rotenone produces 
selective nigrostriatal degeneration and more importantly, the formation of LB-like 
inclusion bodies which are highly immunoreactive for a-synuclein, as well as inducing 
microglial activation in the SNc of rodents (Betarbet et al, 2000b; Sherer et al 2003), 
thereby suggesting that commonly-used pesticides can penetrate the human blood brain 
barrier (BBB) and cause nigrostriatal degeneration. Interestingly, the herbicide paraquat 
bears a striking structural similarity to MPTP (McCormack et al, 2002), causes 
nigrostriatal degeneration in rodents by inhibition of complex I (Richardson et al, 2005). 
Additionally, paraquat increases the rate at which a-synuclein forms fibrils in vitro 
(Uversky et al, 2001; 2004) and increases a-synuclein expression in vivo leading to 
formation of inclusion bodies in nigral DA neurones (Manning-Bog et al, 2002). It is 
noteworthy therefore, that all of these agents are either inhibitors of mitochondrial 
complex I or induce some form of protein aggregation, suggesting a proteasomal deficit, 
both of which have been suggested to be involved in the pathogenesis of idiopathic PD 
(see section 1.8). Interestingly, compounds which inhibit proteasome activity appear to 
induce pathology and symptoms similar to PD in experimental models of PD 
(McNaught et al, 2002b; 2004a; Zeng et al, 2006). The relevance of these findings to 
idiopathic PD is further confirmed by the observation of specific complex I and 
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proteasomal deficits in post-mortem tissue from PD patients (Schapira et al, 1989; 1990; 
McNaught and Jenner, 2001; McNaught et al, 2001; 2002a). 
Exposure to heavy metals such as iron, manganese, copper, lead, amalgam, zinc 
or aluminium have also been suggested as possible risk factors for the development of 
PD due to accumulation of metals in the SNc and increased oxidative stress (Olanow, 
2004). Indeed, manganese is neurotoxic to the BG and individuals exposed to 
manganese dioxide ore have an increased risk of developing a parkinsonian-like 
syndrome, due to chronic inhalation of manganese dust (Huang et al, 2003). 
Additionally exposure to manganese fumes from welding has been suggested to 
increase the incidence of PD amongst welders, but this remains unsubstantiated 
(Jankovic, 2005). Interestingly, manganese is also constituent of many pesticides, 
further suggesting a link between pesticide exposure and I'D (Schapira, 2006). 
Importantly, environmental factors exist which are suggested to decrease the risk 
of developing PD. Of these only cigarette smoking and coffee drinking are commonly 
cited as lowering the risk of developing PD, although the mechanism by which this 
occurs is unknown (Grandinetti et al, 1994; Hernan et al, 2001; 2002). With respect to 
smoking, nicotine is implicated since this compound may stimulate DA release, has 
antioxidant properties, alters the activity of MAO-B and is neuroprotective in animal 
models of PD (Ross and Petrovich, 2001; Quik, 2004). However nicotine is not 
neuroprotective in all experimental models and this idea remains controversial (Pauly et 
al, 2004). In terms of coffee drinking, caffeine appears to be the active agent, since 
caffeine intake is inversely related to the risk of developing PD (Ross et al, 2000). 
Interestingly, caffeine consumption appears to reduce the relative risk of developing PD 
further for males compared to females (Ascherio et al, 2001). Estrogen is known to 
inhibit caffeine metabolism in a competitive manner, which may explain the differential 
effect in men and women (Ascherio et al, 2001; Xu et al, 2006). Interestingly, caffeine 
is also an Adenosine A2A receptor antagonist, which have been proposed as potential 
non-doparninergic treatments for PD (see section 1.8.2). 
In addition, increasing evidence suggests that neuroinflammation; particularly 
infiltration of reactive microglia may contribute to the pathogenesis and/or progression 
of PD (Hirsch et al, 2003). In support of this, the use of nonsteriodal anti-inflammatory 
drugs (NSAIDs) 2 or more times per week appears to result in a 45% lower risk of 
developing PD (Chen et al, 2005; Ton et al, 2006; Hernan et al, 2006). 
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1.6.4 Genetic risk factors and inherited forms of Parkinson's disease 
Although 90-95% of I'D cases are sporadic in nature, approximately 5-10% of cases are 
hereditary with clear genetic origins, which are termed familial I'D (Farrer, 2006). In 
support of a genetic component of PD, relatives of PD patients have an approximate 2-3 
fold higher risk of developing PD in comparison to age-matched controls (Bonifati et al, 
1996; Vieregge et al, 1995; Gasser, 1998). In addition, comparison of concordance 
between mono- and dizygotic twins, which is a commonly used tool to investigate the 
genetic contribution to the eitology of a specific disease (Farrer, 2006) revealed a non- 
significant concordance for PD among monozygotic twins suggesting the absence of a 
genetic contribution to PD (Tanner et al, 1999). However, when similar comparisons 
were made for twins with age of PD onset before 50 years old, a significant 
concordance was observed, suggesting that young-onset PD may have a genetic 
component (Tanner and Aston 2000; Schragg and Scott, 2006). Additionally, imaging 
studies in both affected and unaffected mono- and dizygotic twin pairs revealed a 
significant concordance for PD in identical twins. Taken together, these findings 
suggest that genetics may be important in PD eitology (Farrer, 2006). 
Importantly, a major breakthrough in this respect involved large scale linkage 
analysis studies which have led to the mapping and cloning of several genes that cause 
monogenetically inherited forms of the disease in an autosomal dominant or recessive 
fashion, which are summarised in Table 1.2. Additionally, genetic studies have also 
identified numerous "susceptibility genes" for PD by linkage association studies which 
have demonstrated a significant association between polymorphisms in suspected 
candidate genes and increased prevalence or incidence of PD (BerMoyal-Segal and 
Soreq, 2006). To date, polymorphisms in 16 candidate susceptibility genes have been 
identified which are associated with an increased risk of PD (BenMoyal-Segal and 
Soreq, 2006). Interestingly, all the identified gene mutations which cause inherited PD, 
or in susceptibility genes are present in genes encoding proteins involved in DA 
synthesis and transmission, oxidative stress, protein accumulation and degradation, 
mitochondrial function, and xenobiotic metabolism, implicating these cellular processes 
in PD pathogenesis (see section 1.8). 
Thus, taken together the current consensus is that sporadic PD may result from a 
combination of interacting genetic and environmental factors although the nature and 
time course of these interactions is debated (Allam et al., 2005; BenMoyal-Segal and 
Soreq, 2006). 
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Gene Locus Age of Mutations Clinical Pathology Comments onset phenotype 
Slow 
PARK6 Recessive progression Rare, 1-2% PINK] I p_3 5- 20-40 years missense and parkinsonism, Undefined cases, age onset 
p3 6) exon deletions L-DOPA 50 years. 
responsive 
Recessive, Slow 
PARK7 
missense progressive 
parkinsonism, 
Rare cause 
DJJ 
I p_36) 
20-40 years mutation (L I 66P and some 
Undefined (<1%) cases 
with age onset 
exon 1-5 
behavioural 
<50 years 
deletions and psychiatric 
disturbance 
193M Undefined 
55-58 years 
for 193M S18Y 
polymorphism is 
UCHLI PARK5 
(193M) S18Y 
cases; 
UCHL I is a associated with 
(4p]4) polymorphism 
Sporadic PD 
prominent increased risk of 
Late onset associated with constituent 
sporadic PD 
(meta-analysis 
susceptibility to ofLewy , functional data) 
sporadic PD Bodies 
Dominant Progressive L- Diffuse 
A53P, A53T, DOPA Lewy body Common 
PARKI 38-65 years E46K responsive parkinsonism 
disease, 
prominent promoter and 
SNCA and (duplications) substitutions, , cognitive nigral and 
intronic 
PARK4 24-48 years genomic decline, hippocampal variability are (4q2l) (triplications) duplications 
autonomic (CA2-3) associated with and dysfunction neuronal sporadic 
PD 
triplications 
and dementia loss 
Mutations 
Parkinsonism account for Recessive, 
often presents 
Nigral cell -50% familial, 
PARK2 missense (>57), with dystonia, 
loss also juvenile and 
PARK2 (6q25.2- -30 years exon deletions, response to some 
Lewy early onset 
q27) 
(range 16-72) duplications 
very low doses 
Body and parkinsonism 
and of 
Tau and 18% 
triplications L-DOPA pathology sporadic cases (<50 years age 
at onset) 
Dominant Parkinsonism Lewy Body 
substitutions consistent with disease, rare incl. 
sporadic PD, cases have 
Common coding 
LRRK2 PARK8 50-70 years R 144 1 C/G/H, dystonia and NFTs, variations might (12pl2) (range 32-79) YI 699C, dementia and/or nigral affect risk 
in 
12012T, 
occasionally neuronal sporadic 
PD 
G2019S, develop loss 
12020T I I I 
Table 1.2 Genetic causes of parkinsonism PINK], PTEN-induced kinase 1, SNCA, 
gene that encodes the protein a-synuclein, UCHLI, ubiquitin carboxyl-terminal esterase 
I, PARK2, locus which encodes the protein Parkin, LRRK2, leucine rich repeat kinase 2, 
NFT, neurofibrillary tangles (adaptedftom Farrer, 2006 Nat Rev Genet 7(4)306-18) 
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1.7 Current treatment strategies for PD 
Current pharmacological treatment of PD is focussed on DA replacement therapy, 
which aims to either replace the lost DA in the striaturn or mimic the action of DA by 
the use of selective DA receptor agonists. These strategies provide remarkable long- 
term symptomatic control of the cardinal motor features of PD and the use of these 
drugs significantly improves the motor function of PD patients, lowers morbidity and 
mortality and improves patient quality of life (Clarke et al, 1995; Karlson et al, 2000; 
Raiput, 2005, Lang and Obeso, 2005). 
1.7.1 Dopamimetic therapy for PD 
1.7.1.1 Levodopa (L-DOPA) 
The DA precursor L-DOPA provides effective relief of bradykinesia and rigidity 
(Birkmayer and Hornykiewicz, 1962; Yahr et al, 1968) of PD by replacing lost DA in 
the putamen (Lloyd et al, 1975; Agnati and Fuxe, 1980). L-DOPA remains efficacious 
throughout the course of PD, but its effects are modified as the disease progresses and 
the DA cells required to metabolise the drug, store and release DA are lost (Johnston 
and Brotchie, 2006). As a consequence, the duration of the beneficial effects following a 
dose of L-DOPA shortens and mirrors the plasma half-life (ti/2) of L-DOPA (Fabbrini et 
al, 1988). This results in rapid fluctuations in the beneficial effects of L-DOPA, defined 
as "on" and "off " responses (Marsden and Parkes, 1976). Prolonged L-DOPA treatment 
also results in development of L-DOPA induced dyskinesias, (LIDs), which are 
disabling involuntary movements (Brotchie et al, 2005). These complications occur in 
90% of PD patients receiving L-DOPA, usually with 5-10 years of the initiation of L- 
DOPA treatment (Ahlskog and Muenter, 2001). The mechanism by which this occurs is 
not understood, but may include pulsatile stimulation of DA receptors by L-DOPA and 
the degree of striatal dennervation (Lang and Obeso, 2004a, b) although non- 
dopaminergic mechanisms, including imbalances in non-dopaminergic striatal output 
pathways (Jenner, 2000) or sereotonergic, cholinergic and importantly, glutamatergic 
dysfunction in the striatum (Bezard et al, 2001b; Brotchie, 2005). 
Combination of L-DOPA with catechol-0-methyltransferase (COMT) 
inhibitors, such as tolcapone or entacapone reduces L-DOPA metabolism in the 
periphery resulting in increased L-DOPA bioavailability and ti/2 (Nutt et al, 1994). This 
beneficial increase in L-DOPA pharmacokinetics results in a continuous rather than 
pulsatile stimulation of DA receptors in the putamen as L-DOPA is metabolised 
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(Stocchi, 2005). Importantly, this is associated with significantly increased "on" time 
and decreased "off' time in patients (Heikkinen et al, 2001). Furthermore, evidence 
from MPTP-treated marmosets suggests combination with entacapone results in 
reductions in LID severity and onset (Pearce et al, 2001). Similarly, L-DOPA may be 
combined with a DOPA-decarboxylase inhibitor (Stalevo), which produces similar 
beneficial effects (Stocchi, 2005). Studies have suggested the use of L-DOPA may be 
toxic to remaining DA neurones, by virtue of auto-oxidation, but the evidence for L- 
DOPA toxicity is not convincing (Datla et al, 2001a; Agid et al, 2002; Olanow et al. 
2004). 
1.7.1.2 Dopamine agonists 
Alternative to L-DOPA is the use of DA D2-like receptor agonists, which are effective 
at managing the motor symptoms of PD either as a monotherapy or as an adjunct to L- 
DOPA use, which allows lower doses of L-DOPA be to administered (Kondo, 2002). 
As a monotherapy, DA receptor agonists provide effective relief of motor symptoms 
over a prolonged period of time, thus delaying the need for L-DOPA therapy and onset 
of motor complications (Rascol et al, 2000; Holloway et al, 2004). However, inevitably 
patients will require L-DOPA supplementation leading to development of motor 
complications (Olanow and Jankovic, 2005). Partly this may be obviated by the use of 
long-acting ergot D2-like DA receptor agonists such as cabergoline in combination with 
existing prescribed DA receptor agonists pramixpexole or ropinorole (Stocchi et al, 
2003). This is also useful in the management of dyskinesia, by providing continuous 
DA receptor stimulation and avoiding rapid fluctuations (Marco et al, 2002; Olanow et 
al, 2006). In support of this, evidence from MPTP-treated marmosets suggests that 
switching from L-DOPA to the long-acting D2/D3DA receptor agonist piribedil reduces 
dyskinesia whilst still providing effective relief of motor symptoms (Smith et al, 2006). 
However, DA agonists are associated with side effects, which are also common to L- 
DOPA, including cognitive disturbances, hallucinations, confusion episodes, sleepiness 
and potentially oedema (Nutt et al, 2000). Ergot DA receptor agonists are also 
associated with peripheral side effects such as heart valve damage (Dhawan et al, 2005; 
Peralta et al, 2006; Kim et al, 2006) and the development of compulsive behaviours 
(Wientraub et al, 2006; Nirenberg and Waters, 2006). 
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1.71.3 Monoamine Oxidase inhibitors 
Inhibitors of MAO-B can improve motor function when given in combination with L- 
DOPA (Birkmayer et al, 1975) or if administered alone (Lees, 2002). Indeed, the MAO- 
B inhibitors selegilline and rasagiline provide symptom relief in PD patients when given 
alone (Rabey et al, 2000; Parkinsons study group (TEMPO study), 2002) without 
adverse effects (Ives et al, 2004). Importantly, however as with DA agonists, patients 
will eventually require L-DOPA supplementation (Schapira, 2006). 
1.7.2 Non-dopaminergic treatment for PD 
Due to the complications associated with DA-mimetic therapy, it is hypothesised that 
non-dopaminergic therapies which act downstream of the DA system to normalise BG 
output may be of therapeutic benefit to I'D patients, as these would be predicted not to 
be associated with the complications of DA replacement therapy as the striatal. DA 
system is bypassed. Additionally, such drugs may be less likely to induce dyskinesia 
due to normalisation of non-dopaminergic striatal output pathways (Oh and Chase, 
2002) or the restoration of sereotonergic, noradrenergic or glutamatergic functions 
which may be involved in LID development (Oh and Chase, 2002; Brotchie, 2005). 
Current non-dopaminergic therapies are summarised below in Table 1.3. 
1.7.3 Neurosurgical procedures for the treatment of PD 
In recent years a resurgence of interest has occurred in neurosurgical techniques to treat 
PD, particularly due to the complications with dopamimetic drugs in advanced PD 
patients, but also due to improvements in surgical and imaging techniques and a greater 
understanding of the pathophysiology of the BG in the disease (Obeso et al, 2002; 
Lozano and Mahant, 2004). These procedures are outlined in Table 1.4. 
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Treatment Compounds-- Benefits Side-effects References 
No greater 
efficacy over DA 
therapy 
Benzatropine 
Anti-cholinergics Effective relief of Autonomic 
Katzenschlager et 
al 2003 Orphenadrine tremor side-effects , Lees, 2002 
Risk of dementia 
cognitive side 
effects 
Alpha-2- Enhance L-DOPA 
efficacy 
Moderate to no Youdim and 
adrenergic Idazoxan benefit in clinical Buccafusco, 2005 
antagonists Reduce LIDs trial 
Do not prevent 
Selective 
Serotonin reuptake Fluoxetine 
Suppress LIDs in LID occurrence Durif et al, 1995 
inhibitors (SSRIs) PD patients May worsen PD 
motor symptoms 
Anti- parkinsonian 
in MPTP primates 
Do not prime for 
dyskinesia 
Adenosine A2A 
KW6002 
" ' None yet reported 
Jenner, 2003c; 
antagonists No wearing off Jenner, 2005 
effects 
Synergy with 
L-DOPA 
Table 1.3 Current non-DA treatments for PD in research and clinical trials 
1.7.4 Unmet clinical needs in PD treatment 
Whilst DA replacement therapy provides effective relief of PD motor symptoms, patient 
quality of life continues to deteriorate due to the clinical appearance of additional non- 
motor symptoms that are not alleviated by these drugs (Lang and Obeso, 2004a; 
Schapira, 2005). This is further compounded by the onset of motor complications 
associated with prolonged treatment with these drugs. Non-doparninergic treatments 
may alleviate these problems, but many of these are no better than current treatments or 
still in pre-clinical testing and clinical trials (Johnston and Brotchie, 2006). 
Furthermore, neurosurgical options are only of use in specific subgroups of advanced 
PD patients and are associated with numerous risks and post-operative challenges, as 
well as significant costs to both patients and health care systems (Lang et al, 2006; 
Deuschl et al, 2006). Importantly all current I'D treatments are symptomatic in nature 
and do nothing to halt the relentless progression of neuroclegeneration in PD (Lees, 
2002). 
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Procedure Target Benefits Side-effects References 
nuclei 
Relief from Herniballism 
Subthalmotomy STN 
motor 
symptoms/LIDS 
Risk of intercranial Olanow 
in DA refractory 
haemorrhage/haematoma (2002) 
patients Infection 
Relief from Herniballism 
Pallidotomy Pallidum 
motor 
symptoms/LIDS 
Risk of intercranial Olanow 
(GPi/GPe) in DA refractory 
haemorrhage/haematoma (2002) 
patients Infection 
Risk of intercranial 
haemorrhage/haematoma LiMosin et A Relief from 
motor 
Infection of hardware 
1995; 
Lozano and 
symptoms/LIDS 
Leads/Battery Mahant, 2004; 
in DA refractory replacement 
3-4 years Breit et al, 
Deep Brain STN, GN, Do not modify axial 2004; 
Stimulation PPN patients symptoms (gait jenkinson et A 
Less surgical 
disturbance) 
Weight gain, speech 
2005; 2006; 
Lang et al, 
risk than dysfunction, changing 2006; ablation? PD meds, "Off ' period 
Deuschl et A 
2006 
I pain 1 
Table 1.4 Neurosurgical procedures for the treatment of PD 
Interestingly, some pre-clinical evidence exists to suggest that DA receptor agonists 
(Schapira, 2002; Iravani et al, 2006b; Van Kampen and Eckman, 2006) and MAO-B 
inhibitors such as selegelline and rasagiline may be neuroprotective in experimental 
models of PD (Jenner, 2004; Mandel et al, 2005; Olanow, 2006a). However, large-scale 
clinical trials such as DATATOP, CALM-PD, TEMPO (Parkinsonian study group 
1989; 2000; 2002) and Real-PET studies (Whone et al, 2003) have not been able to 
substantiate this, possibly due to compounding symptomatic effects, which make 
identification of a neuroprotective effect difficult (Hauser and Zesiewicz, 2006). Indeed, 
despite widespread research, no agents have been identified as significantly 
neuroprotective in idiopathic PD (Meissner et al, 2004; Johnston and Brotchie, 2006). 
Thus, are significant unmet clinical needs in PD which require novel pharmacological 
agents that provide amelioration of motor symptoms, and prevent disease progression 
by neuroprotection of nigral DA neurones, thus delaying the need for L-DOPA or other 
treatments (Olanow and Jankovic, 2005). Ideally, these drugs should not be associated 
with the development of motor complications (Olanow et al, 2006b). In order to achieve 
this elusive goal, the potential pathogenic mechanisms that underlie neuronal death in 
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PD must be considered to identify potential candidate pathways for therapeutic 
intervention. 
1.8 Pathogenesis of PD 
The trigger mechanisms that initiate the neurodegeneration observed in sporadic PD 
remain elusive and the precise causes of selective neuronal death in the various nuclei 
affected in PD remains enigmatic (Jenner and Olanow, 2006). The current consensus is 
that PD pathogenesis is multi-factorial in nature, resulting from the interaction or 
summation of several biochemical, cellular and molecular alterations including, nitric 
oxide (NO) mediated oxidative stress, mitochondrial dysfunction, impaired protein 
handling and degradation and neuroinflammation, respectively (for reviews see Olanow 
and Tatton, 1999; Jenner, 2003a; Olanow and Jenner, 2006; McNaught and Olanow, 
2006). The bulk of the evidence for these mechanisms has come from the study of post- 
mortem PD tissue and in vivo experimental models of Parkinsonism in vivo (Jenner and 
Olanow, 2006). The possible mechanism(s) by which each of these processes may be 
neurotoxic to nigral DA neurones is illustrated in Figures 1.4 - 1.8. However, it is 
noteworthy that an increasing body of evidence implicates the glutamate excitotoxicity 
in the pathogenesis of sporadic PD, as a result of pathological increases in glutamate 
transmission from either cortical, STN or PPN output pathways following striatal DA 
depletion thereby exacerbating nigral degeneration (Beal, 1992; 1993; 1998; Rodriquez 
et al, 1998; Blandini et al, 2001). The principles of glutamate toxicity and the evidence 
implicating this process in neuronal death in sporadic PD are discussed in the following 
sections. 
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Figure 1.4 Nitric oxide, peroxynitrite and neurodegeneration 
Nitric oxide (NO) reduces cytochrome c oxidase facilitating superoxide (02*-)generation 
from mitochondria. Additionally, NO interferes with complex HI (ubiquniol-cytochrome 
c reductase) activity and increases the rateof 02*-) generation from the mitochondrial 
respiratory chain. Under conditions of persistent NO synthesis such as iNOS induction in 
microglia or sustained NMDAR activation in neurones, 02'-may react with NO to forin 
the peroxynitrite anion (ONOO-). Excess NO may S-nitrosylate proteins, including the 
ubiquitin E3-ligase parkin, which may contribute to PD pathology. Deleterious effects of 
NO are due to peroxynitrite formation, which can oxidise sulfhydryls and cause lipid 
peroxidation; nitrate tyrosine residues and impair protein function; persistently inhibit 
mitochondrial complex I (NADH-ubiquinone-reducatse) and IV (Cyt c oxidase); cause 
DNA damage in neurones leading to poly(ADP-ribose) polymerase-I (PARP-1) 
activation of ADP-ribosylation of proteins, a process which consumes cellular pools of 
NAD+. Replenishment of NAD+ from nicotinamide requires ATP, thus over activation of 
PARP-1 and mitochondrial damage induced by peroxynitrite may synergise to trigger a 
cellular energy crisis and neurotoxicity. Adaptedftom Moncada and Bolanos (2006) J 
Neurochem 97: 1676-89 
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Figure 1.5 The mitochondrial respiratory chain and neurodegeneration 
caused by mitochondrial dysfunction 
The mitochondrial respiratory chain in mammalian cells consists of >20 
electron carriers, grouped into 4 polypeptide complexes (I-IV) as illustrated. 
Complexes 1,11 and III act as oxidation-reduction driven proton pumps. The 
redox carrier within the respiratory chain consists of flavoproteins (FAD or 
FN4N), cytochromes, iron-sulphur clusters, ubiquinone (UQ) and copper. 
Respiration consists of the transfer of reducing equivalents from NADH(H') 
or from succinate dehydrogenase to oxygen. Transfer of reducing 
equivalents is coupled to pumping of protons across the mitochondrial inner 
membrane to generate an electrochemical gradient which provides the 
driving force for phosphorylation of ADP to ATP by ATP synthase (not 
shown). Oxidative damage to complexes 1,111 or IV in PD results in 
impaired mitochondrial function and further oxidative stress, cellular energy 
crisis due to reduced ATP formation, which may lead to subsequent defects 
in the ubiquitin-proteasome system (UPS) and an inability of neurones to 
maintain the ATP-dependant Mg2' block of NMDAR, sensitising neurones 
to glutamate excitotoxicity. 
(Mitochondrial electron transport chain adapted ftom Moncada and 
Bolanos, (2006),. JNeurochem, 97; 1676-89) 
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Figure 1.6 Intracellular protein handling by the ubiquitin proteasome 
system in neurones and glia 
The synthesis of proteins inevitably leads to the generation of unwanted proteins, such as 
short-lived/ regulatory, incomplete, mutant, misfolded, denatured, oxidized and otherwise 
damaged proteins and peptides within cells. These products have a high tendency to 
aggregate, which may interfere with cellular processes and induce cytotoxicity. Thus, these 
must be removed to maintain cell viability. The ubiquitin-proteasome system (UPS) is the 
primary pathway responsible for the degradation and clearance of unwanted proteins. In the 
first step of the UPS, a ubiquitin molecule (a 76-amino acid, 8.5 kDa polypeptide) is attached 
to covalently to unwanted proteins at Lys residues of the substrate protein. Thereafter, 
additional ubiquitin molecules are attached in a sequential manner to form a polyubiquitin 
chain, which requires ATP and is mediated by the consecutive activity of three different 
enzymes: a ubiquitin activating enzyme (El) which activates ubiquitin by forming a 
thioester, followed by a ubiquitin conjugating enzyme (E2) that carries activated ubiquitin as 
a thioester, and finally a ubiquitin ligase (D) which transfers activated ubiquitin to the 
substrate protein. Ubiquintated proteins are recognized by subunits in the PA700 regulatory 
cap of the 26S proteasome complex (60+ subunits/2.5MDa) and are degraded to small 
peptide fragments (2-25 residues) that undergo hydrolysis by peptidases to produce their 
constituent amino acids which are reused in protein synthesis. Before entry into the 
proteasome, polyubiquitin chains are detached from protein conjugates, then disassembled by 
de-ubiquitination enzymes (ubiquitin C-terminal hydrolases) into monomeric ubiquitin which 
is recycled. Additionally, heat shock proteins (HSPs), such as HSP70 and HSP90, also play a 
role in protein handling by promoting the refolding of abnormal proteins to their native state 
and/or facilitating their recognition and degradation by the UPS. (Adaptedftom McNaught 
and Olanow (2006) NeurobioL Ageing 27: 530-45) 
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Figure 1.7 A proposed model for UPS dysfunction and protein aggregation 
resulting in neurodegeneration in Parkinson's disease 
In normal conditions, unwanted proteins are continuously produced 
(incomplete, misfolded, damaged, mutant, short term regulatory proteins) which 
is counterbalanced by efficient degradation and clearance by the UPS and HSPs. 
In PD. a combination of interrelated defects may result in excess production of 
unwanted proteins or an impairment of UPS ftniction leading to proteolytic 
stress and protein aggregation. Gene mutations may produce excess levels of 
misfolded protein (a-synuclein) or defects in UPS enzymes (Parkin, UCH-Ll). 
Abnormal Proteins, oxidative stress, mitochondrial dysfunction, inflammation 
and excitotoxicity could increase the load of oxidised proteins or cause free- 
radical mediated damage to the proteasomal enzymes. Mitochondrial 
dysfunction would also lead to UPS dysfunction through ATP deficit. 
Environmental toxins may also inhibit UPS function. Under these conditions, 
undegraded and unwanted proteins accumulate leading to aggresome forination 
and eventually Lewy Body formation as the cell attempts to sequester the 
proteins to prevent cyotoxicity. Proteolytic stress may also interfere with normal 
cellular processes and the cytoskeleton leading to cyotoxicity and nigral 
neuronal degeneration. This suggests UPS dysfunction may be a common 
pathogenic factor in PD. (Adapted ftom McNaught and Olanow (2006) 
NeurobioL Ageing 27: 530-45) 
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Figure 1.8 Impaired glial cell function in Parkinson's disease 
Oxidative stress, GSH depletion and mitochondrial dysfunction in both 
neurones and astrocytes results in impaired astroglial function characterised 
by a loss of trophic support to neurones and glutamate efflux due to 
reversal/impaired glutamate uptake capacity. Mitochondrial dysfunction in 
DA neurones sensitises them to glutamate, leading to excitotoxicity and cell 
death which may also be cause by loss of trophic signals. Neuronal 
degeneration induces reactive microgliosis into the SNc, activated microglia 
release cytokines including TNF-oc, leading to further inflammation and 
potentially neuronal apoptosis. Cytokines may also act in an autocrine 
fashion to potentiate microglia activation. Activated microglia release NO 
and hydrogen peroxide, which may synergise oxidative stress leading to 
peroxynitrite formation and neurotoxicity. Microglia also release glutamate, 
possibly leading to excitotoxicity. Thus, NO production, inflammation, 
glutamate release and mitochondrial dysfunction may form a destructive 
cycle which combines to produce neurodegeneration 
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1.8.1 Glutamate toxicity 
Glutamate is the primary fast excitatory neurotransmitter in the mammalian CNS, the 
effects of which are mediated by two distinct receptor families the ionotropic and 
metabotropic glutamate receptors (see Table 1.5) (Ozawa et al, 1998). Metabotropic 
glutamate receptors (mGluR) are part of the family C heptahelix G-protein coupled 
receptors (GPCR) (Conn and Pin, 1997; see section 1.10). lonotropic glutarnate 
receptors (iGluR) consist of three families named after their selective pharmacological 
agonists, the N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionate (AMPA) and Kainate (KA) receptors all of which mediate fast 
synaptic transmission in the CNS (Hollmann. and Heinemann, 1994; Ozawa et al, 1998). 
Physiologically', activation of AMPA receptors (AMPAR) generates short- 
duration fast excitatory postsynaptic potentials (EPSPs), whereas activation of NMDA 
receptors (NMDAR) produces longer-lasting depolarisation of neurones (Ozawa et al, 
1998). Both AMPAR and NMDAR play critical roles in synaptic plasticity associated 
with memory and learning (Collingride, 1987; Calabresi et al, 1992; Bliss and 
Collingridge, 1993; Malenka and Nicoll, 1993), including dendritic sprouting (Luscher 
et al, 2000; Fischer et al, 2000), synaptic modification and control of gene expression 
(Nicoll and Malenka, 1999; Wang et al, 2004). Additionally, activation of iGluR (and 
mGluR) regulates the excitation of numerous BG nuclei and thus plays a central role in 
the normal functioning of the BG nuclei in movement (Young and Penney, 1984; 
Carlsson, 1993; Hauber, 1998; Vezina and Kim, 1999). 
In order to mediate neuronal depolarisation all iGluR receptors are ligand-gated 
cation channels and molecular biology studies have revealed iGluR have an oligomeric 
structure, comprised of various subunits (see Table 1.5) (Kutsuwada et al, 1992; 
Nakanishi, 1992; Ishii et al, 1993). The subunit composition of the receptor has direct 
bearing on the properties of the receptor thus the oligomeric assembly of iGluR coupled 
with several splice variants for each subunit gene (see Table 1.5) results in a massive 
functional heterogeneity in the brain (Waxman and Lynch, 2005). AMPAR rapidly 
desensitise on activation (Buldakova et al, 2000; Grosskreutz et al, 2003) and are 
usually Ca 2+ impermeable, due to the presence of the GluR2 subunit, although native 
receptors that do not contain this subunit are highly Ca 2+ permeable (Burnashev et al, 
1995; 1996; Angulo et al, 1997). In contrast, NMDAR are highly Ca2+ permeable and 
are the primary mediators of Ca2+ signalling in neurones and undergo much slower rates 
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of desensitisation (Shirasaki et al, 1990; Zhang et al, 1995; Tong et al, 1995; Nahurn- 
Levy et al, 2001). 
Property NMDA AMPA KA mGluR 
Family/ Ion channel Ion channel Ion channel GPCR 
Structure Oligomeric Oligomeric Oligomeric Monomeric 
Subunits/ I NRI subunit 4 GluR 3 GluR 8 known 
subtypes (8 splice subunits (1 -4) subunits (5-7) subtypes, (1-8) 
variants) "Flip/Flop" 2 KA subunits (see Table 1.7) 
4 NR2 subunits splice variants (1,2) 
(A-D) 
Unitary 40-50 pS 10-20 pS <10 ps 
conductance 
Ionic selectivity Na+, K+, C Na +9K+ Na+, 
(GluR2 Ca 2+ 
permeable) 
Desensitization Slow Rapid Rapid Slow 
Selective Glutamate, Glutamate, Glutarnate, (See Table 1.7) 
agonists NMDA, AMPA, Kanic acid, 
lbotenic acid, Quisqualic Domic acid 
Quinolinic acid acid, 
Kanic acid 
Selective 2-APV5 CNQX, CNQX, (See Table 1.7) 
antagonists MK8015 
Memantine 
Regulatory sites Glutamate, Thiazide Glutamate 
glycine, Allosteric site 
polyamine, (TM2-3) 
Table 1.5 Excitatory Amino Acid (EAA) receptor subtypes in the mammalian CNS 
CNQX, 6-cyano-2,3-dihydroxy- 7-nitro-quinoxaline; 2-AP V, 2-amino-5- 
phosphonovaleric acid; MK801, TM, transmembrane. (Adapted ftom Doble, (1999) 
Pharmacol Ther; 8](3). - 163-221). 
1.8.2 Glutamate as a neurotoxin, the principle of excitotoxicity 
Besides the normal physiological roles of glutamate, when neurones are injured or 
become hyperactive, they release glutamate at higher concentrations than those required 
for normal physiological functions, leading to a prolonged excitatory postsynaptic 
response, which if unchecked, results in cellular dysfunction and eventually apoptosis, 
by a process termed "excitotoxicity" (Olney et al, 1971; 1978). Indeed, glutarnate 
excitotoxicity is implicated in a several neurological disorders, including stroke (Sun 
and Cheng, 1999), epilepsy (Chapman, 2000), Amyotrophic lateral sclerosis (ALS; 
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McGeer and McGeer, 2005), Huntington's disease (HD; Rego and de Almeida, 2005), 
and AD (Hynd et al, 2004). 
Glutamate excitotoxicity is due to pathological increases in the extracellular 
concentration of glutamate, which leads to a massive influx of extracellular Ca 2+ into 
neurones, secondary to activation of NMDAR (Frandesen et al, 1989; Meldrum and 
Garthwaite, 1990). Since AMPAR are generally Ca 2+ impermeable, they may contribute 
to excitotoxicity primarily by producing sufficient neuronal depolarisation to activate 
the Ca 2+ permeable NMDAR, suggesting Ca 2+ influx through NMDAR is the primary 
mediator of excitotoxic neuronal damage (Choi, 1992; 1994a, b). In support of this, 
pharmacological blockade of NMDAR markedly reduces the extent of excitotoxic 
lesions (Choi et al, 1988; Michaels and Rothmann, 1990). Similarly, neurones are 
protected from excitotoxicity when stimulated with glutamate in the absence of 
extracellular Ca 2+ or in the presence of intracellular Ca 2+ chelators (Choi et al, 1987; 
Tymianski et al, 1993a, b). Furthermore, NMDAR overstimulation induces elevations in 
intracellular Ca 2+ , which precede cell death (Michaels and Rothmann, 1990; Randall 
and Thayer, 1992; Tymianski et al, 1993a, b). It is noteworthy however, that secondary 
increases in Ca 2+ influx may also occur through activation of voltage-gated Caý+ 
channels (VGCCs) subsequent to NMDAR activation propagating the excitotoxic effect 
(Lynch and Dawson, 1994). This is emphasised by the finding that VGCC blockers such 
as nefopam and nimodipine are also neuroprotective against glutamate excitotoxicity 
(Stuiver et al, 1996; Novelli et al, 2005). 
Importantly, deletion of the C-terminal domain of NMDAR protects against 
glutamate toxicity, although the Ca 2+ response to agonist is not affected (Lynch and 
Guttmann, 2001; 2002). This suggests that intracellular signal transduction mechanisms 
secondary to Ca 2+ influx are the effectors of glutamate excitotoxicity. This is 
highlighted by studies in which uncoupling of NMDAR from their signal transduction 
mechanisms by disruption of interactions between NMDAR and the molecular scaffold 
proteins that regulate the functional clustering and coupling of NMDAR to signal 
transduction systems, such as post-synaptic density-95 (PSD-95) results in 
neuroprotection against glutamate excitotoxicity (Aarts et al, 2002). Multiple signalling 
pathways are implicated in excitotoxic cell death following Ca2+ influx including 
mitochondrial dysfunction and excess activation of calcium-dependent kinases, 
phosphatases and proteases (Sattler et al, 1999; Arundine and Tymianski, 2003; 
Nicholls, 2004). 
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1.8.3 Mechanisms of glutamate neurotoxicity 
Glutamate excitotoxicity in neurones (and glia) may occur through two mechanisms, 
referred to as "fast" and "slow" excitotoxicity, respectively (Beal, 1998; Rodriquez et 
al, 1998). Fast excitotoxicity refers to toxicity resulting from direct activation of 
NMDAR due to excess neuronal glutamate release and subsequent activation of 
downstream signalling pathways (Doble, 1999), whilst "slow excitotoxicity" is caused 
by mitochondrial dysfunction, which is described below (Beal, 1992; 1993; 1998). 
1.7.3.1 Mitochondrial dysfunction and excitotoxicity 
In response to potentially pathological Ca 2+ influxes mitochondria act to sequester Ca2+ 
in an attempt to buffer the increased intracellular [Ca 2+ ] (Schinder et al, 1996; Budd and 
Nicholls 1996a, b; Peng and Greenamyre, 1998). If this process is sustained however it 
becomes a critical step in the initiation of excitotoxic neuronal cell death (Luetjens et al., 
2000; Rego and Oliveira, 2003). Indeed, mitochondrial C2+-overload leads to 
uncoupling of electron transfer from ATP synthesis, creating a cellular energy crisis 
(Beatrice et al, 1980; Gunter and Pfeiffer, 1990; Bernardi et al, 1994). At the same time, 
impaired mitochondrial energy metabolism leads to increased generation of reactive 
oxygen species (ROS) including superoxide anion (Dykens, 1994) indeed, in vitro 
mitochondria generate ROS during NMDAR over-activation (Lafon-Cazal et al, 1993; 
Dugan et al, 1995; Reynolds and Hastings, 1995). Furthermore, mitochondrial Ca2+- 
overload produces mitochondrial depolarisation and loss of the mitochondrial 
membrane potential (AT), which results in opening of the mitochondrial permeability 
transition pore (mPTP) and release of apoptosis inducing factor (AIF) and cytochrome c 
into the cytosol, leading to activation of the mitochondrial cell death pathway (Schinder 
et al, 1996; Leutjens et al, 2000; Nicholls and Ward, 2000). These intersecting pathways 
are illustrated in Figure 1.9A and C. 
Therefore, in cells with a pre-existing mitochondrial dysfunction or one caused 
by another pathogenic mechanism such as oxidative stress, the energy crisis caused by 
this mitochondrial dysfunction can result in "slow excitotoxicity" whereby 
excitotoxicity can occur in the absence of elevated extracellular levels of glutarnate 
(Novelli et al, 1988; Zeewalk and Nicklas, 1991; 1992). As ATP synthesis is disrupted, 
ATP-dependent cellular processes are impaired (Beal, 1993). In particular, the activity 
of the Na+/K+-ATPase membrane pump, which is responsible for maintaining the 
neuronal membrane potential is affected, resulting in increased Na+ influx and 
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decreased K+ efflux, pushing the neuronal membrane potential towards depolarisation 
and forcing the cell to slowly depolarise (Doble, 1999). This increases the probability 
that voltage-dependent Na+ and Ca 2+ channels will open further contributing to 
depolarisation (Riepe et al, 1995). Additionally, depolarisation of the cell membrane 
leads to a removal of the voltage-dependent Mg2+ block of the NMDAR, thus allowing 
NMDAR to be activated by physiological concentrations of glutamate, potentially 
triggering the excitotoxic cascade and neuronal death (Zeewalk and Niklas, 1992; Beal, 
1998; Nicholls and Wood, 2000). This is illustrated in Figure 1.913. Additionally, 
mitochondrial dysfunction in astrocytes may result in impairment or reversal of 
glutamate uptake, thereby increasing extracellular glutamate concentrations and 
subsequently triggering excitotoxicity (see section 1.8.3.3). It is noteworthy therefore 
that nigral DA neurones exhibit a specific complex I deficiency (see Figure 1.5) in PD 
(Schapira et al, 1990) and thus may be particularly susceptible to glutarnate 
excitotoxicity. 
1.8.3.2 NMDA R signal transduction mechanisms in glutamate excitotoxicity 
In addition to, or as the result of, initochondrial dysfunction excess activation of 
NMDAR and subsequent Ca 2+ influx promotes rapid downstream signal transduction 
mediated through the PSD-95 complex, leading to activation of numerous Ca2+- 
dependent kinases including Ca2+/calmodulin dependent kinase II (CaMKII), 
phosphatases including Ca2+/calmodulain-dependent phosphatase 2B (PP2B or 
calcineurin) and importantly, neuronal nitric oxide synthase (nNOS) (Sattler et al, 1999; 
Holmes, 2000; Arundine and Tymianski, 2003; 2004). Indeed, nNOS and nitric oxide 
(NO) are closely linked to glutamate excitotoxicity and cell death (Dawson and 
Dawson, 1998; Beal. ) 1998; 
Sattler et al, 1999). Furthermore, nNOS is closely associated 
with NMDAR by virtue of its binding to PSD-95 through synaptic scaffold proteins, 
such that nNOS is readily activated in response to NMDAR activation, resulting in rapid 
production of NO (Dawson and Dawson, 1998; Sattler et al, 1999). 
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A: Illustration of the various interacting cellular processes which may be triggered and 
contribute to cell death following excess NMDAR activation and Ca 2+ influx into neurones 
undergoing an excitotoxic insult, defmed as "fast excitotoxicity" (Taken ftom Doble, (1999) 
Pharmacol Ther 8](3), 163-221) B: Illustration of some of the cellular mechanisms involved in 
the process of "slow excitotoxicity" whereby mitochondrial depolarisation and interrupted ATP 
synthesis allow cells to become slowly depolarised by physiological concentrations of glutamate 
and increased Na'-influx coupled with reduced K' influx, as a result of decreased Na+/K'- 
ATPase function. Additionally, ATP depletion results in an inability to maintain the Mg2' block 
of NNMAR, such that NMDAR are activated by this limited neuronal depolarisation, resulting in 
a slow, excitotoxic cell death (Taken from Doble, (1999) Pharmacol Ther 8](3), 163-221) C: 
Schematic representation of of potential pathways by which mitochondrial dysftinction could act 
as an effector of excitotoxic neuronal death. NMDAR overstimulation induces excessive Ca2+ 
influx and abnormal elevations of [Ca 2+ ]1 which is sequestered by increased mitochondrial Ca 2+ 
uptake, leading to mitochondrial depolarisation and loss of the mitochondrial membrane potential 
(AT). Additionally, Ca 2+-overload inhibits ATP synthesis further collapsing AT, which leads to 
opening of the mitochondrial permeability transition pore (mPTP), release of apoptotic mediators 
and stimulation of the mitochondrial cell death pathway as well as prompting a cellular energy 
crisis, leading to reduced ftinction of key cellular machinery, such as the Na+/K+-ATPase. 
Additionally, mitochondrial Ca 2+ uptake results in increased ROS generation. All of these 
pathways may synergise to induce neuronal death (Takenfirom Schinder et al, (1996) JNeurosci; 
16(19): 6125-6133) 
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Whilst NO is not inherently toxic to neurones (Iravani et al, 2006a), it reacts readily 
with superoxide anion ('02-) to produce the highly damaging peroxynitrite species 
(ONOO-, Beckman et al, 1990, Ischiropoulos and Beckman, 2003). Peroxynitrite is a 
powerful oxidising agent, more toxic than hydroxyl radicals, which can also react with 
protons to liberate additional hydroxyl and nitryl radicals as shown below (Przedborksi 
et al, 1992; Olanow and Tatton, 1999; Jenner, 2003a). 
NO 0 +02 
-. 
--> ONOO 
-+ H+--> ONOOH + OH" + N02* 
Thus, increased NO production may synergise with oxidative stress caused by 
mitochondrial dysfunction (see section 1.8.3.1) creating conditions permissive to 
ONOO- formation, which may then lead to cell death by the pathways illustrated in 
Figure 1.4. 
Additionally, activation of Ca 2+ -dependent proteases including the cysteine 
protease calpain is critical to excitotoxic damage (Raynaud and Marcilhac, 2006). 
Indeed, activated calpain cleaves the membrane Na+/Ca 2+ -exchange pump (Bano et al, 
2005) resulting in a lethal Ca 2+ overload as the cells natural defence against Caý+ influx 
is destroyed (Bano et al, 2005; Choi, 2005). Calpain may also indirectly potentiate 
NMDAR activity by cleaving PKC or CaMKII to produce constitutively active forms of 
these enzymes (Wu et al, 2004) and promote apoptosis by cleavage of the pro-apoptotic 
proteins Bid and Bax resulting in release of cytochrome c and AlF from mitochondria 
(Gao and Dou, 2000; Polster et al, 2005). 
Furthermore,, activation of Ca 2+-dependent kinases will modify the 
phosphorylation state of proteins leading to deleterious potentiation of function or 
disruption of normal function (Doble, 1999). Indeed, activation of CaMKII resulting 
from NMDAR over-activation may result in phosphorylation of the NMDAR, 
potentiating its activity (Wu et al, 2006). Signalling through CAMKII also activates a 
plethora of intracellular signalling pathways via activation of the Mitogen Activated 
Protein Kinase (MAPK) signalling cascade (Waxman and Lynch, 2005). Signalling 
through MAPK results in activation of extracellular related kinase (ERK) 1/2 (Li et al, 
2006), Stress Activated Protein Kinase (SAPK or p38 kinase) (Segura-Torres et al, 
2006) and c-Jun N-terminal kinase (JNK; Centeno et al, 2006), all of which regulate 
gene transcription and apoptotic cell death pathways (Johnson and Lapadat, 2002; 
Centeno et al, 2006; Segura-Torres et al, 2006). Furthermore, activation of CaMKII 
inhibits the Synaptic GTPase-Activating Protein (SynGAP), allowing downstream 
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activation of Ras (Chen et al, 1998; Kim et al, 1998), resulting in phosphorylation of 
ERK1/2 and increased trafficking of AMPA receptors to the cell surface, which could 
potentiate excitotoxicity by maintaining cellular depolarisation allowing prolonged 
NMDAR activation (Waxman and Lynch, 2005). 
1.8.3.3 Glial cells and glutamate excitotoxicity 
Glial cells, comprised of astrocytes and microglia constitute more than 90% of the total 
cell population in the adult brain (McGeer and McGeer, 1997). In the normal brain, 
astrocytes provide trophic support to neurones and regulate the homeostatic control of 
the neuronal. extracellular environment (Anderson and Swanson, 2000; Chen and 
Swanson, 2003). Microglial cells on the other hand act as "sensors" of the neuronal 
environment and mediate brain immune responses to injury or trauma (Nakanishi, 2003; 
van Rossum. and Hanisch, 2004). Indeed, following neuronal. injury in the CNS, 
microglia respond rapidly, characterised. by rapid cell proliferation, migration to the site 
of the injury and undergo changes in morphology, phenotype and secretory activity 
(Vila et al, 2001; Teismann et al, 2003). Astrocytes also undergo similar changes, 
characterised by hyperplasia and hypertrophy of cell bodies and processes, increased 
expression of the intermediate filament protein glial. fibrillary acidic protein (GFAP) 
and migration and proliferation into the injured area (Kohutnicka et al, 1998; Vila et al, 
2001). Indeed, in both experimental models of parkinsonism and post-mortern brain 
tissue from sporadic PD patients, there is evidence documenting significant reactive 
microgliosis (Akiyama and McGeer, 1989; Kohutnicka et al, 1998; Cicchetti et al, 2002; 
McGeer et al., 2003; Depino et al, 2003) and to a lesser extent astrocytosis (Kohutnicka 
et al, 1998; Vila et al, 2001; McGeer et al, 2003). 
Interestingly, the pathological changes that are associated with neuronal death in 
PD may not be limited to neurones (Jenner and Olanow, 2006). Indeed, the magnitude 
of the changes in several biochemical parameters measured in nigral homogenates from 
PD post-mortem brain tissue, in particular the increases in nigral iron content (Dexter et 
al. 1991; 1992; 1993) the depletion of reduced glutathione (GSH; Sian et al, 1994a), and 
mitochondrial complex I deficiency (Schapira et al, 1990) are generally in the region of 
30-40% (Jenner and Olanow, 2006). However, in the SNc only 1-2% of the total cell 
population are DA neurones, whilst glial cells are by far the more common cell type 
(McNaught and Jenner, 1999). Thus, a more prudent explanation for the magnitude of 
these biochemical changes is that they are occurring simultaneously in both DA 
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neurones and glial cells in the nigra (McNaught and Jenner, 1999). This is supported by 
the observation of a-synuclein-positive GCIs in parkinsonian conditions such as MSA, 
suggestive of impaired protein handling in glial. cells (Kato et al, 1991; Papp and 
Lantos, 1992; Wakabayashi et al, 1996; 2000). 
Therefore, pathogenic mechanisms implicated in neuronal cell death in PD may 
also induce glial cell death or dysfunction, which indirectly, may cause neuronal death 
as a result of altered glial cell function (McNaught and Jenner, 1999). Thus, activated or 
dysfunctional glial cells may contribute to the pathogenesis of PD (Jenner and Olanow, 
2006). In support of this concept, activation of both microglia and astrocytes by the 
bacterial endotoxin lipopolysaccharide (LPS) in vitro, results in increased release of 
glutamate, NO, H202, oxygen radicals and cytokines (McNaught and Jenner, 1999; 
McNaught and Jenner, 2000a, b) which may lead to neuronal death by oxidative stress 
and, excitotoxicity. particularly since nigral DA neurones may be sensitive to even 
small increases in glutamate release (McNaught and Jenner, 2000a, b; Beal, 1998). 
Furthermore, culturing activated glial cells with primary ventral mesencephalic cultures 
results in selective DA cell loss (McNaught and Jenner, 1999; Iravani et al, 2002). 
Moreover, a supranigral injection of LPS results in glial cell activation and selective DA 
neurone degeneration in the rodent SNc in vivo (Iravani et al, 2005b). 
Importantly, glial cell dysfunction may be an additional source of glutarnate 
toxicity in PD. Indeed, glial cells in both grey and white matter in the CNS express 
functional glutamate receptors of both the iGluR and mGluR subtype (Verkhratsky and 
Steinhauser, 2000; Belachew and Gallo, 2004). Furthermore, activation of iGluR on 
glial cells by glutamate results in physiological regulation of astroglial and microglial 
function, (Verkhratsky and Steinhauser, 2000; Seifert and Steinhauser, 2001). This 
includes Ca 2+ influx similar to that observed in neurones, which is coupled to a large 
number of effector systems including release of neurotransmitters and the modulation of 
neurotransmission, particularly so for glutamate (Volterra and Steinhauser, 2004). 
Interestingly, these receptors have the same basic properties as neuronal glutarnate 
receptors, but importantly they are edited to a lesser extent, (Matute et al, 1999; 2006). 
This is critical since it renders glial cell iGluR potentially more permeable to Caý+ entry 
(Burnashev et al, 1995; 1996), which may have implications under pathological 
conditions of glutamate release. Indeed, plastic changes in iGluR composition are 
known to occur in neurones subjected to intense electrical activity, including 
incorporation of the AMPAR GluR2 subunit into pre-existing receptors on the cell 
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surface rendering them impermeable to Ca 2+ , which is interpreted as a protective 
functional switch against excitotoxicity (Liu and Cull-Candy, 2000). It is not yet known 
if glial. cells undergo similar regulatory mechanisms, but interestingly in response to 
ischaernia, the expression of iGluR in astrocytes and de novo expression of these 
receptors in microglia is altered, suggesting that perhaps these cells do undergo similar 
regulatory changes in response to intense glutamatergic synaptic activity, which may 
explain in part why glial cells are less susceptible to glutamate toxicity (Gottlieb and 
Matute, 1997; Matute et al, 2002; Krebs et al, 2003). 
Thus, one may speculate that pathological increases in glutamate in the SNc may 
not kill astroglial cells but instead, this may induce a lasting dysfunction of these cells 
such that their normal functions are impaired. Oxidative stress in the nigra may also 
impair glial cell function rather than induce cytotoxicity as astrocytes have more robust 
anti-oxidant defences than neurones. Indeed, most brain GSH is present in glial cells 
(Sagara et al, 1993). Furthermore, the activity of both superoxide dismutase (SOD) and 
mitochondrial complex I are significantly higher in astrocytes rather than neurones 
(Savolamen et al, 1978; Stewart et al, 1998). Taken together, therefore, pathogenic 
mechanisms implicated in PD may result in profound astroglial. dysfunction in the nigra 
as well as induced neuronal loss. 
This glial cell dysfunction may be particularly relevant to glutamate toxicity as 
astrocytes express numerous glutamate transporter proteins (GluTs) and play a critical 
role in glutamate homeostasis at excitatory synapses (Danbolt, 2001; Matute et al., 
2006). Indeed, 90% of all synaptically released glutamate is taken up by astrocytes 
where it is exported back to neurones via the glutamine-glutamate cycle (Anderson and 
Swanson, 2000). To date, five GluTs have been cloned and characterised, which are 
expressed differentially in both neurones and glia as illustrated in Table 1.6 (Danbolt, 
2001). Thus, any defects in astroglial-mediated glutamate homeostasis would be 
predicted to have deleterious consequences, including initiation of excitotoxicity. 
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Cell population Transporter protein Properties References 
Neurones GLT (EAAT2), EAAT3 Glutamate uptake (CNS 
Rothstein et a], 1994, 
Conti et al 1998; and 4 wide) , Gegelashvilli et al, 2000 
Danbolt et al, 1992; 
Astrocytes GLT (EAAT2), GLAST Glutamate uptake (CNS Zhou and Kimelberg, 
(EAAT I), EAAT3 and 4 wide) 200 1; 
Matthias et al, 2003 
Nakajima et al, 2001 
Activated micro! zlia 
GLT (EAAT2), GLAST Glutarnate scavenger 
Vallat-Decouvelaere et 
(EAATI) al, 2003, 
Chretien et al, (2004) 
Table 1.6 Patterns of expression of glutamate transporter proteins (GluTs) in 
Neurones and glial cells in the adult CNS (adapted ftom Danbolt, (2001) Prog 
Neurobiol; 65(l). -I-105 and Matute et al, (2006) Glia; 53(2). -212-24) 
In support of this concept, NO inhibits mitochondrial respiration in cultured astrocytes 
at the level of complex IV, resulting in a rapid, time-dependent release of glutarnate 
from rat brain synaptosomes (McNaught and Brown, 1997; 1998). Furthermore, NO is 
suggested to inhibit the activity of mitochondrial complex II and III, which has been 
linked to increased glutamate release in vivo (Beal et al, 1993; Bolanos et al, 1994). 
Additionally, mitochondrial dysfunction in astrocytes and subsequent ATP depletion 
results in impaired Na+/K+-ATPase function causing decline of the plasma membrane 
Na+ gradient. This causes a reversal of the Na+-dependent GluT proteins, resulting in 
efflux of the metabolic pool of glutamate into the extra-neuronal environment 
(McNaught and Brown, 1998; McNaught and Jenner, 2000b). Interestingly, high levels 
of H202 and ONOO- formation also impair glutaminase activity in astrocytes, therefore 
inhibiting conversion of glutamate to glutamine and increasing the available metabolic 
pool of glutamate which could efflux from astrocytes (Sorg et al, 1997; McNaught and 
Jenner, 2000b). Additionally, activated microglia also release large amounts of 
glutamate, which may contribute to neuronal toxicity (Takeuchi et al, 2005). Therefore, 
in summary, oxidative stress, mitochondrial dysfunction and glutarnate itself may result 
in damage to astroglia leading to impaired glial glutamate transport resulting in release 
of glutamate from astrocytes, which may induce excitotoxicity in DA neurones 
particularly sensitive to changes in extracellular glutamate, by virtue of their own 
mitochondrial deficiency. This may also synergise with fast excitotoxic mechanisms 
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due to impaired synaptic clearance of glutamate released from STN or PPN axon 
terminals. 
1.8.4 Glutarnate excitotoxicity and the pathogenesis of PD 
An increasing body of indirect evidence supports the concept of glutamate 
excitoxtoxicity in the pathogenesis of PD (Jenner and Olanow, 2006). Anatomical 
studies have confirmed the existence of excitatory synaptic connections between the 
STN, PPN and SNc (see section 1.5). Furthermore, substantial laboratory evidence 
exists to confirm these structures and their output pathways are hyperactive in PD. 
Indeed, it has been clearly demonstrated that both the STN and PPN show increased 
metabolic activity under conditions of DA depletion in experimental models of PD 
(Porter et al, 1994; Vila et al, 1996; 1997; 2000; Nakao et al, 1998; Orieux et al, 2000a; 
Armentero et al, 2005; Oueslati et al, 2005). Consistent with these data, 
electrophysiological evidence has demonstrated both an increase in the firing rate and 
the generation of aberrant burst firing patterns in the STN and PPN in response to DA 
depletion in both experimental models of PD (Albin et al, 1989; DeLong, 1990; Hassani 
et al, 1996; Burbaud et al, 1999; Benazzouz et al, 2000; Hirsch et al, 2000; Breit et al, 
2001; 2005; Jeon et al, 2003; Chang et al, 2006). Importantly this is also apparent from 
intraoperative recordings from PD patients undergoing DBS neurosurgery (Hutchison et 
al, 1998; Benazzouz et al, 2002). 
Importantly, DA neurones in the SNc express both NMDA and AMPA receptors 
as well as Group I mGluR (Mereu et al, 1991; Christoffersen and Meltzer, 1995; Gotz et 
al, 1997; Chatha et al, 2000; Ravenscroft and Brotchie, 2001) and degenerate both in 
vitro and in vivo when exposed to excitotoxins such as glutamate or NMDA (Mateu et 
al, 1997; Zhang et al, 1998; Miranda et al, 1999). Interestingly, nigral DA neurones 
appear to express the NRI-NR2A/B subtype of NMDAR, which in vitro is associated 
with greater sensitivity to excitotoxicity (Chatha et al, 2000; Lynch and Guttmann, 
2001; 2002). It is also noteworthy that the expression of both iGluR and mGluR is 
altered in the SNc in experimental models of I'D (Betarbet et al, 2000a; Mandel et al, 
2000; Messenger et al, 2002; Kaneda et al, 2003; 2005). Additionally, in post-mortem 
PD brain tissue radioligand binding to NMDAR is reduced in the SNc of PD cases 
compared to age-matched controls (Difazio et al, 1992). These data confirm these 
receptors are located on vulnerable neuronal populations in PD that are exposed to 
increasing concentrations of glutamate from STN or PPN axon terminals or as a result 
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of glial cell dysfunction and may reflect a compensatory mechanism to increased 
glutamate transmission (Kaneda et al, 2005). Equally however, this may simply be a 
reflection of nigral cell loss (Messenger et al, 2002). 
Furthermore, increased 3-NT staining is observed in the SNc in post-mortem PD 
tissue which is perhaps suggestive of glutamate mediated NO-toxicity (Good et al, 
1998). Moreover, the expression of vesicular glutamate transporters (VGLUT) I and 2 
are significantly upregulated in the putamen of PD patients, whilst VGLUTI/2 
expression was significantly downregulated in the prefrontal and temporal cortex of PD 
patients, compared to age-matched controls (Kashani et al, 2006). These are consistent 
with reports, which show that the glutarnatergic cortico-striatal pathway is overactive in 
PD (Calabresi et al, 1993) and that glutamate release in increased in the putamen in 
response to DA depletion (Lindefors and Ungerstedt, 1990). Surprisingly, no changes 
were observed in the STN or globus pallidus, although this could be related to 
methodological problems and warrants further investigation (Kashani et al, 2006). 
Importantly, the authors did not investigate the expression levels of VGLUTs in the 
SNc, which would be interesting, particularly with respect to possible dsyregulation of 
astroglial glutamate transport. These findings are consistent with alterations in VGLUT 
expression in experimental models of PD (Araki et al, 2000; Dervan et al, 2004). Taken 
together, these findings are perhaps indicative of a role for deregulated glutarnate 
neurotransmission in PD pathogenesis. 
In further support of glutamate excitotoxicity in PD, the results of numerous 
studies have demonstrated that reducing excitatory drive from the STN or PPN onto 
midbrain DA neurones by surgical lesioning results in neuroprotection of the 
nigrostriatal system in experimental models (see section 1.5.4.5) Interestingly, this 
correlates with a reduction in the number of nigral cells expressing c-Jun and 
phosphorylated c-Jun, both classical markers of apoptosis (Winter et al, 2006). 
Similarly, STN-DBS in experimental models of PD produces dramatic amelioration of 
parkinsonian symptoms as observed in humans (see section 1.7.3), which in the 
experimental models correlated with a neuroprotective effect on the nigrostriatal system 
compared to non-stimulated lesioned animals (Darbaky et al, 2003; Maesawa et al, 
2004). Additionally, pharmacological blockade of NMDAR is similarly neuroprotective 
in experimental models of PD (Klockgether and Turski, 1990; Turski et al, 1991; 
Zuddas et al, 1992; Srivastava et al, 1993; Vaglini et al, 1994; Sonsalla et al, 1998; 
Blandini et al, 2001b). Taking all of these findings into account provides compelling, 
albeit indirect evidence to suggest that as a secondary glutamate excitotoxicity may be a 
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contributory factor in the pathogenesis of PD, downstream of the DA depletion in the 
putamen. 
1.9 Anti-glutamatergic drugs for the treatment of Parkinson's 
disease 
The progressive clarification of the pathophysiology of PD have clearly established that 
DA depletion in the putamen results in significant increases in glutarnate transmission at 
corticostriatal synapses, but also from STN and PPN output pathways (see section 1.5). 
Importantly, glutarnatergic and DA neurotransmission functionally interact in the BG, 
particularly at the level of the striatum (Morari et al, 1998; Blandini et al, 2000; Bustos 
et al, 2004). Indeed, the release of glutamate is enhanced in the striaturn following 
striatal DA depletion or a chronic DA D2-like receptor blockade (Calabresi et al, 1993; 
Yamamoto and Cooperman, 1994). Furthermore, in rodents bearing a unilateral 
nigrostriatal lesion, blockade of NMDAR by 5S, 1 OR)-(+)-5-Methyl- 10,11 -dihydro-5H- 
dibenzo[a, d]cyclohepten-5,10-imine maleate (MK-801) results in potentiation of 
circling behaviour and increased striatal c-Fos expression induced by DA DI-like 
receptor stimulation (Morelli et al, 1994; 1996; 1997). Similarly, stimulation of Group I 
mGluR in the striaturn in rodents elicits a contralateral turning behaviour which is likely 
due to increased release of striatal DA (Kaatz and Albin, 1995; Kearney et al, 1997; 
1998). Thus, modifications in DA tone in the striaturn causes changes in downstream 
glutamate transmission through striatal output pathways. 
Accordingly, in both 6-OHDA lesioned rats and MPTP-lesioned primates' 
significant increases in glutamate transmission at corticostriatal synapses and from STN 
and PPN output pathways is observed (Calabresi et al, 1993; Greenamyre, 2001; 
Gubellini et al, 2002), which correlates with the manifestation of parkinsonian 
symptoms in these models (Greenamyre, 2001). Indeed, stimulation of glutarnatergic 
pathways in the BG by microinjection of NMDAR/AMPAR agonists into the striaturn, 
GPi, STN and SNr induces parkinsonian-like muscle-rigidity and akinesia in rodents 
(Klockgether and Turski, 1993). Therefore it may suggested that pathological synaptic 
plasticity at corticostriatal synapses along with increases in the activity of STN and PPN 
output pathways represents the cellular basis of PD motor symptoms (see section 1.5) 
(Gubellini et al, 2004). Critically, these pathological increases in glutamate transmission 
may also potentiate nigral degeneration through excitotoxicity (see section 1.8.4) 
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In support of this concept, STN or PPN-DBS that normalises the activity of 
these structures correlates with a remarkable amelioration of parkinsonian symptoms in 
experimental models of PD and humans (see section 1.5.2). Although the mechanism by 
which DBS produce this effect are under debate (Breit et al, 2004), it is possible these 
effects are due to correction of abnormal excitatory output from these nuclei (see 
section 1.5). Therefore, pharmacological manipulation of glutamatergic 
neurotransmission, particularly at the level of the striaturn STN (or PPN), may represent 
a useful tool to reduce the hyperactivity of the BG projection nuclei, thereby leading to 
an improvement in I'D symptoms (Blandini et al, 2000). In this way, it would be 
possible to pharmacologically mimic the beneficial effects of neurosurgical procedures 
such as DBS. Clearly, a pharmacological means of mimicking such procedures would 
be of benefit, as this would not be associated with the risks and costs of neurosurgery 
(see section 1.7.3). 
Importantly, if one considers the increasing evidence that hyperactivity of these 
pathways also contributes to the pathogenesis of PD, by aggravating nigrostriatal 
degeneration though excitotoxicity (see section 1.5.4.5 and 1.8.3), it logically ensues 
that drugs which are capable of antagonising the effects of glutamate may have a 
beneficial effect as a non-dopaminergic PD therapy, which importantly may have both a 
symptomatic and a neuroprotective benefit, which could delay the need for DA 
replacement therapy in PD patients or potentiate the action of DA mimetic drugs 
Olanow and Jankovic, 2005). Importantly, as the striatal system is bypassed would be 
predicted not to be associated with the severe motor complications seen with DA 
therapies (see section 1.7.1). 
1.9.1 Symptomatic treatment 
In support of this concept, the results of several studies suggest that pharmacological 
antagonism of glutamate transmission by microinjection of NMDA or AMPA receptor 
antagonists into the striatum, STN, GPi or SNr or systemic administration, results in 
dramatic anti -parkinsoni an effects in experimental models of PD (Klockgether and 
Turski, 1990; Klockgether et al, 1991; Loschmann et al. 1991; Wullner et al, 1992; 
Hallet and Standaert, 2004). Interestingly, the antiparkinsonian action of NMDAR 
antagonists appears to show similar or better responses than L-DOPA alone 
(Greenamyre et al, 1994). Moreover, both NMDA and AMPA antagonists have been 
demonstrated to correct the increases in metabolic activity of STN neurones in vivo as 
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measured by CO-I levels and GAD mRNA levels, suggestive of a normalisation of the 
output of these nuclei as observed following DBS (Blandini et al, 2001). 
Importantly, abnormal glutamate activity, particularly in the striatum, may 
underlie the development of LIDs (Brotchie, 2005). In the striaturn, NMDAR and DA 
DI-like receptors form an oligomeric complex to regulate the strength of corticostriatal. 
transmission (Brotchie, 2005) and this interaction also appears to regulate the trafficking 
and insertion of NMDAR into the postsynaptic membrane (Dunah et al, 2003; 2004). 
Interestingly, in rodent and primate experimental models of DA depletion results in a 
specific reduction in the protein abundance of NRI and NR213 subunits in striatal. 
synaptosomal membrane fractions, suggesting a selective reduction of NMDAR 
complexes composed of NRl/NR2B (Dunah et al, 2000; Betarbet et al, 2004). 
Importantly, similar alterations in NMDAR subunits occur in dyskinetic MPTP-lesioned 
primates (Hurley et al, 2005; Hallet et al, 2005; Fiorentini et al, 2006). This 
downregulation may represent a functional compensation to overactive cortico-striatal 
input (Hallet et al, 2005). 
Interestingly, the total levels of DA DI-like/NMDAR complexes in these 
animals are not reduced, suggesting that the selective decreases observed are a 
reflection of altered receptor trafficking (Fiorentini et al, 2006). In support of this, 
trafficking of NMDAR in vitro and in vivo in the striaturn is dependent on co-activation 
of DA DI-like and NMDAR (Dunah and Standaert, 2003; Fiorentini et al, 2006). These 
data suggest development of LIDs may be due to agonist-mediated changes in NMDAR 
subunit composition at the post-synaptic membrane from NRl/NR2B to NRl/NR2A 
containing NMDAR. 
Thus , in the "normal" state NMDA receptors are composed of 
heterodimeric 
NRl/NR2A and NRl/NR2B receptors (Dunah and Standaert, 2003). Following DA 
depletion in the "parkinsonian" state, the number of NRl/NR2B heterodimeric 
receptors is selectively reduced, resulting in a relative enrichment of NMDAR 
containing NR2A subunits (Hallet et al, 2005). Interestingly, in these animals, chronic 
L-DOPA treatment reverses this phenomenon, but also causes hyperphosphorylation of 
both NR2A and NR213 subunits (Dunah et al, 2000). Thus, in dyskinetic animals, there 
is a normalisation of NMDAR composed of NRI and NR213 subunits and an increase in 
NMDAR containing NR2A subunits (Hallet et al, 2005). Thus, increases in NR2A- 
containing NMDAR may bring about important changes to NMDA receptor-mediated 
signalling to induce dyskinesia (Hallet et al, 2005). 
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In support of this concept, non-subtype selective NMDAR antagonists such as 
amantadine and dextromethorphan are effective at reducing LID onset and severity, 
alone or in combination with L-DOPA (Papa and Chase, 1996; Blanchet et al. 1998; 
Hill et al, 2004). Furthermore, blockade of both NMDAR by amantadine is synergises 
with L-DOPA to produce a greater anti-dyskineitc effect than either L-DOPA or 
amantadine alone, suggesting iGluR subtypes contribute to the development of 
dyskinesia (Bibbiani et al, 2005). 
Taken together, these findings provide solid experimental evidence exists to 
suggest a potential symptomatic benefit of anti -glutamatergic drugs in PD. 
1.9.2 Neuroprotection 
The view that indirect glutamate excitotoxicity may also contribute to nigral 
degeneration in PD (see section 1.8.4) is further supported by the findings of several in 
vivo studies which have demonstrated that pharmacological blockade of NMDAR 
activity by intranigral, intrastriatal, intracerebroventricular or systemic administration of 
non-competitive, non-subtype selective NMDAR antagonists, such as MK-801 prevent 
nigral cell death caused by either MPTP or 6-OHDA in both rodents and non-human 
primates, implying neuroprotection against glutamate excitotoxicity (see section 1.8.4). 
Thus, solid laboratory evidence exists to suggest that by pharmacologically 
manipulating glutainate transmission onto midbrain DA neurones it may be possible to 
slow the disease progression by neuroprotection as well as providing a symptomatic 
benefit. 
1.9.3 Clinical li-aitations of targeting lonotropic glutamate receptors 
In the CNS, physiological NMDAR activity is essential for neuronal and brain functions 
controlled by glutamate (Cull-Candy et al, 2001). Thus, NMDAR antagonists that are 
non-competitive and result in ion channel block, or competitive NMDAR antagonists 
that act at the LIlutamate binding site on the NRI subunit, are likely to result in global 
inhibition of total NMDAR activity in the brain, thus leading to numerous and severe 
extra-pyramidal effects (Montastruc et al, 1992; Muir and Lees, 1995; Lee et al, 1999). 
In particular, pyschotornimetic effects including hallucinations, agitation, peripheral 
sensory disturbance and catatonia have been described, as well as nausea and vomiting 
(Muir and Lees, 1995; Lee et al, 1999). Non-selective NMDAR antagonists are also 
sympathomimetic and increase blood pressure (Muir and Lees, 1995). Thus, the CNS- 
side effects of these compounds limit the dose that may be administered in humans, 
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producing a n:, tcrow therapeutic index and limited efficacy (Montastruc et al, 1992). 
Importantly, Such non-competitive NMDAR antagonists were actually shown to 
enhance parkinsonian symptoms in MPTP-primates with advanced parkinsonian 
symptoms (Fox et al, 2006), further limiting the potential use of such compounds. 
Therefore., despite the efficacy of iGluR antagonists as symptomatic and 
neuroprotective agents in experimental models of PD, they are unlikely to enter the 
clinic (Muir, 2006). 
However, recent advances in the identification of the structure and regulation of 
NMDAR acti\-Ity have produced a renaissance in targeting iGluR in neurodegenerative 
disease (Chen _i'id Lipton, 2006). In particular, antagonists which are selective for the 
NR213 subunit, SUch as Ifenprodil have been proposed as potential new symptomatic 
treatments for PD and have shown good anti-parkinsonian and anti-dyskinetic efficacy 
in animal models when administered with L-DOPA (Nash et al, 2000; Loschmann et al, 
2004; Gogas, 2oG6) whilst other NR213 selective antagonists such as Traxoprodil and 
besonprodil are currently in phase I clinical trials (Muir, 2006). 
Interesti, ioly, memantine (Namenda TM )a derivative of the non-competitive zn 
inhibitor amaivadine appears to preferentially block excess NMDAR activity without 
disrupting nomi-il function (Chen and Lipton, 2006). Thus, this compound has become 
the first clinicý,, '. ý, ' tolerable NMDAR antagonist to be used as a treatment for cognitive 
decline in Alzi,. eliner's disease (Moreira et al, 2006). However, testing of memantine 
has revealed ii, cffect on LIDs in PD patients in a preliminary study (Merello et al, 
1999). Selectl\, -, NMDAR antagonists are also predicted to be neuroprotective in 
experimental ii-)ciel of stroke and traumatic brain injury (Gogas, 2006), although no 
evidence exisi, ) o for a neuroprotective action in models of neurodegenerative 
disorders. lm, )ortantly, NR2B antagonists have also exacerbated parkinsonian 
symptoms in exl', -rimental models, including dyskinesia when given alone (Nash et al, 
2004 Fox et al. 2006). 
Thus &. Tý . te these recent advances, blockade of iGluR as an anti-glutamatergic 
drug strategy --ýinains problematic and to date clinical data is inconclusive. These 
finding sugges. tiiat instead a drug target, which modulates neuronal function rather 
than directly .. iediating it, may 
be a more appropriate and subtle method to 
pharmacologicLi., 
-ý' 
interfere with glutamate transmission in PD. In this respect, recent 
attention has s,. At,. -, d to the role of metabotropic glutamate receptors in the BG nuclei in 
PD (Nicolettl, L, ý. al, 1996; Marino et al, 2003a; Conn et al, 2005). 
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1.10 Meta',,, )tropic glutamate receptors 
Metabotropic 
_ýý'Utamate receptors are GPCRs which transmit extracellular signals by 
coupling to an-i activating heterotrimeric guanine triphosphate (GTP) binding proteins 
consisting of a aiiJ P7 subunits (Pin and Duvoisin, 1995). Glutamate binding to mGluR 
stimulates of bound guanosine diphosphate (GDP) in the (I subunit for 
GTP, which al',, I)ws the P7 subunit dimer to dissociate from the a subunit and regulate 
the activity of membrane enzymes and ion channels involved in signal transduction 
mechanisms (P I ii and Duviosin, 1995; Pin and Archer, 2002). 
All GPCR have a common structural domain comprised of 7 transmembrane 
JM) a-helices, (tlie heptahelical domain, HD), with the N and C-termini extracellular 
and intracellLt'; _: -, respectively (Spooren et al, 2003; Pin et al, 2003). The N-terminus 
contains the binding domain, whilst the C-terminal domain is critical for 
coupling to C-9r,, teins and interactions with signal transduction proteins (Pin et al, 
2003). Thes- tural features and the typical effector systems of mGluR are 
illustrated in 1.1 OA and B. 
In three GPCR families exist. Family one is comprised of rhodopsin 
and related including DA receptors, whilst family two consist of peptide 
activated rec.:, _, ors 
(Hermans and Challis, 2001). Metabotropic glutamate receptors 
'ý L of the family three (class Q heptahelical GPCR and do not share (mGluR) f6i'm 
any sequencl-, '.., )mology with rhodopsin-like GPCR (Pin et al, 2003). GPCRs activated 
by glutani,. - first identified as phospholipase C (PLC)-coupled receptors 
(Sladeczek e, . 985; Nicoletti et al, 1986; 
Sugiyama et al, 1987) and mGluRla was 
the first to (Houamed et al, 199 1; Masu et al, 199 1). Based on this sequence, 
to date, ei(_, ý!, t of mGluR have been cloned and are classified into three groups, 
based on . -.. L, -ience 
homology, pharmacological properties and signal transduction 
pathways as \I 'Ain Table 1.7 (Conn and Pin, 1997). 
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Propet- cýý Group I Group 11 Group III 
mGIuR4 
Subt\; ý,, mGIuR1 mGluR2 mG1uR6 mGluR5 mG1uR3 mGIuR7 
mGIuR8 
G-protLý*, n 
Gq5 G, (mGIuRI) Gi Gi, Gt (mGIuR6) 
Signal transduc C)II PPI hydrolysis cAMP cAMP 
path\, 
L-AP4 > 
Quisqualate > DCG-IV > CPAP4 (mGlu4) > 
3,5-DHPG > L-CCG-I > L-SOP > 
Glutarnate > 2R, 4R-APDC > Glutamate > 
A om , s 
IS, 3R-ACPD Glutarnate > L-CCG-I (mGlu4) > 
g , - lbotenate > IS, 3 S-ACPD IS, 3 S-ACPD > 
L-CCG-I > IS, 3 R-ACPD > IS, 3R-ACPD 
3-HPG > 4C3HPG (mGlu2) > 
t-ADA lbotenate 
LY')67. ')'85 (mGlul) 
MPEP (mGlu5) MCPG 
CPCCOEt (mGlu 1) MPPG 
MCPG MSPG MPPG, 
Antagoms's 4CPG MTPG MAN 
4C3HPG MCCG-I 
AIDC 2S, 4S- ADPD 
7HCCMA PCCG-IV 
ABHD-l 
Table 1.7 C., as, ý,: -', cation and properties of 
the metabotropic family of glutamate 
ý'NS receptors i.. -, I- 
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A 
NH, 
N-terminal 
extracellular 
ligand-binding 
domain 
Cysteme-rich domain 
7TM domain 
Intracellular 
C-tenrninal domain 
0 oooo--, ý, - 0 0000 P- 
Competitive 
agonists, or antagonists 
0 
("ý, 
-COOH 
Noncompetitive 
antagonists 
i RENDS m PharmaooiogicaoSciences 
B Melabotropic, receptors, 
Group I Group 11 + Group III 
mGlul. 5 mGlLj2,3 + t-nGlu4.6,7.8 
lonotropic, rtýceplc)rs 
NMDA. AMPA, 
Kainate 
Figure 1.10 
A: Functional domains, membrane topology and structure of a typical mGluR receptor 
monomer (takenfirom Spooren et al, (2003) Behav PharmacoL 14 (4): 257-77 
B: Glutamate receptors and their effector systems (takenfrom Spooren et al, (2003) Behav 
PharmacoL 14 (4): 257-77 
-80- 
s. vu, . _flI,,, 
1.10.1 The Group I metabotropic glutamate receptors 
Group I mGluR consist of mGluR1 and 5, which are coupled to Gq-proteins although 
may also activate other G-proteins including G, and Gi/O (Aramori and Nakanishi, 1992; 
Francesconi and Duvoisin, 2000). In Xenopus Oocytes and native systems in vitro 
Group I mGluR are positively coupled via Gq proteins to phospholipase C (PLC) and 
phosphoinositide (PI) hydrolysis (Pin et al 1992; Schoepp and Conn, 1993; Schoepp et 
al, 1994; Toms et al, 1995). Activation of Group I mGluR leads to PLC-mediated 
increases in intracellular Ca 2+ by release from intracellular stores through the inositol 
1,4,5-trisphosphate (IP3) pathway (Crawford et al, 2000; Nakamura et al, 2000; 
Morikawa et al, 2003), which also stimulates protein kinase C (PKQ activity (Pizzi et 
al, 1996). Activation of Group I mGluR also potentiates L-type VGCCs; Choi and 
Lovinger, 1996; Bianchi et al, 1999) and inhibits K+ conductances (Stefani et al, 1994; 
1998; Hay and Lindsley, 1995). Group I mGluR may also activate intracellular signals 
independently of G-proteins by direct activation of the tyrosine kinase, Src (Heuss et al, 
1999). Additionally, activation of Group I mGluR leads to phospholipase A2 activity in 
cortical neuron-glial. cultures resulting in increased Arachidonic Acid (AA) release in 
cortical astrocytes (Stella et al, 1994a, b). Release of AA is a mechanism by which 
neurones may inhibit the activity of glial GluTs, thus over activation of neuronal. or glial. 
Group I mGluR may regulate glutamate uptake (Conn and Pin, 1997). 
Numerous splice variants exist for both mGluRI and 5, mGluRI has four splice 
variants a, b, c and d, of which mGluR Ib and d are the main splice variants, found in the 
brain and are characterized by heavily truncated carboxy terminal tail (Houamed et al, 
1991; Tanabe et al, 1992; Desai et al, 1995; Laurie et al, 1996). In contrast, mGluR5 has 
two splice variants a and b, which are distinguished by insertion of 32 amino acid 
residues 49 residues downstream of the 7-TM HD (Abe et al, 1992; Minakami et al, 
1994; Joly et al, 1995). Additionally, two mGluR5 transcripts exist with different 5' 
untranslated regions (UTR), which allows for differential regulation of mGluR5 in 
different cell types (Yamaguchi and Nakanishi, 1998). 
Group I mGluR are primarily localized in the postsynaptic element, around the 
post synaptic density (PSD), away from the active zone of glutamate release and 
confined to postsynaptic terminals at excitatory glutarnatergic synapses (Lujan et al 
1996; 1997; Shigemoto et al, 1997). Interestingly, some evidence exists for presynaptic 
Group I mGluR which may facilitate glutamate release (Thomas et al, 2000; 2001; Fazal 
et al, 2003). Group I mGluR localization is tightly regulated by interactions with homer 
proteins which contain a PDZ-Iike interaction domain (Brakeman et al, 1997; Xiao et al, 
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1998; Ciruela et al, 1999) which through interactions with Shank couples Group I 
mGluR to PSD-95 (Tu et al, 1999). Thus, interactions with homer specifically target and 
couple Group I mGluR to signalling complexes at the postsynaptic membrane where 
they regulate K+ and Ca 2+ VGCC activity (Kammermier et al, 2000; 2006), ryanodine 
receptor activity and thus release of intracellular Ca 2+ (Westhoff et al., 2003; Hwang et 
al, 2005). Importantly, activation of Group I mGluR also potentiate the function of 
iGluR, including NMDAR by virtue of homer clustering at the PSD (Tu et al, 1999) 
which is critical in LTP/LTD (Fujii et al, 2003; 2004; Harney et al, 2006). 
Thus taken together, it may be surmised that Group I mGluR activation is 
associated with modulation of neuronal excitation either directly, or by influencing 
NMDAR-mediated responses (Conn et al, 2005). Thus, activation of Group I mGluR 
has critical roles in postsynaptic plasticity phenomena related to learning and memory 
(see section 1.10.65), but also under pathological conditions of glutamate release may 
potentiate excitotoxicity (Nicoletti et al, 1996). 
1.10.2 The Group 11 metabotropic glutamate receptors 
Group 11 mGluR consist of mGluR2 and 3, which are coupled to Gi proteins and 
negatively regulate adenylyl cyclase (AC) activity, thereby preventing cyclic adenosine 
monophosphate (cAMP) formation (Genazzani et al, 1993; Winder and Conn 1995; 
Monn et al, 1996; Schaffhauser et al, 1997). Group II mGluR are found on both pre- and 
postsynaptic elements on both glutamatergic and GABAergic synapses at perisynaptic 
sites located away from the active zone of transmitter release (Petralia et al, 1996; 
Shigernoto et al., 1997). Thus, Group 11 mGluR appear to function as autoreceptors at 
glutarnatergic synapses and as heteroreceptors at GABAergic synapses to negatively 
modulate both glutamate (Lovinger and McCool, 1995; Battaglia et al, 1997; Attwell et 
al, 1998b; Xi et al, 2002; Wang et al, 2005) and GABA release (Salt et al, 1996; 
Schaffhauser et al, 1998b; Zhao et al, 2001). Activation of Group 11 mGluR inhibits the 
opening of L, N and P/Q-type VGCCs (Chavis et al, 1996; Perroy et al, 2000) and 
stimulates hyperpolarising K+ conductances (Saugstad et al, 1996), thus preventing Ca2+ 
and depolarization-dependent synaptic release of glutamate (Conn and Pin, 1997; 
Cartmell and Schoepp, 2000). Interestingly, the perisynaptic localization of Group II 
mGluR may facilitate this role, since it is predicted to be activated only under 
sufficiently high concentrations of extracellular glutamate that "spillover" from the 
synaptic cleft (Scanziani et al, 1997). Thus, activation of Group 11 mGluR may function 
to prevent pathological levels of glutamate accumulating in the synaptic cleft, which 
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could potentially causes excitotoxicity (Nicoletti et al, 1996; Cartmell and Schoepp, 
2000). 
1.10.3 The Group III metabotropic glutamate receptors 
The remaining mGluR (4,6,7 and 8) make up Group III mGluR, which are coupled to 
Gi/,, G-proteins and also inhibit AC activity in vitro (Schafthauser et al, 1997). However 
their primary action in neurones appears to be inhibition of VGCCs (Trombley and 
Westbrook, 1992; Stefani et al, 1996; 1998; Guo and Ikeda et al. 2005) and activation of 
K+ conductances (Schaffhauser et al, 1998b; Katayama et al, 2003). Interestingly, 
Group III mGluR appear to be localised in or near presynaptic active zones (Shigemoto 
et al, 1997), where they function to negatively modulate glutamate release in a manner 
analogous to Group 11 mGluR (Scanziani et al, 1997; Cartmell and Schoepp, 2000). 
Additionally, mGluR4 and 7 are also found on both glutarnatergic and GABAergic 
synapses, suggesting mGluR4 may also regulate GABA release (Bradley et al, 1999; 
Kosinski et al, 1999). 
By virtue of their negative modulatory role, it is noteworthy that both Group II 
and III mGluR also play critical roles in synaptic plasticity, acting to shape the strength 
of glutarnate transmission during UP to prevent postsynaptic excitotoxicity 
Furthermore, activation of Group II and III mGluR is a critical requirement for the 
induction of LTD in the hippocampus and cerebellum, (Manahan-Vaughan, 1997; 1998; 
2000; Klausnitzer et al, 2004; Poschel et al, 2005; Naie et al, 2006) 
1.10.4 Metabotropic glutamate receptor expression in glial cells 
Glial cells also express functional receptors of all three Groups of mGluR (see Table 
1.8). In situ hybridisation and immunocytochemical studies suggest that mGluR3 is the 
predominant subtype expressed in astrocytes (Testa et al, 1994; Petralia et al, 1996; 
Wroblewska et al. 1998; Aronica et al, 2000) although astrocytes also predominantly 
express mGluR5 and some expression of mGluR1 is reported in spinal cord astrocytes 
(Biber et al, 1999; Agrawal et al, 1998; Aronica et al, 2001a; 2003; 2005). Astroglial 
mGluR are localised to glial cell processes surrounding the neuronal soma, or to glial 
processes that are intimately associated with glutamatergic synapses (Chong et al, 
2003). In contrast, microglia appear to express virtually all mGluR subtypes, but again, 
mGluR5 predominates (Biber et al, 1999) although expression of Group II and III 
mGluR has also been reported (Taylor et al, 2003; 2005). 
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Cells Receptor type Properties References 
PLC activation and 
Group I mGluR release 
Ca 2+ from Biber et al, (1999), 
Astrocytes 
(mGluR5) internal stores and Aronica et al, 200 1 a; 
Pro stagl and in-mediated 2003; 2005 
glutamate release 
Astrocytes Group I and Group 11 Inhibition of CAMP 
Testa et al, 1994; 
Petralia et al 1996; mGluR (mGluR3 and5) formation , Wroblewska et al, 1998; 
Aronica et al, 2000 
Microglia 
Group I mGluR Release of Ca 2+ from B iber et a], (1999) 
(mGluR5) internal stores 
Microglia 
Group 11 mGluR TNFa release and Taylor et al, (2003) 
(mGluR2) neuronal death 
Group III mGluR Activation Gp III 
Microglia mGluR. is Taylor et al, (2005) 
(not mGluR7) neuroprotective 
Table 1.8 Glial cells in the mammalian CNS express functional glutamate 
receptors of both the ionotropic and metabotropic glutamate receptors (adapted 
ftom Matute et al, (2006) Glia; 53(2): 212-24) 
1.10.5 Regulation of mGluR function in the CNS 
The majority of studies to unravel the mechanisms by which mGluR activity is 
regulated have been performed on Group I mGluR (Dhami and Ferguson, 2006), whilst 
in contrast the mechanisms underlying Group 11 and III mGluR regulation are less 
understood (Iacovelli et al, 2004). 
1.10.5.1 Regulators of G-protein signalling (RGS) 
In the CNS, the responsiveness of GPCRs is controlled by regulation of receptor 
activity at the level of both the G-protein and the receptor. The activity of G-protein 
signalling is attenuated by a family of proteins known as Regulators of G-protein 
Signalling (RGS), which specifically recognise the a-subunit of the heterotrimeric G- 
protein (Saitoh et al, 1997). Indeed, RGS act as GTPase activating proteins (GAPs), 
which accelerate the hydrolysis of GTP by the Ga subunit as illustrated in Figure 1.11 
(Hunt et al, 1996; Watson et al, 1996) thereby, providing a physiological control of G- 
protein signalling (Dohlman and Thorner, 1997). The RGS family of proteins consists 
of over 20 isoforms and share a common core domain, although outside of this they 
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exhibit a high degree of divergence suggesting a variety of roles and functions (Koelle 
and Horvitz, 1996). In terms of the regulation of Group I mGluR function, in native and 
recombinant expression systems the RGS family members RGS2 and RGS4 have been 
demonstrated to specifically interact with Gaq/1 -like G-proteins and block Group I 
mGluR signal transduction including PLC activation and the inhibition of K+ and Ca2+ 
currents mediated by both mGluR Ia and mGluR5 (DeBlasi et al, 2001). Therefore, RGS 
proteins provide one level of control at which coupling and signal transduction of Group 
I mGluR are tightly regulated (Alagarsamy et al, 2001). 
1.10.5.2. Agonist-stimulated receptor desensitization and internalisation 
GPCRs responsiveness is also regulated at the level of the receptor through the process 
of receptor desensitization, a "feedback" mechanism which protects against both 
chronic and acute receptor overstimulation (Dhami and Ferguson, 2006). Group I 
mGluR undergo both homolgous (agonist-dependent) and heterologous (agonist- 
independent) desensitisation in response to agonist stimulation, primarily mediated 
through the action of G-protein receptor kinases (GRKs), GRK2, and 4 (Dale et al, 
2000; 2002; Dhami et al, 2002; Sallese et al, 2000; lacovelli et al, 2003) or second 
messenger-dependent kinases, in particular PKC (Herrero et al, 1994; Gereau and 
Heinemann. 1998; Francesconi and Duviosin, 2001). However, substantial evidence also 
suggests a clear role for CAMKII in this process (Mundell et al, 200 1; 2003; 2004). 
Several studies have described this phenomenon in response to agonist 
stimulation of Group I mGluR (Dhami and Ferguson, 2006). The canonical model for 
GPCR desensitisation involves G-protein receptor kinase (GRK) or second messenger 
dependent kinase-mediated phosphorylation of the C-terminus of GPCR, which 
promotes the binding of non-visual arrestins (particularly P-arrestin). These serve to 
uncouple receptors from their heterotrimeric G-proteins and target the GPCR for 
endocytosis via clathrin coated pits, by functioning as an adaptor molecule to recruit 
clathrin and 02-adaptin leading to GPCR endocytosis in a clathrin- and dynamin- 
dependent manner (Dale et al, 2000a and b; Mundell et al, 2001; 2003; 2004; Pula et al, 
2004). Once internalised, GPCR are then dephosphorylated in an endosomal 
compartment and rapidly recycled back to the cell surface or targeted for degradation 
through a lysosomal pathway (Krupnick and Benovic, 1998) as illustrated in Figure 
1.12. 
Interestingly, in vitro Group I mGluR also appear to undergo constitutive 
intemalisation, which is agonist-independent (Dale et al, 2001 a, b; Pula et al, 2004). 
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This Process appears to be independent of GRK-mediated phosphorylation and is not 
associated with agonist-induced internalisation since overexpression of GRK2 does not 
appear to reduce agoni st- independent internalisation of Group I mGluR (Dale et al, 
2001 a, b). 
In contrast to the well-characterised mechanisms underlying Group I mGluR 
desensitization and internalisation describe above studies of the desensitization and 
internalisation of Group 11 and III mGluR are limited (lacovelli et al, 2004). However, 
in vitro studies suggest a clear role for second messenger-dependent kinases (Macek et 
al, 1998; Schaffhauser et al, 2000; Cai et al, 2001) and GRKs, in particular GRK2 
(lacovelli et al, 2002; 2003; 2004) in facilitating heterologous desensitisation of Group 
11 and III mGluR in manner analogous to that for Group I mGluR (see also section 
4.4.4). However, the precise mechanisms underlying these process remain enigmatic 
and under debate. 
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Figure 1.11 The cycle of G-protein activation and inactivation by RGS 
A: When GDP is bound to the G-protein, the Ga subunit is inactive and 
associated with the Gpy complex. Agonist binding to the GPCR promotes 
guanidine nucleotide exchange, causing Ga to release GDP, bind GTP and 
dissociate from Gpy. The dissociated Ga subunit then activates target effector 
proteins leading to signal transduction. Once GTP is hydrolysed by the 
intrinsic GTPase activity of Ga, the subunits reassemble. Gpy antagonises 
GPCR action by inhibiting guanidine nucleotide exchange. RGS proteins bind 
to Ga and act as GTPase activating proteins (GAPs) to stimulate GTP 
hydrolysis and reverse G-protein activation B: The roles of the GPCR, Gpy 
and the RGS protein are analogous to the GDSs, GDls and GAPs which 
regulate small monomeric G protein function such as Ras. (GDI: guanidine 
nucleotide dissociation inhibitor, GDS: guanidine nucleotide dissociation 
stimulator) 
Schematic reproducedftom Dohlman and Thorner, (1997) JBC 272 (7): 3871- 
3874 
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I. GRK phosphorylation, G 
protein uncoupling and 
arrestin binding 
2. Adaptin binding g 
4. Recycling 
S. Lysosomal 
degradation and 
receptor 
downregUation 
Clathrin-coated pit 
3. Clathrin and dynamin 
dependent endocytosis 
Figure 1.12 Schematic to illustrate the canonical model of GPCR 
desensitization 
G protein receptor kinases (GRKs) and second messenger dependent kinases 
(not shown) phosphorylate the carboxy terminus of GPCR which promotes the 
binding of the non-visual arrestin, P-arrestin (Parr), which promotes G protein 
uncoupling and serves as an adaptor molecule to target GPCR for clathrin and 
dynamin dependent endocytosis to the endosomal compartment. GPCR are then 
dephosphorylated by association with G protein coupled receptor phosphatases 
(GRP) and either recycled back to the cell surface for a second round of 
stimulation, retained in the endosomal compartment or degraded via a 
lysosomal degradation pathway. 
Schematic adapted in part ftom Dhami and Ferguson (2006) Pharmacology 
and Therapeutics, 111: 260-2 71. 
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1.10.6 Distribution and function of mGluR in the basal ganglia 
If targeting mGluR is to be beneficial in I'D it is crucial to identify the distribution and 
functions of mGluR in the BG in both the normal and parkinsonian state (Rouse et al, 
2000). The results of several studies have demonstrated that mGluR are heavily, but 
differentially expressed throughout the BG nuclei, with the exception of mGluR6, 
which appears to be absent (Testa et al, 1994; 1998; Messenger et al, 2002). 
Furthermore, numerous in vitro electrophysiological studies with selective agonists and 
antagonists in recombinant expression models and native systems have demonstrated 
that all three mGluR subtypes play critical modulatory roles in regulating activity 
through the parallel neuronal circuits and different synapses in the BG. 
1.10.6.1 Neuronal Group I mGluR function in the BG nuclei 
Within the BG, Group I mGluR are expressed in the striatum, STN, pallidum. and both 
the SNr and SNc (Rouse et al, 2000). In the striatum, both mGluR1 and 5 are expressed 
on medium spiny GABA neurones and cholinergic intemeurones (Testa et al, 1994; 
1998; Gubellini et al, 2004). Activation of striatal mGluR5 amplifies NMDAR currents 
in both striatal MSNs and cholinergic interneurones (Pisani et al, 1997; 2001; 
Tallaksen-Greene et al, 1998; Colwell and Levine, 1999; Domenici et al, 2003; Marti et 
al. 2003). Additionally, combined activation of NMDAR and mGluR5 results in gene 
expression through rapid and transient phosphorylation of the ELKI transcription factor 
and the cAMP responsive element binding protein (CREB), due to activation of the 
MAPK pathway and inhibition of protein phosphatase (PP) I and 2A downstream of 
these receptors (Mao and Wang, 2003a, b; Choe et al, 2004). 
Interestingly, mGluR5 receptors also physically interact with DA D2-like 
receptors and adenosine A2Areceptors in the striaturn, both of which are involved in the 
regulation of the indirect pathway (Ferre et al, 1999; Turle-Lorenzo et al, 2005). 
Activation of these receptors produces synergistic interactions to promote downstream 
signalling, including MAPK activation (Ferre et al, 2002; Nishi et al, 2003), such that a 
tri-partite interaction between NMDA, A2Aand mGluR5 counteracts the effect of DA 
on striatal MSNs that form the indirect pathway (Conn et al, 2005). 
Doparninergic neurones in the SNc express both mGluRl and 5 (Testa et al, 
1994; 1998; Kosinski et al, 1998; Hubert et al, 2001). Activation of mGluRl produces 
bi-phasic responses in SNc DA neurones, which may be hyperpolarising (Fiorillo and 
Williams, 1998) or directly depolarising (Mercuri et al, 1993; Meltzer et al, 1997a; Shen 
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and Johnson, 1997-, Fiorillo and Williams, 1998). Potentially this may be due to the 
duration and or temporal nature of mGluRI activation (Marino et al, 2001). Activation 
of glutarnatergic afferents to DA neurones in the SNc results in the induction of 
inhibitory postsynaptic potentials mediated by increased in Ca2+-dependent K+ 
conductance (Fiorillo and Williams, 1998). Additionally, mGluRI is localised 
presynaptically on nigrostriatal DA fibres, which converge with corticostriatal 
glutarnatergic fibres on the dendrites of striatal MSNs (Conn et al, 2005). Thus, 
glutamate released from corticostriatal axon terminals can activate mGluRI on 
nigrostriatal axon terminals leading to a suppression of DA release in the striatum 
(Zhang and Sulzer, 2003). 
Activation of Group I mGluR also have functional effects in other BG nuclei, 
which consistent with findings in the striaturn and SNc appears to increase 
neurotransmission through the indirect pathway, counteracting the effect of DA (Rouse 
et al, 2000; Conn et al, 2005). In the GPe and SNr, activation of Group I mGluR (both 
mGluRl and 5) produces direct increases in neuronal excitability (Valenti et al, 2002; 
Poisik et al. 2003). In the GPe activation of Group I mGluR results in direct membrane 
depolarisation and inhibition of N and P/Q-type VGCCs (Stefani et al, 1996; Poisik et 
al, 2003). Interestingly, both mGluRl and 5 appear to influence Ca 2+ entry into GPe 
neurones, but only mGluRl activation results in direct depolarisation (Poisik et al, 
2003). However, pharmacological inhibition of mGluR5 potentiates the depolarisation 
induced by mGluR1 activation, perhaps by preventing cross-desensitisation between the 
two receptors (Poisik et al, 2003; Conn et al, 2005). A similar pattern is observed in the 
STN in which neurones also express both mGluR1 and 5 (Awad et al, 2000). In STN 
neurones activation of mGluR5 induces membrane depolarisation and increases burst- 
firing patterns with a clear postsynaptic mechanism of action (Awad et al, 2000). In 
contrast, activation of presynaptic mGluRl has the opposite effect and reduces 
excitatory transmission (Awad-Granko and Conn, 2001). Finally, excitatory 
transmission at subthalamonigral. synapses is modulated by mGluRl, whilst both 
mGluRl and 5 are localised on GABA nerve terminals in the SNr, where they function 
to negatively modulate GABA release (Marino et al, 2001; Wittmann et al, 2001b). 
Interestingly, in the SNc, both mGluRl and 5 are also present, but in contrast to 
mGluR1 no functional data exist for a role of mGluR5 (Valenti et al, 2002). These 
findings suggest that although Group I mGluR may be expressed in the same neuronal 
population this does not reflect a functional redundancy and these receptors may couple 
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to different signal transduction pathways and sub-serve distinct functional roles (Valenti 
et al, 2002). 
Taking all these findings together suggests that the combined actions of Group I 
mGluR in the normal brain is to counteract the action of DA on the BG neuronal circuit, 
that is, whilst DA reduces net activity through the indirect pathway, activation of Group 
I mGluR appears to promote it (Rouse et al, 2000; Conn et al, 2005). Furthermore, 
Group I mediated reductions in transmission at SNr inhibitory synapses further reduces 
activity in the direct pathway (Rouse et al, 2000; Conn et al, 2005). Additionally, 
activation of postsynaptic Group I mGluR positively modulates neuronal excitation and 
firing rate in the striaturn, STN, GPe and SNc. 
1.10.6 2 Neuronal Group H mGluR function in the BG 
Group II mGluR also play critical roles in the BG neural circuits. In the corpus striaturn, 
activation of mGluR2/3 on corticostriatal fibres negatively modulates activity through 
the corticostriatal pathway, the primary excitatory input to the BG, with a clear 
presynaptic mechanism of action (Lovinger et al, 1991; Lovinger and McCool, 1995; 
Cozzi et al, 1997; Gubellini et al, 2004). Extrasynaptic glutamate release, presumably 
from astroglia can also suppress DA release by activation of mGluR2/3 on nigrostriatal 
axon terminals (Baker et al, 2002). Importantly, excitatory projections from the striaturn 
to the SN are negatively modulated by activation of presynaptic mGluR2/3 on afferent 
axon terminals (Wigmore and Lacey, 1998). A combination of these actions in the 
normal brain could reduce the regulation of striatal function by DA (Conn et al, 2005). 
Interestingly, injection of potent mGluR2/3 agonists appears to enhance DA release in 
the striaturn (Cartmell et al, 2000), thus the role of mGluR2/3 in regulating DA function 
is unclear (Conn et al, 2005). 
Perhaps the most important function of Group 11 mGluR in the BG is the 
regulation of excitatory transmission from the STN at subthalamonigral synapses. 
Indeed, activation of presynaptic mGluR2/3 reduces excitatory drive from the STN onto 
the SNr therefore modulating BG output nuclei activity (Wigmore and Lacey, 1998; 
Bradley et al, 2000; Wittmann et al, 200 1). This suggests that mGluR2/3 activation may 
be similar to DA effects on the indirect pathway, although this effect is mediated at the 
final synapse in the indirect pathway well downstream of the effects of DA in the 
striaturn (Conn et al, 2005). Interestingly, activation of mGluR2/3 also negatively 
modulates glutamate transmission on to SNc neurones from the STN (Wigmore and 
Lacey, 1998; Katayama et al, 2003; Wang et al, 2005), which may be important in terms 
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of the reciprocal interactions between the STN and SNc to mutually regulate the activity 
of both nuclei in the normal brain. In support of this concept, activation of Group II 
mGluR has been demonstrated to inhibit excitatory transmission from STN neurones 
with a clear presynaptic mechanism of action (Shen and Johnson, 2003). 
Taken together, it may be surmised that activation of Group 11 mGluR tends to 
decrease activity through the indirect pathway and negatively modulates nigral neurone 
excitability. 
1.10.6.3 Neuronal Group III mGluR function in the BG 
Both mGluR4 and 7 are localised presynaptically in the BG motor loop and negatively 
modulate both glutamate and GABA release (Testa et al, 1994; 1998; Kosinski et al, 
1999; Wittmann et al. 2001; Corti et al, 2002; Matsui and Kita, 2003; Valenti et al, 
2003). Importantly, activation of presynaptic mGluR4 at the striatoPallidal synapse in 
the indirect pathway suppresses GABA release (Valenti et al, 2003). This is the initial 
synapse in the indirect pathway, which is under tight control by striatal DA tone and 
nigrostriatal pathway function (Conn et al, 2005). Importantly therefore, activation of 
mGluR4 could act downstream of DA neurones to exert a DA-like effect by reducing 
transmission at the striatopallidal synapse (Rouse et al, 2000; Valenti et al, 2003; Conn 
et al, 2005). However, activation of Group III mGluR also reduces GABA release in the 
SNr (Wittmann et al, 200 1 a), which immunocytochernical evidence suggests is likely to 
be mediated by mGluR7, not mGluR4 (Kosinski et al, 1999). This raises the interesting 
possibility that different Group III mGluR subtypes may have predominant roles in 
regulating transmission between the direct and indirect pathways (Conn et al, 2005). 
Importantly, Group III mGluR also negatively modulate glutamate transmission from 
STN axon terminals onto nigral DA neurones (Wigmore and Lacey, 1998; Katayama et 
al. 2003; Valenti et al, 2005), which evidence suggests is primarily mediated by 
mGluR4, although a role of mGluR7 cannot be excluded (Valenti et al, 2005). In situ 
hybridisation evidence suggests mGluR8 mRNA is expressed in the BG nuclei; 
particularly in the nucleus accumbens and SNc (Messenger et al, 2002) but to date no 
immunocytochemical studies exist to describe the localisation of mGluR8 receptor 
protein nor to date, has any functional study identified a role for mGluR8 in any BG 
nuclei (Valenti et al, 2005), although this does not preclude a functional role of this 
receptor in modulating glutamate neurotransmission in the BG. 
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1.10.6.4 Glial cell mGluR functions in the basal ganglia 
Recent evidence suggests that activation of glial mGluR subtypes is critical for the 
modulation of glial cell function and in neurone to glia communication, particularly 
under pathological conditions (Winder and Conn, 1996; Aronica et al, 2001; 2003; 
2005). In this respect, in vitro evidence suggests that both mGluR5 and mGluR3 
differentially modulate glutamate transporter function in astrocytes and neurones 
(Gegelashvili et al, 2000; 2001; Aronica et al, 2003). Indeed, activation of glial Group I 
mGluR. by the selective Group I mGluR agonist (S)-3,5-dihydroxyphenylglycine ((S)- 
3,5-DHPG), results in downregulation of both GLAST and GLT- I in astrocytes in vitro, 
which is reversed by the mGluR5 selective antagonist 2-Methyl-6- 
(phenylethynyl)pyridine hydrochloride (MPEP) but not the mGluRl selective 
antagonist 7-(Hydroxyimino)cyclopropa[b]chromen- I a-carboxylate ethyl ester 
(CPCCOEt) suggesting this is regulated by astroglial mGluR5. In contrast, activation of 
mGluR3 by the selective mGluR2/3 agonist (2SI'R, 2'R, 3'R)-2-(2,3- 
dicarboxycyclopropyl)glycine (DCG-IV) positively modulates the expression of both 
GLAST and GLT-1, but also appears to upregulates EAAT3 expression in neurones 
(Aronica et al, 2003). This is reversed by application of the selective mGIuR2/3 
antagonist (2S)-a- Ethyl glutamic acid (EGLU), confirming a role for mGluR3 (Aronica 
et al, 2003). 
Additionally, activation of glial cell mGluR may influence the synthesis and 
secretion of trophic factors and/or cytokines. Indeed, activation of mGluR3 by DCG-IV 
in the presence of interleukin- IP (IL- I P) results in upregulation of interleukin-6 (IL-6) 
secretion from astrocytes in vitro (Aronica et al, 2005). Furthermore, activation of 
Group III mGluR on astroglia inhibits the secretion of the inflammatory chemokine 
RANTES (from regulated upon activation of normal T cell expressed and secreted) 
(Besong et al, 2003). Furthermore, activation of astroglial Group II and III mGluR is 
associated with increased expression and secretion of numerous trophic factors 
including transforming growth factor-P (TGF-P), nerve growth factor (NGF) and SI OOP 
in vitro (Bruno et al, 1999; Ciccarelli et al, 1999) and BDNF in vivo (Matarredona et al., 
2002; Venereo et al, 2003). Addtionally, blockade of Group I mGluR has recently been 
suggested to increase BNDF expression in vivo (Legutko et al, 2006). Interestingly, in 
vitro evidence suggests that these responses are mediated through both the P13K and 
MAPK pathways, since inhibitors of these kinases block the mGluR-mediated 
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regulation of glial glutarnate transporter proteins and secretion of trophic factors and/ or 
chemokines (D'Onofrio et al, 2001) 
Importantly, activation of mGluR on microglia may also regulate their function. 
Indeed, activation of microglial Group III mGluR appears to reduce microglial toxicity 
in vitro and inhibits microglial proliferation (Taylor et al, 2003). However, in contrast, 
activation of microglial mGluR2 promotes microglial toxicity and proliferation in vitro 
and is associated with activation of apoptotic cell death pathways through Fas ligand 
(Taylor et al, 2005). Similarly, activation of Group I mGluR on microglial cells, in 
particular mGluR5, also appears to activate the canonical signal transduction pathways 
associated with these receptors, that is PLC activation, increased PI hydrolysis, 
increases in intracellular Ca 2+ and activation of PKC (Conn and Pin, 1997; Biber et al, 
1999). Interestingly, activation of PKC may be associated with secretion of 
inflammatory mediators such as tumour necrosis factor-cc (TNF-cc) from reactive 
microglia (Nakajima et al, 2003a, b; 2004). Thus, speculatively, activation of microglial 
mGluR5 may be involved in mediating increases in cytokine secretion by reactive 
microglia in vivo. However, relatively sparse or no data exists on the function of 
mGluRI on either astroglia or microglia (Aronica et al, 2003). 
1.10.6 5 Metabotropic glutamate receptors and striatal synaptic plasticity 
Long-term changes in synaptic efficacy by UP and LTD in the striatum appear to 
underlie motor learning and 'habit memory', and the flexibility of synaptic plasticity 
allows motor habits to be changed in relation to processes of associative leaming (Pisani 
et al, 2005). These mechanisms may be disrupted in pathological conditions, resulting in 
the compulsive execution of stereotyped, purposeless movements, for example, those 
seen in levodopa (L-DOPA)-induced dyskinesias (Gubellini et al, 2004). At 
corticostriatal synapses LTD is induced by an increase in intracellular Ca2+ and requires 
the co-activation of DA D, and D2-like receptors (Calabresi et al, 1992; 1997; Choi and 
Lovinger, 1997). Several studies have demonstrated a critical role for Group I mGluR 
activation in UP and LTD in the cerebellum and hippocampus (Manahan-Vaughn D, 
1997; Bordi et al, 1997; Bortolotto et al, 1999). Interestingly, the combined use of 
subtype-selective antagonists and knockout mice has shown that induction of LTD at 
corticostriatal synapses also requires the activation of mGluR1 receptors (Conquet et al, 
1994; Gubellini et al, 2001; Sung et al, 2001). Additionally, activation of postsynaptic 
mGluRI receptors may result in intracellular Ca 2+ release, activation of protein kinase 
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PKC and formation of endocannabinoids, all of which have been demonstrated to be 
crucial for LTD induction (Calabresi et al, 1994; 1996; Gerdeman et al, 2002). 
As activation of mGluR2/3 receptors depresses excitatory synaptic transmission 
it follows these receptors have a critical role in the induction of LTD in the dorsal 
striaturn (Sung et al 2001). In contrast, the induction of UP in striatal neurons is 
mediated by the entry of Ca 2+ through NMDAR channels and requires the activation of 
DA DI-like receptors, but appears to be negatively modulated by DA D2-like receptors 
(Calabresi et al, 2000; Gubellini et al, 2004). Thus, activation of both mGluR1 and 
mGluR5 receptors is necessary for UP in the striaturn (Conquet et al, 1994; 
Chiamulera et al, 2001; Gubellini et al, 2003). This may amplify NMDAR currents in 
the dendritic spines of medium spiny neurons to facilitate LTP, or may act on 
cholinergic interneurons to stimulate the release of ACh, which, in turn, facilitates 
NMDAR responses by activating muscarinic receptors (Calabresi et al, 1999; 2001; 
Pisani et al, 2001). 
1.10.7 Selective mGluR ligands as potential treatments for PD 
The discovery of mGluR has altered previous views on glutamate transmission, since 
activation of mGluR appear to modulate activity in glutamatergic circuits, thus 
providing a mechanism whereby glutamate may "fine-tune" activity at the same 
synapses at which it also elicits a fast-synaptic response (Conn and Pin, 1997). In 
addition, these receptors display a rich diversity and uniquely heterogeneous 
distribution and sub-cellular localizations, which provide an exciting opportunity to 
develop pharmacological compounds which can selectively interact with mGluRs which 
modulate only one or a limited number of CNS functions (Conn and Pin, 1997; Spooren 
et al, 2002; Marino et al, 2003a). Thus, such a subtle approach is likely to be associated 
with significantly reduced side-effects as compared to targeting fast-synaptic 
transmission through iGluRs (Marino and Conn, 2003). Moreover, targeting glutamate 
transmission through these receptors downstream of the DA system in the BG would 
not be expected to be associated with the side-effects commonly associated with 
dopamimetic drugs (Marino et al, 2003a). 
-95- 
1.10.7.1 Potential anti-parkinsonian actions of mGluR ligands 
The progressive delineation of the distribution and function of mGluR in the BG 
suggest that selective mGluR ligands may induce anti-parkinsonian actions at several 
sites in the BG and thus be of benefit as symptomatic treatments for PD (Conn et al, 
2005; Bonsi et al, 2006). 
Indeed, as discussed above, activation of Group I mGluR appears to counteract 
the effect of DA in the BG. Consistent with this functional data, intrastriatal injection of 
Group I mGluR agonists in rodents, produces selective activation of the indirect 
pathway and hypolocomotion (Kearney et al, 1997; 1998). Therefore, pharmacological 
antagonism of Group I mGluR would be predicted to be anti-parkinsonian at multiple 
sites in the BG. Indeed, blockade of mGluR5 would be predicted to inhibit the mGluR5- 
mediated excitation of STN neurones, thereby normalising STN and BG output nuclei 
activity (Awad et al, 2000). Additionally, blockade of mGluR5 may amplify the 
mGluR1 mediated excitation of inhibitory GPe neurones which project to the STN, 
thereby also reducing STN hyperactivity (Poisik et al, 2003). Furthermore, blockade of 
mGluR5 in the striaturn may reduce the activity of striatal MSNs of the indirect pathway 
and striatal cholinergic intemeurones thus normalising altered striatal output through the 
indirect pathway (Conn et al, 2005). 
In support of this, the results of several studies have demonstrated that mGluR5 
antagonists are antiparkinsonian (Senkowska and Ossowska, 2003). Indeed, chronic 
systemic treatment with MPEP reverses akinesia in bilaterally 6-OHDA lesioned 
rodents (Breyesse et al, 2002; 2003; Coccurello et al, 2003; Turle-Lorenzo et al, 2005). 
Similarly, MPEP reverses haloperidol induced catalepsy and muscle rigidity in rodents 
(Ossowska et al, 2001; 2002; 2003). Moreover, microinjections of MPEP into the STN 
significantly relieve forelimb akinesia, postural instabilities and sensorimotor deficits in 
unilaterally 6-OHDA lesioned rats (Phillips et al, 2006). Importantly, mGluR5 
antagonists appear to alleviate LIDs in rodents by preventing potentiation of NMDAR 
responses in the striaturn (Dekundy et al, 2006) (see section 1.9.1). 
In contrast, selective antagonists of mGluRl have not been rigorously 
investigated in experimental models of Parkinsonism, but potentially could also be anti- 
parkinsonian by acting in the striaturn to facilitate activation of the direct pathway and 
in the SNr to decrease nigral GABA release and facilitate activation of thalamocortical 
pathways (Conn et al, 2005). Additionally, antagonism of mGluRI at striatopallidal 
synapses may produce anti-parkinsonian effects (Marino et al, 2002b; Ossowska et al, 
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2003). Consistent with this hypothesis, bilateral intrastriatal injections of the mGluR1 
antagonists (+)-2-Methyl-4-carboxyphenylglycine (LY367385), CPCCOEt or (RS)-l- 
Aminoindan-1.5-dicarboxylic acid (AIDA) significantly attenuated increases in pre- 
proenkphalin (PENK) expression in the striatum induced by haloperidol administration 
(Ossowska et al, 2002; 2003; 2006; Wardas et al. 2003). Furthermore bilateral injections 
of AIDA also significantly attenuated muscle rigidity induced by haloperidol treatment 
(Ossowska et al, 2002; 2003). These data suggest that mGluR1 antagonism may show 
an antiparkinsonian effect by modulation of glutamate transmission at the striatopallidal 
synapse. However, it may be possible that this does not reflect a central action at 
mGluRl, since each antagonist was injected at millimolar concentrations, thus 
potentially these concentrations of antagonists were at the border of their selectivity for 
mGluR1 (Ossowska et al, 2006). Thus a contribution of striatal mGluR5 to this response 
cannot be definitively excluded (Ossowska et al, 2006). Interestingly in contrast to these 
data, intracerebroventricular injection of CPCCOEt did not produce any significant 
amelioration of akinesia in rodents treated acutely with reserpine (Marino et al, 2003b) 
suggesting mGluRl antagonists may not produce antiparkinsonian effects. However, 
these data do not completely preclude a possible anti-parkinsonian action of mGluR1 
antagonists. In support of this, the novel mGluR1 antagonist (3-ethyl-2-methyl- 
quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate (EMQMCM) 
slightly inhibited haloperidol-induced catalepsy in rodents, although this compound had 
no effects on LIDs (Dekundy et al, 2006). 
Activation of Group 11 mGluR would also be predicted to be anti -parkinsonian 
by reducing transmission at corticostriatal and subthalamonigral synapses (Bradley et al, 
2000; Rouse et al, 2000). In support of this, intranigral administration of the mGluR2/3 
agonist DCG-IV reverses reserpine- induced akinesia in rodents (Dawson et al, 2000). 
Similarly, i. c. v administration of the mGluR2/3 agonist (lS, 2S, 5R, 6S)-2- 
aminobicyclo[3.1.0]hexane-2,6-dicarboxylate-monohydrate (LY354740) reverses 
haloperidol-induced catalepsy and muscle rigidity (Konieczny et al, 1998; Bradley et al, 
2000). Moreover, intranigral or i. c. v administration of the mGluR2/3 agonist, 
(IR, 4R, 5S, 6R-2-oxa-4-aminobicyclo[3.1.0. ]hexane-4,6-dicarboxylate (LY379268) in 
unilaterally 6-OHDA lesioned rodents has been demonstrated to be anti-parkinsonian 
(Murray et al, 2002). 
Similarly, activation of Group III mGluR at striatopallidal synapses would be 
predicted to be anti-parkinsonian by virtue of indirect reductions in STN hyperactivity 
and thus BG output nuclei hyperactivity, counteracting the increases in indirect pathway 
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activity due to striatal DA depletion (Matsui and Kita, 2003; Valenti et al, 2003). 
Consistent with this hypothesis, i. c. v injection of the selective Group III mGluR agonist 
L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) reverses akinesia in rodents with 
comparable efficacy to L-DOPA (Valenti et al, 2003; MacInnes et al, 2004). 
Interestingly, in 6-OHDA lesioned rodents, the response of striatal neurones to L-AP4 is 
enhanced in terms of the ability of this compound to reduce neuronal activity (Zhang 
and Albin, 2000), suggesting that Group III mGluR may have a higher therapeutic index 
in DA-depleted animals (Gubellini et al, 2004). Taken together, these findings provide 
substantial evidence to suggest that selective antagonists of mGluR5, and selective 
agonists of Group 11 and III mGluR may be of benefit as symptomatic treatments for I'D 
either alone or in combination with L-DOPA. 
1.10.7.2 Putative neuroprotective effects of mGluR ligands 
Importantly, whilst the potential symptomatic benefits of mGluR ligands have been 
widely investigated as described above, it is noteworthy that activation of mGluR also 
play critical roles in modulating neuronal excitation of several nuclei in the BG (see 
section 1.10.6). Thus, selective mGluR ligands which reduce glutamate 
neurotransmission through the indirect pathway may also reduce secondary excitotoxic 
damage to nigral DA neurones (Nicoletti et al, 1996; Conn et al, 2005). Thus, selective 
activation of presynaptic Group 11 or III on corticostriatal, STN or PPN axon terminals 
would be predicted to be neuroprotective by virtue of down-regulating glutamate 
transmission from these structures onto nigral DA neurones (Nicoletti et al, 1996; Conn 
et al, 2005). Additionally, antagonism of postsynaptic Group I mGluR would be 
predicted to be neuroprotective by preventing pathological increases in excitation of 
either STN or SNc neurones (Nicoletti et al, 1996; Conn et al, 2005). 
In support of this hypothesis, pharmacological blockade of mGluR1 or mGluR5 
is neuroprotective against glutamate or NMDA-mediated toxicity in vitro (Bruno et al, 
1995a; 1999; 2000b O'Leary et al, 2000). Furthermore, pharmacological blockade of 
mGluR5 is neuroprotective against MPTP-toxicity in mice (Battaglia et al, 2005). 
Moreover, mGluR5 KO mice show increased survival of nigral DA neurones following 
MPTP intoxication (Battaglia et al, 2005). Similarly, antagonism of Group I mGluR is 
also neuroprotective against MPTP toxicity in vivo (Aquirre et al, 2001). Furthermore, 
pharmacological activation of Group 11 and III mGluR with selective agonists is also 
neuroprotective against striatal glutamate or NMDA-mediated toxicity in vitro and in 
vivo (Bruno et al, 1995b; 1996; 1997; 1999; 2000a,; 2001; Battaglia et al, 1998; Lafon- 
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Cazal et al, 1999a, b; Henrich-Noack et al, 2000). Moreover, Group 11 mGluR agonists 
have also been demonstrated to produce mild neuroprotective effects in vivo against 6- 
OHDA toxicity (Murray et al, 2002) and MPTP-toxicity (Battaglia et al, 2003). 
Additionally, given the likely contributions of glial cells to neuronal 
degeneration through both excitoxicity (see section 1.8.3.3) and through inflammation 
(see Figure 1.8) and taking into account the findings that functional mGluR are 
expressed also on glial cell populations (see section 1.10.4) and regulate glial cell 
functions in vivo (see section 1.10.6.4) it is equally likely that selective mGluR ligands 
may also be neuroprotective through an action at mGluR on either astroglia or microglia 
in the SNc. 
Taking all these data together, suggests that antagonists of Group I mGluR or 
agonists of Group Il and III mGluR may provide both symptomatic and neuroprotective 
actions in PD, as illustrated in Figure 1.13. Importantly, the fact that mGluR modulate 
excitatory synaptic transmission suggests that drugs targeting these receptors may cause 
fewer side effects than NMDAR antagonists (Bruno et al, 2001; Conn et al, 2003; 
2005). In cases where the behavioural effects of mGluR ligands have been tested in 
rodent models of PD there appears to be a remarkable agreement between what is 
predicted from functional studies, leading to a general agreement on the potential anti- 
parkinsonian activity of these compounds. However, the putative neuroprotective effect 
of these compounds remains hypothetical and have not been rigorously investigated in 
vivo in an experimental model of PD to determine whether or not mGluR ligands have 
the predicted neuroprotective effects in vivo. This is particularly important since in light 
of the documented anti-parkinsonian actions of mGluR ligands a demonstration of a 
neuroprotective, disease-modifying action would clearly greatly enhance the potential 
therapeutic impact of such compounds. 
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Figure 1.13 mGluR ligands acting at neuronal mGluR may protect nigral 
DA neurones against secondary glutamate excitotoxicity 
Postsynaptic Group I mGluR (mG]uRI/5) modulate DA nigral neurone excitation and may 
potentiate NMDAR activity by virtue of interactions with scaffold proteins. Activation of 
Group I mGluR also causes potentially deleterious release of Ca2' from intracellular stores 
and inhibit hyperpolarising K' conductances. Therefore antagonists of these receptors would 
be predicted to be neuroprotective against glutamate excitotoxicity. By contrast, activation of 
presynaptic Group 11 and III mGluR autoreceptors on STN axon terminals (and potentially 
PPN or cortical axon terminals) results in decreases in glutamate transmission and release by 
inactivation of voltage-gated Ca 2+ channels. Thus agonists of Group 11 and III mGluR would 
also be predicted to be neuroprotective against pathological increases in glutamate 
transmission from the STN (or PPN, cortex additionally). 
Importantly, both astroglia and microglia express functional mGluF, particularly mGluR5, 
mGluR3 and Group III mGluR. Furthermore, activation of these receptors in vivo using 
selective mGluR ligands is demonstrated to regulate some glial cell functions including 
glutamate transporter protein activity/expression and potentially cytokine production (see 
section 1.10.64). Given the evidence which implicates glial cells in excitoxicity and 
neurotoxicity due to inflammation in PD, it follows that mGluR ligands may also be 
neuroprotective through an action on mGluR expressed on glial cells in the SNc. 
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1.11 Aims of study 
The recent availability of many highly selective group and subtype specific 
agonists/antagonists of mGlu receptors now allows a detailed examination of the 
hypothesis that mGlu receptor ligands may be neuroprotective in vivo in experimental 
models of PD. Based on individual potencies and pharmacological selectivity four 
newly developed, potent and selective compounds which have previously been shown to 
have antiparkinsonian effects in experimental models of PD were selected for study, 
these being the mGluR1 selective antagonist LY367585, the mGluR5 selective 
antagonist MPEP, the mGluR2/3 agonist 2R, 4R-4-aminopyrrolidine-2,4-dicarboxylate 
(2R, 4R-APDC) and the broad-spectrum Group III receptor agonist L-AP4 
(mGluR8>4>6>7) the structures of which are shown in Figure 1.14. Importantly, the 
majority of studies on mGluR ligands and Parkinsonisin have been performed in vitro, 
thus, the specific aims of this project are as follows: 
1. To examine the putative neuroprotective effects of treatment with four, potent 
and selective mGluR ligands (as listed above) in a rodent 6-OHDA-experimental 
model of PD and if any neuroprotective effects are observed, to determine if this 
effect is (a) concentration-dependent and (b) receptor-mediated in vivo 
2. Should any neuroprotection be observed in (1), to investigate the potential 
neuroprotective effects of selected mGluR ligands following acute treatment to 
examine the possibility the receptor agonist-mediated desensitisation or 
antagonist-mediated supersensitivity affects the potential neuroprotective effect 
of these compounds in vivo 
3. Further, should any neuroprotection be observed in (1) and (2), to investigate the 
possibility that treatment with combinations of sub-maximal concentrations of 
mGluR ligands result in additive interactions to provide a greater 
neuroprotective effect than that observed with individual compounds alone in 
vivo 
4. Finally, should any neuroprotection be observed from (1), (2) and (3), to 
investigate the potential neuroprotective effect of selected mGluR ligands 
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following post-lesion treatment to investigate if treatment with these compounds 
can slow or modify disease progression in vivo 
In order to test these aims, these compounds will be tested for putative neuroprotective 
activity in the classical 6-hydroxydopamine (6-OHDA) experimental model of PD, 
which produces selective degeneration of the rodent nigrostriatal system (Betarbet et al, 
2002; Deumens et al, 2002). In order to test the neuroprotective effects of these 
compounds, they and the 6-OHDA neurotoxin will be focally administered into the SNc 
via a chronically implanted guide cannulae using a number of different concentrations 
of each compound and dosing regimes. The putative neuroprotective effects of these 
compounds will then be assessed by analysing their effect on both the integrity and 
functionality of the nigrostriatal tract following 6-OHDA lesioning. In order to quantify 
effects on nigrostriatal integrity, immunohistochemical studies and quantitative cell 
counting of the number of Tyrosine hydroxylase cells will be performed in the SNc- 
Additionally, to quantify the effects on nigrostriatal functionality, the concentrations of 
DA and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA) in the corpus striaturn will be quantitatively measured biochemically by High 
Performance Liquid Chromatography with Electrochemical Detection (HPLC-ECD). 
The relative amount of striatal DA metabolism will also be calculated. These parameters 
will then be compared between vehicle- and mGluR-ligand treated groups. 
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Figure 1.14 Metabotropic glutamate receptor ligands used in the current 
study (Source: Tocris Cookson Ltd, Bristol, UK) 
A: (+)-2-Methyl-4-carboxyphenylglycine (LY367385), potent competitive 
mGIuR1 selective antagonist (IC50 8.8 pM). No effect of mGluR5 at 
concentrations up to 100 pM, negligible effects on Group 11 or III mGluR 
(Clark et al, 1997; Chapman et al, 1999; Bruno et al, 1999) 
B: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), potent, non-competitive 
negative allosteric modulator of mGluR5 UC50 36 n-M) No activity at mGluRI 
at concentrations up to 100 pM although may antagonise NMDAR at 
concentrations greater than 10 pM, also a weak positive allosteric modulator of 
mGluR4 (Gasparini et al, 1999; Kuhn et al, 2002; Mathiesen et al, 2003) 
C: 2R,, 4R-4-aminopyffolidine-2,4-dicarboxylate (2R, 4R-APDC), highly 
selective and potent mGluR2/3 agonist OC50 0.4 pM). No effect at mGluRI, 5 
or 4 at concentrations up to 100 pM and mGluR7 at concentrations up to 300 
pM (Schoepp et al, 1995; Monn et al, 1996; Schoepp et al, 1999) 
D: L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) potent, broad spectrum 
non-subtype selective Group III mGluR agonist (potency/affinity mGluR4 >8 
>6> 7). Negligible effects on either Group I or 11 mGluR at concentrations up 
to 100 pM (Schoepp et al, 1999). 
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Chapter Two 
Materials and Methods 
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2.1 In vivo methods 
2.1.1 The 6-hydroxydopa mine in vivo experimental model of Parkinson's disease 
2.1. LI Overview 
Experimental models of Parkinson's disease (PD) are essential for gaining insights into 
the possible pathophys io logical mechanisms which underlie the degeneration of 
doparninergic neurones in the substantia nigra pars compacta (SNc) in this disease. 
Furthermore, they are vital for the testing of novel therapeutic strategies, either 
pharmacological or other strategies such as stem cell implantation or delivery of genes 
by viral vectors (Betarbet et al, 2002; Deumens et al, 2002). Whilst no animal model 
exists that replicates all aspects of the disease, a number of models are available, often 
utilising toxins, that replicate certain aspects of the disease. One such model is the 6- 
hydroxydoparnine (6-OHDA) in vivo model of PD. In the current study, this model was 
employed to evaluate the neuroprotective potential of ligands acting at metabotropic 
glutamate receptors (mGluR) on the nigrostriatal system. 
The chemical neurotoxin 6-OHDA is a hydroxylated analogue of the 
neurotransmitter dopamine (Axlerod et al, 1998) and it was the first chemical agent to 
be discovered which has specific neurotoxic effects on catecholaminergic pathways, 
including the doparninergic nigrostriatal system (Ungerstedt, 1968). 6-OHDA induces 
selective catecholaminergic neurone degeneration by entering these cells through the 
dopamine or noradrenaline transporters (DAT and NAT, respectively), leading to 
degeneration of nerve terminals and cell bodies (Jonsson and Sachs, 1970; 1971), which 
appears to show both non-apoptotic morphology (Jeon et al, 1995) and apoptotic 
morphology (Vila and Przedborski, 2003; Silva et al, 2005). 6-OHDA if administered 
systemically cannot cross the blood-brain barrier (BBB), thus, to model PD by 
specifically targeting the nigrostriatal pathway, 6-OHDA must be injected by 
stereotaxic means into one of three distinct targets, these being the medial forebrain 
bundle (MFB), the substantia nigra (SN) or into the corpus striaturn (Deumens et al, 
2002). Following injection of 6-OHDA into the SN or MFB, doparninergic neurones in 
the SNc begin to degenerate within 24 hours and dopamine in the corpus striatum is 
depleted 2-3 days later (Carmen et al, 1991; Jeon et al, 1995; Blanchard et al, 1996). In 
contrast, injection of 6-OHDA into the caudate putamen complex of the rodent striatum. 
at one or more sites, produces acute loss of doparninergic fibres in the striaturn but 
critically, produces a progressive, retrograde loss of nigral doparninergic cells which 
develops over several weeks, which has been suggested to more closely mimic the 
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progressive nature of idiopathic PD in humans (Sauer and Oertel, 1994; Kirik et al, 
1998). Generally, 6-OHDA is injected unilaterally into one hemisphere of the brain (the 
ipsilateral hemisphere) whilst the other serves as an internal control (the contralateral. 
hemisphere; Betarbet et al, 2002). Since PD affects the brain bilaterally, bilateral 
injection models of 6-OHDA also exist and are considered to be more relevant for the 
assessment of behavioural changes. However, these are commonly associated with a 
high morbidity rate due to aphagia caused by the severity of the nigrostriatal lesion 
induced and as a result are not widely used since the animals require intensive nursing 
care (Bove et al, 2005). Thus, unilateral lesions are the most common method of 6- 
OHDA lesioning, although it should be noted that unilateral lesions may induce changes 
in the contralateral unlesioned hemisphere of the brain including changes in striatal 
neuropeptide and doparnine levels, as well as the electrical activity of subthalamic 
neurones (Salin et al, 1996; Perier et al, 2000). However, since unilateral lesioning 
allows greater control over the extent of doparnine depletion it is therefore the method 
of choice for evaluating novel PD therapeutics (Beal et al, 2001) and as such, a 
unilateral lesion model was employed in the current study. 
The magnitude of the nigrostriatal lesion induced is dependent on the 
concentration of 6-OHDA injected (Przedborski et al, 1995), the site of 6-OHDA 
administration (Deumens et al, 2002) and whether noradrenaline uptake blockers such 
as desipramine are employed (Luthman et al, 1989). Thus, it remains obscure which of 
the models (MFB, SNc or striatum) is most appropriate for modelling PD and indeed 
testing potential therapeutic agents. In the current study, 6-OHDA was injected directly 
into the substantia nigra and the choice of this lesioning method is addressed in chapter 
7, whilst the remainder of this section focuses on injection of 6-OHDA into the SNc (for 
a detailed review of the additional lesioning pathways see Deumens et al, 2002). 
2.1.1.2 Substantia nigra pars compacta lesions 
In order to investigate the putative neuroprotective effects of mGluR ligands, ideally a 
partial lesion model would be most appropriate which replicates the early clinical stages 
of the disease when such treatments are likely to be administered and effective. In this 
respect, lesioning of the SNc is characterised by a more moderate striatal dopamine 
depletion than that seen following either MFB or caudate-putamen complex (CPu) 
lesions (Carmen et al, 1991). Commonly, a single injection is made into the lateral 
portion of the SN, which results in a typical dopaminergic neuronal loss of 60 to 80%, 
although as much as 90% may be achieved with two injections into both the medial and 
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lateral portions of the SN (Carmen et al, 1991; Schwarting and Huston, 1996; Blanchard 
et al, 1996; Finkelstein et al, 2000; Stanic et al, 2003; 2004). In the current study, 6- 
OHDA was administered by a single infusion into the lateral portion of the SNc. 
Despite of the proximity of the injection to the nearby ventral tegmental. area (VTA), 
there is a limited loss of doparninergic cells in this structure (Carmen et al, 1991; 
Dentresangle et al, 200 1, see also Figure 3.4 chapter 3). Interestingly, when 6-OHDA is 
injected in this way, a moderate sparing of doparninergic cells in the medial portion of 
the SNc is observed, which appears to reflect the pattern of neuronal loss seen in PD 
patients (German et al, 1989; Goto et al, 1989). Furthermore, 6-OHDA lesions of the 
SNc induce greater doPamine depletion in the lateral portion of the striaturn, which 
again correlates well with observations from human PD brain tissue (Deumens et al, 
2002). The use of noradrenaline uptake inhibitors such as desipramine were also not 
employed in order to generate a more partial lesion (Luthman et al, 1989). Additionally, 
it was also desired to investigate the effects of these compounds following focal 
administration in to the SNc over time (see section 7.2.1.1). Taking these factors into 
account, a chronically-implanted guide cannulae supranigral to the SNc and 
administration of 6-OHDA into the SNc appeared to present the most sensible option to 
produce a partial lesion of the nigrostriatal tract (see section 7.2.1.1). 
2.1.1.3 Mechanisms of 6-OHDA toxicity 
The potential mechanisms by which 6-OHDA is neurotoxic are illustrated in Figure 2.1. 
6-OHDA rapidly auto-oxidises to form both hydrogen peroxide and para-quinone as 
illustrated in Figure 2.1 A (Heikkila and Cohen, 1971; Sachs and Jonsson, 1975; Cohen, 
1984) which leads to generation of reactive oxygen species (ROS). 6-OHDA also 
interferes with cellular anti-oxidant defences by depleting the levels of reduced 
glutathione (GSH) and reducing the activity and brain mRNA levels of superoxide 
dismutase (SOD) in the basal ganglia, resulting in increased levels of hydrogen peroxide 
(Perumal et al, 1989; Kunikowska and Jenner, 2001). This can result in the formation of 
highly toxic hydroxyl radicals (OH*) by Fenton chemistry, through reaction of excess 
hydrogen peroxide with iron that accumulates in the SNc in response to 6-OHDA 
injection, which also stimulates the release of bound Fe 2+ from ferritin (Ben-Shachar 
and Youdim, 1991; Youdim et al, 1993 a, b). These processes cumulatively result in 
prolonged oxidative stress, thereby leading to cell death (Blum et al, 2001; Figure 
2.1 B), as characterised by the observation of increased levels of 
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Figure 2.1 Mechanisms of 6-OHDA neurotoxicity 
(A) The neurotoxin 6-OHDA undergoes rapid autoxidation in the presence of molecular 
oxygen to form para-quinone and hydrogen peroxide, resulting in the generation of toxic 
reactive oxygen species and development of oxidative stress (Takenftom Przedborski and 
Ischriopoulos, (2005) Antioxid Redox Signal 7: 685-693). 
(B) Putative mechanisms by which 6-OHDA-mediated oxidative stress leads to death of 
dopaminergic neurones following uptake through the dopamine transporter (DAT) 
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malondialdehyde, indicative of lipid peroxidation a common marker for oxidative 
damage, in the SNc of 6-OHDA lesioned rodents (Ogawa et al, 1994; Kumar et al, 
1995). In addition, 6-OHDA causes potent inhibition of the mitochondrial electron 
transport chain enzymes, complexes I and IV, leading to generation of superoxide 
radicals and cellular energy crisis by depletion of adenosine triphosphate (ATP) 
production (Glinka and Youdim, 1995; Blum et al, 2001; Figure 2.113). These 
mechanisms appear to synergise in vivo to produce the neuronal degeneration observed 
following 6-OHDA injection into the brain (Schober et al, 2004). Interestingly, 
increasing evidence also exists to suggest that 6-OHDA-induced neuronal death may be 
associated with proteolytic stress. Indeed, exposure of SH-SY5Y neuroblastorna and 
PC-12 cell lines to 6-OHDA increased the levels of free ubiquitin and ubiquitin- 
conjugated proteins in these cells (Elkon et al, 2001). Furthermore, metabolic labelling 
with 35 S-methionine, demonstrated that 6-OHDA markedly increased protein 
degradation, as indicated by the secretion of protein metabolites to the medium (Elkon 
et al, 2001). Additionally in vitro 6-OHDA treatment increased carbonyl group 
accumulation in the SNc and free ubiquitin levels in the striatum suggesting an increase 
in protein oxidation and impaired degradation (Elkon et al, 2004; Pierson et al, 2005). In 
addition, an increase in trypsin-, chymotrypsin-, and postacidic-like proteasome 
activities in cells treated with 10-100 ýtM 6-OHDA, whereas higher doses caused a 
marked decline in these activities (Elkon et al, 2004). Moreover, it is noteworthy that 6- 
OHDA exposure results in the specific upregulation of a number of the expression of 
proteins involved in the unfolded protein response (UPR) pathway in the endoplasmic 
reticulum (ER) including the transcription factor CHOP/GaddI53 and the molecular 
chaperone BiP (Holtz and O'Malley, 2003; Yamamuro et al, 2006a, b). These data 
indicate that oxidative stress associated with 6-OHDA cell death results in increased 
protein damage and UPS defects. 
Importantly, these biochemical defects correlate strongly with similar 
observations in post-mortem brain tissue from the SNc of PD patients (Dexter et al,; 
1991; 1992; 1994a, b; Schapira et al, 1991; Sian et al, 1994a ; Gerlach et al, 1997; 
McNaught and Jenner, 2001; 2002). Lesioning with 6-OHDA also results in extensive 
reactive gliosis in the SNc characterised by the presence of reactive astrocytes and 
infiltration of reactive microglia (Akiyama and McGeer, 1989; Cicchetti et al, 2002), 
consistent with observations of a similar inflammatory response in post-mortem PD 
tissue (Hirsch et al, 2003). Importantly, 6-OHDA lesioning also results in increases in 
both STN (Vila et al, 2000) and PPN (Breit et al, 2001; 2005) neuronal firing rate and 
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mode (spike to burst firing), which may result in increases glutamate transmission onto 
midbrain doparninergic neurones, thereby creating conditions for secondary glutamate 
excitotoxicity (see also section 1.7.5.3). 
2.1.1.4 Motor impairments induced by 6-OHDA lesions 
Additionally, a near complete destruction of the nigrostriatal system in rodent's results 
in the appearance of significant motor impairments, similar to the bradykinesia, 
akinesia, and muscle rigidity and postural / gait abnormalities observed in humans 
diagnosed with idiopathic PD (Gerlach et al, 1996). Indeed, bilaterally 6-OHDA 
lesioned rats display postural abnormalities at rest and are unable to maintain balance 
when challenged with a destabilizing force (Wolfarth et al, 1996; Rodter et al, 2000). 
Furthermore these animals display gait abnormalities and show marked hypolocomotion 
(Schallert et al, 1978; 1979). Moreover, these animals display muscle resistance to 
stimuli which has electromyo graphic similarities to muscle rigidity observed in PD 
(Spirduso et al, 1985; Wolfarth et al, 1996). However, evidence for resting tremor in 
these animals is scarce and controversial (Cenci et al, 2002). Bilaterally 6-OHDA 
lesioned animals also show marked akinesia as measured by significantly increased 
response times in reaction time tasks (Amalric and Koob, 1987). However, as 
mentioned, bilateral 6-OHDA lesion models are not common, since they are associated 
with aphagia, adipsia and high mortality rates, thus, most behavioural investigations are 
performed in rodents bearing a unilateral lesion of the nigrostriatal tract (Cenci et al, 
2002; Henderson et al, 2003). Severe unilateral 6-OHDA lesions produce a 
herniparkinson syndrome in rodents associated with marked postural abnormalities and 
contralateral sensorimotor deficits (Schallert et al, 1988; Schwarting and Huston 1996). 
Unilaterally 6-OHDA lesioned animals also display classical rotational asymmetry after 
challenge with dopamine agonists (Ungerstedt, 1971a, b; Carey, 1986). Indeed, animals 
display spontaneous circling behaviour usually towards the lesioned side of the brain 
(ipsiversive rotation), but not to the unlesioned side of the brain (contraversive rotation; 
Ungerstedt, 1971a, b; Carey, 1986). Aside from this these animals appear outwardly 
normal and are able to initiate controlled forward-directed movement (Schwarting and 
Huston, 1996). However, when challenged with drugs which stimulate dopamine 
release (indirect dopamine agonists) such as amphetamine or dopamine re-uptake 
inhibitors, a marked ipsiversive circling is observed, as a result of the preferential 
increase in synaptic dopamine content in the contralateral striatum (Ungerstedt, 1976). 
In contrast, when challenged with agents that act on postsynaptic dopamine D2-like 
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receptors (direct doparnine agonists) such as apomorphine or levodopa, this produces a 
profound contraversive rotation as a result of dopamine receptor supersensitivity and 
preferential activation of dopamine receptors in the dennervated ipsilateral striaturn 
(Ungerstedt, 1971a, b; 1976; Schwarting and Huston, 1996). Interestingly, this 
asymmetric circling behaviour appears to be directly correlated to the degree of nigral 
cell loss and striatal dopamine depletion (Heikkila et al, 1981; Schwarting et al, 1991; 
Carmen et al, 1991). Indeed, weak ipsilateral rotations can be detected in rodents with a 
partial lesion, where approximately -50% of nigral doparninergic neurones are 
destroyed (Hefti et al, 1980). However, significant contraversive rotational behaviour is 
usually only detectable in animals with very severe nigrostriatal lesions, in which 
approximately -90% of nigral dopaminergic neurones are destroyed (Hefti et al, 1980; 
Carmen et al, 1991), particularly with respect to SNc lesions, where fewer than 10% of 
nigral. neurones must remain in order to observed a consistent rotational response to 
amphetamine or apornorphine (Deumens et al, 2002). Thus, whilst stimulation of 
contraversive rotation is often used as test of the degree of nigrostriatal lesion in rodents 
(Schwarting and Huston, 1996) and to identify drug compounds with potential 
antiparkinsonian activity (Heikkila et al, 1981; Winkler et al, 1999), including mGluR 
ligands (Spooren et al, 2000; Breyese et al, 2002; 2003; Murray et al, 2002), such 
testing is unlikely to be suitable in partial lesion models such as employed in theses 
studies, since the level of dopamine depletion achieved is unlikely to be sufficient to 
observe significant rotational asymmetry behaviour (Deumens et al, 2002). 
As well as rotational asymmetry, unilaterally 6-OHDA lesioned rats also display 
reaching deficits of the contralateral paw and hypolocomotion (Schwarting et al, 1991; 
Henderson et al, 1999). These motor deficits are suggested to be similar to the 
bradykinesia, rigidity and akinesia seen in humans (Gerlach et al, 1996). Interestingly, 
the appearance of these more subtle motor deficits in these animals also appears to be 
correlated with the degree of nigrostriatal cell loss and striatal dopamine depletion and 
may be apparent in animals with more partial lesions of the nigrostriatal system (Olsson 
et al. 1995; Schwarting and Huston 1996; Deumens et al, 2002; Henderson et al, 2003). 
These unique motor deficits have been exploited to develop a number of specific 
behavioural tests, which are also often used to measure the anti-parkinsonian actions of 
putative neuroprotective agents (Cenci et al, 2002; Deumens et al, 2002). 
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2.1-1.5 Criticisms of the 6-OHDA model 
It should be noted that the intracerebral injection of 6-OHDA does not replicate all of 
the clinical and pathological features that are characteristic of PD (Schober et al, 2004). 
Indeed, 6-OHDA does not induce neuronal loss in other brain regions affected in PD 
such as the locus coeruleus, anterior olfactory structures or lower brain stem nuclei, nor 
does it result in proteinaceous cytoplasmic inclusion bodies reminiscent of Lewy 
bodies, which are observed in PD (Schwarting and Huston, 1996; Del Tredici et al, 
2002; Betarbet et al, 2002; Schober et al, 2004). Furthermore, the acute nature of the 
degeneration induced differs from the progressive degeneration observed in PD 
(Betarbet et al, 2002). 
Despite these limitations however, the 6-OHDA model represents a widely-used, 
popular in vivo model of PD, which reproduces many (although not all) of the key 
features of PD and robustly replicates molecular alterations comparable to those seen in 
idiopathic PD (Blum et at, 2001; Bove et at, 2005). Furthermore, it has been 
successfully used to predict the clinical efficacy of current clinically used anti- 
parkinsonian agents such as levodopa and D2-like dopamine receptor agonists (Asin et 
at, 1995; Prikhojan et at, 2000; Lundblad et at, 2002) and additionally, has been shown 
to be highly useful in evaluating potential neuroprotective strategies for the treatment of 
PD (Armstrong et at, 2002; Datla et at, 2001b; He et at, 2001; Vernon et at, 2005, 
2006). The unilateral 6-OHDA model has also aided identification of the 
neurotransmitter pathways governing the functional anatomy of the basal ganglia (Chen 
et at, 2000; Maesawa et at, 2004). Thus the 6-OHDA model represents a valid 
experimental model of PD in which to test the potential neuroprotective actions of 
selective activation or antagonism of metabotropic glutamate receptors. 
2.1.2 Stereotaxic Surgery 
2.1.2.1 Animals 
Male Sprague-Dawley rats (Harlan, UK) weighing 200-210g on arrival were housed in 
groups of three at 21 ±I OC on a 12 hr light: dark cycle (lights on 07: 00am, lights off 
19: 00pm) with access to standard rat chow and water ad libitum. Animals were allowed 
to acclimatise for 7 days in the Charing Cross Central Biomedical Unit (CBU) before 
any experimentation. During this period the rats' body weight increased such that on the 
day of surgery the rats weighed between 250-270g. The weight of the animal is critical 
for this procedure since coordinates derived from the Paxinos and Watson rat brain atlas 
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for stereotaxic surgery are only designed for rats up to 290g in weight. As such, it was 
ensured by careful weighing and sorting of animals during their acclimatisation period 
in the CBS that at the time of surgery the rats were consistently in the weight range of 
250-270g and no rat exceeded 290g, thereby reducing the probability of errors in the 
accuracy of cannulae positioning. Only male rats were employed in this study since 
recent studies have reported that estrogen may have a neuroprotective effect on 
doparninergic neurones after 6-OHDA lesions (Datla et al, 2001 a). 
2.1.2.2 Stereotaxic implantation ofguide cannulae above the SNc 
Groups of rats (n=8) were implanted stereotaxically with guide cannulae I mm superior 
to the left substantia nigra pars compacta. (SNc) according to the protocol of Datla and 
colleagues, (2001a) as outlined below. The intended position of the implanted cannula 
is illustrated in Figure 2.2. Surgery was carried out on batches of 30-36 animals at a 
time, operating on 6 to 8 rats per day over the course of a week. 
On the day of surgery, rats were individually weighed and the pre-operative 
weight recorded. Rats were anaesthetised using isoflurane (5%) in oxygen (2 L/min) in 
an anaesthetic chamber and then transferred to a stereotaxic frame (David Kopf 
instruments, USA) with the incisor bar set 5 mrn below the interaural line. Whilst in the 
frame, rats were kept on a thermostatically controlled heated mat to maintain body 
temperature at 37C. Anaesthesia was maintained thereafter with isoflurane (1-3%) in 
oxygen (I L/min) supplied from a separate gas machine attached by flexible tubing to a 
facemask on the stereotaxic frame, where it was inhaled by the animal. A second tube 
from the facemask to an air scrubbing apparatus removed exhaledC02and any excess 
isoflurane. The level of anaesthesia was adjusted to each individual animal's rate of 
respiration and reflex response. Once under stable anaesthesia, as established by a loss 
of paw pinch reflex, the scalp area was shaved and swabbed with iodine solution 
(Betadine, Seton Healthcare Group Plc, Oldham, UK) to sterilise the surgical field. 
Before any incision, rats were administered 0.1 ml bupivacaine hydrochloride (Marcain, 
AstraZeneca, Chesterfield UK) by subcutaneous (s. c. ) injection at four sites on the scalp 
as a local anaesthetic and 5 ml of 4% glucose in 0.18% saline by intraperitoneal (i. p. ) 
injection to prevent dehydration during surgery. A midline scalp incision was then 
made, the skin retracted and the periosteurn removed from the cranium, which was then 
scraped dry and cross-hatched with the edge of a scalpel blade. This was done to ensure 
a clean, dry and slightly abraded surface of the cranium to facilitate the adherence of 
dental cement, which was used to anchor the cannula in place. All bleeding from blood 
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vessels was controlled by the use of direct pressure with sterile gauze swabs. If bleeding 
could not be contained in this manner, powdered human fibrin was sparingly applied to 
the site of bleeding. The fibrin is subsequently converted to fibrinogen and a small scab 
forms over the vessel preventing any further bleeding. Once all bleeding was controlled, 
the procedure to implant the indwelling guide cannula at a site above the left SNc was 
begun. All subsequent stereotaxic coordinates are measured in millimetres with anterior 
and lateral coordinates made relative to bregma and ventral coordinates made relative to 
dura. Stainless steel guide (26-gauge, II mm in length); dummy (26-gauge, 32 mm in 
length) cannula and infusion needles (33-gauge) were purchased from Plastics One Ltd 
(Roanoke, USA). Guide cannulae were certified free of obstruction prior to implantation 
by checking patency with the dummy cannulae. A burr hole was drilled into the skull 
using a dental drill with a size three bit above the left SNc to allow placement of the 
guide cannula (A: -3.0 and L: +2.5). The meninges were then gently cleared from 
beneath this hole using a needle tip. Stainless steel screws (1.6 mm, Modern screws Ltd, 
Dartford, UK) were inserted intracranially into two additional buff holes above and to 
the side of the cannula implantation site to form a triangle. The indwelling guide 
cannula, which was held in a modified holder attached to the surgical frame, was then 
stereotaxically lowered -7.6 mm. ventral to dura, so that its tip was I mm above the left 
SNc and the remaining 3 mm protruding 2 mm. above the I mm-thick skull. Once in 
place, the skin was un-retracted as the incision area was kept open by the intracranial 
screws. Quick-setting acrylic dental cement (Simplex rapid acrylic powder premixed 
with methyl methacrylate, Associated Dental Products, Swindon, UK) was made up and 
applied to the area using a sterile spatula and allowed to dry for at least 5-10 min. The 
purpose of the cement is to firmly anchor the indwelling guide cannula to the 
intracranial screws and keep it in place. The cement was judged set when it could no 
longer be deformed by pressure with the edge of the spatula. The top of the guide 
cannula was then carefully removed from its special holder attaching it to the frame. 
During this time, the cannula was held firm with forceps to prevent any slight 
alterations in position. Once removed from the holder, a further application of cement 
was then made to completely cover the implantation site and further secure the cannula. 
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Figure 2.2 Stereotaxic co-ordinates for guide cannulae implantation 
Diagrammatized coronal brain section (plate 37 of the standard rat brain atlas, Paxinos and Watson, 
1986) to illustrate the stereotaxic coordinates used to implant indwelling guide cannula I mm 
superior to the left substantia nigra pars compacta (SNc), as indicated by the arrow. Coordinate I is 
equal to 2.5 mm lateral to the midline and coordinate 2 to is equal to -7.6 mm ventral to dura. The 
anterior coordinate is not shown, but is equal to -3.0 mm anterior to bregma. These co-ordinates 
were measured with the incisor bar set 5 mm above the interaural line. The Paxinos and Watson 
atlas (1986) diagrams are based on incisor bar set 3 mm above the interaural line, hence these 
markers are purely illustrative and not intended to be to exact scale. 
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A dummy cannula, previously cut to the correct length was then inserted into the guide 
cannula to keep it patent. 
Post-surgery, rats were placed in a heated recovery chamber for I hour to 
recover from the anaesthetic. Post-operative care included individual caging with extra 
bedding material (changed every 2 days) and a mashed diet. Rats were allowed to 
recover for a minimum period of 10 days before any experimentation was started. 
During this period, rats were visually checked each day for signs of distress such as 
porphyrin staining around the eyes and nose, or irritation such as scratching at the 
cranial cap and implanted cannula. Additionally, rats were weighed daily to assess 
recovery. Any animal which managed to dislodge its cranial cap and thereby remove the 
indwelling guide cannula, or showed excessive distress coupled with a failure to regain 
body weight was culled immediately by a Home Office approved Schedule One method 
following advice from the named vetinary surgeons attached to the CBU. All scientific 
procedures were carried out in accordance with the Home Office Animals (Scientific 
Procedures) Act, UK, 1986 and associated guidelines. 
2.1.2.3 Optimisation ofsurgical technique 
The surgical technique described in section 2.1.2, at the commencement of this project, 
underwent a series of optimisation steps. It was observed in early procedures that 
approximately 25% of the implanted rats were irritated by their cranial caps and 
managed to dislodge them, resulting in the removal of the indwelling guide cannulae. 
These animals were culled immediately by a Schedule One method, as outlined in 
section 2.1.2. This loss significantly reduced the number of animals available for study 
causing delays to progress and clearly could not be sustained nor tolerated under the 
premise of the three R's (the Replacement of procedures with others which do not use 
animals, the Reduction of the number of animals used and the Refinement of procedures 
to minimise pain and suffering) as set out in the Home Office Animals (Scientific 
Procedures) Act, UK, 1986 and associated guidelines. Thus, urgent steps were taken to 
resolve the problem and optimise the surgical procedure accordingly. 
It was evident that two intracranial screws were inadequate to anchor the guide 
cannula sufficiently. Therefore, the first modification was to insert three intracranial 
screws, one in each quadrant of the skull around the cannula implantation site, such that 
a square was formed. This immediately made an improvement and a significant 
reduction in the number of dislodged caps was observed. Additionally, it was found that 
the use of powdered human fibrin to stop bleeding was interfering with cement 
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adherence to the skull, which was contributing to some animals being able to dislodge 
their caps. The use of fibrin was therefore discontinued and all bleeding was controlled 
by direct pressure with a sterile gauze swab or cotton bud. If the bleeding was severe 
and could not be stopped with direct pressure alone, a compound known as bonewaXTM 
(Ethicon, San Angelo, USA) was employed which did not affect cement adherence. 
This was probably due to the much smaller quantity of bonewax required to staunch 
bleeding from cranial vessels and the ease with which it could be applied very 
specifically to small areas on the skull, in marked contrast to the powdered fibrin. Taken 
together these modifications significantly reduced the loss of animals to around 1-2 per 
batch of 30-36, clearly representing a significant optimisation and improvement of the 
procedure. 
2.1.2.4 Verification ofguide cannulae placement 
Following implantation of indwelling guide cannulae, accurate cannulae placement and 
verification of the injection site were confirmed by histological staining with cresyl fast 
violet (CFV). Eight male Sprague-Dawley rats weighing 250-270g were cannulated as 
described in section 2.2.2. Animals were allowed to recover for 10 days and were then 
sacrificed by decapitation and the brain quickly dissected out onto a chilled platform. 
The post-mortem protocol as outlined in section 2.6 was then carried out, with the 
hindbrain blocks fixed for 5 days in 4% paraformaldehyde (PFA), followed by 
cryoprotection in a 30% sucrose solution, until the blocks were observed to have sunk 
(24-48 hrs). Hindbrain blocks were then stored at -80'C until subsequent cryostat 
sectioning. Coronal tissue sections equivalent to the entire rostral to caudal extent of the 
SNc equivalent to plates 37 to 43 (4.80 to -6.30 mm from bregma respectively) from 
the standard rat brain atlas of Paxinos and Watson (2 "d Ed. 1986) were cut 20 RM thick 
using a cryostat maintained at -20'C (Bright Instruments, Cambridge, UK). Sections 
were cut directly onto polylysine-coated slides (VWR, Lutterworth, UK) and allowed to 
adhere completely by air-drying. Subsequently, these sections were then counterstained 
with CFV. Briefly, sections were immersed in 0.1% CFV solution containing 10% 
acetic acid for 5 minutes at room temperature and then rinsed in distilled water. Staining 
was then differentiated using CFV differentiator solution (99.75% ethyl alcohol, plus 
0.25% glacial acetic acid), followed by washing in distilled water. The amount of 
differentiation was examined under light microscopy at low magnification (xIOO) to 
confirm only the Nissl substance and nuclei were stained violet whilst the background 
remained colourless. Sections were then dehydrated through ascending alcohol and 
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xylene solutions and coverslipped using DPX mountant, allowed to dry and cleaned. 
Cytoarchitectural verification of the injection site was then made by examination of 
CFV-stained sections under a light microscope at x100 and x 400 magnifications with 
reference to a standard rat brain atlas (Paxinos and Watson, 1986). In addition, 
verification of cannulae placement was also made by visual examination of needle tracts 
in freshly dissected tissue and tissue sections. 
2.1.3 Induction of substantia nigra lesions with 6-hydroxydopamine 
Unilateral lesions of the left SNc were induced by infusion of 12 ýtg 6- 
hydroxydoparnine into the SNc (6-OHDA, free base in 4 ýtl 0.1% ascorbic acid/saline 
solution) via the stereotaxically implanted indwelling guide cannulae in conscious, 
freely-moving male Sprague-Dawley rats. The 6-OHDA was made fresh for each 
experiment and during lesioning was stored on ice and shielded from light to prevent 
degradation. The 6-OHDA was infused over a2 minute period via a 33-gauge stainless 
steel injection cannula inserted fully through and extending I mm ventrally below the 
tip of the guide cannula, connected by flexible plastic tubing (Portex, Hythe, UK) to a 
25 ýtl 700 series Hamilton syringe mounted on a motorised syringe pump (Harvard 
Apparatus, Edenbridge UK). The infusion was made at a rate of 2 ýd / minute, followed 
by a five minute equilibration time when the needle remained in place to minimise any 
reflux of toxin back up the guide cannula, before it was slowly removed and the dummy 
cannula replaced. Sham-lesioned animals received identical surgery as 6-OHDA- 
lesioned animals, but 4 ýtl of sterile saline containing 0.1% ascorbic acid (6-OHDA 
vehicle) was infused instead. In all experiments, all animals were lesioned according to 
this paradigm with strict adherence (especially to time) to minimise potential 
differences in lesion size between groups of animals. 
2.1.4 Preparation of drug solutions for focal injection 
Stock solutions of the following metabotropic glutamate receptor (mGluR) ligands were 
made: the Group I mGluRl receptor antagonist (S)-(+)-a-amino-4-carboxy-2- 
methylbenzeneacetic acid (LY367385), the Group 11 mGluR2/3 receptor agonist 
(2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R, 4R-APDC), the broad spectrum 
Group III mGluR agonist L(+)-2-amino-4-phosphonobutyric acid (L-AP4), the specific 
Group II mGluR2/3 receptor antagonist (2S)-a-ethylglutamic acid (EGLU) and the 
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selective Group III mGluR antagonist (RS)-a-methylserine-0-phosphate (MSOP; all 
purchased from Tocris Cookson, UK). Each ligand was dissolved by sonication in 
phosphate buffered saline (PBS [mM]: NaCl 137, KCI 2.7, KH2PO4 1.8, Na2HP04 10, 
titrated with IM NaOH to pH 7.4) such that the final concentration of each individual 
stock solution was 5 mM. These were subsequently serially diluted in PBS to produce 
solutions at the final concentrations required for focal injection (for these concentrations 
see individual Results chapters). These solutions were then stored as 50 ýd aliquots at - 
80'C until use, as recommended by Tocris Cookson, to maintain ligand activity. 
The exception to this method was the Group I mGluR5 receptor antagonist 2- 
methyl-6(phenylethynyl)-pyridine. hydrochloride (MPEP. HCL henceforth abbreviated 
as MPEP; Tocris Cookson, Bristol, UK), which precipitates in saline solution. Thus, 
MPEP stock solutions were made up in sterile water in which it does not precipitate. It 
should be noted that the pH of this solution is around pH 3.6, which is too low (even 
allowing for intracerebral buffering) for use in intracerebral injections. However, after 
serial dilutions of the 5 mM stock solution in sterile water to produce a solution at the 
concentrations required for injection (see individual Results chapters for concentrations) 
the pH is raised to around pH 5.5. This solution was then titrated to pH 7.4 using IM 
NaOH to allow it to be used for focal injections. As with the other ligands, these 
solutions were then stored as 50 ýtl aliquots at -80'C until use to maintain ligand 
activity. On each day of mGluR ligand intracerebral administration, a fresh aliquot of 
each concentration of each mGluR ligand was thawed from the freezer for use. Frozen 
aliquots were not kept frozen for more then one month on the advice of Tocris Cookson, 
since stability cannot be guaranteed after this period. Furthermore, new stock solutions 
of mGluR ligand were prepared fresh for each individual set of experiments. 
Additionally, all mGluR ligand solutions were pH-checked once diluted and all 
solutions were made titrated to pH 7.4 as necessary. Additionally, in experiments where 
mGluR agonists were co-administered with selective antagonists (see Chapter 3) and 
where mGluR ligands were administered in combination (see Chapter 5), individual 
drug solutions for each mGluR ligand were made up as described above, but at twice 
the desired final concentration. Individual mGluR ligand solutions were then mixed in 
half the volume to produce the final desired concentrations, such that only one injection 
would be required to administer the mGluR agonist and antagonist, or the combination 
of mGluR ligands, thus importantly keeping the injection volume the same. 
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2.1.5 Intranigral administration of selective mGluR ligands 
In the current study, the mGluR ligands were all focally administered intranigrally using 
the following paradigm in each individual set of experiments (for specific details of 
concentrations and dosing regimes see individual Results chapters). Intranigral 
infusions of mGluR ligands were made into the left SNc via the stereotaxically 
implanted indwelling guide cannula (AP: -3.0 mm, L: +2.5 mm. and V: -7.6 mm) in the 
same manner as 6-OHDA was administered, as described in section 2.1.3, in conscious, 
freely-moving male Sprague-Dawley rats. Thus, the ligands were infused via a 33- 
gauge stainless steel injection cannula inserted fully through and extending I mm below 
the tip of the guide cannula, connected by flexible tubing (Portex, Hythe, UK) to a 25 ýd 
700 series Hamilton syringe mounted on a motorised syringe pump (Harvard Apparatus, 
Edenbridge, UK). As with 6-OHDA, the infusion was made over 2 minutes at a rate of 2 
[d / minute, followed by a five minute equilibration time when the needle remained in 
place, before being slowly removed and the dummy cannula replaced. Control vehicle- 
treated animals received identical infusions, but 4 ýd of PBS or sterile water (mGluR 
ligand vehicle) were infused instead, in order to test that injection of mGluR ligand 
solutions was not simply neuroprotective by dilution of 6-OHDA toxicity or other non- 
specific effects. 
2.1.6 Generalised post-mortem procedure and collection of brain tissue 
At the defined end-point of each individual experiment (for full details see individual 
Results chapters) animals were sacrificed by decapitation and the brain quickly removed 
and cut coronally at the level of the infundibular system (4.16 mm from bregma) on a 
chilled platform using a rodent brain matrix. The resultant hindbrain and forebrain 
blocks were then separated. Hindbrain blocks containing the SNc were fixed for 5 days 
in 4% PFA made up in IM PBS (pH 7.4), then cryoprotected in a 30% sucrose solution 
until it was observed that the blocks had sunk (maximum of 48 hours). Brains were then 
stored desiccated at -80'C until subsequent cryostat sectioning. From the 
forebrain 
blocks, the left and right corpus striata were rapidly dissected out, flash frozen on solid 
C02 and stored at -80'C until subsequent assaying for monoamine content 
by High 
Performance Liquid Chromatography with Electrochemical Detection (HPLC-ECD), as 
described in section 2.2.3 
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2.2 Ex-vivo methods 
2.2.1 Avidin-Biotin Immunohistochemistry 
2.2. LI The ABC immunohistochemistry technique 
In the current study all immunohistochernical analysis was carried out using a standard 
avidin-biotin immunoperoxidase method, also known as the "ABC technique" which is 
summarised below (adaptedftom www. vectorlabs. com/uk/protocols. asp). 
Avidin is a 68 kDa molecular weight glycoprotein, which has an extraordinarily 
high affinity for the low molecular weight vitamin protein biotin, thus the binding of 
avidin to biotin is essentially irreversible. In addition to this high affinity the avidin- 
biotin system may be exploited since avidin has four binding sites for biotin and several 
molecules of biotin can be readily conjugated to proteins including antibodies and 
enzymes. These aspects provide the potential for formation of macromolecular 
complexes to be formed between biotinylated proteins and avidin. Based on these 
properties an immunoperoxidase method was developed to localise antigens in tissue 
sections. This is a widely used technique in which unlabelled primary antibody is first 
applied to the tissue section, followed by biotinylated secondary antibody. A preformed 
avidin conjugated horseradish peroxidase macromolecular complex is then added. The 
antibody binding can then be visualised by the addition of a substrate for the peroxidase. 
Traditional substrates include diaminobenzidine tetrachloride (DAB) and 3-amino-9- 
ethyl carbazole (AEC). Diaminobenzidine produces a brown precipitate in tissue 
sections, or a grey/black colour in the presence of divalent cations such as nickel or 
cobalt. This precipitate is insoluble in alcohol and clearing agents such as xylene, 
allowing sections to be permanently mounted. The ABC method is depicted graphically 
in Figure 2.3. This simple, rapid method has several advantages over directly coupling a 
marker to an antibody or using lectin or nucleic acid probes. Firstly, the extraordinarily 
high affinity between avidin and biotin (affinity constant : ý, 1015 M-1) means a stable 
complex is rapidly formed between the avidin conjugate and the biotinylated secondary 
antibody. Secondly, since biotin is able to bind more than one molecule of avidin, the 
binding of the avidin peroxidase conjugate to the biotinylated secondary antibody 
means a large amount of peroxidase can bind to a single antigen site. This significantly 
amplifies the observed staining, which greatly enhances the sensitivity of the 
immunohistochernistry performed, allowing smaller dilutions of primary antibody to be 
used and reducing staining times. 
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Figure 2.3 Cartoon to illustrate the ABC immunohistochemistry 
technique. 
In brief, following quenching of endogenous peroxidase activity, unlabelled primary 
antibody is applied to the tissue sections followed by biotinylated secondary 
antibody. A prefonned avidin-biotin-horseradish peroxidase macromolecular 
complex is then applied to form a molecular scaffold bound to the secondary 
antibody. Antibody binding is then visualised by the addition of the chromagen 3,3'- 
diaminobenzidine (DAB) which, in the presence of the peroxidase substrate 
hydrogen peroxide, forms an insoluble brown precipitate or a grey/black precipitate 
in the presence of divalent cations such as nickel (Ni2+). 
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In the following sections, the ABC immunohistochernistry performed for each 
specific marker protein studied is outlined. All ABC immunohistochernistry was 
performed using a standard protocol, which is outlined below in section 2.2.1.2. Any 
modifications to this standard protocol are covered in the individual sections. Details of 
all antibodies employed and appropriate working dilutions may be found in Table 2.1. 
All antibodies were stored as per the manufacturer's instructions. In general, primary 
antibodies were pipetted into 10 ýtL aliquots, kept frozen at -20'C and thawed on the 
day of use. Secondary antibodies were reconstituted from powdered form by the 
addition of I mL distilled water as per the manufacturer's instructions and stored at 4'C. 
2.2.1.2 Standard protocolfor ABC immunohistochemistry 
In the current study all ABC immunohistochemistry was performed using a standard 
immunoperoxidase protocol, as outlined below. Where modifications were made to this 
protocol, details of these may be found in the sections relating to each marker protein 
studied. All antibodies were extensively tested to ensure good immunostaining and 
optimisation of appropriate working dilutions for all primary and secondary antibodies. 
Details of all antibodies used and appropriate working dilutions may be found in Table 
2.1. 
Coronal tissue sections equivalent to the entire rostral to caudal extent of the 
SNc equivalent to plates 37 to 43 (4.80 to -6.30 mm. from bregma respectively) from 
the standard rat brain atlas of Paxinos and Watson (2 nd Ed, 1986) were cut 20 gM thick 
on a cryostat maintained at -22'C (Bright Instruments, Cambridge, UK). Tissue sections 
were then collected and stored free-floating in IM PBS (pH 7.40) containing 0.05% 
sodium azide as a preservative. Prior to immunostaining, sections were transferred into 
individual wells on a 24-well plate (Falcon, Beckton Dickenson, Cowley, UK) with 2-3 
sections per well in I mL of IM PBS (pH 7.40). Plates containing free-floating tissue 
sections were then placed on a vibrating platform to ensure sections were gently 
agitated in each solution. In all subsequent steps the volume of all reagents and buffers 
added to each individual well was I mL. Tissue sections were rinsed 3x5 min in IM 
PBS (pH 7.40) before endogenous peroxidase activity was quenched by incubating 
sections in 3% H202 in IM PBS for 30 min. Antibody penetration was then facilitated 
by rinsing tissue sections in IM PBS containing 0.1 % Triton X- 100 (PBS-TX, pH 7.40) 
for a further 15 minutes to permeabilise cell membranes in individual tissue sections. In 
order to eliminate any non-specific antibody binding, tissue sections were blocked for 2 
hours in 3% non-immune serum diluted in IM PBS (pH 7.40). Where polyclonal 
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primary antibodies were used, tissue sections were blocked in normal goat serum (NGS) 
for one hour, as the secondary antibodies were all raised in goat. In contrast, where 
mouse monoclonal antibodies were employed, tissue sections were blocked for I hour 
in 3% normal horse serum (NHS), as the secondary antibodies to these were all raised in 
horse. This is indicated for each antibody in Table 2.1. In each case, powdered serum 
was reconstituted by the addition of distilled water as per the manufacturer's 
instructions. Serum was then pipetted into 5 mL aliquots and stored at -20'C and 
thawed on the day of use before dilution with IM PBS (pH 7.40). After blocking, tissue 
sections were incubated with unlabelled primary antibody, diluted in PBS-TX (pH 7.40) 
containing 3% serum, again goat or horse depending on whether poly- or monoclonal 
antibodies were used. The addition of goat (or horse) serum to the antibody solution was 
done to further minimise any chance of non-specific antibody binding, whilst the PBS- 
TX facilitates antibody penetration as previously indicated. 
Tissue sections were incubated in primary antibody at room temperature for 18 
hours, before addition of biotinylated secondary antibody diluted in IM PBS (pH 7.40), 
in which tissue sections were incubated for a further 2 hours at room temperature. This 
was followed by incubation for I hour in a pre-formed avidin conjugated horseradish 
peroxidase macromolecular complex (Vectastain Elite ABC kit PK-6100, Vector Labs, 
Peterborough, UK). This was used as per the manufacturer's instructions, diluted in IM 
PBS (pH 7.40), made up 30 minutes before use and stored at 4'C and shielded from 
light to prevent its degradation. Antibody binding was then visualised by incubating 
tissue sections in DAB solution, using a specific DAB peroxidase kit, as per the 
manufacturer's instructions (DAB peroxidase kit SK-4100, Vector Labs, Peterborough, 
UK). The amount of time sections were incubated in DAB solution was optimised for 
each individual protein under study. Good staining was defined as robust labelling of 
cells with minimal background. In general, sections were incubated in the DAB solution 
for between I and 3 minutes, until DAB staining was confirmed visually by formation 
of the characteristic DAB brown precipitate. Tissue sections were then rinsed for 5 
minutes in distilled water to terminate the DAB staining reaction. In between each 
individual step in this protocol, tissue sections were rinsed in IM PBS (pH 7.40) (3 x5 
min). For each immunostain, a negative control in which the primary antibody was 
omitted was performed. In each case when this was done no immunoreactivity was 
observed. Once the staining protocol was completed, tissue sections were mounted onto 
polylysine coated slides and allowed to dry. Tissue sections on slides were then 
dehydrated through ascending alcohol solutions for 2 minutes in each, followed by 
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clearing in two changes of neat xylene for 3 minutes before coverslipping with DPX 
mounting medium. Where appropriate tissue sections were counterstained with cresyl 
fast violet (CFV) as described in section 2.1.2.4 before proceeding with dehydration. 
All dehydration and mounting was performed in a fume hood and slides were allowed 
to dry overnight before removal of excess DPX Slides were then cleaned with ethanol 
and stored in labelled slide boxes, prior to cell counting and image analysis. Details of 
how immunolabelled cells were quantified using image analysis software under light 
microscopy may be found in section 2.2.2 
2.2.1.3 Tyrosine hydroxylase immunohistochemistry 
Doparninergic cells in the SNc were visualised by Tyrosine Hydroxylase (TH) 
immunohistochernistry. This protein is the rate-limiting enzyme in the synthesis of 
noradrenaline and dopamine from tyrosine in catecholarninergic neurons (Nagatsu et al, 
1964; 1965) and thus labels both types of neuron (Pickel et al, 1975; 1976; 1977). 
Importantly in the SNc, the only catecholamine neurones present are dopaminergic, thus 
TH-immunoreactivity (TH-IR) is an effective marker for labelling nigral doparninergic 
cells (Pickel et al, 1977; Wassef et al, 198 1) and provides a rapid, reproducible method 
by which the number of doparninergic cells in the SNc may be quickly and accurately 
quantified following lesioning with neurotoxins such as 6-OHDA. Furthermore, it 
provides a useful method to quantify the effect of potential neuroprotective drug 
treatments on doparninergic cell number in the SNc and thus, the integrity of the 
nigrostriatal tract. In the current study, TH immunohistochernistry was carried out on 
alternate free-floating 20 ýM thick tissue sections from sham-lesioned, 6-OHDA- 
lesioned and drug-treated animals, cut in series on a cryostat maintained at -22'C 
(Bright instruments, Cambridge, UK), as previously described by Dexter et al, (1994) 
using the standard protocol outlined in section 2.2.1.2. Details of the TH antibody 
utilised and optimal working dilutions may be found in Table 2.1. Following TH- 
immunohistochemistry, stained tissue sections were counterstained with cresyl fast 
violet (CFV) as described in section 2.1.2.4, to visualise the nucleus of TH-IR cells to 
facilitate cell counting. Additionally, some tissue sections from each animal were 
stained with CFV alone in order to facilitate identification of cannula placement in each 
animal. The numbers of TH-IR cells were then quantified in the ipsilateral and 
contralateral hemispheres of stained sections as described in section 2.2.2. 
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2.2.1.4 Neuronal marker N immunohistochemistry 
Whilst TH immunohistochernistry is an effective marker for doparninergic cells, 
changes in the number of TH-IR cells may not reflect actual loss of dopaminergic 
neurones, but could be explained by transient cellular atrophy and regulation of TH 
expression rather than representing true neuronal death, or indeed neuroprotection 
(Sherman and Moody, 1995; Meuer et al, 2006; Yuan et al, 2005). Therefore, to address 
this possibility, in a separate experiment, sections from both sham and 6-OHDA- 
lesioned animals were immunostained with the specific neuronal marker protein 
Neuronal N (NeuN, Mullen et al, 1992). Immunostaining for NeuN was performed as 
for TH using the standard protocol outlined in section 2.2.1.2 on free-floating 20 [im- 
thick sections, with the following modifications. Serum blocking was performed using 
normal horse serum (NHS) and tissue sections were incubated with monoclonal NeuN 
primary antibody (see Table 2.1 for details) diluted 1: 2000 in 0.1% PBS-Triton 
containing 3% NHS at room temperature for 18 hours, followed by biotinylated a- 
mouse IgG secondary antibody, diluted 1: 200 in IM PBS (pH 7.40) for 2 hours. As with 
TH. antibody-binding signal was amplified using the Vectastain Elite ABC kit (Vector 
Labs, Peterborough, UK) and antibody binding visualised using a specific DAB 
peroxidase kit, as per the manufacturer's instructions (DAB peroxidase kit SK-4100, 
Vector Labs, UK) utilising a nickel-enhancement step. All details of antibodies used 
and optimal working dilutions are shown in Table 2.1. Additionally, as with TH-IR, 
some tissue sections were stained with CFV alone, in order to facilitate identification of 
correct cannula placement. The numbers of NeuN-IR cells were then quantified in the 
ipsilateral and contralateral hemispheres of stained sections (see section 2.2.2.2) 
2.2.1.5 Glial Fibrillary acidic protein (GFAP) and OX-42 (CR3) immunohistochemistry 
A likely consequence of guide cannulae implantation and repeated insertion of injection 
needles is the occurrence of gliosis and scarring in brain tissue (Hatten et al, 1991). The 
formation of a glial scar is a common reaction to a traumatic brain injury or insult and 
this could compromise the neurochemical integrity of the tissue. This scarring is 
predominately characterised by an increase in the number of reactive astrocytes in the 
hemisphere of the brain in which the cannula is implanted and these are characterised by 
a larger cell body and extensive processes and a greater intensity of glial fibrillary acidic 
protein (GFAP) staining. Glial fibrillary acidic protein belongs to the intermediate 
filament family of proteins, which are a distinct class of molecularly heterogeneous 
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cytosekeletal filaments. In astrocytes, GFAP is the specific intermediate filament 
protein and thus represents a biochemical marker for cells of the astrocyte lineage, 
providing a useful marker to allow qualitative analysis of the degree of astrocytosis and 
the morphology of these cells in brain tissue sections. Astrocytosis is usually preceded 
by an increase in the number of reactive microglia, the brain resident immune- 
competent cells, in the implanted hemisphere of the brain. The OX42, or CDllb/c 
equivalent antibody, recognises a common epitope shared by CD II b/c, the complement 
receptor 3 (CR3), and is a useful biochemical marker for microglia in nervous tissue. 
OX42 labels all cells with microglial morphology in the brain including cells of the 
macrophage lineage and therefore represents a useful method for analysis of the number 
and morphology of microglia in brain tissue sections. 
It is also widely known that inflammatory responses are associated with the 
effects of doparninergic neurotoxins such as 6-OHDA and MPTP (Hirsch et al, 2003). 
Indeed, intrastriatal in ection of 6-OHDA in rodents causes proliferation of both 
astrocytes with a concomitant large increase in GFAP-IR in the lesioned SNc and a 
significant increase in the number of reactive astrocytes (Kurkowska-Jastrzebska et al, 
2001; Chichetti et al, 2002) and this astrogliosis is proceeded by an increase in the 
number of microglial cells, demonstrating an activated, reactive, morphology 
(Kurkowska-Jastrzebska et al, 2001; Chichetti et al, 2002). 
Therefore, to investigate the degree of inflammation and glial scarring following 
cannulae implantation, animals were implanted with guide cannula as described above 
and sacrificed after 10 days, equivalent to the timepoint at which drug treatment and 6- 
OHDA lesioning was initiated. In addition, in order to investigate the degree of 
inflammation and reactive gliosis following 6-OHDA lesioning, additional groups of 
animals were implanted with guide cannula and lesioned with 6-OHDA as described in 
section 2.1.2 and 2.1.3. Animals were then sacrificed and the brain tissue collected and 
processed as described in section 2.1.6, and free-floating sections stained for GFAP and 
OX42 respectively using the standard immunoperoxidase method as outlined in section 
2.2.1.2 Details of antibodies and working dilutions may be found in Table 2.1. As in 
previous experiments adjacent sections to those immunostained for GFAP or OX42 
were counterstained with CFV as described above in order to facilitate confirmation of 
correct cannulae placement. Sections immunostained with GFAP or OX42 were not 
counterstained with CFV in order to facilitate observation of GFAP or OX42 
immunostaining. For both GFAP and OX42 immunostaining, negative control 
experiments were performed in which the primary antibody was omitted as described 
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. above. In both cases this resulted in no immunostaining. Additionally, for OX42 
immunostaining, positive control experiments were performed to ensure specificity of 
immunostaining. In these experiments sections from rodents which had been subjected 
to brain transect injuries, which are known to induce extensive reactive microgliosis at 
the site of injury (kindly provided by Dr D. T Walsh, Dept Cellular and Molecular 
Neuroscience). OX42 staining was then compared between these and sham and 6- 
OHDA lesioned animals to ensure correct identification of OX42-positive cells. 
Primary arThbody 
Secondary 
Epitope (working Soume antibody 
dilution) (working 
dilution) 
Tyros in e 
Polyclonal rabbit 
rryd roxyl ase a-rat 
TH 
(1: 3000) 
AB5395 
Chernicon Europe, 
UK 
Biotinýlated goat 
a-rat I gG 
(l. '200) 
Monoclonal mouse 
Neuronal N a-rat NeuN 
(1., 2000) 
Glial Fibrillary Monoclonal mouse 
Acidic Protein a-rat GFAP (1. - 1000) 
Monoclonal mouse 
OX-42 (Ccl 11 b) a-rat OX42 
(1., 2000) 
MAB377. 
Chemicon Europe, 
UK 
G3893 
Sigma, UK 
Abl2ll 
Abcam, UK 
Biotinylated horse 
a-mou3e IgG 
(1. *200) 
Biotinylated horse 
a-mouse IgG 
(1., 200) 
Biotinylated horse 
a-mouse IgG 
(1: 200) 
Table 2.1 Details of all primary and secondary antibodies utilised in ABC 
immunohistochemistry. Sources and catalogue numbers as well as optimal working 
dilutions are also shown. 
2.2.2 Image analysis and cell counting 
2.2.2.1 Quantitative cell counting of nigral TH-IR cells in the SNc 
Before quantitative TH-IR cell number analysis was performed, in each animal, in each 
treatment group tissue sections stained with CFV alone were examined in order to 
confirm the correct cannula placement (see section 2.1.2.4). In animals where the 
cannula was not correctly located, quantitative TH-IR cell number analysis was not 
performed. 
In order to quantitatively assess the number of tyrosine-hydroxylase 
immunoreactive (TH-IR) nigral cells, quantitative counting of the number of TH-IR cell 
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bodies in the SNc was then performed manually using a Nikon Eclipse E800 
microscope (Nikon, Tokyo, Japan) connected to a JVC digital camera at, x200 
magnification. In all treatment groups, TH-IR cell bodies were counted in the 
contralateral and ipsilateral hemispheres of the brain in each of the stereotaxic regions 
of the SNc, defined A, B, C, D, and E (-4.80, -5.30, -5.60, -5.80 and -6.30mm from 
bregma, respectively) (Carmen et al, 1991) to ensure complete sampling of the entire 
SNc structure. These regions and the shapes and distribution of TH-IR cells in each are 
illustrated in Figure 2.4. In each section, the stereotaxic region of the SNc was identified 
by examination of the shape and distribution of TH-IR cells, at low magnification (x40) 
with reference to previous descriptions of these patterns (Carmen et al, 1991). The SNc 
was then delineated from the VTA by reference to anatomical landmarks such as the 
medial terminal nucleus (MTN) of the accessory optic tract level and the third nerve 
rootlets, as previously described (Iravani et al, 2002). The number of TH-IR cells in 
both lesioned and contralateral hemispheres of the SNc in each tissue section was then 
counted manually at high magnification (x 200 and x 400). Prior to cell counting, 
operators were assessed for consistency of counting and the ability to distinguish the 
SNc and VTA reproducibly in each stereotaxic level of the SNc. Only cells that were 
intact and displayed a robust TH-IR with a nucleus and a clear cytoplasm and axonal 
processes were counted and cells that appeared severely deformed were not included 
(Iravani et al, 2002; Yuan et al., 2005). For each animal, a minimum of 5 adjacent 
sections were counted at each SNc level and these were pooled to give a mean cell 
count for each individual animal. These counts were further pooled to give a total mean 
cell count for the contralateral and ipsilateral hemispheres in each treatment group. The 
lesion size was then expressed as a percentage of the intact contralateral side. This 
approach to cell counting has been used previously to ensure that comparable rostral to 
caudal levels of the SNc are sampled between animals (Datla et al, 2001a, b; 2002; 
Iravani et al, 2002; Vernon et al, 2005; 2006). Furthermore, this approach prevents 
errors in counting the numbers of cells residing in the SNc and VTA. In order to ensure 
the absence of bias, the operator was blind to the treatment group under analysis at all 
times and cell counts were verified by a second operator, also blind to the treatment 
group and the data compared for consistency. At the same time as quantitative analysis 
was performed, representative photomicrographs were captured at x 40 magnification 
using the same microscope, camera and Image Pro Plus v5.0 software (Media 
Cybernetics, Finchampstead, UK). 
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Figure 2.4 The five stereotaxic levels of the substantia nigra. pars compacta 
(SNc) 
Representative images of coronal sections cut through the SNc to illustrate the 
five stereotaxic levels of the SNc. denoted A (4.80 mm), B (-5.30 mm. ), C (-5.60 
mm), D (-5.80 mm) and E (-6.30 mm from bregma, respectively) as defined by 
Carmen and colleagues (1991) at which the number of nigral TH-IR cells was 
counted to give a final mean cell number. The SNc and the nearby ventral 
tegmental area (VTA) are highlighted. Initial cell counts were performed on 
sections corresponding to stereotaxic level B and then extended to cover the entire 
SNc structure. 
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2.2.2.2 Quantitative cell counting of nigral NeuN-IR cells in the SNc 
A similar approach was used to quantitatively analyse the number of NeuN-IR cells in 
the SNc from vehicle-treated, sham and 6-OHDA lesioned animals. In NeuN-IR stained 
sections, the SNc and VTA were defined by reference to representative TH- 
immunostained sections. As with TH-IR cells, cell counting was not performed in 
animals where the guide cannula was not correctly located as determined by analysis of 
CFV-stained nigral sections. If the cannula was correctly located, quantitative analysis 
of the number of NeuN-IR cells was performed exactly as described for TH-IR in the 
proceeding section and the data pooled and expressed in the same manner as for TH-IR 
cell counts. As with TH-IR cell counting, only NeuN-IR cells that displayed a darkly 
stained nucleus and with a clear cytoplasm and axonal processes were counted and cells 
that appeared severely deformed were not included. To ensure an absence of bias in cell 
counting, the operator was blind to the treatment group being counted and cell counting 
was corroborated by a second operator also blinded to the treatment group. At the same 
time as cell counting was performed, representative photornicrographs of nigral cells 
displaying TH-IR or NeuN-IR were captured at x 40 magnification, using the same 
microscope apparatus and image analysis software. 
2.2.2.3 Qualitative assessment of GFAP and OX42 immunoreactivity and cell 
morphology in the SNc 
Due to the essentially qualitative nature of determining the morphology of astroglia and 
microglia and significant difficulty in assessing total cell numbers of both cell types on 
semi-thick (20 ýtm) sections a qualitative approach was used to grade the degree of both 
GFAP and OX42-immunoreactivity (GFAP-IR and OX424R, respectively) in the 
present study. Immunoreactivity was graded in the following manner, as described 
previously by Cicchetti and colleagues (2002), which is described on the following 
page. 
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1. None: no GFAP-IR or OX-42-IR cells displayed the morphology of 
reactive or activated phenotype 
11. Focal: some of the GFAP-IR or OX42-IR cells displayed morphology 
typical of reactive astrocytes or activated microglia and the GFAP/ OX42 
staining was side-specific and confined to the SNc on the ipsilateral side of 
the lesion. 
III. Widespread: the majority of GFAP-IR and OX42-IR cells displayed 
morphology typical of reactive astrocytes or activated microglia. The 
GFAP/OX42 staining was widespread and not confined to the ipsilateral 
side of the lesion, but was also observed in the contralateral. side. 
Qualitative assessment of GFAP and OX42-IR was performed in a minimum of ten 
sections per animal using the same microscope set-up as described above for both TH- 
and NeuN-IR quantitative cell counting, at xlOO magnification. At the same time as 
sections were graded, representative photomicrographs were captured. Typical 
morphology of reactive astrocytes was defined as cells with intense GFAP-staining, 
displaying an enlarged cell body with one or two long and thickened processes. Typical 
morphology of "resting" astrocytes was defined as cells displaying moderate GFAP- 
staining with a small cell body and several processes. Typical morphology of activated 
microglia / macrophages was defined as cells with intense OX42-staining, characterised 
by larger cell bodies, shorter proximal processes and reduced ramification of the distal 
processes. Non-activated or "ramified" microglial cells were defined as cells with 
moderate OX42 staining, with small cell bodies and numerous processes with extensive 
ramification. To illustrate the clarification of these different cell types, representative 
photomicrographs taken at x400 magnification of each type are shown in Figure 2.5. 
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Figure 2.5 Representative photomicrographs of glial cell types and 
morphology 
High power representative photomicrographs to illustrate reactive and non- 
reactive morphology of astroglia (GFAP) and microglia (OX42) in the SNc of 
sham and 6-OHDA lesioned animals. (A) GFAP-IR cells contralateral, (B) 
GFAP-IR cells ipsilateral, (C) OX42-IR cells contralateral, (D) OX42-IR cells 
ipsilateral. All images are x 400 magnification, scale bar = 250 ýtm. 
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2.2.3 Analysis of striatal monoamines by HPLC-ECD 
In order to assess the functionality of the nigrostriatal tract, the concentrations of 
dopamine (DA) and its metabolites dihydroxyphenylacetic acid (DOPAQ and 
homovanillic acid (HVA) were measured in the corpus striaturn using high performance 
liquid chromatography with electrochemical detection (HPLC-ECD), as previously 
described by Datla et al, (2001a). Additionally, for control purposes, the concentrations 
of the indolamine neurotransmitter 5-hydroxytryptamine (5-HT) and its metabolite 5- 
hydroxyindoleaceticacid (5-HIAA) were also measured in the corpus striaturn. Briefly, 
individual striata were weighed and homogenised in 500 [d of ice-cold homogenising 
buffer (50 mM trichloroacetic acid, 0.5 mM disodium ethylenediaminetetraacetic acid 
(EDTA)) containing 0.5 pmol/ýtl 3,4-dihydroxybenzylamine hydrobromide (DHBA) as 
an internal standard. Samples were homogenised for 20 sec using an ultrasonicator 
(Soniprep, Sanyo, Loughborough, UK) and placed on ice for 10 min to allow complete 
extraction of monoamines, followed by centrifugation at 13,000 rpm for 10 min at 4*C 
(Heraeus centrifuge, Newport Pagnell, UK). The resultant supernatant was then filtered 
through a 0.2 [tM PTFE syringe pore filter (Whatman, UK) into glass HPLC vials and 
loaded onto an autosampler (Gina 50; Dionex, Camberley, UK) maintained at 5'C 
connected to a PC-based control system running Chromeleon software (Dionex, 
Camberley, UK). From each sample 20 [tl were injected and prior to passing through the 
column and detector, samples were passed through a guard cell (model 5020, ESA 
Biosciences, Chelmsford, UK) containing a large single porous graphite electrode set at 
+400 mV to remove any electroactive impurities, thereby decreasing background 
currents and improving baseline noise. Samples were then chromatographically 
separated on an Altex ultrasphere 5 [M column (4.6 min x 7.5 cm; Beckman-Coulter, 
High Wycombe, UK) using a mobile phase consisting of 0.1 mM 
KH2PO4.0-1 MM 
EDTA, I mM octyl sodium sulfonate, 10% methanol VN, adjusted to pH 2.75 with 
orthophosphoric acid, at a flow rate of 0.9 ml/min. Before use, the mobile phase was 
filtered and degassed. Samples were quantified by an online electrochemical analytical 
cell (model 5011; ESA Biosciences, Chelmsford, UK) containing two porous graphite 
electrodes, electrode one set at -0.20 V and electrode two at +0.34 V with respect to the 
palladium reference electrode, connected to a Coulochem 11 electrochemical 
detector 
(ESA Biosciences, Chelmsford, UK). Before analysis of samples, calibration curves 
were calculated for each monoamine to ensure a linear relationship 
between solute and 
concentration of each monoamine. Additionally, external standards of 
known 
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concentration were analysed prior to samples from drug or vehicle-treated groups to 
determine exact retention times for each monoamine and to facilitate quantification of 
the concentrations of monoamines in drug treatment samples. 
Control and drug-treated groups were analysed on the same day and 
chromatographic data was collected and analysed using PC-based Chromeleon software 
(Dionex, Camberley, UK). The concentration of each monoamine was then calculated 
and expressed as ng per mg of tissue wet weight. The levels of striatal monoamines in 
the lesioned and unlesioned striata for control and drug treated groups were then 
compared and analysed statistically as described in section 2.3. A representative 
chromatograrn trace is shown in Figure 2.6. Additionally, the amount of striatal 
dopamine turnover was calculated by measuring the ratio of dopamine (DA) to its major 
interneuronal metabolite DOPAC and its major extraneuronal metabolite HVA, using 
the expression (DOPAC + HVA)/DA, (all values in pmol/ml) to provide a measure of 
any possible compensatory mechanisms occurring in striatal doparninergic terminals in 
response to 6-OHDA lesion and to measure the effect of drug treatment on this ratio. 
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Figure 2.6 Representative chromatogram trace showing detection of 
monoamines in the corpus striatum by HPLC-ECD. Typical retention times 
were: Internal std 1.75 min, dihydroxyphenylacetic acid (DOPAC) 2.6 min, 
dopamine (DA) 2.8 min, 5-hydroxyindoleacetic acid (5-HIAA) 3.8 min, 
homovanillic acid (HVA) 5.3 min and 5-hydroxytryptamine (5-HT) 6.0 min. 
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2.3 Statistical analysis of data 
All data (except where stated) are presented as the mean ± SEM based on n independent 
observations. Individual comparisons were made using a two-tailed paired or unpaired 
Student's t-test for, as appropriate. Where multiple comparisons were made, one-way 
ANOVA with post-hoc Tukey's test for multiple comparisons was employed. Data for 
cell loss in vehicle and drug treated groups is presented as the mean percentage change 
± SEM in the ipsilateral hemisphere relative to the contralateral hemisphere, but mean 
cell numbers were also compared between both hemispheres. Biochemical data for 
monoamines is expressed in the same manner in ng/ml, except for doparnine turnover 
data, which is expressed as the mean values ± SEM in pmol/ml. In all figures, n values 
are shown in parenthesis. Differences were considered statistically significant at P<0.05 
and all statistical data analysis was performed using GraphPad Prism v4.00 software 
(GraphPad software, San Diego, CA, USA). 
2.4 Materials and Sources 
Metabotropic glutarnate receptor ligands were obtained from Tocris Cookson (Bristol, 
UK) and stainless steel cannulae from Plastics One (Roanoke, USA). 6- 
hydroxydoparnine was supplied by Sigma-Aldrich Chemical Co. Ltd (Poole, Dorset, 
UK). Primary antibodies were purchased from Chemicon Europe Ltd. (Chandlers Ford, 
UK), NGS and NHS from MP Biomedicals (Eschweger, Germany) and biotinylated 
goat anti-rabbit IgG secondary antibody, Vectastain Elite ABC staining kits and 
Vectastain VIP kits were obtained from Vector laboratories (Peterborough, UK). Pore 
filters for HPLC were purchased from Whatman (via VWR International, Lutterworth, 
UK). All other chemicals and reagents were supplied by either Sigma-Aldrich Chemical 
Co. Ltd. (Poole, UK) or VWR International Ltd. (Lutterworth, UK) unless otherwise 
stated in the text. 
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Chapter 3 
Sub-chronic administration of selected 
metabotropic glutamate receptor agonists and 
antagonists is neuroprotective in vivo against 6- 
hydroxydopamine toxicity 
- 138- 
3.1 Introduction 
Ligands acting at metabotropic glutamate receptors (mGluR) have been suggested as 
potential symptomatic treatments for PD, highlighted by a number of studies in 
experimental models (Senkowska and Ossowska, 2003) (see section 1.10.7.1). However, 
increasing evidence suggests that these ligands may also be neuroprotective and potentially 
slow disease progression (Conn et al, 2005) (see section 1.10.7.2). 
Recent studies have identified mGluR as playing a key modulatory role on 
glutamate neurotransmission within the basal ganglia (BG; Rouse et al, 2000) (see section 
1.10.6). Indeed, by virtue of their unique and restricted patterns of expression with the BG, 
it has been suggested that targeting mGluR may provide a unique approach to treating brain 
disorders in which glutamate excitotoxicity is implicated, including stroke and 
neurodegenerative disorders such as Huntington's disease (1-113), Alzheimer's disease (AD) 
and Parkinson's disease (PD) (Marino and Conn, 2003). Within the BG, it is generally 
suggested that activation of neuronal postsynaptic Group I mGluR is associated with an 
increase in neuronal excitation, whilst activation of neuronal Group 11 and III mGluR is 
associated with a reduction in neuronal excitation, by virtue of their proposed role as 
presynaptic inhibitory glutamate autoreceptors (Conn and Pin, 1997). Thus, it is 
hypothesised that selective antagonism of Group I mGluR and selective activation of Group 
11 and III mGluR would be predicted to be neuroprotective in disorders in which glutamate 
excitotoxicity is implicated (Nicoletti et al, 1996). In support of this hypothesis, numerous 
studies have documented a neuroprotective action of mGluR ligands in models of 
ischaemic brain injury (Bond et al, 1999; 2000; Rao et al, 2000) and striatal excitoxicity 
both in vitro and in vivo (Bruno et al, 1997; 1999; 2000a, b; Battaglia et al, 1998; Henrich- 
Noack et al, 2000). Interestingly, there is Preliminary evidence to suggest that mGluR 
ligands may be neuroprotective in experimental models of Parkinsonism. Indeed, 
antagonism of Group I mGluR is reported to be neuroprotective against MPTP toxicity in 
vivo (Aquirre et al, 2001) whilst selective activation of Group 11 mGluR has also been 
documented as neuroprotective against 6-OHDA toxicity in vivo (Murray et al, 2002). 
Importantly, evidence also exists for a neuroprotective action of selective Group III mGluR 
activation against excitotoxicity both in vitro (Lafon-Cazal et al, 1999a) and in vivo 
(Henrich-Noack et al, 2000). 
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Thus, the aim of the work described in this chapter was firstly to further investigate, 
characterise and provide in vivo evidence of the potential neuroprotective actions of 
selective Group I mGluR antagonism or Group 11 and III mGluR activation as has been 
described in other model systems. In order to do this, the widely-used rodent 6-OHDA 
experimental model of PD was utilised and classical toxicity experiments performed in vivo 
in which animals were lesioned with 6-OHDA and subsequently treated with either mGluR 
ligand or vehicle. The effects of 6-OHDA toxicity on the nigrostriatal system in mGluR 
ligand-treated animals were then compared to the effects seen in vehicle-treated animals. 
For this purpose, four recently developed, potent and selective mGluR ligands were chosen 
for study, these being the selective Group I mGluR antagonists LY363785 and MPEP, the 
highly-selective Group 11 mGluR agonist 2R, 4R-APDC and the broad spectrum Group III 
mGluR agonist L-AP4. The potential neuroprotective actions of these compounds were 
assessed in rodents bearing a unilateral 6-OHDA partial lesion of the nigrostriatal tract, 
using a sub-chronic (7 day) treatment regimen. Previous studies have reported 
neuroprotective effects of selective activation of Group 11 mGluR or antagonism of Group I 
mGluR in vivo following both acute (Aquirre et al, 2001; 2005; Battaglia et al, 1998; 2002; 
Bruno et al, 1997; 1999; 2000a, b; Henrich-Noack et al, 2000) and more chronic treatments 
(Murray et al, 2002). Thus in the first instance it was decided to utilise a sub-chronic 7 day 
treatment regimen, with the potential to test other treatment regimens, both acute (see 
Chapter 3) and post-lesion (see Chapter 6) in subsequent experiments for comparative 
purposes. 
In this study, unilateral lesions of the SNc were produced by infusion of 6-OHDA 
via a chron ical ly-i mp I anted guide cannulae through which all drugs were also infused (see 
sections 2.1.3 and 2.1.5), one hour before 6-OHDA. This was done because we currently do 
not know the time-course at which the mGluR ligands may have a neuroprotective effect. 
Thus, in these initial preliminary studies, an initial pre-treatment injection of each mGluR 
ligand was administered one hour prior to the infusion of 6-OHDA. Three concentrations 
were selected for each mGluR ligand to establish if any potential neuroprotective effect 
shows a concentration-dependent relationship and furthermore, to attempt to identify the 
minimum dose needed to achieve significant neuroprotection. The concentrations chosen 
for study are listed in Table 3.1. These were selected to Provide significant and selective 
receptor blockade or stimulation at each mGluR targeted, with no significant effects at any 
other mGluR subtype (dependent on subtype selectivity) or ionotropic glutamate receptors 
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(iGluR), as determined by previous studies from the literature. This is discussed for each of 
the mGluR ligands chosen for study in the following paragraphs. 
3.1.1 Group I mGluR antagonists 
The selective Group I antagonist LY367385 is reported to have an IC50of 8.8 gM at human 
mGluRla stably expressed in AV-12 cells as measured by an agonist-induced 
phosphoinositide (PI) hydrolysis assay (Clark et al, 1997). LY367385 shows no activity at 
concentrations >300 gM at either cloned human mGluR5, or at any Group 11 or Group III 
mGluR as measured by forskolin-induced cAMP assay (Clark et al, 1997; Kingston et al, 
2002), thus confirming LY367385 as a selective mGluR1 antagonist. In experimental 
models of epilepsy, LY367385 has been reported to have a powerful anticonvulsant effect 
in vivo. Indeed, bilateral focal administration of 40 to 160 nmol in LY367385 into the 
inferior colliculus effectively suppresses sound-induced clonic seizures in a concentration- 
dependent manner (Chapman et al, 1999). In terms of its proposed role as a 
neuroprotectant, intrastriatal injection of 100 nmol LY367385 was significantly 
neuroprotective against excitotoxic neuronal death when co-infused into the striatum with 
100 nmol NMDA in rodents (Battaglia et al, 2001). Subsequent experiments also reported 
a neuroprotective effect of LY367385 in a rodent model of transient focal ischaemia at 
similar concentrations (Kingston et al, 1999). Based on these data, a concentration range of 
40ý 200 and 1000 nmol in 4 ýd was selected as appropriate for neuroprotection studies with 
LY367385 in our experimental model of PD. 
The Group I selective mGluR5 antagonist MPEP is reported to have an IC50of 36 
nmol at cloned human mGluR5a stably expressed in L(tk-) cells, as measured by a PI 
hydrolysis assay, with no appreciable agonist or antagonist activity at human mGluRlb 
(closely related to mGluR5) or purinoceptors in the same cell line, up to concentrations of 
100 ýM (Gasparini et al, 1999; Kuhn et al, 2002). Furthermore, MPEP shows no agonist or 
antagonist activity in cAMP accumulation or [35 S]GTPyS binding assays at recombinant 
Group 11 or III mGluR (human mGluR2, -3, -4a, -6, -7b, -8a), NMDAR I A/2A, -I B/2B, rat 
AMPA (GluR3) or human Kainate (GluR6) receptor subtypes stably expressed in cell lines, 
at concentrations up to 10 ýM, thus confirming MPEP as a highly potent and selective 
mGluR5 antagonist (Gasparini et al, 1999; Kuhn et al, 2002). As with LY367385, MPEP is 
a potent anticonvulsant in several experimental epilepsy models. Indeed, in DBA/2 mice, 
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MPEP suppresses sound-induced clonic seizures with an ED50 of 46 nmol following 
intracerebroventricular (i. c. v. ) administration (Chapman et al, 2000). Additionally, in 
experimental models of focal ischaemia, MPEP reduces infarct volume and facilitates 
neurological recovery in rats following middle cerebral artery occlusion (MCAo) over a 
range of 25,75 and 250 nmol following i. c. v administration (Bao, et al, 2001). Furthermore, 
MPEP is neuroprotective against striatal lesions induced by excitotoxins (Bruno et al., 
2000a). Indeed, as little as 5 nmol of MPEP has been reported to have a neuroprotective 
action following intrastriatal co-infusion with 100 nmol NMDA (Bruno et al, 2000a). 
Based on these data, a concentration range of 2,10 and 50 nmol in 4 ý11 of MPEP was 
decided to be appropriate in our studies. Further evidence to support the use of these 
concentrations is provided in a recent study by Phillips and colleagues (2006) who report 
that microinjections of 5,10 and 25 nmol of MPEP in 4 ýtl into the STN shows a 
concentration-dependent reversal of motor abnormalities induced by unilateral 6-OHDA 
lesions in rats. Furthermore, the same study reports the effects of microinjections of 
concentrations of up to 50 nmol in 4 pl MPEP into the SNr (Phillips et al, 2006), supporting 
the use of this concentration in the current study. 
3.1.2 Group 11 and III mGluR agonists 
The Group 11 mGluR agonist 2R, 4R-APDC potently inhibits forskolin-stimulated cAMP 
formation with an EC50of 12.9 ýM in adult rat hippocampus tissue (Schoepp et al, 1995), 
and has no significant effect on PI hydrolysis or any activity at ionotropic receptors in the 
same tissue at concentrations up to 1000 gM (Schoepp et al, 1995). Similar results were 
obtained in AV-12 cells stably expressing both human mGluR2 and mGluR3 (Schoepp et 
al, 1995). No data has been reported for the selectivity of 2R, 4R-APDC for mGluR2 or 
mGluR3 due to a lack of subtype selective agonists, so it is generally assumed that 2R, 4R- 
APDC acts as an mGluR2/3 agonist. Data from experimental models of epilepsy in rodents 
shows the presynaptically active but non-selective mGluR agonist I-aminocyclopentyl- 
IS, 3R-dicarboxylate (IS, 3R-ACPD) significantly attenuates seizures in rats following focal 
microinjection of 10 nmol into the amygdala (Attwell et al, 1995). Since 2R, 4R-APDC is a 
derivative of IS, 3R-ACPD and thus is structurally similar it is predicted that similar 
concentrations of 2R, 4R-APDC would be effective when injected focally. In support of this, 
Attwell and colleagues (1998a) have reported an anticonvulsant effect following intra- 
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amygdaloid administration of 2R, 4R-APDC at 10 nmol. Furthermore, this effect was shown 
to be a concentration -dependent, such that even low nanomolar doses had mild 
anticonvulsant activity (Attwell et al, 1998a). Similarly, in DBA/2 mice, 2R, 4R-APDC has 
a dose-dependent anticonvulsant effect when injected i. c. v at amounts ranging from 10 to 
40 nmol (Moldrich et al, 2001a). However, in mice, 2R, 4R-APDC no longer exhibited 
effective anticonvulsant activity at amounts greater than 80 nmol (Moldrich et al, 2001a). 
Based on these data, a concentration range of 2,10 and 50 nmol in 4 ý11 was decided as 
appropriate in the neuroprotection studies described herein. A concentration of 50 nmol in 4 
ýil was set as the upper limit based on reports that 2R, 4R-APDC shows mild proconvulsant 
activity in both rats and mice at concentrations greater than this suggesting non-selectivity 
of action at this concentration (Attwel I et al, 1998a; Moldrich et al, 200 1 a). 
The widely used broad-spectrum Group III mGluR agonist L-AP4 shows agonist 
activity at all subtypes of Group III mGluR in the rank order of potency mGluR4>6>7>8 
(Pin and Duviosin, 1995) and its activity is negatively linked to adenylate cyclase activity 
via presynaptic receptors (Kemp et al, 1994). Indeed, L-AP4 is reported to potently inhibit 
forskolin stimulated cAMP formation in rat striatal slices and in support of an agonist 
action at all Group III subtypes, this activity shows a biphasic response, with a low and 
high affinity component (EC50 260 ýiM and 6 pM in vitro, respectively), postulated to 
represent a sequential recruitment of mGluR4 or 8 and mGluR7 (Schafthauser et al, 1997). 
In experimental models of epilepsy, similar to 2R, 4R-APDC, intra-amygdaloid 
microinjection of 10 nmol L-AP4 shows a significant antiepiletic and anticonvulsant action 
in fully kindled rats (Abdul-Ghani et al, 1997). Furthermore, complimentary in vitro and in 
vivo evidence confirm that L-AP4 shows neuroprotective activity against excitotoxic 
insults. Lafon-Cazal and co-workers (1999a) reported that L-AP4 protects murine striatal 
cultures against NMDA toxicity at concentrations of >0.3 [tM whilst Bruno and colleagues 
(1996) have reported similar neuroprotective effects of L-AP4 in vitro in the same model. 
Similarly, the selective Group III mG1uR agonist (R, S)-PPG is reported as neuroprotective 
against striatal excitotoxic lesions in vivo (Bruno et al, 2000b). Thus, single intrastriatal 
injections of either 10 or 100 nmol (R, S)-PPG resulted in significant neuroprotection when 
co-administered with 50 nmol NMDA in mice (Bruno et al, 2000b). Furthermore, (R, S)- 
PPG shows an anticonvulsant action following i. c. v administration up to 2200 nmol 
(Gasparini et al, 2000). (RS)-PPG shows a markedly similar potency for Group III mGluR 
to that observed for L-AP4 at cloned human Group III mGluR in vitro (EC50 values: 
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mGluR4a 5.2 [tM; mGluR6 4.7 pM; mGluR8a 0.2 [tM and mGluR7b 185pM, respectively) 
(Gasparini et al, 2000). Thus, it is conceivable that similar concentrations of L-AP4 may be 
effectively neuroprotective in vivo. Based on these data, a concentration range of 2,10 and 
50 nmol in 4 pl was selected as appropriate to study the potential neuroprotective effects of 
L-AP4 against 6-OHDA toxicity in the rat. In support of this, i. c. v injections of L-AP4 at 
10 and 100 nmol in 2 pl is anti-parkinsonian in reserpine-treated rats (MacInnes et al, 
2004). 
Quantification of any potential neuroprotection by mGluR ligands was carried out 
by assessment of both the integrity and functionality of the nigrostriatal tract. Integrity of 
the nigrostriatal system was assessed by quantification of the number of doparninergic 
neurones in the SNc, as measured by TH-immunoreactivity (TH-IR) and functionality was 
assessed by measuring the levels of dopamine (DA) and its metabolites and the amount of 
DA turnover in the corpus striatum, the target region for DA axons projecting from the 
SNc. 
An additional set of experiments was performed where the individual mGluR 
ligands were administered sub-chronically in sham-lesioned animals to determine if these 
compounds alone have any baseline effects on the nigrostriatal system in vivo. 
3.1.3 Group 11 and III mGluR antagonists 
Additionally, a separate set of experiments was also performed to investigate if the 
potential neuroprotective effects of Group 11 and Group III mGluR ligands are receptor 
mediated. From the concentration-response studies a concentration of 2R, 4R-APDC and L- 
AN which provided maximal neuroprotection was co-administered with specific 
antagonists of Group 11 and III mGluR using an identical sub-chronic treatment regimen. 
The integrity and functionality of the nigrostriatal system in these groups was then 
compared to animals which received agonist alone, thus, if neuroprotection is reversed in 
the antagonist-treated group, it is reasonable to assume that the neuroprotection is receptor- 
mediated. 
In order to test this hypothesis for ligands acting at Group 11 mGluR, the selective 
mGluR2/3 antagonist (S)-a-ethylglutamic acid (EGLU), an a-methyl analogue of (S)- 
glutamate was co-administered with 2R, 4R-APDC. This compound selectively antagonises 
(IS, 3R)-ACPD, but not L-AP4-induced depression of the monosynaptic excitation of 
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neonatal rat motoneurones, with a KDof 66 pM (Jane et al, 1996). Furthermore, EGLU was 
reported to show no activity at either Group III mGluR or ionotropic glutamate receptors at 
concentrations up to I mM in the same preparation, thus EGLU was concluded to act as a 
Group 11 mGluR antagonist (Jane et al, 1996). In support of this, the binding of [3 H]- 
(2S, 2'R, 3'R)-2-(2', 3'-dicarboxycyclopropyl)glycine (DCG-IV) a highly selective Group 11 
mGluR agonist, to rat mGluR2 transfected CHO membranes is inhibited by EGLU with a 
Ki value of 42 VM (Cartmell et al, 1998a). Furthermore, the relief of akinesia in reserpine- 
treated rats by intranigral injection of 0.5 nmol DCG-IV was significantly inhibited by pre- 
treatment with 100 nmol EGLU (Dawson et al, 2000). A more recently developed 
compound (+)-2-aminobicyclo-[3.1.0] hexane-2,6-di carboxyl ate (LY341495) shows 
nanomolar potency as an antagonist at mGluR2 and mGluR3 (Ki values 23.4 and 3.6 nmol 
respectively, Kingston et al, 1998). However, this compound also shows a nanomolar 
activity at mGluR8 (Ki value 57 nmol; Schoepp et al, 1999). Thus, despite the lower 
potency of EGLU compared to LY341495, its greater selectivity for Group 11 mGluR was 
the determining factor in choosing this antagonist. 
In order to test this hypothesis for ligands acting at Group III mGluR, the selective 
Group III mGluR antagonist (RS)-a-methylserine-0-phosphate (MSOP), an a-methyl 
substituted analogue of the Group III mGluR antagonist L-SOP was co-administered with 
L-AP4. This compound is a moderately potent antagonist of L-AP4 stimulated depression 
of synaptic transmission in the neonatal rat spinal cord (KDvalue 51 ýIM; Thomas et al, 
1996), with very low activity against (IS, 3R)-ACPD-mediated depression in the same 
preparation (KDvalue >700 pM). This is in good agreement with data for the Group III 
mGluR antagonist MAN in the same preparation (Jane et al, 1994), thus MSOP is thought 
to act as a selective Group III mGluR antagonist. In support of this, MSOP antagonises 
[3 H]-L-AP4 binding to human mGluR4a expressed on CHO cell membranes with a KD 
value of 19 pM (Schoepp et al, 1999). Thus, MSOP appears to be a selective Group III 
mGluR antagonist. However, pharmacological data for the activity of MSOP at Group 11 
and III mGluR is not complete and thus its absolute selectivity cannot be determined with 
certainty. Indeed, surprisingly in contrast to the data of Thomas and colleagues (1996), 
MSOP has been reported to show potent antagonism at rat mGluR2 receptors in vitro 
(Cartmell et al, 1998a). This could be explained by the fact that mGluR2 receptors do not 
mediate the (IS, 3R)-ACPD-induced depression in the spinal cord and either mGluR3 or an 
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as yet uncharacterised mGluR is responsible for this effect (Schoepp et al, 1999). In general 
however there is a lack of potent and selective Group III mGluR antagonists, thus limiting 
the tools available for study. The choice of MSOP is supported by previously published 
data. Indeed, microinjection of 50 nmol of MSOP into the SNr significantly antagonises the 
L-SOP-mediated reversal of akinesia in reserpine-treated rats (MacInnes et al, 2004). Both 
L-SOP and L-AP4 show relatively similar potency as agonists of Group III mGluR, thus 
MSOP would be predicted to be similarly effective against L-AP4 mediated responses 
(Schoepp et al, 1999). Thus, it was decided to use a similar concentration of 50 nmol in 4 [d 
MSOP in these studies. In a separate experiment, the same concentrations of EGLU and 
MSOP were administered alone in sham and 6-OHDA-lesioned animals to establish any 
baseline effects of these compounds on the nigrostriatal system. In these studies 
quantification of integrity and functionality of the nigrostriatal tract was performed as 
described for the concentration response studies. 
Thus, in summary the aims of this first chapter are firstly, to rigorously investigate 
the potential neuroprotective effects of selective Group I mGluR antagonism or Group 11 
and III mGluR activation in vivo as has been suggested previously in other models. 
Secondly, to investigate if these effects are concentration-dependent and thirdly to 
determine if any neuroprotective effects observed following mGluR ligand administration 
are receptor-mediated. 
3.2 Experimental Design 
3.2.1 Effects of selective mGluR ligands in sham-lesioned animals 
To determine whether sub-chronic mGluR ligand administration has any effect on the 
nigrostriatal system alone, groups of male Sprague-Dawley rats were implanted with 
indwelling guide cannulae above the substantia nigra pars compacta (SNc) and were sham- 
lesioned (see sections 2.1.2.2,2.1.3). Subsequently, these animals were divided into 
treatment groups (n =8 per group) and treated sub-chronically (7 days) with a single 
concentration of either 200 nmol LY367385, or 10 nmol MPEP, 2R, 4R-APDC, or L-AP4, 
in a final injection volume of 4 ýtl, administered intranigrally (see section 2.1.5). Control 
animals received an equal volume of drug vehicle (4 [d) for the same length of time. These 
concentrations were decided upon since the studies outlined in section 3.2.2 had revealed a 
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positive neuroprotective effect for each of these ligands at this concentration. This 
experimental design is illustrated graphically in Figure IIA. 
Action 
Time point 
7 days 10 days 1 hour 
IN 
7 days drug 1 hour 
or vehicle 
treatment 
Figure 3.1A Experimental design to assess the effects of sub-chronic treatment with 
mGluR ligands on the nigrostriatal system alone in sham-lesioned animals. CBU, Central 
Biomedical Unit. 
3.2.2 Neuroprotective studies with selective mGluR ligands 
To investigate whether mGluR ligands are neuroprotective against 6-hydroxydopamine (6- 
OHDA) toxicity in vivo, male Sprague-Dawley rats (250-270 g) were cannulated above the 
SNc (see section 2.1.2.2) allowed to recover and subsequently treated according to the 
experimental design shown graphically in Figure 3.1 B. 
Action 
Time point 
7 days 10 days 1 hour 
lip 10 
7 days drug 1 hour 
or vehicle 
treatment 
Figure 3.1B Experimental design used to investigate the potential neuroprotective effects 
of mGluR ligands against 6-hydroxydoparnine toxicity in vivo. CBU, Central Biomedical 
Unit. 
To assess the effect of sub-chronic treatment with mGluR ligands on 6-OHDA 
toxicity, cannulated animals were divided into treatment groups (n =8 per group) and 
Animals enter Stereotwic 16t focal drug 6-OHDA Final focal Animals 
CBU facility surgery injection i rif usi on drug injection sacrificed 
Animals ente r Stereotaxic 1st focal drug 6-OHDA Final focal Animals 
CBU facility surgery injection infusion drug injection sacrificed 
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administered a single unilateral intranigral injection of either LY367385, MPEP, 2R, 4R- 
APDC, L-AP4 or drug vehicle alone into the SNc. In all treatment groups, this injection 
was performed one hour before a unilateral lesion of the left SNc was induced by 6-OHDA 
infusion (see sections 2.1.3 and 2.1.5). Treatment groups then received single intranigral 
injections of mGluR ligand (or drug vehicle) for a further 7 days. A range of concentrations 
of each ligand was tested to investigate if any neuroprotective effect exhibited a 
concentration-dependence relationship, determined prior to the experiment (see section 3.1) 
details of each individual treatment group are shown in Table 3.1. 
Group Treatment Concentration(s) Duration (nmol in 4 pl) 
Vehicle PBS / sterile saline n/a 7 days 
Group I rnGluR I LY367385 40,200 and 1000 7 days receptor antagonist 
Group I rnGluR5 MPEP 25 10 and 50 7 days receptor antagonist 
Group 11 mGluR2/3 2R, 4R-APDC 2,10 and 50 7 days receptor agonist F Group III rnGlu L-AP4 2ý 10 and 50 7 days 
receptor agonist 
Table 3.1 Treatment groups for neuroprotection studies; each mGluR ligand was tested in 
vivo at three previously determined concentrations for 7 days. 
3.2.3 Proof of receptor-mediated mechanism of neuroprotection 
To determine if any observed neuroprotective effects of Group 11 and III mGluR agonists 
were receptor-mediated, male Sprague-Dawley rats (250-270 g) were cannulated as 
described in (see section 2.1.2.2) allowed to recover and subsequently treated as shown 
graphically in Figure 3.2. 
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Action 
Time point 
Animals enter Stereotwic 1 9tfocal 6-OHDA Final focal Animals 
COU facility surgery injection iI usi on drug injection sacrificed 
P. P. No 10 P. 
7 days 10 days 1 hour 7 days treatment 1 hour 
Agonist + 
antagonist 
Antagonist alone 
Drug vehicle 
Figure 3.2 Experimental design used to determine whether neuroprotection by Group 11 
and III mGluR agonists in vivo is receptor-mediated and to establish the effects of the 
antagonists alone on the nigrostriatal system. 
To investigate if neuroprotection by Group 11 and III mGluR agonists is receptor- 
mediated, cannulated animals were divided into treatment groups (n =8 per group). Two 
groups were administered with a single, unilateral intranigral injection of either 2R, 4R- 
APDC or L-AP4 onto the SNc. Each agonist was injected at the concentration that resulted 
in the optimal amount of neuroprotection, as determined from the studies outlined in 
section 3.2.2 (both 10 nmol in 4 ýd, respectively), but co-administered with a highly 
selective Group 11 or Group III mGluR antagonist (EGLU and MSOP, respectively) at a 
concentration determined to block agonist activity at the mGluR targeted (1000 and 50 
nmol in 4 pl, respectively). These concentrations were determined prior to the experiment 
(see section 3.1). As before all injections were made one hour before induction of sham or 
6-OHDA lesions and treatment groups then received single intranigral injections of either 
drug vehicle, agonist or agonist + antagonist (see Figure 3.2) for seven consecutive days. 
In all experimental designs described above, all mGluR ligands were made up as 
previously described (see section 2.1.4). At the defined end point of the experiment (see 
Figures IIA, B and 3.2) animals were sacrificed by decapitation and the brains removed 
and dissected (see section 2.1.6). To quantify the effects of mGluR ligands in each separate 
study on the integrity of the nigrostriatal system following 6-OHDA lesioning, 
immunohistochernistry for tyrosine hydroxylase (TH) was then performed as described in 
section 2.2.1.3 and the numbers and morphology of TH-immunoreactive (TH-IR) cells in 
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the SNc were then determined as described section 2.2.2.1. Similarly, to deten-nine the 
effects on nigrostriatal functionality, concentrations of striatal monoamines were measured 
by HPLC-ECD and subsequently analysed as described in section 2.2.3. Furthermore, in all 
experimental groups the positioning of the guide cannula was assessed by examination of 
needle tracts in freshly dissected tissue and histological analysis of CFV-stained tissue 
sections (see section 2.1.2.4). Animals that showed incorrect cannula placement were not 
included in subsequent data analysis. 
3.2.4 Statistical analysis of data 
All data (except where stated) are presented as the mean ± SEM based on n independent 
observations. Individual comparisons were made using a two-tailed paired or unpaired 
Students t-test as appropriate. Where multiple comparisons were made, one-way ANOVA 
with post-hoc Tukeys test for multiple comparisons was employed. Data for cell loss in 
vehicle and drug treated groups is presented as the mean percentage change ± SEM. 
Biochemical data for monoamines is expressed in the same manner, in ng/ml wet weight 
tissue. Striatal DA turnover, is expressed as the mean values ± SEM calculated using the 
equation ((DOPAC + HVA)/DA) and mean values for each monoamine in pmol/ml. For 
TH-IR cell numbers and biochemical data for monoamines, mean values were also 
compared. In all figures, n values are shown in parenthesis. Differences were considered 
statistically significant at P<0.05 and all statistical data analysis was performed using 
GraphPad Prism v4.00 software (GraphPad software, San Diego, CA, USA). 
3.3 Results 
In vehicle-treated sham and 6-OHDA-lesioned animals and in subsequent drug studies in 
both sham and 6-OHDA-lesioned animals, both the number of TH-IR cells in the 
contralateral hemisphere (171 . 951 P=0.109) and the concentrations of DA (F, . 547 P=O. 195) 
DOPAC (F1.216 P=0.309), HVA (F2.483 P=0.066) in the contralateral striata were not 
significantly different from one another. 
In vehicle-treated animals, intranigral infusion of 12 ýtg in 4 [11 6-OHDA produced a 
significant reduction of nigral TH-IR cells in the ipsilateral SNc when compared to the 
contralateral side (65.6 ± 1.6%; 95% confidence interval (CI): 61.15 - 70.09; P<0.01) 7 
days post-lesion as shown in Figure 3.3A. Loss of nigral TH-IR cells was more pronounced 
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in the medial portion of the SNc with the lateral portion showing some sparing of TH-IR 
cells. In contrast, the TH-IR cells in the nearby VTA were preserved. The degree of lesion 
induced by 6-OHDA in the SNc is illustrated in a representative photomicrograph of TH-IR 
cells from a vehicle-treated animal in Figure 3.4. 
Concomitant with the loss of nigral TH-IR cells, intranigral infusion of 12 ýtg 6- 
OHDA produced a significant depletion of striatal dopamine (DA; 54.6 ± 5.9%; 95% CI: 
42.29 - 66.86; P<0.01, Figure 3.313) and both dihydroxyphenyl acetic acid (DOPAC) and 
homovanillic acid (HVA; (51.7 ± 5.9%; 95% CI: 39.47 - 63.88; P<0.01 and 47.9 ± 4.3%; 
95% CI: 39.02 - 56.78; P<0.001; Figures 3.313). A significant increase in the DA turnover 
ratio in the ipsilateral striata compared to the contralateral striata was also observed, (0.151 
± 0.02 vs. 0.093 ± 0.008 pmol/ml; P=0.0340; Figure 3.3C) indicating an increased 
metabolism of DA by the surviving nigral TH-IR cells in vehicle-treated animals. This 
increase is not as significant as has been reported elsewhere (Yuan et al, 2005) and this may 
be explained by the size of the DA depletion in this model. Indeed, it is widely suggested 
that increases in DA turnover as a compensatory mechanism are strongly correlated with 
the percentage lesion of TH-IR cells in the SNc (Agid et al, 1973; Zigmond et al, 1984). 
Thus, the -60-65% loss of nigral TH-IR cells may only result in moderate fold increases in 
DA turnover. Indeed, significant increases in DA turnover are reported commonly at lesion 
sizes of >75% (Yuan et al, 2005) and very significant increases at lesion sizes of >90% 
(Zigmond et al, 1984; Sherman and Moody, 1995). 
In contrast, in sham-lesioned animals, intranigral infusion of 4 RI of 0.1% ascorbic 
acid/saline solution resulted in no significant loss of either nigral TH-IR cells (Figure 3.3A) 
or striatal DA, DOPAC or HVA (Figure 3.313). Additionally, no increases in striatal DA 
turnover were observed (Figure 3.3C). In both sham-lesioned and 6-OHDA lesioned 
animals, no significant changes in the levels of 5-hydroxytryptamine (5-HT) or 5- 
hydroxyindoleacetic acid (5-HIAA) were observed in the striatum. 
Importantly, in 6-OHDA lesioned animals a significant loss of NeuN-IR cells was 
also observed in the SNc (73.31 ± 4.63%; P<0.001; Figure 33A) which is directly 
comparable to the loss of nigral TH-IR cells (65.6 ± 1.6% vs. 73.31 ± 4.63%). In sham- 
lesioned animals, no significant loss of NeuN-IR cells was observed in the SNc (Figure 
33A). These data suggest that the loss of TH-IR nigral cells reflects a cell death process 
rather than a decrease in the expression of TH in nigral cells and transient autophagy. 
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In addition to these cellular studies, the degree of inflammation, namely the degree 
of reactive microgliosis and astroglial scarring was investigated in both sham- and 6- 
OHDA lesioned animals by qualitative assessment of GFAP and OX42-immunoreactive 
cells (GFAP-IR and OX424R) in the SNc at 7 days post-lesion (see section 2.2.1.5). 
In sham-lesioned animals, focal GFAP-IR was observed around the injection site in 
the ipsilateral hemisphere with few GFAP-IR cells displaying an activated phenotype (see 
section 2.2.1.5). In general, the number of GFAP-IR cells was increased throughout 
ipsilateral hemisphere of tissue sections compared to the contralateral side, which most 
likely is due to the cannulation procedure and subsequent injections, but these cells 
displayed a non-reactive morphology, with moderate GFAP-IR intensity, small cell bodies 
and numerous thin processes. On the contralateral side, GFAP-IR cells displayed a similar 
normal, non-activated morphology. Similarly, in sham-lesioned animals, focal OX42-IR 
was observed around in the injection site in the ipsilateral hemisphere, with a few OX42-IR 
cells displaying a reactive morphology (see section 2.2.1.5). In general, however 
throughout the ipsilateral and contralateral hemispheres OX42-IR cells were present but 
displayed quiescent or resting morphology, with a characteristic "meshwork" appearance, 
associated with a low OX42-IR staining intensity. 
In contrast, in 6-OHDA-lesioned animals, widespread GFAP-IR was observed with 
a greatly increased number of GFAP-IR cells in the ipsilateral hemisphere, characterised by 
increased intensity of GFAP-IR staining, with enlarged cell bodies and processes, 
suggesting an activated, reactive, phenotype (see section 2.2.1.5). Interestingly, this 
phenomenon was not confined to the ipsilateral hemisphere and an increase in GFAP-IR 
cells displaying an activated, reactive phenotype was also observed in the contralateral 
hemisphere. Similarly, in 6-OHDA-lesioned animals widespread OX42-IR was observed in 
the ipsilateral hemisphere, with the majority of cells displaying an activated, reactive 
morphology (see section 2.2.1.5), whilst in the contralateral side, OX42-IR cells displayed 
a non-reactive normal morphology. 
In the nearby VTA, moderate, focal increases in the numbers of GFAP-IR and 
OX42-IR cells was observed in both sham- and 6-OHDA lesioned animals, but the 
response in 6-OHDA lesioned animals was not as great as observed in the SNc. 
Importantly, the patterns of both GFAP-IR and OX42-IR were consistent across the 
stereotaxic regions of the SNc (A-E, Carmen et al, 199 1). 
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Taken together these data suggest that in sham-lesioned animals, the cannulation 
procedure produces a modest glial scarring response, with a limited focal increase in the 
number of reactive astroglia and microglia respectively, consistent with previous 
observations (Moon et al, 2002). In contrast, in 6-OHDA lesioned animals there is a 
widespread increase in both reactive microgliosis and astrogliosis in the ipsilateral 
hemisphere, which is also consistent with previous observations in this model (Kurkowska- 
Jastrzebska et al, 1998; Cicchetti et al, 2002). These data are illustrated for 6-OHDA 
lesioned animals in representative photom icro graphs in Figure 3.4 
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Figure 3.3 Effects of sham and 6-OHDA lesioning on the 
nigrostriatal system in rodents 
A: Infusion of 12 [tg in 4 ýd 6-OHDA into the left SNc results in a significant 
loss of both tyrosine hydroxylase and Neuronal N immunoreactive (TH and 
NeuN-IR) cells at 7 days post-lesion, whereas in sham-lesioned animals no 
significant TH or NeuN-IR cell loss observed. Data shown are mean 
percentage loss of cells ± SEM, **P<0.01 6-OHDA vs. sham-lesioned 
animals. 
B: Concomitant with nigral cell loss is a significant depletion of striatal DA, 
DOPAC and HVA in the corpus striaturn following 6-OHDA lesioning at the 
same time point, which is not observed in sham-lesioned animals. Data 
shown are mean percentage loss of DA, DOPAC and 14VA ng/ml ± SEM, 
**P<0.01 6-OHDA vs. sham-lesioned animals. 
C: Lesioning with 6-OHDA induces a significant increase in striatal DA 
metabolism, calculated using the equation (DOPAC+HVA)/DA (Pmol/ml), 
which is not observed in sham-leisoned animals, *P<0.05 contralateral vs. 
ipsilateral hemispheres. 
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Figure 3.4 Representative photomicrographs to illustrate nigral cell loss 
and neuroinflammation following 6-OHDA lesioning. 
A: Nigral TH-IR cells in contralateral hemisphere following 6-OHDA lesioning 
B: Nigral TH-IR cells in ipsilateral hemisphere following 6-OHDA lesioning 
C: Nigral NeuN-IR cells in contralateral hemisphere following 6-OHDA lesioning 
D: Nigral NeuN-IR cells in ipsilateral hemisphere following 6-OHDA lesioning 
E: GFAP-IR cells in ipsilateral hemisphere following sham-lesioning 
F: GFAP-IR cells in ipsilateral hemisphere following 6-OHDA lesioning 
G: OX42-IR cells in ipsilateral hemisphere following sham-lesioning 
H: OX42-IR cells in ipsilateral hemisphere following 6-OHDA lesioning 
All images were taken at x 40 magnification, scale bar = 250 pm. The SNc and VTA 
are highlighted. 
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3.3.1 Effects of selective mGluR ligands in sham-lesioned animals 
3.3. LI Effects on nigrostriatal tract integrity 
Sub-chronic intranigral treatment (7 days) with a single concentration of each mGluR 
ligand (10 nmol of MPEP, 2R, 4R-APDC, L-AP4 or 200 nmol in 4 [d of LY367385) in 
sham-leisoned animals had no significant effects on the mean number of TH-IR nigral cell 
bodies in the ipsilateral SNc when compared to the contralateral side, as clearly shown in 
Figure 3.5A. However, in each treatment group a slight, but importantly, not significant 
reduction in the mean number of TH-IR cells in the ipsilateral SNc was observed (Figure 
3.5A). This is most likely attributable to a minor amount of mechanical damage to the 
tissue as a result of cannulae implantation, insertion of the injection needle and intranigral 
infusions over the seven days of the treatment regime. Thus, sub-chronic intranigral 
treatment with mGluR ligands appears to have no significant effects on nigrostriatal tract 
integrity in sham-lesioned animals. This is illustrated in representative photomicrographs 
in Figure 3.6. Furthermore, no gross behavioural abnormalities were observed following 
injections of MPEP, 2R, 4R-APDC or L-AP4 or LY36785 in these animals. 
3.3.1.2 Effects on nigrostriatal tractfunctionality 
Sub-chronic (7 day) intranigral treatment with a single concentration of mGluR ligand (10 
nmol of MPEP, 2R, 4R-APDC, L-AP4, or 200 nmol LY367385) in sham-lesioned animals 
had no significant effect on the concentration of DA in the ipsilateral corpus striatum when 
compared to the contralateral striatum in any treatment group as clearly shown in Figure 
3.513. Additionally, no significant differences were observed either in the concentrations of 
DOPAC or HVA in the ipsilateral corpus striatum when compared to the contralateral 
striaturn in any treatment group, as shown in Figures 3.5C and 3.513. Furthermore, no 
significant changes in the DA turnover ratio in the striaturn were observed when comparing 
the ipsilateral and contralateral striata as clearly illustrated in Figure 3.5E. Moreover, in 
these animals no significant changes were observed in either 5-HT or 5-HIAA 
concentration (data not shown). Taken together, these data clearly indicate that sub-chronic 
intranigral treatment with mGluR ligands does not result in any significant effects on the 
functionality of the nigrostriatal system in sham-lesioned animals. Thus, these data suggest 
that any subsequent effects seen in 6-OHDA lesioned animals are likely to be due to the 
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neuroprotective actions of these drugs against 6-OHDA toxicity, rather than a modifying 
action of these compounds on the nigrostriatal system itself. 
3.3.2 LY367385 is neuroprotective against 6-OHDA toxicity in vivo 
3.3.2.1 Effects of L Y36 7385 on nigrostriatal tract integrity 
The 6-OHDA-induced loss of nigral TH-IR cells was significantly attenuated by sub- 
chronic (7 day) intranigral treatment with the selective mGluRI receptor antagonist 
LY367385. One-way ANOVA revealed significant differences between LY367389 and 
vehicle-treated groups (F19.23 P<0-0001), Indeed, post-hoc analysis revealed that all 
concentrations of LY367385 tested significantly reduced the loss of TH-IR cells in the 
ipsilateral SNc (40 nmol: 49.6 ± 4.7%; P<0.05; 200 nmol: 35.7 ± 4.4%; P<0.01; 1000 
nmol: 23.0 ± 4.7%; P<0.01) compared to vehicle-treated animals (Figure 33A). To 
illustrate the magnitude of the neuroprotection, a representative photomicrograph of nigral 
TH-IR cells from an animal treated with 200 nmol in 4 jil LY367385 is shown in Figure 
3.6. It should be noted however, that when comparing the mean number of TH-IR cells 
within the treatment group, there was still a significant difference (P<0.05 data not shown) 
in the mean TH-IR cell number between the ipsilateral and contralateral SNc in all the 
LY3673 85 -treated groups, indicating that 6-OHDA still induces a significant, but markedly 
reduced lesion of the SNc in LY3 673 85 -treated animals. 
In vehicle-treated animals, one-way ANOVA analysis did not reveal any significant 
effect of SNc region for the mean percentage loss of TH-IR cells (F, . 213 
P=0.3121), 
indicating a consistent lesion size in all regions of the SNc as illustrated in Figure 3.7B. In 
40 nmol LY3673 85 -treated animals ANOVA indicated significant differences in lesion size 
between regions (F4.119 P=0.0280). Post-hoc analysis indicated that the lesion size was 
significantly smaller in region A compared to B (P<0.05; Figure 3.7B) and in region C 
compared to region B (P<0.05; Figure 3.713). Interestingly, when compared to the lesion 
sizes in each region of vehicle-treated animals, only region A showed a significantly 
smaller lesion. No other region was significantly different to vehicle-treated animals at this 
concentration of LY367385. These data suggest neuroprotection of nigral TH-IR cells at 
lower concentrations of LY367385 may be confined to the rostral regions of the SNc. 
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Contralateral 
In 200 nmol LY367385-treated animals, one-way ANOVA indicated significant 
differences in lesion size between regions (F3.614 P=0.0408), but post-hoc analysis only 
revealed a significant difference in lesion size between region A and B (P<0.05; Figure 
3.713). However, the lesion size was significantly reduced compared to that observed in 
vehicle-treated animals in all regions of the SNc (P<0.05; Figure 3.7B) indicating a 
consistent neuroprotection of TH-IR cells throughout the extent of the SNc structure. 
In animals treated with 1000 nmol LY367385, although the lesion size was 
apparently reduced in regions A and C compared to the other regions, this just failed to JV 
reach statistical significance (one-way ANOVA; F2.772 P=0.0725), again indicating no 
significant differences in lesion size between SNc regions in this group. Similar to the 200 
nmol-treated group, the lesion size was significantly reduced to that observed in vehicle- 
treated animals across all regions of the SNc (P<0.05; Figure 3.7B) indicating a consistent 
neuroprotection of TH-IR cells throughout the extent of the SNc structure. 
Taken together, these data suggest that sub-chronic intranigral treatment with 
LY367385 results in a robust protection of TH-IR cells in the SNc following lesioning with 
6-OHDA. Furthermore, this effect is concentration-dependent and appears to exhibits some 
significant regional differences, especially at lower concentrations. No gross behavioural 
abnormalities were observed following intranigral administration of 40 and 200 nmol 
LY36758, although the highest concentration (1000 nmol in 4 111) did induce teeth 
chattering and head bobbing behaviour and hypolocomotion which lasted approximately 
10-15 minutes after injection, although no other gross behavioural abnormalities were 
observed. Based on this, 200 nmol in 4 [il LY367385 appears to be the optimum 
concentration for neuroprotection of nigral TH-IR cells in this model. 
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Figure 3.6 Representative photomicrographs of nigral TH-111 
cells from sham and 6-OHDA lesioned animals treated with 
selective mGluR ligands 
Panels A-D, low power representative photomicrographs to illustrate that sub- 
chronic treatment with selective mGluR ligands has no effect on the integrity of 
the nigrostriatal system (A) LY367385, (B) MPEP, (C) 2R, 4R-APDC, (D) L- 
AP4. Panels E-H, low power representative pbotomicrographs to illustrate the 
degree of neuroprotection of nigral TH-IR cells following sub-chronic 
treatment with selective mGluR ligands (E) LY367385, (F) MPEP, (G) 2R, 4R- 
APDC, (H) L-AP4. All images correspond to region B of the SNc (-5.30 mm 
from bregma), at x 40 magnification, scale bar = 250 ýtm). The SNc, VTA and 
medial terminal nucleus (MTN) are highlighted in panel A. 
B 
" -. ----"" . 
". ""- 
/ \;: 
" 
D 
I' 
F 
H 
-161- 
Sf2 
a) 0 
± I- 
a) 
C 
ol 
Treatment group 
=vehicle 111111111111111111200 nmol 
8 
7 
U) 
r5 
0) 
1 
r---l Annnnni ý -i nnr% ýý-i 
Figure 3.7 Effects of sub-chronic LY367385 treatment on 
nigrostriatal tract integrity following 6-OHDA leisoning. 
A: Sub-chronic intranigral treatment with LY367385 significantly attenuates the 6- 
OHDA induced loss of TH-IR cells in a concentration dependent manner. Data 
shown are mean percentage loss TH-IR cells ± SEM, n values are shown in 
parenthesis. *P<0.05, **P<0.01 LY367385 vs. vehicle-treated animals. B: Different 
concentrations of LY367385 appear to show significant regional differences in 
neuroprotection of nigral TH-IR cells. Data shown are mean percentage loss of TH- 
IR cells calculated from 4-5 sections of each region of the SNc in vehicle and 
LY367385-treated male rats following 6-OHDA leisoning, *P<0.05 vs. vehicle- 
treated animals, tP<0.05 indicates a significant difference to other regions. 
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3.3.2.2. Effects of LY367385 on nigrostriatal tractfunctionality 
One-way ANOVA analysis revealed that in animals treated sub-chronically with intranigral 
injections of LY367385, this compound significantly attenuated the 6-OHDA-induced 
depletion of striatal DA (F7.926 P=0.0003) compared to vehicle-treated animals, at all 
concentrations tested, which is clearly illustrated in Figure 3.8A. Maximal attenuation of 6- 
OHDA-induced striatal DA depletion was observed in animals treated with 1000 nmol 
LY367385 (13.5 ± 3.2%; P<0.05, Figure 3.8A). In animals treated with 200 nmol of 
LY367385 the reduction was reduced compared to the 1000 nmol-treated group, (23.1 ± 
6.1%), although this was significant when compared to vehicle-treated animals (P<0.05; 
Figure 3.8A). In animals treated with 40 nmol LY367385, the percentage reduction of 
striatal DA was similar to that observed in animals treated with 200 nmol LY367385, and 
was significantly reduced compared to vehicle-treated animals (23.7 ± 1.7%; P<0.05; 
Figure 3.8A). 
Treatment with LY367385 also significantly attenuated the 6-OHDA induced 
depletion of DOPAC in the ipsilateral striatum of 6-OHDA-lesioned rats. Again, maximal 
attenuation was achieved in animals treated with 1000 nmol LY367385 compared to 
vehicle-treated animals (6.9 ± 2.6%; P<0.01; Figure 3.813). As with DA, reduced 
attenuation of DOPAC depletion was observed in animals treated with 200 and 40 nmol 
LY367385, but this was still significantly lower than observed in vehicle-treated animals 
(200 nmol: 16.1 ± 4.1%; P<0.01; 40 nmol: 22.3 ± 3.7%; P<0.05; Figure 3.813). A similar 
pattern was observed for striatal HVA depletion in animals treated with 1000 and 200 nmol 
LY367385, (1000 nmol: 12.7 ± 4.8%, P<0.001; 200 nmol: 15.8 ± 6.7%; P<0.001; Figure 
3.8C) but interestingly, in animals treated with 40 nmol LY367385, although the depletion 
of striatal HVA was reduced compared to vehicle-treated animals, this just failed to reach 
statistical significance (40 nmol: 30.3 ± 4.8%; P=0.07; Figure 3.8Q. In all LY367385 
treatment groups, no significant changes were observed in either striatal 5-HT or 5-HIAA 
concentrations (data not shown). 
Taken together, these data suggest that restoration of striatal monoamine levels by 
LY367385 is concentration -dependent. Interestingly, in animals treated with 200 nmol of 
LY367385, there was no significant difference in the mean concentration of striatal DA 
between the ipsilateral and contralateral striata. However, in animals treated with 40 and 
1000 nmol LY367385, small but significant differences were observed (P<0.05, data not 
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shown). Small but significant reductions in striatal DOPAC and FIVA were also observed 
in all LY3673 85 -treated groups (P<0.05, data not shown) Taken together, these data 
suggest a reduced but still significant lesion induced by 6-OHDA in these groups. 
Treatment with LY367385 also completely blocked the increase in the striatal DA 
turnover ratio in the ipsilateral striatum observed in vehicle-treated animals. Indeed, this 
ratio was not significantly different between the ipsilateral and contralateral striata in any 
LY3673 85 -treated group (Figure 3.813). This suggests that the prevention of DA depletion 
following LY367385 treatment is due to neuroprotective actions on nigral TH-IR cells and 
axon terminals, rather than compensatory upregulation of DA metabolism in the striaturn. 
Taken together, these data suggest that sub-chronic intranigral treatment with LY367385 
provides significant protection of nigrostriatal functionality following 6-OHDA lesioning 
and that this is not due to increases in metabolic activity by the remaining TH-IR nigral 
cells. Due to the possible side effects at higher concentrations (see section 3.3.2.1) 200 
nmol in 4 jil LY367385 appears to be the optimum concentration for neuroprotection of 
striatal monoamines in this model. 
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Figure 3.8 Effects of sub-chronic LY367385 treatment on 
nigrostriatal tract functionality following 6-OHDA leisoning 
Sub-chronic treatment with LY367385 significantly prevents the 6-OHDA- 
induced depletion of DA (A), DOPAC (B) and HVA (C) in the corpus 
striatum. of male rats. Data shown are mean striatal DA,, DOPAC and 14VA 
content in ng/ml ± SEM, n values are shown in parenthesis, *P<0.05, 
**P<0.01, ***P<0.001, vehicle- vs. LY367385-treated animals. Treatment 
with LY367385 does not increase striatal monoamine metabolism 
following 6-OHDA leisoning as shown in (D) compared to vehicle-treated 
male rats where striatal dopamine metabolism is significantly increased 
(*P<0.05 ipsilateral vs. contralateral striata). Data shown are mean striatal 
monoamine turnover ratio ± SEM, in pmol/ml, calculated using the 
equation ((DOPAC+FWA)/DA)x 100. 
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3.3.3 MPEP treatment is neuroprotective against 6-OHDA toxicity in vivo 
3.3.3.1 Effects of MPEP on nigrostriatal integrity 
Sub-chronic intranigral administration of the selective mGluR5 antagonist MPEP 
significantly attenuated the 6-OHDA-induced loss of nigral TH-IR cells, as indicated by 
one-way ANOVA, which revealed significant differences between MPEP and vehicle- 
treated groups (1713.92 P<0.0001). Indeed, post-hoc analysis revealed that the mean 
percentage loss of TH-IR cells in the ipsilateral SNc was significantly reduced in animals 
treated with 2 and 10 nmol MPEP compared to vehicle-treated animals (48.6 ± 2.3%; and 
39.9 ± 3.1%; P<0.01 and P<0.001 respectively; Figure 3.9A). In contrast, in animals 
treated with 50 nmol MPEP, the mean percentage loss of TH-IR cells in the ipsilateral SNc 
was not significantly different to vehicle-treated animals (54.4 ± 3.4%; P>0.05; Figure 
3.9A) indicating that at these higher concentrations the neuroprotective action of MPEP on 
nigral TH-IR cells is lost. Thus, MPEP displays a bell-shaped neuroprotective profile. To 
illustrate the magnitude of the neuroprotection, a representative photomicrograph of TH-IR 
cells in the SNc from an animal treated with 10 nmol MPEP is shown in Figure 3.6. It 
should be noted however, that a comparison of the mean number of nigral TH-IR cells 
between the ipsilateral and contralateral hemispheres in animals treated with 2 and 10 nmol 
MPEP revealed a significant reduction (P<0.05, data not shown) indicating that 6-OHDA 
still induces a significant, but markedly reduced lesion of the SNc in these groups. 
One-way ANOVA analysis revealed that significant differences in lesion size 
between regions of the SNc only existed in animals treated with 2 nmol MPEP (F15.65 
P<0.0001). Post-hoc testing revealed that the lesion size was significantly smaller in 
regions A and B compared to C, D and E (P<0.001; Figure 3.913), suggesting a rostral to 
caudal pattern of neuroprotection. In agreement with this, the lesion size in 2 nmol MPEP- 
treated animals was only significantly reduced compared to vehicle-treated animals in 
regions A and B (Figure 3.913). 
In both the 10 and 50 nmol MPEP-treated groups, one way-ANOVA analysis 
indicated an absence of significant differences in lesion size between regions of the SNc 
(F 1 . 102 
P=0.3895 and Fo. 4812 P=0.7492, respectively; Figure 3.913). When compared to 
vehicle-treated animals, the lesion size was significantly reduced in regions A, B, C and D 
of 10 nmol MPEP-treated animals (P<0.01; Figure 3.913), suggesting more extensive 
neuroprotection than observed in the 2 nmol MPEP-treated group. In animals treated with 
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50 nmol MPEP, the lesion size was not significantly different from vehicle-treated animals 
in any SNc region (Figure 3.9) in good agreement with the total cell loss data shown in 
Figure 3-9A. 
Taken together these data indicate that MPEP robustly protects TH-IR cells against 
6-OHDA toxicity in a concentration -dependent manner and at low concentrations this 
neuroprotection is more distinct in rostral than caudal regions of the SNc. Furthermore, at 
higher concentrations of MPEP this protective effect is lost. Importantly, intranigral 
injections of MPEP resulted in no overt gross behavioural abnormalities at any 
concentration tested. Thus, 10 nmol in 4 [tl MPEP appears to be the optimum concentration 
for maximal neuroprotection of nigral TH-IR cells in this model. 
3.3.3.2 Effects of MPEP on nigrostriatalfunctionality 
Sub-chronic intranigral administration of MPEP significantly attenuated the 6-OHDA- 
induced reduction of striatal DA concentration in the ipsilateral striaturn in a concentration- 
dependent manner as clearly illustrated in Figure 3.10A. As with the neuroprotection of 
nigral TH-IR cells MPEP displays a bell-shaped neuroprotective profile. Maximal DA 
preservation was observed in animals treated with 10 nmol MPEP (12.4 ± 3.8%; P<0.01; 
Figure 3.10A). In 2 nmol MPEP-treated animals, the prevention of striatal DA depletion 
was moderately decreased but still significantly lower than in vehicle-treated animals (19.0 
± 1.7%; P<0.05; Figure 3.10A). In contrast, in animals treated with 50 nmol MPEP the 
degree of striatal DA depletion was not significantly different from vehicle-treated animals 
(P<0.05; Figure 3.10A) in good agreement with an absence of neuroprotection of nigral 
TH-IR cells (see section 3.3.3.1). Similar concentration-dependent reductions were 
observed for the depletion of striatal DOPAC in animals treated with 2 and 10 nmol MPEP 
compared to vehicle-treated animals (2 nmol: 21.7 ± 4.4%; P<0.05; 10 nmol: 22.5 ± 6.5%; 
P<0.05), whereas in animals treated with 50 nmol MPEP this was not significantly different 
from vehicle-treated animals (50 nmol: 60.3 ± 5.4%; P=0.41 1), as shown in Figure 3.1 OB. 
The same pattern was also observed for striatal HVA depletion (2 nmol: 23.2 ± 4.2%; 
P<0.05; 10 nmol: 10.1 ± 3.6%; P<0.001; 50 nmol: 60.6 ± 5.0% P=0.147) as shown in 
Figure 3.1 OC. 
Importantly, increases in striatal DA turnover ratio in the ipsilateral striata induced 
by 6-OHDA in vehicle-treated animals were completely blocked by treatment with 2 and 
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Figure 3.9 Effects of sub-chronic MPEP treatment on 
nigrostriatal tract integrity following 6-OHDA leisoning. 
A: Sub-chronic intranigral treatment with MPEP significantly attenuates the 6-OHDA 
induced loss of TH-IR cells in a concentration dependent manner. Data shown are 
mean percentage loss TH-IR cells (all levels SNc) ± SEM, n values are shown in 
parenthesis, **P<0.01, ***P<0.001 MPEP vs. vehicle-treated. B: Different 
concentrations of MPEP show some significant regional differences in neuroprotection 
of nigral TH-IR cells. Data shown are mean percentage loss of TH-IR cells ± SEM 
calculated from 4-5 sections of each region of the SNc in vehicle and MPEP-treated 
animals. *P<0.01 NWEP vs. vehicle-treated, tP<0.05 indicates a significant difference 
to other regions. 
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10 nmol MPEP, such that no significant difference existed between the ipsilateral and 
contralateral striata (Figure 3.1013; P>0.05). In contrast, in animals treated with 50 nmol 
MPEP a significant increase in this ratio is observed in the ipsilateral striata (0.234 ± 0.02 
vs. 0.156 ± 0.005 pmol/ml; P<0.01; Figure 3.1013) similar to that seen in vehicle-treated 
animals, consistent with a loss of neuroprotective effects of MPEP on striatal monoamines 
described above at higher concentrations of MPEP. Importantly, in all MPEP treatment 
groups no significant changes were observed in either striatal 5-HT or 5-HIAA 
concentrations (data not shown). It should be noted however, that a comparison of the mean 
striatal monoamine content between the ipsilateral and contralateral striata revealed a 
significant reduction in animals treated with 2 and 10 nmol MPEP (P<0.05, data not 
shown), indicating that 6-OHDA still induces a significant, but markedly reduced striatal 
monoamine depletion in these groups. 
Taken together, these data indicate that sub-chronic intranigral infusion of MPEP 
robustly preserves nigrostriatal tract functionality following 6-OHDA lesioning. 
Furthermore, this is not associated with increased metabolic activity by the surviving nigral 
TH-IR cells. At high concentrations however, this protective effect is markedly absent. 
Thus, 10 nmol in 4 ýtl MPEP appears to be the optimum concentration for maximal 
neuroprotection of striatal monoamines in this model. 
3.3.4 2R, 4R-APDC is neuroprotective against 6-OHDA toxicity in vivo 
3.3.4.1 Effects of 2R, 4R-APDC on nigrostriatal integrity 
Sub-chronic intranigral administration of the selective mGluR2/3 receptor agonist 2R, 4R- 
APDC significantly attenuated the 6-OHDA-induced loss of nigral TH-IR cells in the 
ipsilateral SNc with a clear concentration-dependence (Figure 3.1 IA). Indeed, one-way 
ANOVA analysis revealed significant differences between 2R, 4R-APDC and vehicle- 
treated groups (F23.11 P<0.0001) and post-hoc analysis revealed that the mean percentage 
loss of TH-IR cells in the ipsilateral SNc was significantly reduced at all the concentrations 
of 2R, 4R-APDC tested (2 nmol: 51.0 ± 2.3%; P<0.05; 10 nmol: 36.3 ± 5.6%; P<0.001; 50 
nmol: 27.9 ± 3.0%; P<0.001, respectively Figure 3.1 IA). To illustrate the magnitude of the 
neuroProtection, a representative photomicrograph of TH-IR cells in the SNc from an 
animal treated with 10 nmol 2R, 4R-APDC is shown in Figure 3.6. As with LY367385 and 
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Figure 3.10 Effects of sub-chronic MPEP treatment on 
nigrostriatal tract functionality following 6-OHDA leisoning 
Treatment with MPEP significantly reduces the 6-OHDA induced loss of 
striatal monoamines in the corpus striatum in a concentration dependent 
manner. Data shown are (A) mean percentage depletion of striatal DA (B) 
DOPAC and (C) HVA in ng/mL ± SEM, n values are as shown parenthesis, 
*P<0.05, **P<0.01, ***P<0.001 vehicle vs. MPEP-treated. No significant 
alterations in striatal DA turnover were observed following treatment with 2 
or 10 nmol NWEP as shown in (D) compared to vehicle-treated male rats. In 
contrast, in animals treated with 50 nmol MPEP a significant increase in 
striatal DA turnover was observed similar to that seen in vehicle-treated 
animals Data shown are mean striatal monoamine turnover ratio calculated 
using the expression ((DOPAC+HVA)/DA) in pmol/ml ± SEM, *P<0.05, 
**P<0.01 contralateral vs. ipsilateral striata. 
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MPEP however, a comparison of the mean number of nigral TH-IR cells between the 
ipsilateral and contralateral hemispheres in animals treated with 2,10 and 50 nmol 2R, 4R- 
APDC revealed a small but significant reduction (P<0.05, data not shown) indicating that 
6-OHDA still induces a significant, but markedly reduced lesion of the SNc in these 
groups. 
A significant difference in lesion size across different regions of the SNc was only 
observed in animals treated with 2 nmol 2R, 4R-APDC (ANOVA F3.702 P=0.0294). Post- 
hoc analysis showed that the lesion size in region A was significantly smaller compared to 
that seen in region E (P<0.05; Figure. 3.11 B). Indeed, the lesion size in this group of 
animals was only significantly different from vehicle-treated animals in region A (Figure 
3.1113). No other significant differences between SNc regions were observed. In the 10 and 
50 nmol-treated groups, one-way ANOVA analysis revealed no significant differences in 
lesion size between regions of the SNc (Fo. 3993P=0.8059 and F3.167P=0.0634, respectively 
Figure 3.11 B). In the 10 nmol-treated group, the lesion size was significantly reduced in 
regions A-D compared to vehicle-treated animals (P<0.05; Figure 3.11 B), whilst in 50 
nmol-treated groups, the lesion size was significantly smaller in all regions of the SNc, 
when compared to vehicle-treated animals (P<0.05; Figure 3.11 B). 
Taken together, these data indicate that sub-chronic intranigral infusion of 2R, 4R- 
APDC effectively and robustly protects nigral TH-IR cells against 6-OHDA toxicity in a 
concentration-dependent manner. As with MPEP, no significant gross behavioural or 
seizure-like activity was observed following intranigral administration of 2R, 4R-APDC at 
concentrations below 10 nmol in 4 [d. However, in animals treated with 50 nmol 2R, 4R- 
APDC some teeth chattering and increased rearing activity was observed. This effect was 
transient and short-lived following injection (approx 10-15 minutes) and no other gross 
behavioural abnormalities were observed. Based on this, 10 nmol in 4 ýLl 2R, 4R-APDC 
appears to be the optimum concentration for neuroprotection of nigral TH-IR cells in this 
model. 
3.3.4.2 Effects of 2R, 4R-APDC on nigrostriatalfunctionality 
Sub-chronic intranigral administration of 2R, 4R-APDC significantly attenuated the 6- 
OHDA-induced reduction of striatal DA concentration in the ipsilateral striaturn (ANOVA 
FIO. 24 P"ýý0-0001) in a concentration dependent manner, as illustrated in Figure 3.12A. 
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Figure 3.11 Effects of sub-chronic 2R, 4R-APDC treatment on 
nigrostriatal tract integrity following 6-OHDA lesioning. 
A: Sub-chronic intranigral treatment with 2R, 4R-APDC significantly attenuates 6- 
OHDA induced loss of nigral TH-IR cells in a concentration dependent manner. Data 
shown are mean percentage loss nigral TH-IR cells (all levels SNc) ± SEM, n values 
are shown in parenthesis. *P<0.05, ***P<0.001 2R, 4R-APDC vs. vehicle-treated. B: 
Significant differences in neuroprotection. between SNc regions were only observed 
in 2 nmol 2R, 4R-APDC-treated animals, but not 10 or 50 nmol-treated, *P<0.05 vs. 
vehicle-treated, tP<0.05 indicates a significant difference to other regions. Data 
shown are mean percentage loss nigral TH-IR cells calculated firom 4-5 sections of 
each region of the SNc in vehicle and 2R, 4R-APDC-treated male rats ± SEM. 
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Indeed, post-hoc analysis showed that all three concentrations of 2R, 4R-APDC resulted in 
significantly reduced striatal DA depletion compared to vehicle-treated animals (2 nmol: 
17.7 ± 3.4%; P<0.05; 10 nmol: 9.9 ±2.7%; P<0.05; 50 nmol 15.4 ± 3.0%; P<0.05; Figure 
3.12A). It should be noted however that a small but significant loss of striatal DA is 
observed when comparing the concentrations between the ipsilateral and contralateral 
striata within each 2R, 4R-APDC -treated group (P<0.05, data not shown). Thus, 6-OHDA 
still induces a loss of striatal DA in 2R, 4R-APDC -treated animals, but this is markedly and 
significantly reduced when compared to the depletion seen in vehicle-treated animals. 
Similar concentration -dependent neuroprotection was observed for the 6-OHDA-induced 
depletion of striatal concentrations of DOPAC (2 nmol: 30.5 ± 4.9%; P<0.05; 10 nmol: 
18.7 ± 7.3%; P<0.05; 50 nmol: 18.8 ± 7.2%; P<0.05; Figure 3.12B) and HVA (2 nmol: 
16.7 ± 2.5%; P<0.05; 10 nmol: 9.9 ± 3.5%; P<0.01; 50 nmol: 12.6 ± 3.8%; P<0.01; Figure 
3.12C) in all the 2R, 4R-APDC -treated groups. 
Additionally, treatment with 10 and 50 nmol 2R, 4R-APDC completely blocked the 
increases in the striatal DA turnover ratio observed in vehicle-treated animals, such that no 
significant difference in this ratio were observed between the ipsilateral and contralateral 
striata (P>0.05; Figure 3.12D). This suggests that the neuroprotective effects of these 
concentrations of 2R, 4R-APDC on striatal monoamines are not due to increases in 
metabolic activity by the surviving nigral TH-IR cells. In contrast, in the 2 nmol-treated 
group a small but significant increase in this ratio was observed in the ipsilateral striata 
when compared to the contralateral side (0.199 ± 0.01 vs. 0.152 ± 0.01 pmol/ml; P<0.05; 
Figure 3.12). This increase is similar to that observed in vehicle-treated animals and thus it 
is likely that the neuroprotective effects of this concentration of 2R, 4R-APDC on striatal 
monoamines may be partly the result of increased metabolic activity by the surviving nigral 
TH-IR cells. In all 2R, 4R-APDC treatment groups no significant changes were observed in 
either striatal 5-HT or 5-HIAA concentrations (data not shown). It should be noted 
however, that a comparison of the mean concentration of each striatal monoamine between 
the ipsilateral and contralateral hemispheres in animals treated 2,10 and 50 nmol 2R, 4R- 
APDC revealed a small but significant reduction (P<0.05, data not shown) 
indicating that 
6-OHDA still induces a significant, but markedly reduced depletion of striatal monoamines 
in these groups. 
Taken together, these data indicate that sub-chronic intranigral infusion of 2R, 4R- 
APDC robustly prevents loss of nigrostriatal functionality following 
6-OHDA lesioning in 
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a concentration-dependent manner. Furthermore, reduced striatal DA depletion in animals 
administered low concentrations of 2R, 4R-APDC may also be the result of changes in 
striatal DA turnover coupled with a modest neuroprotective effect on TH-IR cells in the 
SNc. 
3.3.5 L-AP4 is neuroprotective against 6-OHDA toxicity in vivo 
3.3.5.1 Effects of L-AP4 on nigrostriatal integrity 
Sub-chronic intranigral administration of the broad-spectrum Group III mGluR agonist L- 
AP4 significantly attenuated the 6-OHDA-induced loss of TH-IR cells in the ipsilateral 
SNc, as indicated by one-way ANOVA, which revealed significant differences between L- 
AP4 and vehicle-treated groups (F20.42 P<0.0001). Indeed, post-hoc analysis revealed that 
the mean percentage loss of TH-IR cells in the ipsilateral SNc was significantly reduced in 
animals treated with 2 and 10 nmol L-AP4 compared to vehicle-treated animals (2 nmol: 
47.6 ± 3.7%; P<0.01; 10 nmol: 33.9 ± 4.2%; P<0.001; respectively, Figure 3.13A). In 
contrast, in animals treated with 50 nmol L-AP4, the mean percentage loss of TH-IR cells 
in the ipsilateral SNc was not significantly different to vehicle-treated animals (60.6 ± 
3.2%; Figure 3.13A). These data suggest that similar to MPEP, L-AP4 shows a clear bell- 
shaped neuroprotective profile with a clear concentration-dependence relationship. To 
illustrate the magnitude of the neuroprotection by L-AP4, a representative photomicrograph 
of TH-IR cells in the SNc from an animal treated with 10 nmol L-AP4 is shown in Figure 
3.6. However, despite this robust protection of nigral TH-IR cells, it is important to note 
that a small but significant loss of TH-IR cells was still observed when comparing the mean 
TH-IR cell numbers in the contralateral and ipsilateral hemispheres of the brain within each 
treatment group (P<0.05, data not shown). No significant differences in lesion size across 
the different regions of the SNc were observed for any L-AP4-treated group (Figure 
3.1313). In animals treated with both 2 and 10 nmol L-AP4, the lesion size was significantly 
reduced in all regions except region E compared to vehicle-treated animals (P<0.05, Figure 
3.1313). In contrast, in animals treated with 50 nmol L-AP4 the lesion size was not 
significantly different from that observed in vehicle-treated animals in any SNc region 
(P>0.05, Figure 3.1313) in good agreement with the total cell loss data shown in Figure 
3.13A. 
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Figure 3.12 Effects of sub-chronic 2R, 4R-APDC treatment on 
nigrostriatal tract functionality following 6-OHDA leisoning 
Sub-chronic treatment with 2R, 4R-APDC significantly reduces the 6-OHDA- 
induced loss of striatal monoamines in the corpus striatum in a concentration 
dependent manner. Data shown are mean (A) striatal doparnine, (B) DOPAC 
and (C) HVA content in ng/mL ± SEM, n values are shown in parenthesis, 
*P<0.05, **P<0.01 2R, 4R-APDC vs. vehicle -treated. (D) In animals treated 
with 2 nmol 2R, 4R-APDC striatal DA turnover is significantly increased in 
the ipsilateral striata, as observed in vehicle-treated animals. In contrast, in 
animals treated with 10 or 50 nmol 2R,, 4R-APDC no significant increases in 
striatal DA turnover were observed. Data shown are mean striatal monoamine 
turnover ratio calculated using the expression ((DOPAC+HVA)/DA) in 
pmol/ml ± SEM, *P<0.05 contralateral vs. ipsilateral striata. 
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Figure 3.13 Effects of sub-chronic L-AP4 treatment on 
nigrostriatal tract integrity following 6-OHDA leisoning. 
A: Sub-chronic intranigral treatment with L-AP4 significantly attenuates 6-OHDA 
induced loss of TH-IR cells in a concentration dependent manner. Data shown are 
mean percentage loss TH-IR cells (all levels SNc) ± SEM, n values are shown in 
parenthesis. **P<0.01, ***P<0.001 L-AP4 vs. vehicle-treated. B: No significant 
regional differences in neuroprotection of nigral TH-IR cells were observed at any 
concentration of L-AP4. Data shown are mean percentage loss of nigral TH-IR cells 
± SEM calculated from 4-5 sections of each region of the SNc in vehicle and L-AP4- 
treated male rats following 6-OHDA leisoning, *P<0.05 vehicle vs. L-AP4-treated. 
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Taken together, these data indicate that sub-chronic intranigral infusion of L-AP4 
effectively and robustly protects nigral TH-IR cells against 6-OHDA toxicity in a 
concentration -dependent manner with a bell-shaped profile. Importantly, intranigral of L- 
AN resulted in no observation of any gross behavioural abnormalities at any concentration 
tested. 
3.3.5.2 Effects of L-AP4 on nigrostriatalfunctionality 
Sub-chronic intranigral administration of L-AP4 significantly attenuated the 6-OHDA- 
induced depletion of striatal DA in the ipsilateral striatum (ANOVA F10.24 P<0.0001) as 
clearly illustrated in Fig 3.14A. As with nigral TH-IR cells, post-hoc analysis showed that 
significant preservation of striatal DA was only observed in animals treated with 2 and 10 
nmol L-AP4 compared to vehicle-treated animals (2 nmol: 17.0 ± 3.5%; P<0.05; 10 nmol: 
11.3 ± 2.6%; P<0.05; respectively, Figure 3.14A). In animals treated with 50 nmol L-AP4 
the mean percentage reduction of striatal DA was not significantly different from vehicle- 
treated animals (59.2 ± 12.5%; P>0.05; Figure 3.14A) in good agreement with an absence 
of neuroprotection of nigral TH-IR cells (see section 3.3.5.1). 
Additionally, L-AP4 treatment significantly prevented the depletion of striatal 
DOPAC levels in a concentration-dependent manner, indeed, 2 and 10 nmol L-AP4 were 
significantly protective (2 nmol: 24.8 ± 4.5%; P<0.05; 10 nmol: 17.9 ± 4.5%; P<0.05; 
Figure 3.1413) compared to vehicle-treated animals, but in contrast, this effect was absent in 
animals treated with 50 nmol L-AP4 (55.4 ± 10.0% P=0.946; Figure 3.1413). Similar results 
were observed for striatal HVA depletion with significant reductions in HVA depletion in 
animals treated 2 and 10 nmol L-AP4 (2 nmol: 25.7 6.5%; P<0.05; 10 nmol: 19.1 ± 6.4%; 
P<0.01; Figure 3.14C) but not 50 nmol L-AP4 (44.7 10.7% P=0.752; Figure 3.14C). 
Interestingly, no significant differences between the mean striatal DA concentration 
in the ipsilateral and contralateral striata was observed in animals treated with 10 nmol L- 
AP4, although the p value was very close to statistical significance (P = 0.0597). It should 
be noted however, that in the 2 nmol L-AP4-treated group a small but significant reduction 
of striatal DA was observed (P<O. 05, data not shown). Importantly, in both 2, and 10 nmol- 
treated groups, small but significant reductions were also observed when comparing the 
mean striatal concentrations of DOPAC and HVA between the contralateral and ipsilateral 
striata (P<0.05, data not shown). Taken together, these data suggest 6-OHDA still induces a 
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significant depletion of striatal monoamines, but this is markedly and significantly reduced 
in animals treated with L-AP4 when compared to the depletion seen in vehicle-treated 
animals. 
In terms of striatal DA metabolism, treatment with 2 and 10 nmol L-AP4 
completely blocked the increases in the striatal DA turnover ratio observed in vehicle- 
treated animals, such that no significant difference in this ratio was observed between the 
ipsilateral and contralateral striata (P>0.05, Figure 3.14D). This suggests that the 
neuroprotective effects of these concentrations of L-AP4 on striatal monoamines are not 
due to increases in metabolic activity by the surviving nigral TH-IR cells. In contrast, in the 
50 nmol-treated group, a significant increase in this ratio was observed in the ipsilateral 
striata when compared to the contralateral side (0.259 ± 0.03 vs. 0.172 ± 0.007; P<0.05) 
similar to that observed in vehicle-treated animals. In all L-AP4 treatment groups no 
significant changes were observed in either striatal 5-HT or 5-HIAA concentrations (data 
not shown). 
Taken together, these data suggest that sub-chronic intranigral infusion of L-AP4 at 
low concentrations effectively prevents loss of nigrostriatal functionality following 6- 
OHDA lesioning in a concentration -dependent manner, with a bell-shaped profile. 
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Figure 3.14 Effects of sub-chronic L-AP4 treatment on 
nigrostriatal tract functionality following 6-OHDA 
leisoning 
Sub-chronic treatment with L-AP4 significantly reduces the 6-OHDA 
induced loss of monoarnines in the corpus striaturn in a concentration 
dependent manner. Data shown are mean striatal (A) DA, (B) DOPAC 
and (C) HVA content in ng/mL ± SEM, n values are shown in 
parenthesis *P<0.05, **P<0.01 L-AP4- vs. vehicle-treated. (D) In 
animals treated with 2 and 10 nmol L-AP4 no significant alterations in 
striatal DA metabolism were observed compared to vehicle-treated 
male rats, in which a significant increase in striatal dopamine 
metabolism was observed. In contrast, a significant increase in striatal 
DA metabolism in the ipsilateral striata was observed in animals 
treated with 50 nmol L-AP4. Data shown are mean striatal monoamine 
turnover ratio calculated using the expression ((DOPAC+HVA)/DA) 
in pmol/ml ± SEM, *P<0.05 contralateral vs. ipsilateral striata. 
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3.3.6 Effects of selective Group 11 and III mGluR antagonists in 6-OHDA-lesioned 
animals 
3.3.6.1 Effects of EGLU and MSOP on nigrostriatal integrity in sham and 6-OHDA- lesioned animals 
Sub-chronic intranigral administration of 1000 nmol EGLU in 6-OHDA lesioned animals, 
had no significant effect on the mean percentage loss of nigral TH-IR cells induced by 6- 
OHDA, as clearly illustrated in Figure 3.15A. Similarly, sub-chronic intranigral 
administration of 50 nmol MSOP had no significant effect on mean TH-IR cell number in 
6-OHDA lesioned animals as illustrated in Figure 3.15B. This is illustrated in 
representative photorn icro graphs shown in Figure 3.18. Importantly, following intranigral 
injection of either EGLU or MSOP no gross behavioural abnormalities were observed. 
3.3.6.2 Effects of EGLU and MSOP on nigrostriatal functionality in sham and 6-OHDA- 
lesioned animals 
In 6-OHDA lesioned animals, treatment with EGLU did not alter the 6-OHDA-induced 
depletion of DA, DOPAC or HVA in the ipsilateral SNc (Figures 3.16A, B and C). 
Additionally, administration of EGLU did not block the 6-OHDA-induced increases in 
striatal DA turnover ratio (Figure 3.16D). Identical results were observed in animals treated 
with MSOP in 6-OHDA-lesioned animals (Fig 3.17A -D). In either the EGLU or MSOP 
treatment groups no significant changes were observed in either striatal 5-HT or 5-HIAA 
concentrations (data not shown). 
Taken together, these data indicate that sub-chronic intranigral administration of 
either EGLU or MSOP in 6-OHDA lesioned animals, does not significant alter the 
depletion of striatal monoamines, or block increases in striatal monoamine metabolism 
induced by 6-OHDA. These data are also in good agreement with those observed for TH-IR 
cells in the SNc (see section 3.3.6 1) 
3.3.7 The neuroprotective action of 2R, 4R-APDC is receptor-mediated 
Sub-chronic intranigral administration of 10 nmol 2R, 4R-APDC significantly attenuated the 
mean percentage loss of TH-IR cells in the ipsilateral SNc (see section 3.3.4. and Figure 
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3.15A). In contrast, in animals where 10 nmol 2R, 4R-APDC was co-administered with 
1000 nmol EGLU this effect was completely reversed and the mean percentage loss of 
nigral TH-IR cells was not significantly different from vehicle-treated animals (74.0 ± 2.3% 
vs. 70.2 ± 3.0% ; P>0.05; Figure 3.15A). No significant differences in lesion size were 
observed between SNc regions in any treatment group, nor were the lesion size 
significantly different from vehicle-treated animals in any region of the SNc (data not 
shown). This is illustrated in a representative photomicrograph in Figure 3.18. 
Similarly, sub-chronic intranigral administration of 10 nmol 2R, 4R-APDC in 6- 
OHDA lesioned animals resulted in significant attenuation of the 6-OHDA-induced 
depletion of striatal DA, DOPAC and HVA and also completely blocked the 6-OHDA- 
induced increase in striatal DA metabolism (see section 3.3.4.2). This is clearly illustrated 
in Figures 3.16A - D. In contrast, when 10 nmol 2R, 4R-APDC was co-administered with 
1000 nmol EGLU these neuroprotective effects on nigrostriatal functionality and striatal 
DA metabolism were completely reversed such that they were not significantly different 
from vehicle-treated animals, which is clearly illustrated in Figure 3.15A-D. Additionally, 
no significant effects were observed in striatal 5-HT or 5-HIAA concentrations (data not 
shown). Taken together, these data suggest that the neuroprotective effects of 2R, 4R-APDC 
on nigrostriatal integrity and functionality following 6-OHDA lesioning are mediated by 
Group 11 mGluR i. e. mGluR2 or mGluR3. 
3.3.8 The neuroprotective action of L-AP4 is receptor- m ed iated 
Sub-chronic intranigral administration of 10 nmol L-AP4 significantly attenuated the mean 
percentage loss of TH-IR cells in the ipsilateral SNc (see section 3.3.5.1) as illustrated 
clearly in Figure 3.15B. In contrast, in animals where 10 nmol L-AP4 was co-administered 
with 50 nmol MSOP this effect was completely reversed and the mean percentage loss of 
nigral TH-IR cells was not significantly different from vehicle-treated animals (74.0 ± 2.3% 
vs. 80.5 ± 2.1%; P>0.05; Figure 3.1513). No significant differences in lesion size were 
observed between SNc regions in any treatment group, nor were the lesion size 
significantly different from vehicle-treated animals in any region of the SNc (data not 
shown). This is illustrated by a representative photomicrograph in Figure 3.18 
Similarly, sub-chronic intranigral administration of 10 nmol L-P4 in 6-OHDA 
lesioned animals resulted in significant attenuation of the 6-OHDA-induced depletion of 
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striatal DA, DOPAC and HVA, and also completely blocked the 6-OHDA-induced increase 
in striatal DA metabolism (see section 3.3.5.2), which is clearly illustrated in Figures 3.17A 
- D. In contrast, when 10 nmol L-AP4 was co-administered with 50 nmol MSOP, these 
neuroprotective effects on the nigrostriatal system were completely reversed such that they 
were not significantly different from vehicle-treated animals, which are clearly illustrated in 
Figures 3.17A-D. Additionally, no significant changes were observed in striatal 5-HT or 5- 
HIAA concentrations (data not shown). Taken together, these data suggest that the 
neuroprotective effects of L-AP4 on nigrostriatal integrity and functionality following 6- 
OHDA lesioning are mediated by Group III mGluRs. Furthermore, these data indicate that 
MSOP is an effective Group III selective antagonist in the SNc in vivo. 
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Figure 3.15 Neuroprotection of nigrostriatal integrity following Group 
11 and III mGluR agonist treatment is receptor-mediated 
A: Sub-chronic co-administration of the selective Group 11 mG1uR2/3 antagonist EGLU 
reverws the neuroprotective action of the specific Group 11 mGluR2/3 agonist 2R, 4R- 
APDC on TH-IR cells in the SNc following 6-OHDA leisoning. B: Sub-chronic co- 
administration of the selective Group III mGluR antagonist MSOP reverses the 
neuroprotective action of the Group III mGlu receptor agonist L-AP4 on TH-IR cells in the 
SNc following 6-OHDA leisoning. Taken together these data suggest the neuroprotective 
effects of these receptors on nigrostriatal integrity are receptor-mediated by Group 11 and 
III mGl-uR respectively. Data shown are mean percentage loss TH-IR cells (all levels SNc) 
± SEM, n values are shown in parenthesis. *P<0.01 mGluR agonist-treated vs. vehicle - 
treated, tP<0.01 mGluR agonist-treated vs. mGluR agonist + antagonist-treated animals. 
The chemical structures of EGLU and MSOP are also illustrated. 
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Figure 3.16 Sub-chronic co-administration of the specific 
mGluR2/3 antagonist EGLU reverses the neuroprotective 
effects of 2R, 4R-APDC on the functionality of the 
nigrostriatal system following 6-OHDA lesioning. 
Sub-chronic (7 day) treatment with 1000 nmol EGLU alone has no 
significant effects on the reduction of striatal monoamines induced by 6- 
OHDA, whilst this is significantly attenuated by treatment with 10 nmol of 
2R, 4R-APDC. In contrast, sub-chronic co-administration of 1000 nmol 
EGLU with 10 nmol 2R, 4R-APDC significantly attenuates the 
neuroprotective effects of 2R, 4R-APDC on nigrostriatal functionality 
following 6-OHDA lesioning, suggesting that the neuroprotective effects 
of 2R, 4R-APDC are mediated through Group 11 mGluR, mGluR2 and 3. 
Data shown are mean percentage reduction of (A) DA, (B) DOPAC, (C) 
HVA ± SEM (ng/ml), n values are shown in parenthesis. *P<0.01 2R, 4R- 
APDC- vs. vehicle-treated, tP<0.05 2R, 4R-APDC- vs. EGLU + 2R, 4R- 
APDC-treated (D) Significant differences were observed in striatal 
monoamine turnover in vehicle, EGLU and EGLU + 2R, )4R-APDC-treated 
animals, but not in the 2R, 4R-APDC treated group Data shown are mean 
striatal monoamine turnover ratio calculated using the expression 
((DOPAC+fIVA)/DA) in pmol/ml ± SEM, *P<0.05 contralateral vs. 
iPsilateral striata. 
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Figure 3.17 Sub-chronic co-administration of the selective 
Group III mGluR antagonist MSOP reverses the 
neuroprotective effects of L-AP4 on the functionality of the 
nigrostriatal system following 6-OHDA lesioning. 
Sub-chronic treatment with 50 nmol MSOP alone has no significant 
effects on the depletion of striatal monoamines induced by 6-OHDA, 
whilst this is significantly attenuated by treatment with 10 nmol of L- 
AP4. In contrast, sub-chronic co-administration of 50 nmol MSOP with 
10 nmol L-AP4 significantly attenuates the neuroprotective effects of L- 
PA4 on nigrostriatal functionality following 6-OHDA lesion, suggesting 
that the neuroprotective effects of L-AP4 are mediated through Group III 
mGluR. (A-C) Data shown are mean percentage reduction of striatal 
monoamines ± SEM (ng/ml), n values are shown in parenthesis. *P<0.01 
L-AP4- vs. vehicle-treated, tP<0.05 L-AP4- vs. MSOP + L-AP4-treated 
(D) Significant differences were observed in striatal monoamine turnover 
in vehicle, MSOP and MSOP + L-AN-treated animals but not in the L- 
AN-only treated animals (*P<0.05 ipsilateral vs. contralateral SNc. Data 
shown are mean striatal monoamine turnover ratio calculated using the 
expression ((DOPAC+HVA)/DA) in pmol/ml SEM, *P<0.05 
contralateral vs. ipsilateral striata. 
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Figure 3.18 Representative photomicrographs to illustrate that 
neuroprotection mediated by selective Group 11 and Group III mGluR 
agonists is receptor- mediated 
Low power representative photomicrographs of nigral TH-IR cells to illustrate that sub- 
chronic treatment with the selective Group 11 mG1uR antagonist EGLU and the Group III 
mGluR antagonist MSOP do not affect the lesion size induced by 6-OHDA infusion into 
the SNc. Importantly, co-administration of these antagonists with either the selective 
mGluR2/3 agonist 2R, 4R-APDC or the Group III mGluR agonist L-AP4 completely 
reverses the neuroprotective effects of these compounds on nigrostriatal integrity. For 
comparative purposes, photomicrographs to illustrate the neuroprotective effects of 
2R, 4R-APDC and L-AP4 alone are also shown. All images correspond to region B of the 
SNc (-5.30 mm from bregma) at x 40 magnification, scale bar = 250 [tm. The SNc, VTA 
and nearby medial terminal nucleus (MTN) are highlighted in panel A. 
SNc 
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3.4 Discussion 
The aims of the current study were (1) to test four novel potent and selective mGluR 
ligands for their putative neuroprotective actions on the nigrostriatal system following 6- 
OHDA lesioning, (2) to establish if any observed neuroprotection exhibits a concentration- 
dependent relationship and (3) to test if any observed neuroprotection mediated by Group 11 
or Group III mGluR agonists was receptor-mediated. These aims were based on the 
hypothesis that selective ligands acting on mGluR in the basal ganglia may protect nigral 
DA neurones by modifying the activity of the indirect pathway (Conn et al, 2005). In 
agreement with this, the data presented herein demonstrate that sub-chronic, intranigral 
treatment with the selective Group I mGluR antagonists LY367385 and MPEP, the 
selective Group 11 mGluR agonist 2R, 4R-APDC and the broad-spectrum Group III mGluR 
agonist L-AP4 provides robust neuroprotective effects on both the integrity and 
functionality of the nigrostriatal system following 6-OHDA lesioning in a rodent model of 
Parkinsonism (Vernon et al, 2005; 2006). Furthermore, the neuroprotective effects of each 
mGluR ligand showed a clear concentration-dependent relationship. Moreover, in the case 
of the Group 11 and III mGluR agonists, it is demonstrated that these neuroprotective effects 
are receptor-mediated. It is noteworthy however, that a significant reduction of nigral TH- 
IR cells and striatal monoamines is still observed in the ipsilateral compared to the 
contralateral side for each group, (with the exception of striatal DA levels in animals 
treated with 10 nmol L-AP4) despite the apparent robust neuroprotective effects of each 
mGluR ligand tested. This is perhaps not surprising since 6-OHDA is toxic to nigral DA 
neurones through several mechanisms, which mGluR ligands may not protect against. 
Importantly, it is also demonstrated that each mGluR ligand when administered sub- 
chronically in sham-lesioned animals at a concentration that imparts significant 
neuroprotection in 6-OHDA-lesioned animals, results in no significant effects on either the 
integrity or functionality of the nigrostriatal tract. These data are reported for the first time 
for these compounds in this particular experimental model of PD and have been previously 
published in part elsewhere (Vernon et al, 2005; 2006). 
Theoretically, the observed decrease in nigral TH-IR cells and the neuroprotective 
effects of each mGluR ligand could be due to transient atrophy of cells and 
downregulation 
of TH expression rather than true cell death and neuroprotection 
(Sherman and Moody, 
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1995; Yuan et al, 2005; Meuer et al, 2006). This possibility was addressed by staining 
sections from vehicle-treated 6-OHDA-lesioned animals for the specific neuronal marker 
NeuN (Mullen et al, 1992). Subsequently the number of NeuN-IR cells was quantified in 
the SNc at each stereotaxic level of the SNc exactly as for TH-IR cells (see section 2.2.1.4). 
From these sections it was observed that infusion of 6-OHDA into the SNc produces a 
directly comparable reduction of NeuN-IR cells as well as TH-IR cells (65.62 ± 1.61% vs. 
73.31 ± 4.63%; P>0.05)). Thus, it may be suggested that the observed loss of TH-IR cells 
in the SNc following 6-OHDA lesioning may be attributed to cell death and not simple 
downregulation of TH in atrophic neurones. Accordingly, the observed neuroprotective 
effects of these mGluR ligands cannot be explained by TH up-regulation. Importantly, sub- 
chronic mGluR ligand treatment also attenuated the 6-OHDA-induced depletion of striatal. 
DA and its metabolites, which indicates preservation of axonal projections. The observation 
that each mGluR ligand tested also blocks 6-OHDA-induced increases in striatal DA 
turnover suggests that the prevention of DA depletion by mGluR ligand treatment is due to 
neuroprotection of DA terminals rather than increased DA metabolism by the surviving 
nigral TH-IR cells. Furthermore, because of the short time between 6-OHDA lesioning and 
HPLC measurements (7 days post-6-OHDA lesion) it is unlikely that the preservation of 
striatal DA could be explained by sprouting of the remaining axonal projections, which is 
suggested to occur 4 weeks after 6-OHDA lesioning (Finkelstein et al, 2000; Stanic et al, 
2001; 2003). Taken together, these data support a true neuroprotective effect of mGluR 
ligands in vivo in our experimental model, which is discussed in more detail for each 
individual compound in the following sections. 
3.4.2 Neuroprotective actions of Group I mGluR antagonists 
3.4.2.1 Neuroprotection by the mGluR, antagonist LY367385 
In the current study, sub-chronic intranigral administration of the mGluR1 antagonist 
LY367385 resulted in robust, significant protection of nigral TH-IR cell bodies and 
prevented striatal DA depletion in a concentration-dependent manner in animals bearing a 
partial unilateral 6-OHDA lesion of the nigrostriatal tract. Although maximal protection of 
nigral TH-IR cells and striatal DA was achieved at concentrations of 1000 nmol LY367385, 
this was not significantly different to that observed in animals treated with 200 nmol 
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LY367385. Furthermore, sub-chronic administration of high concentrations of LY367385 
resulted in observed some gross motor abnormalities following intranigral administration, 
consistent with a previous report in which similar concentrations of LY367385 
administered into the inferior colliculus resulted in similar behavioural abnormalities 
(Chapman et al, 1999). These effects were not observed in animals treated with 200 nmol 
LY367385, thus it would appear this is the optimum concentration for neuroprotection 
against 6-OHDA toxicity in this experimental Paradigm. Interestingly, some regional 
differences in neuroprotection of nigral TH-IR cells were apparent, at lower concentrations 
sparing of TH-IR cells appeared to be confined to the rostral tip of the SNc, which may be 
due to expected the low concentration of drug, which may not have been able to diffuse and 
antagonise mGIuR1 throughout the entire SNc. This is reflected in the fact that at higher 
concentrations, significant neuroprotection is observed throughout the SNc, which may 
reflect a higher degree of receptor occupancy and functional antagonism as a result of the 
higher concentrations administered. These data suggesting a neuroprotective action for 
mGIuR1 antagonists are consistent with evidence which suggests postsynaptic mGIuR1 
expressed on nigral DA neurones are involved in regulating the excitation of nigral DA 
neurones (Mercuri et al, 1993; Shen and Johnson, 1997; Meltzer et al, 1997a; Fiorillo and 
Williams, 1998). Furthermore, the neuroprotective actions of LY367385 in this model are 
consistent with previous studies which have demonstrated a neuroprotective effect of this 
compound in experimental models of stroke in which glutamate-mediated excitotoxicity is 
implicated (Rao et al, 2002). Additionally, LY367385 is neuroprotective against NMDA 
toxicity when either applied to mixed cortical cultures or when locally infused into the 
caudate nucleus of rodents at concentrations similar to those used in the current study 
(Battaglia et al, 2001). Moreover, significant neuroprotection of dopaminergic cells in the 
SNc against MPTP toxicity in the mouse was observed following a single 
intracerebroventricular injection of the Group I mGluR antagonist I-Aminoindan-1,5- 
dicarboxylic acid (AIDA), at a concentration identical to that employed in these studies 
(Aquirre et al, 2001). Importantly, the latter study did not investigate the neuroprotective 
effect of AIDA on nigrostriatal functionality, which is reported here for the first time with a 
similar, selective mGluRl antagonist, LY367385 (Vernon et al, 2005). Taken together, 
these data suggest that antagonism of mGluRI may be neuroprotective against 
neurodegeneration induced by 6-OHDA in vivo. 
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3.4.2.2 Neuroprotection by the mGluR5 antagonist MPEP 
Sub-chronic intranigral administration of the mGluR5 antagonist MPEP demonstrated a 
bell-shaped neuroprotective profile against 6-OHDA neurotoxicity. Interestingly the 
neuroprotective effects of MPEP at 2 and 10 nmol were similar and not significantly 
different, perhaps because a maximal protection was already conferred by the lower dose. 
This is in good agreement with previous data demonstrating an anti -parkinson ian effect of 
MPEP on 6-OHDA induced akinesia in rodents following chronic treatment with two 
different doses of MPEP (1.5 and 3.0 mg/kg) (Breyesse et al, 2002). Moreover, MPEP was 
significantly neuroprotective when co-administered into the caudate nucleus of rodents with 
NMDA at concentrations as low as 5 nmol in 0.5 gl consistent with the observations of 
neuroprotective effects at similar concentrations of MPEP used in the present study (Bruno 
et al, 2000a; Flor et al, 2002). Importantly, in contrast to LY367385, no behavioural 
abnormalities were observed following administration of any concentration of MPEP into 
the SNc. However, similar to LY367385, regional effects on the neuroprotection of TH-IR 
cells was observed in MPEP-treated animals, with a marked rostral to caudal pattern of 
neuroprotection. 
Overall, these data are consistent with previous evidence that suggests antagonism 
of mGluR5 is neuroprotective. Indeed, intrastriatal administration of MPEP protects striatal. 
doparninergic terminals against methamphetamine toxicity (Battaglia et al, 2002). 
Similarly, acute systemic administration of MPEP is moderately neuroprotective against 
MPTP-induced toxicity in mice and the degree of neuroprotection observed was similar to 
that observed in the current study (Battaglia et al, 2005). Importantly, this study also 
demonstrated that this neuroprotective effect is due to antagonism of mGluR5 receptors 
activated by physiological concentrations of endogenous glutamate since mGluR5 
knockout (KO) mice were less susceptible to MPTP toxicity (Battaglia et al, 2005). 
Interestingly, these mice were not completely protected from MPTP toxicity suggesting 
other mGluR subtypes may mediate an additional component of MPTP toxicity (Battaglia 
et al, 2005). 
The neuroprotective effect of MPEP described herein in the 6-OHDA model 
(Vernon et al, 2005) is supported by data published during the course of this thesis, which 
reports a neuroprotective effect of MPEP following chronic systemic administration in 
rodents against the progressive loss of DA neurones in the SNc induced by injections of 6- 
-190- 
OHDA into the caudate putamen (CPu) complex, although the effect on striatal monoamine 
levels was not investigated in this study (Armentero et al, 2005). Interestingly, the degree 
of neuroprotection of nigral TH-IR cells was markedly similar to that observed in the 
current study, but was also associated with an apparent normalisation of the metabolic 
hyperactivity of both STN and SNr/EPN neurones, as measured by cytochrome oxidase I 
immunoreactivity (COMR), compared to vehicle-treated animals. These data indirectly 
suggest that the mechanism underlying the neuroprotective action of MPEP may in part be 
due to reductions in the excitation of STN neurones with a concomitant reduction in 
glutamate transmission onto nigral DA neurones (Armentero et al, 2005). These data 
further suggest a possible role for secondary glutamate excitotoxicity in the pathogenesis of 
6-OHDA toxicity (and potentially sporadic PD) in vivo. In the current study however, 
MPEP was administered intranigrally, thus any neuroprotective effects of MPEP would be 
predicted to only be mediated by postsynaptic mGluR5 receptors expressed on SNc DA 
neurones or on STN axon terminals, or potentially on astroglia and microglia in the SNc. It 
is noteworthy that no functional studies have described a role for mGluR5 expressed in 
nigral DA neurones (Valenti et al, 2002), although this is discussed further below, whilst 
other studies have suggested that mGluR5 appears to regulate STN neurone depolarisation 
(Awad et al, 2000). Furthermore, very recent evidence by Phillips and colleagues (2006) 
demonstrated that microinjections of MPEP into the STN at concentrations directly 
comparable to those used in the current study, produced a greater reversal of behavioural 
deficits induced by 6-OHDA, than microinjections into the SNr or EPN- Interestingly, this 
effect was also concentration dependent, consistent with the observations made in the 
current study pertaining to neuroprotective actions of MPEP. Taking these data together, it 
is tempting to speculate that antagonism of mGluR5 expressed on STN neurones is the 
primary site of action for both neuroprotective and anti -parkinsoni an effects. This 
hypothesis is further strengthened by the recent findings of Aquirre and colleagues (2005) 
who demonstrated that a single i. c. v injection of MPEP at a concentration comparable to 
those used in the current study completely protects TH-IR cells in the SNc against MPTP 
toxicity and is similarly effective when administered systemically (20 mg/kg), in both cases 
MPEP was administered prior to the MPTP neurotoxin, as in the current study. In contrast, 
our data do not show complete protection by MPEP of nigral TH-IR cells nor striatal 
monoamine levels (Vernon et al, 2005). The route of MPEP administration could explain 
this disparity between the two studies, since if MPEP is administered systemically or by 
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i-c-v injection MpEP would be expected to antagonise mGluR5 receptors on STN neurones, 
in the striaturn and at subthalamonigral synapses, which potentially all combined could 
produce a greater reduction in the hypothesised aberrant glutamate transmission onto 
midbrain DA neurones, thereby resulting in a greater neuroprotective effect. Thus, it would 
be interesting in future studies to see if greater neuroprotection of the nigrostriatal system 
could be observed following microinjections of MPEP into the STN as per the paradigm of 
Phillips and colleagues (2006). 
It is interesting that no functional evidence exists to describe a role for mGluR5 
expressed in DA neurones in the SNc (Valenti et al, 2002) despite the evidence which 
clearly demonstrates the expression of both mRNA and receptor protein for mGluR5 which 
in both the soma and dendrites of nigral DA neurones at both the light and electron 
microscope level (Marino et al, 2001; Hubert et al, 2001; Messenger et al, 2002). 
Electrophysiological evidence suggests that the excitation of nigral neurones is regulated by 
mGluRI (Mercuri et al, 1993; Shen and Johnson, 1997; Meltzer et al, 1997a; Fiorillo and 
Williams, 1998). Thus, although mGluR5 and mGluRI subtypes appear to co-localise, they 
may be functionally segregated. This is consistent with similar observations made in other 
BG nuclei (Valenti et al, 2002). Indeed, activation of Group I mGluR by the specific Group 
I mGluR agonist (S)-3,5-DHPG produces a direct excitation of neurones in both the STN 
and the SNr (Awad et al, 2000; Marino et al, 2001). Accordingly, immuocytochemical 
studies demonstrated the presence of both mGluR1 and mGluR5 receptor protein in these 
structures (Awad et al, 2000; Marino et al, 2001; 2002b; Hubert et al, 2001), however 
pharmacological investigations with the subtype selective antagonists MPEP and 
LY367385 or CPCCOEt demonstrated that in STN neurones, it appears Group I mGluR- 
mediated depolarisation is mediated entirely by mGluR5 (Awad et al, 2000), whilst in the 
SNr the opposite is true and depolarisation is mediated by mGluRI (Marino et al, 2001), as 
observed in the SNc (Fiorillo and Williams, 1998). Recent data also suggests a similar 
situation occurs in both the rodent and primate globus pallidus (Hanson and Smith, 1999; 
Poisik et al, 2003) These findings are surprising since in recombinant expression systems 
the coupling of these receptors to second messenger systems is identical and co-localisation 
is generally assumed to indicate a redundancy of function (Marino et al, 2002b). Thus, 
there appears to be an apparent "degree of plasticity" in the coupling to second messenger 
systems and function of Group I mGluR in the BG. Indeed, Marino and colleagues (2002a) 
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have demonstrated that electrophysio logical recordings from SNr neurones in slices 
obtained from haloperido I -treated animals to reproduce parkinsonian-like conditions 
revealed that both mGluR1 and mGluR5 were able to regulate neuronal depolarisation and 
entry of Ca 2+' in contrast to non-haloperidol treated animals where this effect was mediated 
solely by mG1uR1 (Marino et al, 2001; 2002a). These data raise the interesting possibility 
that both Group I mGluR subtypes may mediate excitatory transmission under pathological 
conditions in these structures. If a similar relationship exists for the Group I mG1uR in the 
SNc, this would suggest that pharmacological blockade of either mGluR1 or mGluR5 could 
potentially be neuroprotective against glutamate excitotoxicity or indeed, other insults 
under conditions of DA depletion. These findings also raise the possibility that 
pharmacological blockade of both mGluR1 and mGluR5 by co-application of LY367385 
and MPEP could result in an additive interaction and provide a greater degree of 
neuroprotection. Consistent with this hypothesis, co-application of MPEP and LY367384 
has been demonstrated to produce enhanced neuroprotection against NMDA-mediated 
toxicity in mixed cultures of cortical neurones in vitro (Battaglia et al, 2001). In the current 
studies, this possibility has been investigated in vivo and the findings are presented in 
Chapter 5. 
Taking all these data together raises important questions about the putative 
mechanisms underlying the neuroprotective action of MPEP following intranigral injection, 
since in the absence of functional data, any suggestion of mechanisms involving actions on 
nigral neurone excitation mediated through pharmacological blockade of postsynaptic 
mGluR5 by MPEP, must remain speculative. Alternatively, one cannot exclude the 
possibility that MPEP is acting on mGluR5 expressed on STN axon terminals. Perhaps 
more importantly, MPEP may be exerting neuroprotective effects through an action on 
astroglia or microglia in the SNc, both of which express functional mGluR5 (Pearce et al, 
1986; Bezzi et al, 1998; Biber et al, 1999) as previously suggested (Nicoletti et al, 1999). 
Interestingly, Aquirre and colleagues (2005) reported that whilst acute MPEP treatment 
completely protects TH-IR cells in the SNc, it is only partially (although still significantly) 
neuroprotective on TH-IR density in the dorsal striaturn. Moreover, the MPTP-induced 
reduction of striatal DA levels was not counteracted by acute systemic treatment of high 
doses of MPEP (20 mg/kg). These results suggest that the striatal DA terminals are 
protected but are dysfunctional after MPEP and MPTP co-treatment (Aquirre et al, 2005). 
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This is consistent with the data in the current study in which striatal DA levels were not 
significantly protected following intranigral treatment with high concentrations of MPEP, 
although whether the axon terminals were intact, suggesting dysfunction was not 
investigated in the current study. It is noteworthy also that Aquirre and colleagues (2005) 
reported that high doses of MPEP (20 mg/kg) induced a significant and long lasting 
reduction in nigral DA, DOPAC and HVA levels (Aquirre et al, 2005). Although in the 
current study levels of monoamines in the SNc were not investigated, the absence of a 
protective effect of high concentrations of MPEP on monoamine levels at the level of the 
striaturn would tend to suggest that a similar effect may occur in the SNc, although it will 
be interesting to confirm this in future studies. However, the strong cellular neuroprotection 
in the SNc noted by Aquirre and colleagues (2005) is not consistent with the findings in the 
current study, since intranigral administration of high concentrations of MPEP did not 
produce significant neuroprotection of nigral TH-IR cells. This discrepancy may be 
explained by interactions between mGluR5 and the dopamine transporter (DAT; Page et al, 
2001). It is suggested that DAT activity may be dynamically regulated by phosphorylation 
(Copeland et al, 1996; Vaughan et al, 1997) although the signalling pathway(s) mediated 
this effect have remained unresolved (Page et al, 2001). Recently, it has been demonstrated 
that a direct activation of Group I mGluR by the mixed Group I agonist (S)-3,4-DCPG 
leads to phosphorylation of the DAT through PKC and Calcium Calmodulin dependent 
Kinase 11 (CaMKII) mechanisms, leading to an increase in DAT activity and uptake 
efficiency in a rat striatal synaptosome preparation (Page et al, 2001). Interestingly this 
effect was blocked by the addition of MPEP but not the mGluRl antagonist CPCCOEt, 
suggesting that DAT phosphorylation in the striatum is regulated by mGluR5 not mGluR1 
(Page et al, 2001). In the CNS, MPTP is converted to the toxic MPP+ ion by the action of 
monoamine oxidase B in glial cells, particularly astrocytes (Bove et al, 2005). This toxic 
species is then taken up by neurones via the DAT where once inside the cell, MPP+ results 
in neurotoxicity by powerful inhibition of mitochondrial complex 1, leading to cell death 
due to impaired ATP production and oxidative stress (Bove et al, 2005). Thus, the toxic 
action of MPTP is intrinsically linked to the activity of neuronal DAT. Therefore it is 
conceivable that high concentrations of MPEP administered systemically could impair 
DAT activity leading to reduced uptake of MPP+ by neurones which potentially would lead 
to reduced toxicity. This could explain the protection of striatal axon terminals and if a 
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similar relationship exists between mGluR5 and DAT activity in the SNc, the significant 
neuroprotection of nigral TH-IR cells observed by Aquirre and colleagues (2005). 
In contrast, although 6-OHDA toxicity is also dependent on DAT activity (Blum et 
al, 2001; Bove et al, 2005) it is noteworthy that extracellular 6-OHDA may undergo rapid 
auto-oxidation leading to ROS formation, with subsequent oxidative stress thereby leading 
to neurotoxicity, even under conditions of possible reduced DAT activity due to high 
concentrations of MPEP. Alternatively, MPEP has also been reported to directly interact 
with the norepinephrine transporter (NET) in the amygdala, which has been postulated as 
critical for its antidepressant and anxiolytic effects (Heidbreder et al, 2002). Thus, it is 
conceivable that at high concentrations MPEP could block uptake of 6-OHDA into 
noradrenergic neurones thereby effectively increasing the concentration of 6-OHDA which 
nigral DA neurones are exposed to, resulting in degeneration of DA neurones rather than 
neuroprotection. Alternatively, 6-OHDA may induce glial cell dysfunction and/or 
neuroinflammation leading to cell death. 
3.4.2.3 A controversial rolefor Group I mGluR in neuroprotection 
Despite the increasing availability of subtype selective drugs acting at Group I mGluR, the 
role of these receptors in neuronal degeneration remains controversial (Nicoletti et al, 
1999). The idea that antagonising Group I mGluR would be neuroprotective is based on the 
simplistic assumption that stimulation of Group I mGluR would be predicted to enhance 
glutarnate excitotoxicity by promoting SNc neuronal depolarisation or by potentially 
facilitating glutamate release presynaptically (although this idea remains controversial). 
Indeed, there is in fact solid evidence suggesting both a neuroprotective (Blaabjerg et al, 
2001; 2003; Baskys et al, 2005) and a neurotoxic action of Group I mGluR agonists 
(Nicoletti et al, 1999). Possible explanations for this contrasting data have been suggested 
to include the presence of the NR2C subunit in NMDAR in neurones and the presence of 
glial cells which also express functional Group I mGluR (Nicoletti et al, 1999). 
Interestingly, it has been suggested that Group I mGluR may undergo a time- and activity- 
dependent switch mediated by protein kinase C (PKC)-desensitisation (Nicoletti et al, 
1999; Bruno et al, 2001). This "switch" is critically dependent on the previous exposure of 
the receptor to endogenous glutamate. Thus, it is postulated that an initial activation of 
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"naYve" Group I mGluR by a high concentration of extracellular glutamate may be 
neurotoxic, but with prolonged stimulation, Group I mGluR quickly desensitise through 
PKC-dependent phosphorylation of critical serine and threonine residues in the carboxyl- 
terminal tail (Mundell et al, 2003; 2004a). This desensitisation results in the uncoupling of 
the receptor to its G protein effectors and subsequent internalisation by an arrestin and 
clathrin-dependent pathway (Mundell et al, 2001; 2002; 2003; 2004a; Pula et al, 2004). 
These compounding factors make it difficult to establish if the neuroprotective effects of 
Group I mGluR antagonists is receptor-mediated. Indeed, it is difficult to imagine that a 
simple co-administration of a Group I mGluR agonist with a competitive antagonist such as 
LY367385 would lead to a reversal of neuroprotection. This problem is even more difficult 
where MPEP is concerned, since it is a non-competitive negative allosteric modulator of 
mGluR5 and binds at a distinct site within transmembrane domains 2 and 3 of mGluR5 
(Gasparini et al, 1999; Pagano et al, 2000; Malherbe et al, 2005). Thus, the antagonism of 
mGluR5 by MPEP is independent of endogenous glutamate levels (Battaglia et al, 2005) 
and it would therefore not be possible to fully reverse this by addition of a competitive 
Group I mGluR agonist. It may be possible to reverse the effects of LY367385 by using a 
positive allosteric modulator of mGluRl, since these bind at sites within the transmembrane 
domain of mGluR, independent of the N-terminal ligand-binding domain, to allosterically 
enhance receptor activity (Spooren et al, 2002). However, currently, such compounds are 
not commercially available, thus these experiments would be difficult to perform. 
However, despite these drawbacks and the apparent contradictory role of Group I 
mGluR in neurotoxicity/neuroprotection it would be interesting to test agonists of Group I 
mGluR alone in the 6-OHDA model and assess the effect on the nigrostriatal system. 
Similarly, as new positive allosteric modulators of mGluRl become available, co- 
administration of these with mGluRl antagonists would provide interesting experiments to 
further delineate the role of Group I mGluR in the observed neuroprotection against 6- 
OHDA in this model, and may also provide further evidence for a possible beneficial effect 
of Group I mGluR antagonists as a treatment for PD. 
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3.4.2 Neuroprotection by Group 11 and Group III mGluR agonists 
3.4.2.1 Neuroprotection by the mGluR213 agonist 2R, 4R-APDC 
In the current study intranigral sub-chronic administration of the Group 11 mGluR2/3 
agonist 2R, 4R-APDC provided marked histological and functional neuroprotection of the 
nigrostriatal system following 6-OHDA lesioning in a concentration-dependent manner. 
Interestingly, however there were no significant differences in the degree of 
neuroprotection of the nigrostriatal system in animals treated with either 10 or 50 nmol 
2R, 4R-APDC. This suggests that in this study and model 10 nmol in 4 [d of 2R, 4R-APDC 
appears to be the lowest optimum concentration for neuroprotection against 6-OHDA. This 
could be important since following intracerebral administration 2R, 4R-APDC has been 
reported to be show pro-convulsant activity at >20 nmol (Attwell et al, 1998a, b; Moldrich 
et al, 2001a). Consistent with this, some transient behavioural abnormalities such as teeth 
chattering and head-bobbing, as well as an increase in rearing activity, were observed 
following intracerebral injection of 50 nmol 2R, 4R-APDC; thus, the effectiveness of Group 
II mGluR agonists may be reduced by such side-effects at high concentrations. 
Interestingly, in animals treated with 2 nmol 2R, 4R-APDC there was a significant 
increase in striatal DA metabolism in the ipsilateral striatum, suggesting that at low 
concentrations the restoration of striatal DA by 2R, 4R-APDC is not entirely due to 
neuroprotection of nigral TH-IR cells and implies a maintained dysfunction of nigral 
dopaminergic terminals in the striaturn. Consistent with this observation is the finding that 
the neuroprotection of nigral TH-IR cells at low concentrations of 2R, 4R-APDC is only 
significantly different from vehicle-treated animals in region A of the SNc, whilst this is 
not the case in regions B-E suggesting a marked rostral to caudal pattern of neuroprotection 
as observed with low concentrations of both LY367385 and MPEP. 
The neuroprotective actions of 2R, 4R-APDC reported here are consistent with 
previous studies which report a neuroprotective action of Group 11 mGluR agonists in other 
experimental models of Parkinsonism. Indeed, intrastriatal injection of the mGIuR2 agonist 
DCG-1V is reported to protect against intrastriatal infusion of MPTP in rodents 
(Matarredona et al, 2001), whilst systemic administration of the Group 11 mGIuR agonist 
LY379268 has been reported as neuroprotective against MPTP toxicity in the mouse 
(Battaglia et al, 2003) whilst preliminary evidence also suggests a neuroprotective action 
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following intranigral 6-OHDA lesioning in the rat (Murray et al, 2002). Thus, the findings 
presented here are consistent with and extend those of Murray and colleagues (2002). 
Indeed, in the current study a more marked neuroprotection of striatal DA and TH-IR cells 
was observed. This discrepancy may be explained on the basis of dopamine: glutamate 
interactions in the basal ganglia and the finding that DA modulates the function of Group 11 
and III mGluR in the SN (Wittmann et al, 2002). Interestingly, DA depletion by reserpine 
produces a marked decrease in the ability of Group 11 mGluR agonists to inhibit excitatory 
transmission at STN: SNr synapses (Wittmann et al, 2002). Furthermore, this effect of 
reserpine was mimicked by the application of haloperidol (Wittmann et al, 2002). 
Moreover, in slices taken from reserpine-treated animals, the Group 11 mGluR-mediated 
effects were rescued by the application of DA D2-like receptor agonists (Wittmann et al, 
2002). Taken together, these findings suggest that the activity of Group 11 mGluR as 
presynaptic autoreceptors is dependent on tonic levels of somatodendritically released DA, 
which is suggested to be necessary to maintain Group 11 mGluR in an active state 
(Wittmann et al, 2002; Conn et al, 2005). Thus, if Group 11 mGluR expressed on STN 
nerve terminals also regulate glutamate transmission onto dopaminergic neurones in the 
SNc, DA depletion in the SNc as a result of nigral degeneration may lead to a decrease in 
Group 11 mGluR function, reducing their ability to act as presynaptic autoreceptors 
modulating glutamate release onto the SN. In PD, a pathological loss of nigral DA would 
be expected to exacerbate the hyperactivity of the STN and subsequently the degeneration 
of SNc neurones through excitotoxicity (Wittmann et al, 2002). In support of this 
hypothesis, recent evidence suggests that Group 11 mGluR mediate excitatory transmission 
at STN: SNc synapses both in vitro (Katayama et al, 2003) and in vivo (Wang et al, 2005). 
In the studies by Murray and colleagues (2002) extensive DA depletion occurs in response 
to 6-OHDA lesioning due to the use of noradrenaline uptake blockers that enhance the 6- 
OHDA-lesion size. In contrast, in the current study more partial DA depletion is generated 
since these compounds are not used. Thus, it is conceivable that in our model, the proposed 
autoreceptor activity of Group II mGluR at STN: SNe synapses may be maintained, thus 
explaining the greater neuroprotective efficacy of 2R, 41? -APDC in these studies (Vernon et 
al, 2005). However the findings of Battaglia and colleagues (2002) in the mouse MPTP 
model seem at odds with this hypothesis. In this stLidy, the Group 11 mGluR agonist 
LY379268 did not show significant neuroprotective activity against MPP+ toxicity when 
,, _gested 
that this finding could be partial MPTP lesions were induced. The authors siio 
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explained by the activity of endogenous glutamate at neuronal Group 11 mGluR, which 
under partial lesion conditions may mask the effectiveness of LY379268 acting at 
mGluR2/3 (Battaglia et al 2002). In contrast, in mice treated with high doses of MPTP to 
produce almost complete nigrostriatal degeneration, LY379268 provided significant 
neuroprotection. This appears to be at odds with the theory that tonic DA levels may 
control Group 11 mGluR activity, although possibly may reflect a species difference in 
receptor activity/function between mice and rodents. However, a more parsimonious 
explanation is that the neuroprotection observed in animals with large MPTP lesion is 
likely to be due to activation of mGluR2/3 on astroglia and microglial cells to produce 
neurotrophic factors which may induce neuronal survival, as previously suggested in vivo 
by Matarredona and colleagues (2001) and more recently, by Venero and co-workers 
(2003), who observed that the neuroprotective action of DCG-IV on MPTP toxicity 
appeared to be due to increased BDNF production from glial cells. Thus, the 
neuroprotective effects of Group 11 mGluR may involve both a neuronal component, which 
involves reductions in glutamate release from neurones and a glial component, which may 
involve the production of neurotrophic factors. Furthermore, the contribution of each 
component appears to be critically dependent on the extent of the dopaminergic lesion in 
vivo (Battaglia et al, 2003). 
Interestingly, these previous studies utilised a systemic administration of LY379268 
(Murray et al, 2002; Battaglia et al, 2003) thus the site of action of this agonist in the BG is 
not accurately identified. Group 11 mGluR show a restricted distribution in the BG nuclei 
and are found primarily presynaptically at corticostriatal, striatopallidal and 
subthalamonigral synapses (Rouse et al, 2000). Thus, one might predict that Group 11 
mGluR agonists would exert a greater neuroprotective effect when microinjected into the 
SNc by reducing glutarnate transmission by acting on multiple glutamatergic inputs to the 
SNc such as STN, PPN or cortical axon terminals, which could also explain the greater 
degree of neuroprotection seen with 2R, 4R-APDC in these studies. Therefore it would be of 
interest to examine the degree of neuroprotection following systemic administration of 
2R, 4R-APDC. Importantly, LY379268 has also been reported to show agonist activity at 
other mGluR subtypes, particularly mGluR8 at relatively high concentrations (Schoepp et 
al, 1999), thus an action at mGluR8 cannot be ruled out in the studies by Battaglia and 
colleagues (2003) and Murray and colleagues (2002) either on neurones or glial cells. 
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Interestingly, recent reports suggest that mGluR8 is not involved in the regulation of 
excitatory transmission at STN: SNc synapses (Valenti et al, 2005), however this does not 
preclude an effect of mGluR8 stimulation on glial cells in the SNc or at other BG nuclei 
following systemic administration. In contrast) 2R94R-APDC is a highly selective Group 11 
mGluR agonist at mGluR2/3 up to concentrations of 100 gM (Schoepp et al, 1999), thus at 
the concentrations administered in the current study, it is likely 2R, 4R-APDC may only be 
acting at Group 11 mGluR subtypes, which suggests mGluR2/3 stimulation alone may be 
responsible for the neuroprotective effects of 2R, 4R-APDC. This suggesting is confirmed 
by the reversal of 2R, 4R-APDC-mediated neuroprotection when co-administered with the 
selective mGluR2/3 antagonist EGLU, confirming a receptor-mediated mechanism of 
neuroprotection. This data is consistent with previous studies, which have reported a 
reversal of LY3 79268 -mediated neuroprotection against MPTP when it was co- 
administered with the Group 11 antagonist LY341495 (Battaglia et al, 2003). Interestingly, 
LY341495 also has nanomolar potency at mGluR8, which is consistent with a possible 
involvement of mGluR8 in neuroprotection by LY379268. The Group 11 mGluR antagonist 
EGLU shows no such activity, thus confirming the involvement of mGluR2/3 in the 
neuroprotection by 2R, 4R-APDC in the current study. Interestingly, EGLU appears to 
preferentially act at mGluR3 compared to mGluR2 receptors (Jane et al, 1996; Schweitzer 
et al, 2000). This may suggest that mGluR3 has greater involvement in the neuroprotective 
effects of 2R, 4R-APDC. Thus, it will be important to confirm whether activation of 
mGluR2 or 3 results in greater neuroprotection of the nigrostriatal tract. To this end it 
would be interesting to evaluate the putative mGluR3 selective agonist N- 
acetylaspartylgl utarn ate (NAAG) or the recently developed mGluR2-selective positive 
allosteric modulator N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl) - 
pyrid-3-ylmethylamine (LY487379) in the 6-OHDA model and compare the effects on 
nigrostriatal integrity and functionality. Importantly, the latter compound has effects almost 
identical to traditional orthosteric mGluR2/3 agonists (Poisik et al, 2003; Galici et al, 
2005). 
3.4.2.2 Neuroprotection by the Group III mGluR agonist L-AP4 
In the current study sub-chronic intranigral administration of the broad-spectrum Group III 
mGluR agonist L-AP4 significantly protected nigral TH-IR cells compared to vehicle- 
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treated animals in a concentration-dependant manner. In good agreement with the cellular 
data, L-AP4 also effectively prevented depletion of striatal monoamines following 6- 
OHDA-lesioning in a similarly con centrati on-dependant manner. These neuroprotective 
effects of L-AP4 are consistent with previous reports of neuroprotection against glutamate- 
mediated toxicity in vitro (Bruno et al, 1994; Ambrosini et al, 1995; Bruno et al, 1996; 
Buisson et al, 1996; Lafon-Cazal et al, 1999a; Bruno et al,, 2000; Henrick-Noack et al, 
2000) and oxidative stress in vitro (Sagara and Schubert, 1998). Furthermore, they are 
consistent with the findings that L-AP4 is neuroprotective against infusion of quinolinic 
acid or kainite into the striata of rodents (Sheardown et al, 1992; Colwell et al, 1996), 
suggesting that L-AP4 is an effective neuroprotective agent against glutamate-mediated 
toxicity both in vitro and in vivo. Moreover, the current study is the first to document such 
an action for L-AP4 in an experimental model of PD in vivo, a finding which may have 
important implications for the treatment of PD and provides further compelling evidence 
for a role of glutamate-mediated toxicity in PD pathogenesis. 
Intriguingly, similar to the effects of MPEP, L-AN shows a bell-shaped 
neuroprotective profile, such that high concentrations of L-AN failed to protect nigral TH- 
IR cells and striatal monoamine levels against 6-OHDA toxicity. Interestingly, similar 
findings have been reported in vitro with L-AN against NMDA-toxicity in striatal 
GABAergic neuronal cultures (Lafon-Cazal et al, 1999b). Indeed, high concentrations of L- 
AN enhanced NMDA toxicity. This was Presumed to be due to activation of mGluR7 due 
to the high concentrations of L-AN used, which was subsequently confirmed by the 
finding that the L-AN enhancement of NMDA toxicity was sensitive to pertussis toxin 
(PTX) indicating the involvement of a Gi/,, -coupled protein receptor and the detection of 
both mGluR7 receptor protein and mRNA in these neurones (Lujan et al, 1998; Lafon- 
Cazal et al, 1999b). Interestingly, however this is in contrast with previous findings in 
glutarnatergic cerebellar granule cells where high concentrations of L-AN were 
neuroprotective against NMDA toxicity (Lafon-Cazal et al, 1999a). Thus, in cultures of 
striatal GABA neurones, the L-AN enhancement of NMDA toxicity was suggested to be 
due to inhibition of GABA release by activation of presynaptic mGluR7 resulting in 
enhanced NMDA toxicity by removal of the hyperpolarising influence of GABA on striatal 
neurones and thus sensitising these cells to glutamate excitotoxicity (Lafon-Cazal et al, 
1999b). It is noteworthy that a similar role for presynaptic Group III mGluR as negative 
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modulators of GABA release in both the SNc (Giustizeri et al, 2005) and the SNr 
(Wittmann et al, 2001a) has been suggested, consistent with data reporting localisation of 
mGluR7 receptor protein at symmetric (inhibitory) synapses in the SNr (Kosinski et al, 
1999). Synaptically released GABA in the both the SNc and SNr is implicated in the 
control of doparninergic cell firing (Wittmann et al, 2001 a; Giustizieri et al, 2005). Thus, it 
is conceivable that when high concentrations of L-AP4 are administered intranigrally 
GABA as well as glutamate transmission is inhibited by activation of presynaptic mGluR7. 
This perturbation of tonic GABA release may potentially cancel out the positive effect of 
reducing glutarnate transmission from excitatory afferents by increasing nigral cell 
excitability. Thus, speculatively, this could account for the absence of a neuroprotective 
effect at high concentrations of L-AP4. 
Alternatively, activation of presynaptic mGluR7 on SNr GABAergic neurones 
forming axo-axonic synapses on glutamatergic STN efferent terminals may inhibit GABA- 
mediated control of glutamate release from STN axon terminals, thereby enhancing 
glutarnatergic transmission onto nigral neurones leading to neurotoxicity. This is 
anatomically possible, as it is known that the SNc sends dendrites deep into the SNr (Iribe 
et al, 1999) and furthermore STN axon terminals are known to associate with and terminate 
on dopaminergic dendrites in the SNr (Smith et al, 1990). However, it should be noted that 
presynaptic inhibition of inhibitory transmission in the SNr has been reported to be 
sensitive to DA depletion in a manner similar to Group 11 mGluR-mediated inhibition of 
glutamate transmission. Thus, DA depletion by reserpine effectively reduces the ability of 
L-AP4 to inhibit GABA release in vitro (Wittmann et al, 2002), an effect that was 
mimicked by the DA D2-like receptor antagonist haloperidol suggesting an involvement of 
dopamine D2-like receptors in this function (Wittmann et al, 2002). However, inhibition of 
excitatory transmission by L-AP4 does not appear to be affected by DA depletion 
(Wittmann et al, 2002). Therefore, in the Parkinsonian nigra, inhibition of GABA release 
by activation of Group III mGluR on GABAergic nigral neurones would be reduced by DA 
depletion. As with Group 11 mGluR, the extent of the lesion appears to critically determine 
the function of the mGluR subtypes involved. In the current study, the mild DA depletion 
induced by 6-OHDA may not sufficiently affect mGluR7-mediated inhibition of GABA 
release by high concentrations of L-AP4, thus it is still possible that perturbation of 
GABAergic as well as Glutamatergic inputs to nigral DA neurones could explain the 
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absence of neuroprotection. It is interesting to note that 6-OHDA toxicity is not enhanced 
by high concentrations of L-AP4, as was observed in the striatal neuronal cultures when 
GABA release was blocked by high concentrations of L-AP4 (Lafon-Cazal et al, 1999b). 
Presumably this is because the mGluR4-mediated reduction of glutamate release may 
balance out reductions in GABA transmission at high concentrations of L-AP4 in our in 
vivo studies. However, taken together the finding that high concentrations of L-AP4 are not 
neuroprotective is difficult to explain and further investigation is required to elucidate the 
mechanisms behind the absence of neuroprotection against 6-OHDA toxicity in this model 
at this concentration of L-AP4. Thus, it appears 10 nmol of L-AP4 is the optimum 
concentration for neuroprotection in this model of PD. 
The finding that the neuroprotection mediated by 10 nmol L-AP4 is completely 
reversed by co-administration of the selective Group III mGluR antagonist MSOP indicates 
the neuroprotection is mediated by Group III mGluR receptors. However, it does not 
indicate which receptor subtype since is involved since L-AP4 is a broad-spectrum agonist 
with activity at all Group III mGluR subtypes (Schoepp et al, 1999). Based on the in vitro 
potency of L-AP4 for Group III mGluR however, an action at mGluR4 or 8 is most likely. 
An action at mGluR7 is unlikely since activation of this receptor requires much higher 
concentrations of L-AP4 (Schoepp et al, 1999), although we cannot definitively exclude a 
role for mGluR7 in vivo. Interestingly recent studies by Valenti and colleagues (2005) 
provide electrophysiological and pharmacological evidence to suggest that excitatory 
transmission at STN: SNc synapses is mediated by mGluR4 but not mGluR8. However, 
confirmation of the exact subtypes involved awaits development of Group III mGluR 
subtype selective agonists or positive/negative allosteric modulators. Importantly, 
activation of Group III mGluR on either astroglial or microglial cells may also lead to a 
neuroprotective action (see section 7.3.2). 
3.5 Conclusions 
Taken together, the data presented here show for the first time in this experimental model 
of PD a neuroprotective action of selective Group I mGluR antagonists and Group 11 and III 
mGluR agonists, which at least for Group 11 and III mGluR is receptor-mediated. 
Importantly, in these studies all drug-treated groups were pre-treated with mGluR ligands, 
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therefore it will be important to determine the effect of different dosing regimens, including 
acute and post-lesion treatments on neuroprotection by these compounds. Moreover, the 
synergistic potential of these drugs with respect to neuroprotection has not been addressed 
in vivo and the precise mGIuR subtypes involved in neuroprotection still remain elusive. 
Taken together however, these data provide further evidence to suggest that targeting 
mGluR in the BG of Parkinsonian patients may provide a novel, non-dopaminergic 
pharmacotherapy for the treatment of PD. 
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Chapter 4 
Neuroprotection following acute treatment with 
mGluR ligands in a rodent 6-OHDA model of 
Parkinsonism 
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4.1 Introduction 
The data presented in Chapter 3 suggest that sub-chronic (7 day) intranigral injections of 
either the Group I mGluR antagonists LY367385 or MPEP, or the Group 11 or Group III 
mGluR agonists 2R, 4R-APDC and L-AP4, respectively significantly protects the 
nigrostriatal system against 6-OHDA toxicity in vivo in a con centrat i on-dependent manner. 
Moreover, this neuroprotection (for Group 11 and III mGluR ligands at least) was shown to 
be receptor-mediated, since the neuroprotective effect was reversed by the co-application of 
selective Group 11 and III mGluR antagonists, EGLU and MSOP, respectively. However, 
these data are preliminary in nature and there are a number of caveats that need to be 
addressed. 
Firstly, G-protein-coupled receptor activities, including mG1uR responses, are 
tightly linked to their receptor membrane expression and trafficking (Dhami and Ferguson, 
2006). Under conditions of prolonged agonist exposure mGluR undergo decreased agonist 
responsiveness, through a process termed "desensitisation", which acts as a feedback 
mechanism to prevent deleterious consequences of sustained receptor activation (Ferguson 
et al, 2001; see also section 1.10.5). The majority of studies have focused on the 
desensitisation of Group I mGluR and suggest that this is mediated by phosphorylation of 
the C-terminus, uncoupling the receptor from its G-protein, thus preventing signal 
transduction, followed by receptor intemalisation through a clathrin- and dynamin- 
dependent pathway (Mundell et al, 2001; 2002; 2003; 2004). The receptors then enter an 
endosomal sorting compartment where they are dephosphorylated and recycled to the cell 
surface for a second round of activation or they enter a lysosomal degradation pathway 
(Dhami and Ferguson, 2006). 
In contrast, much less is known about the desensitisation and internalisation of 
Group 11 and III mGluR (see section 1.10.5). Studies in hippocampal slice preparations 
have identified a clear role for receptor phosphorylation by protein kinase A (PKA) in this 
respect (Schaffhauser et al, 2000; Cai et al, 2001), but more recent studies have also 
suggested a role for G-protein receptor kinases (GRKs), in particular GRK2 (lacovelli et al, 
2004; Mathiesen and Ramirez, 2006). Therefore, it is conceivable that repeated application 
of the Group 11 or III mGluR agonists, 2R, 4R-APDC and L-AP4, over a sub-chronic period 
as described in Chapter 3 may result in profound receptor desensitisation. In support of this, 
the reversal of akinesia following intracerebroventricular (i. c. v) administration of L-AP4 or 
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L-SOP in reserpine-treated rats is markedly reduced following a second injection of either 
agonist 4h later (Mac1nnes et al, 2004; Broadstock and Duty, 2004). These data suggest that 
Group III mGluR-mediated responses may undergo rapid desensitisation in vivo, thus it can 
be hypothesised that the neuroprotection observed following more acute treatment with 
Group 11 and III mGluR agonists may result in greater or at least similar neuroprotection to 
that observed after sub-chronic treatment. 
An additional complication in this respect is the potential development of Group I 
mGluR supersensitivity following sub-chronic exposure to either LY367385 or MPEP. 
Indeed, in L929sA cells transfected with mGluRl, 24hr pre-treatment with the specific 
mGluRl antagonist 7 -(Hyd roxyi mi no)cyc lopropa[b] chrom en -I a-carboxyl ate ethyl ester 
(CPCCOEt) increased glutamate-mediated mGluRI signalling, as measured by an increase 
in intracellular Ca 2+ and inositol phosphate (IP) production after CPCCOEt was washed out 
of the system (Lavreysen et al, 2002). Additionally, the potency of selective mGluR1 
antagonists to block mGluR I -meidated responses was markedly and significantly decreased 
following pre-incubation with CPCCOEt compared to cells that were not pre-incubated 
(Lavreysen et al, 2002). These changes are suggested to be due to the development of 
mGluRI supersensitivity as a consequence of sustained deprivation of receptor stimulation. 
This phenomenon is well-documented in other neurotransmitter systems and included the 
behavioural changes due to dopamine (DA) receptor supersensitivity following chronic 
treatment with the DA D2 receptor antagonist haloperidol, which is associated with 
increased sensitivity to DA receptor agonists, decreased effectiveness of antagonists and an 
increase in the number of cell surface DA D2 receptors (Creese et al, 1977). Similar 
findings are reported in cerebellar granule cells in vitro, a commonly used model to study 
Group I mGluR function (Aronica et al, 1993), suggesting that pre-treatment with mGluR1 
antagonists similarly alters the signalling properties of Group I mGluR in native systems as 
well as in heterologous expression systems (Lavreysen et al, 2005). Thus, it is conceivable 
that sub-chronic treatment with the Group I mGluR antagonists LY367385 and MPEP 
could be associated with a reduced efficacy due to both receptor supersensitivity of Group I 
mGJuR. It may also be hypothesised, therefore, that acute treatment with these compounds 
may produce more similar or greater neuroprotective effects than more chronic treatment. 
A second caveat is that, in the experiments outlined in Chapter 3, the mGluR 
ligands are assumed to be present in the system for the duration of the experiment as 
animals received daily focal injections of each ligand. However, importantly, with the 
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exception of MPEP, we currently do not have any data on the relative rate of clearance of 
LY367385,2R, 4R-APDC or L-AP4 from the brain. Indeed, numerous studies have reported 
very high and sustained levels of (-90-100%) of receptor occupation in the brain following 
systemic administration of MPEP (Gasparini et al, 1999; Spooren et al, 2000). This effect 
persists for approximately one hour following systemic administration of MPEP as 
measured by a receptor-occupancy assay (Anderson et al, 2002). Other brain penetrant 
mGluR ligands such as the novel orally-active mG1uRl antagonist JNJ16259685 
(Lavreysen et al, 2004a, b) and the system ical ly-active Group 11 mGluR agonist LY354740 
(Schoepp et al, 1997, Morin et al, 1997; Schaffhauser et al, 1998a; Rorick-Kehn et al, 2006) 
are reported to have similar effects. Thus, based on the potency of LY367385,2R, 4R- 
APDC and L-AP4 at their respective mGluR subtypes in vitro (Schoepp et al, 1999) and the 
relatively high concentrations of each ligand administered, it is reasonable to assume that 
each of these ligands produces long-lasting central effects. It is possible therefore, that the 
neuroprotective effects observed following intranigral injection of these compounds may be 
dependent on the presence of the drug, in that the doparninergic cells are irrevocably 
damaged, but are sustained whilst the drug is present in the system. Thus, it is important to 
examine the effect of halting drug treatment and allowing treated animals to survive 
untreated for period of time to determine if the observed neuroprotection is a long lasting 
effect, or transient and dependent on the presence of the drug. 
Therefore in order to investigate both the possibility that acute pre-treatment with 
mGluR ligands may result in equivalent or greater neuroprotection than sub-chronic 
treatment and additionally, to determine if this is a long-lasting and true neuroprotective 
effect against 6-OHDA toxicity in vivo, male Sprague-Dawley rats were treated acutely 
with each mGluR ligand (3 days) and subsequently allowed to survive for a further four 
days until day 7 post-6-OHDA lesion at which point, the integrity and functionality of the 
nigrostriatal system was investigated as described in section 4.2.1 below. This timescale 
was used so that the effects of acute mGIuR ligand treatment on the nigrostriatal system 
may be compared with the effects observed following sub-chronic (7 day) treatment. 
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4.2 Experimental Design 
4.2.1 Acute treatment studies with selective mGluR ligands 
Male Sprague-Dawley rats (250-270 g) were cannulated above the SNc and allowed to 
recover (see section 2.1.2.2) and subsequently treated according to the experimental design 
shown in Figure 4.1. 
Action 
Time point 
Animals enter Stereota(ic 11t focal drug 6-OHDA Finalfocal Animals 
CBU facility surgery injection infusion drug injection sacrificed 
No 10 IN. No 
7 days 10 days I hour 2 days drug 4 days 
or vehicle 
treatm ent 
Figure 4.1 Experimental design used to investigate the potential neuroprotective effects of 
acute mGluR ligand treatment against 6-hydroxydoparnine toxicity in vivo. 
All mGluR ligands and 6-OHDA were made up and administered intracerebrally as 
described previously (see sections 2.1.3,21.4,2.1.5). To assess the effect of acute treatment 
with mGluR ligands on 6-OHDA toxicity, cannulated animals were divided into treatment 
groups (n =8 per group) and administered a single, unilateral intranigral injection of either 
LY367385, MPEP, 2R, 4R-APDC, L-AP4 or drug vehicle onto the SNc. In all treatment 
groups, this injection was performed one hour before a unilateral lesion of the left SNc was 
induced by 6-OHDA infusion (see sections 2.1.4 and 2.1.5) Treatment groups then 
received daily single intranigral injections of mGluR ligand (or drug vehicle) for a further 2 
days, giving a total of three injections. Each mGluR ligand was administered at the 
concentration that provided maximal neuroprotection based on the data from the studies 
presented in Chapter 3. Details of each individual treatment group are shown in Table 4.1. 
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Concentration(s) 
Group Treatment Duration 
(nmol in 4 pl) 
Vehicle PBS / sterile saline n/a 3 days 
Group I rnGlu 
LY367385 200 3 days 
receptor antagonist 
Group I rnG1U5 
MPEP 10 3 days 
receptor antagonist 
Group 11 rnGlU2/3 
2R, 4R-APDC 10 3 days 
receptor agonist 
Group III rnGlu 
L-AP4 10 3 days 
receptor agonist 
Table 4.1 Treatment groups for acute treatment study. Each mGIuR figand was tested in 
vivo at the optimal concentration as determined from chapter 3, for 3 days duration in vivo. 
At the defined end point of the experiment (see Figure 4.1) animals were sacrificed 
by decapitation and the brains removed and dissected (see section 2.1.6). To quantify the 
effects of acute mGluR treatment on the integrity of the nigrostriatal system following 6- 
OHDA lesioning in these animals, immunohistochemistry for tyrosine hydroxylase (TH) 
was then performed and the numbers and morphology of TH-immunoreactive (TH-IR) cells 
in the SNc quantified (see sections 2.2.1.3 and 2.2.2.1). Furthermore, to determine the 
effects on nigrostriatal functionality, the concentrations of striatal monoamines and the 
amount of striatal DA turnover were measured by HPLC-ECD and subsequently analysed 
(see section 2.2.3). 
4.2.2 Statistical analysis of data 
All data (except where stated) are presented as the mean ± SEM based on n independent 
observations. Individual comparisons were made using a two-tailed paired or unpaired 
Students t-test as appropriate. Where multiple comparisons were made, one-way ANOVA 
with post-hoc Tukeys test for multiple comparisons was employed. Data for cell 
loss in 
vehicle and drug treated groups is presented as the mean percentage change ± 
SEM. 
Biochemical data for monoamines is expressed in the same manner, in ng/mI wet weight 
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tissue. Striatal DA turnover, is expressed as the mean values ± SEM calculated using the 
equation ((DOPAC + HVA)/DA) and mean values for each monoamine in pmol/ml. For 
TH-IR cell numbers and biochemical data for monoamines, mean values were also 
compared. In all figures, n values are shown in parenthesis. Differences were considered 
statistically significant at P<0.05 and all statistical data analysis was performed using 
GraphPad Prism v4.00 software (GraphPad software, San Diego, CA, USA). 
4.3 Results 
In all treatment groups the mean number of nigral TH-IR cells in the contralateral 
hemisphere was comparable and not significantly different from each other (F, . 966 
P=0.1244). In vehicle-treated animals, intranigral infusion of 12 ýLg 6-OHDA produced a 
significant loss of nigral TH-IR cells in the ipsilateral SNc when compared to the 
contralateral side (68.8 ± 1.9%; P<0.01) as shown in Figure 4.2A and illustrated in a 
representative photomicrograph in Figure 4.2C. Furthermore, in vehicle-treated animals 
one-way ANOVA analysis did not reveal any significant effect of SNc region in the mean 
percentage loss of TH-IR cells (Fl . 585 
P=0.187), indicating a consistent lesion size in all 
regions of the SNc (Figure 4.213). 
Additionally, in all treatment groups the mean concentrations of DA in the 
contralateral striata were also comparable and not significantly different (FI. 094 P=0.376). 
Similar results were observed for the concentrations of DOPAC and HVA (FI. 216 P=0.309 
and F2.483 P=0.066, respectively). Intranigral infusion of 6-OHDA produced a significant 
depletion of striatal DA (59.3 ± 6.1% [95% CI 46.4 - 72.1; P<0.001; Figure 4.3A), and 
striatal DOPAC and HVA (55.6 ± 6.3% [95% CI: 42.2 - 68.9]; P<0.001 and 48.9 ± 4.6% 
[95% CI 38.5 - 59.5 ]; P<0.001, Figures 4.3B and 4.3C, respectively) and resulted in a 
significant increase in striatal DA metabolism (0.161 ± 0.08 vs. 0.102 ± 0.02; P<0.05; 
Figure 4.3D) when comparing the contralateral and ipsilateral striata. 
4.3.1 Acute LY367385 treatment is neuroprotective against 6-OHDA toxicity 
Acute pre-treatment with 200 nmol in 4 ýtl LY367385 significantly attenuated the 6- 
OHDA-induced loss of nigral TH-IR cells in the ipsilateral SNc compared to vehicle- 
treated animals (25.62 ± 3.03% vs. 68.8 ± 1.9%; P<0.01; Figure 4.2A). Interestingly, acute 
treatment with LY367385 appeared to confer greater neuroprotection of nigral TH-IR cells 
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than sub-chronic treatment at the same concentration, but this failed to reach statistical 
significance (25.62 ± 3.03% vs. 35.7 ± 4.4%; P=O. 1165). The magnitude of the 
neuroprotection is illustrated by a representative photomicrograph shown in Figure 4.3B. 
However, it should be noted that when comparing the mean numbers of nigral TH-IR cells, 
6-OHDA still induces a small but significant loss of nigral TH-IR cells in the ipsilateral 
hemisphere compared to the contralateral hemisphere in animals acutely pre-treated with 
LY367385 (P<0.05), consistent with our previous observations with this compound (see 
section 3.3.2.1). One-way ANOVA analysis revealed no significant differences in lesion 
size in any region of the SNc (F, . 231 
P=0.3395; Figure 4.2B) and the lesion size was 
significantly reduced in all regions compared to vehicle-treated animals (F13.79 P`ý'-0-0001; 
Figure 4.213). These data are also consistent with our previous observations following sub- 
chronic treatment with the same concentration of LY367385 (see section 3.3.2.1). 
Acute treatment with 200 nmol in 4 gl LY367385 also significantly attenuated the 
6-OHDA-induced loss of striatal DA (22.5 ± 4.5% vs. 59.3 ± 6.1 %9 P<0.0 1; Figure 4.3A), 
DOPAC (23.9 ± 5.4% vs. 55.6 ± 6.3%, P<0.05; Figure 4.313) and HVA (22.5 ± 6.6% vs. 
48.9 ± 4.6%, P<0.01; Figure 4.3Q. Furthermore, acute treatment with LY367385 
completely blocked the 6-OHDA-induced increase in striatal DA metabolism (Figure 
4.31)), suggesting that the observed neuroprotective effect of LY367385 on nigrostriatal 
functionality following acute treatment is not due to increased DA metabolism by the 
surviving nigral TH-IR cells. However, when comparing the mean striatal concentrations of 
DA and its metabolites, 6-OHDA still induced a small but significant reduction in DA in 
the ipsilateral striata compared to the contralateral striata following acute treatment with 
LY367385 (P<0.05). Similar results were also observed for DOPAC and HVA (both 
P<0.05 respectively). Interestingly, following sub-chronic treatment with LY367385, no 
significant differences in striatal DA concentration were observed when comparing the 
contralateral and ipsilateral striata (see section 3.3.2.2). However, the mean percentage 
reduction of striatal DA in the ipsilateral striata is not significantly different between 
animals treated or acutely or sub-chronically with the LY367385 (22.53 ± 4.5% vs. 23.1 ± 
6.1%; P>0.05; Figure 4.3A). Moreover, the effects of acute treatment with LY367385 on 
striatal DOPAC and HVA concentrations and striatal DA turnover are consistent with and 
not significantly different from our previous observations following sub-chronic treatment 
with LY367385 at the same concentration (see section 3.3.2.2). Taken together, these data 
suggest that acute treatment with LY367385 provides significant protection of both the 
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integrity and functionality of the nigrostriatal tract against 6-OHDA toxicity in vivo, and 
moreover, the neuroprotection observed is directly comparable to that observed following 
sub-chronic treatment with the same concentration of LY367385. 
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Figure 4.2 Effect of acute LY367385 treatment on nigrostriatal integrity 
following 6-OHDA lesioning 
(A) Acute (3 day) treatment with LY367385 significantly attenuated the 6- 
OHDA induced loss of nigral TH-IR cells and this does not differ from that 
observed following sub-chronic LY367385 treatment **P<0.01 LY367385 vs. 
vehicle-treated (B) There are no differences in lesion size in any region of the 
SNc in animals treated acutely with LY367385. Additionally, the lesion size is 
significantly reduced in LY367385 compared to vehicle-treated animals in all 
stereotaxic regions of the SNc, indicating robust neuroprotection of the entire 
SNc structure. Data shown are mean % loss of nigral TH-IR ± SEM, n values are 
shown in parenthesis; *P<0.05 LY367385 vs. vehicle-treated (C) Representative 
photomicrographs to illustrate the degree of nigral TH-IR loss in vehicle-treated 
animals and neuroprotection of nigral TH-IR cells following acute treatment 
with LY367385. Images correspond to region B of the SNc (-5.30 mm from 
bregma) at x 40 magnification; scale bar 250 ýtm. 
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Figure 4.3 Effects of acute LY367385 treatment on nigrostriatal tract 
functionality following 6-OHDA lesioning 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the 
corpus striatum of vehicle and LY367385-treated male rats. Acute (3 day) 
treatment with LY367385 significantly reduced the 6-OHDA induced loss of 
striatal monoamines. Data shown are mean striatal dopamine, DOPAC and 
14VA content in ng/mL wet tissue weight ± SEM, n values are shown in 
parenthesis. **P<0.01 vehicle vs. LY367385-treated. (D) No significant 
alterations in striatal monoamine turnover were observed following acute 
treatment with LY367385 compared to vehicle-treated animals. *P<0.05 
contralateral vs. ipsilateral striata. Data shown are mean striatal dopamine 
turnover ratio calculated using the expression ((DOPAC+HVA)/DA)*100 
(pmol/ml ± SEM). 
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4.3.2 Acute MPEP treatment is neuroprotective against 6-OHDA toxicity 
Acute treatment with 10 nmol in 4 ýd MPEP significantly attenuated the 6-OHDA-induced 
loss of nigral TH-IR cells in the ipsilateral SNc compared to vehicle-treated animals (33.1 ± 
4.0% vs. 68.8 ± 1.9%; P<0.01; Figure 4.4A). Interestingly, acute treatment with this 
concentration of MPEP did not confer significantly greater neuroprotection of nigral TH-IR 
cells than sub-chronic treatment with the same concentration (33.1 ± 4.0% vs. 39.9 ± 3.4; 
P>0.05; Figure 4.4A). The magnitude of neuroprotection is illustrated by a representative 
photomicrograph shown in Figure 4.4C. However, it should be noted again that when 
comparing the mean numbers of nigral TH-IR cells, 6-OHDA still induced a small but 
significant loss of nigral TH-IR cells in the ipsilateral hemisphere compared to the 
contralateral hemisphere in this treatment group consistent with our previous observations 
with this compound following sub-chronic treatment (P<0.05; see section 3.3.3.1). One- 
way ANOVA analysis revealed no significant differences in lesion size in any region of the 
SNc (F 1 . 392 
P=0.266; Figure 4.413) whilst the lesion size was significantly reduced in 
regions A-D, but not E when compared to vehicle-treated animals (F15.15P<0.0001; Figure 
4.513). This pattern of neuroprotection is identical to that observed following sub-chronic 
treatment with MPEP at the same concentration (see Figure 3.913). 
Acute treatment with 10 nmol in 4 [d MPEP also significantly attenuated the 6- 
OHDA-induced loss of both striatal DA (8.5 ± 2.6% vs. 5 9.3 ± 6.1 %, P<O. 0 1; Figure 4.5A), 
DOPAC (12.4 ± 2.6% vs. 55.6 ± 6.3%, P<0.01; Figure 4.513) and HVA (11.3 ± 0.25% vs. 
48.9 ± 4.6%5 P<0.01; Figure 4.5C). Furthermore, acute treatment with MPEP completely 
blocked the 6-OHDA-induced increase in striatal DA metabolism (Figure 4.51)), suggesting 
that the observed neuroprotective effect of MPEP on nigrostriatal functionality following 
acute treatment is not due to increased DA metabolism by the surviving nigral TH-IR cells. 
Interestingly, when comparing the mean concentrations of both DA and DOPAC there is no 
significant difference between the ipsilateral and contralateral striata (P>0.05). 
Furthermore, the prevention of striatal DA depletion following acute treatment with MPEP 
was not significantly different from that observed with sub-chronic treatment (8.5 ± 2.6% 
vs. 12.4 ± 3.8%; P=0.437; Figure 4.5A). Similar results were observed for striatal DOPAC 
(12.3 ± 4.3% vs. 22.5 ± 6.5%; P=0.240; Figure 4.513) and HVA (11.3 ± 1.0% vs. 10.1 
3.6%; P=0.793; Figure 4.5C). 
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Figure 4.4 Effect of acute MPEP treatment on nigrostriatal integrity 
following 6-OHDA lesioning 
(A) Acute (3 day) treatment with MPEP significantly attenuated the 6-OHDA induced 
loss of nigral TH-IR cells and this is not significantly enhanced compared to that 
observed following sub-chronic MPEP-treatment, **P<0.01 MPEP vs. vehicle-treated 
(B) There are no regional differences in lesion size in any region of the SNc in 
animals treated acutely with MPEP. Additionally, the lesion size is significantly 
reduced in MPEP compared to vehicle-treated animals in all stereotaxic regions of the 
SNc, indicating robust neuroprotection of the entire SNc structure. *P<0.05 MPEP vs. 
vehicle-treated. Data shown in (A) and (B) are mean % loss of nigral TH-IR ± SEM, n 
values are shown in parenthesis (C) Representative photomicrographs to illustrate the 
degree of nigral TH-IR loss in vehicle-treated animals and neuroprotection of nigral 
TH-IR cells following acute treatment with MPEP. Images correspond to region B of 
the SNc (-5.30 mm from bregma) at x 40 magnification scale bar 250 ýtm. 
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Figure 4.5 Effects of acute MPEP treatment on nigrostriatal tract 
functionality following 6-OHDA lesioning 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the 
corpus striaturn of vehicle and MPEP-treated male rats. Acute (3 day) treatment 
with MPEP significantly reduced the 6-OHDA induced loss of striatal 
monoamines. Data shown are mean striatal dopamine, DOPAC and HVA 
content in ng/mL wet weight tissue ± SEM, n values are shown in parentheses. 
**P<0.01 vehicle vs. MPEP-treated. (D) No significant alterations in striatal 
monoamine turnover were observed following acute treatment with MPEP, 
compared to vehicle-treated animals. *P<0.05 contralateral vs. ipsilateral striata. 
Data shown are mean striatal dopamine turnover ratio calculated using the 
expression ((DOPAC+FWA)/DA)* 100 (pmol/mI ± SEM). 
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Taken together, these data suggest that acute treatment with MPEP provides comparable 
neuroprotection of the integrity of the nigrostriatal tract and functionality of the 
nigrostriatal tract against 6-OHDA toxicity in vivo to that previously observed following 
sub-chronic treatment with the same concentration of MPEP (see section 3.3.3.2). 
4.3.3 Acute 2R, 4R-APDC treatment is not neuroprotective against 6-OHDA toxicity 
Acute treatment with 10 nmol in 4 ýd 2R, 4R-APDC did not significantly attenuate the 6- 
OHDA-induced loss of nigral TH-IR cells in the ipsilateral SNc compared to vehicle- 
treated animals (70.5 ± 6.1% vs. 68.8 ± 1.9%; P>0.05; Figure 4.6A). This is in marked 
contrast to the significant neuroprotection previously observed following sub-chronic 
treatment with the same concentration of 2R, 4R-APDC (see section 3.3.4.1 and Figure 
43A). The absence of neuroprotection is illustrated by a representative photomicrograph 
shown in Figure 4.6C. Consistent with these data, when comparing the mean numbers of 
nigral TH-IR cells 6-OHDA induced significant loss of nigral TH-IR cells in the ipsilateral 
hemisphere compared to the contralateral hemisphere in these animals (P<0.01, data not 
shown). One-way ANOVA analysis revealed no significant differences in lesion size in any 
region of the SNc (Fo. 347 P=0.838; Figure 4.613) and the lesion size was not significantly 
different in any region of the SNc compared to vehicle-treated animals (FO. 745 P=0.667; 
Figure 4.613). In contrast, in animals treated sub-chronically with 2R, 4R-APDC, significant 
reduction of the lesion size was previously observed in regions A, B, C and D (see section 
3.3.4.1). 
Consistent with the cellular data, acute treatment with 10 nmol in 4 ýtl 2R, 4R- 
APDC also did not significantly attenuate the 6-OHDA-induced loss of either striatal DA 
(42.1 ± 1.8% vs. 59.3 ± 6.1%, P>0.05; Figure 4.7A), DOPAC (38.1 ± 3.9% vs. 55.9 ± 
6.3%9 P>0.05; Figure 4.713) or HVA (35.3% ± 3.6% vs. 48.9 ± 4.6%; P>0.05; Figure 4.7Q. 
Furthermore, acute treatment with 2R, 4R-APDC did not diminish the 6-OHDA-induced 
increase in striatal DA metabolism seen in vehicle-treated lesioned animals (Figure 4.71)). 
Indeed, a marked increase in striatal DA turnover was observed in this group similar to that 
observed in vehicle-treated animals (Figure 4.713). These data are also in marked contrast to 
the significant prevention of striatal DA (42.1 ± 1.8% vs. 9.9 ± 2.7%; P=0.001; Figure 
4.7A), DOPAC (38.1 ± 3.9% vs. 12.7 ± 5.5%; P<0.05; Figure 4.713) and HVA (35.3 ± 3.6% 
vs. 9.9 ± 3.6%; P<0.01; Figure 4.7C) depletion previously observed in animals treated sub- 
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chronically with the same concentration of 2R, 4R-APDC (see section 3.3.4.2). Comparison 
of the mean striatal concentration (ng/ml) of each monoamine between the ipsilateral and 
contralateral striatum yielded the same results (P<0.01). 
Taken together, these data suggest that acute treatment with 2R, 4R-APDC does not 
provide significant neuroprotection of the integrity or the functionality of the nigrostriatal 
tract against 6-OHDA toxicity in vivo, in marked contrast to the significant neuroprotection 
observed following sub-chronic treatment with the same concentration of this compound. 
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Figure 4.6 Effect of acute 2R, 4R-APDC treatment on nigrostriatal 
integrity following 6-OHDA lesioning 
(A) Acute (3 day) treatment with 2R, 4R-APDC did not significantly attenuate the 6- 
OHDA induced loss of nigral TH-IR cells in contrast to the significant 
neuroprotection observed following sub-chronic treatment. **P<0.01 Sub-chronic 
2R, 4R-APDC vs. vehicle-treated, tP<0.01 acute 2R, 4R-APDC -treated vs. sub-chronic 
2R, 4R-APDC -treated (B) There are no regional differences in lesion size in any 
region of the SNc in animals treated acutely with 2R, 4R-APDC. Additionally, the 
lesion size is not significantly different compared to vehicle-treated animals in any 
stereotaxic region of the SNc, confin-ning the absence of neuroprotection. Data shown 
in (A) and (B) are mean % loss of nigral TH-IR ± SEM, n values are shown in 
parenthesis; (C) Representative photornicrographs to illustrate the degree of nigral 
TH-IR loss in vehicle-treated animals and absence of neuroprotection of nigral TH-IR 
cells following acute treatment with 2R, 4R-APDC. Images correspond to region B of 
the SNc (-5.30 mm from bregma) at x 40 magnification; scale bar 250 ýtm. 
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Figure 4.7 Effects of acute 2R, 4R-APDC treatment on nigrostriatal 
tract functionality following 6-OHDA lesioning 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the 
corpus striatum of vehicle and 2R, 4R-APDC -treated male rats. Acute treatment 
with 2R,, 4R-APDC did not significantly prevent striatal monoamine depletion 
following 6-OHDA lesioning. Data shown are mean striatal dopamine, DOPAC 
and HVA content in ng/mL wet weight tissue ± SEM, n values shown in 
parenthesis. *P<0.05, **P<0.01 vehicle vs. sub-chronic 2R, 4R-APDC-treated, 
tP<0.05; tP<0.01 sub-chronic vs. acute 2R, 4R-APDC treatment (D) A 
significant increase in striatal dopamine turnover was observed in animals 
acutely treated with 2R, 4R-APDC similar to that seen in vehicle-treated animals. 
*P<0.05 contralateral vs. ipsilateral striata. Data shown are mean striatal 
monoamine turnover ratio calculated using the expression 
((DOPAC+HVA)/DA)* 100 (pmol/ml ± SEM). 
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4.3.4 Acute L-AP4 treatment is neuroprotective against 6-OHDA in vivo 
Acute treatment with 10 nmol in 4 ýtl L-AP4 significantly attenuated the 6-OHDA induced 
loss of nigral TH-IR cells (23.8 ± 9.9% vs. 68.8 ± 1.9%; P<0.001; Figure 4.9A). 
Interestingly, acute treatment with L-AP4 appeared to result in greater neuroprotection of 
nigrostriatal integrity but this failed to reach statistical significance (23.8 ± 9.9% vs. 33.89 
± 4.2%; P>0.05; Figure 4.8A). Consistent with the data following sub-chronic 
administration at this concentration of L-AP4 (see section 3.3.5.1), no regional differences 
were observed in neuroprotection of TH-IR cells in any region of the SNc (A-E) following 
acute treatment with L-AP4 (FO. 060 P=0.953; Figure 4.813). Furthermore, acute treatment 
with L-AP4 significantly reduced the mean percentage loss of nigral TH-IR cells compared 
to vehicle-treated animals in every region of the SNc, as illustrated in Figure 4.813. The 
degree of neuroprotection of TH-IR cells is illustrated in representative photomicrographs 
shown in Figure 4.8C. Moreover, when comparing the mean number of nigral TH-IR cells 
in the contralateral and ipsilateral hemisphere in animals treated acutely with L-AP4 no 
significant difference was observed following 6-OHDA lesioning (P>0.05). 
Consistent with the cellular data, acute treatment with 10 nmol in 4 ýil L-AP4 also 
significantly attenuated the reduction of striatal DA in the ipsilateral striata compared to 
vehicle-treated animals (9.4 ± 3.2% vs. 59.3 ± 6.1 %; P<0.0 1; Figure 4.9A) which, although 
this appeared to be greater than that observed in animals treated sub-chronically with the 
same concentration of L-AP4, this did not reach statistical significance (9.4 ± 3.2% vs. 11.4 
± 2.6%; P>0.05; Figure 4.9A). Similar results were observed for the 6-OHDA-induced 
depletion of striatal DOPAC (23.46 ± 3.4 vs. 55.6 ± 6.3%; P<0.01; Figure 4.913) and HVA 
(12.7 ± 4.7% vs. 48.9 ± 4.6%, P<0.01; Figure 4.9C) in animals treated acutely with L-AP4, 
but once again, these data were not significantly different to that observed in animals 
treated sub-chronically with the same concentration of L-AP4 for either DOPAC (9.4 ± 2.2 
vs. 11.4 ± 2.6; P>0.05; Figure 4.913) or HVA (12.7 ± 4.7% ± 23.7 ± 9.4%; P=0.371; Figure 
4.9Q. Moreover, acute treatment with L-AP4 also completely blocked the 6-OHDA 
induced increase in striatal DA metabolism, similar to that observed following sub-chronic 
treatment with this agonist (Figure 4.91)), suggesting that the observed neuroprotective 
effect of L-AP4 on nigrostriatal functionality following acute treatment is not due to 
increased DA metabolism by the surviving nigral TH-IR cells. Interestingly, when 
comparing the mean striatal concentrations of DA, DOPAC and HVA no significant 
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differences were observed between the ipsilateral and contralateral striata (P>0.05), 
whereas in animals treated sub-chronically, significant reductions were observed for 
DOPAC and HVA and the depletion of DA bordered on statistical significance when 
comparing the contralateral and ipsilateral striata (see section 3.3.5.2). 
Taken together, these data suggest that acute treatment with L-AP4 provides very 
significant neuroprotection of both the integrity and functionality of the nigrostriatal tract 
against 6-OHDA toxicity in vivo, and this is comparable to that observed following sub- 
chronic treatment with the same concentration of L-AP4 (see sections 3.3.5.1 and 3.3.5.2), 
although there is a suggestion towards a trend for increased neuroprotection following acute 
treatment with L-AP4, but this is not statistically significant. 
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Figure 4.8 Effect of acute L-AP4 treatment on nigrostriatal integrity 
following 6-OHDA lesioning 
(A) Acute (3 day) treatment with L-AP4 significantly attenuated the 6- 
OHDA induced loss of nigral TH-IR cells and this is not significantly 
different from the neuroprotection observed following sub-chronic 
treatment. **P<0.01 L-AP4 vs. vehicle-treated (B) There are no regional 
differences in lesion size in any region of the SNc in animals treated acutely 
with L-AP4. Additionally, the lesion size is significantly different compared 
to vehicle-treated animals in any stereotaxic regions of the SNc, suggesting 
robust neuroprotection throughout the entire SNc structure. *P<0.05 L-AP4 
vs. vehicle-treated. Data shown in (A) and (B) are mean % loss of nigral 
TH-IR ±SEM, n values are shown in parenthesis; (C) Representative 
photomicrographs to illustrate the degree of nigral TH-IR loss in vehicle- 
treated animals and neuroprotection of nigral TH-IR cells following acute 
treatment with L-AP4. Images correspond to region B of the SNc (-5.30 mm 
from bregma) at x 40 magnification; scale bar 250 ýtm. 
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Figure 4.9 Effects of acute L-AP4 treatment on nigrostriatal tract 
functionality foRowing 6-OHDA lesioning 
Mean percentage reduction of dopamine (A), DOPAC (B) and UVA (C) in the corpus 
striaturn of vehicle and L-AP4-treated male rats. Acute treatment with L-AP4 
significantly prevented depletion of striatal monoamines following 6-OHDA 
lesioning. **P<0.01 vehicle vs. L-AP4-treated Data shown are mean striatal 
dopamine, DOPAC and FWA content in ng/mL wet weight tissue ± SEM, n values are 
shown in parenthesis. (D) No significant increases in striatal monoamine turnover 
were observed in animals acutely treated with L-AP4 in contrast to vehicle-treated 
animals. *P<0.05 contralateral vs. ipsilateral striata. Data shown are mean striatal 
monoamine turnover ratio calculated using the expression 
((DOPAC+FWA)/DA)* 100 (pmol/ml ± SEM). 
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4.4 Discussion 
4.4.1 Neuroprotection of the nigrostriatal system following acute intranigral treatment 
with LY367385, MPEP and L-AP4 
The current study was designed to investigate whether acute intranigral treatment with 
selective mGluR ligands results in similar or greater neuroprotection when compared to 
sub-chronic treatment with these compounds at the same concentration. Additionally, it was 
investigated whether or not the neuroprotection of the nigrostriatal system following acute 
intranigral mGluR ligand injection persists following the cessation of drug treatment. 
Interestingly, acute treatment with either 200 nmol in 4 ýtl of the mGluR1 antagonist 
LY367385, or 10 nmol in 4 ýtl of the mGluR5 antagonist MPEP significantly attenuated the 
loss of nigral TH-IR cells with a concomitant prevention of the depletion of DA and its 
metabolites in the corpus striatum following unilateral infusion of 6-OHDA into the SNc. 
Importantly, these effects were not associated with an increase in striatal DA turnover. 
Similar results were observed following acute intranigral treatment with 10 nmol in 4 [d of 
the Group III mGluR agonist L-AP4 following unilateral 6-OHDA infusion into the SNc. 
Theoretically, the observed decrease in nigral TH-IR cells and the neuroprotective 
effects of each mGluR ligand could be due to transient atrophy of cells and downregulation 
of TH expression rather than true cell death and neuroprotection (Sherman and Moody, 
1995; Yuan et al, 2005; Meuer et al, 2006). This possibility has been previously addressed 
in Chapter 3 (see section 3.4). 
Importantly, acute treatment with LY367385, MPEP and L-AP4 also attenuated the 
6-OHDA-induced depletion of striatal DA and its metabolites, which indicates preservation 
of axonal projections. The observation that acute treatment with these compounds also 
blocks 6-OHDA-induced increases in striatal DA turnover suggests that the prevention of 
DA depletion by following treatment with these compounds is due to neuroprotection of 
striatal DA terminals, rather than increased compensatory DA metabolism by the surviving 
nigral TH-IR cells. Furthermore, because of the relatively short time between 6-OHDA 
lesioning and HPLC measurements (7 days post-6-OHDA lesion) it is unlikely that the 
preservation of striatal DA could be explained by sprouting of the remaining axonal 
projections, which has only been seen to occur 4 weeks after 6-OHDA lesioning 
(Finklestein et al, 2000; Stanic et al, 2003). 
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Importantly, drug treatment was ceased after 3 days and the animals allowed to 
survive for a further four days. Therefore, the fact that significant neuroprotection is still 
observed following this time period strongly argues that the neuroprotective effect of 
intranigral LY367385, MPEP and L-AP4 is relatively long-lasting. However, in future 
experiments it will be important to examine if these effects persist if the animals are 
allowed to survive for longer time periods following cessation of drug treatment, to ensure 
the observed neuroprotection does not simply reflect delayed neuronal death. However, 
careful selection of this time frame will be critical to avoid the complicating effect of 
natural ly-occurring compensatory mechanisms that occur in vivo following 6-OHDA 
lesioning, up to 4 weeks after the lesion is generated, which may cloud the results (see 
Finkelstein et al, 2000; Stanic et al, 2003). 
Taken together, these data support a robust neuroprotective effect following acute 
treatment with LY367385, MPEP and L-AP4 in vivo in the 6-OHDA experimental model 
of PD. Furthermore, these data are consistent with previous reports documenting significant 
neuroprotection against various toxic insults following single injections or acute treatment 
with these compounds. Indeed, acute treatment with MPEP is neuroprotective in vivo in 
experimental models of ischaemic injury, excitotoxic neurodegeneration and other 
experimental models of PD (Bruno et al, 200 1; Bao et al, 200 1; Golembiowska et al, 2003; 
Battaglia et al, 2005; Aquirre et al, 2005; Risterucci et al, 2005). A similar neuroprotective 
action is also documented for LY367385 and other selective mGluRI antagonists following 
acute treatment in experimental models of cerebral ischaemia (Pei legrini-Giampietro et al, 
1999; Rao et al, 2000; Meli et al, 2002), traumatic brain injury (Faden et al, 2001), 
excitotoxin-mediated neuronal damage (Bruno et al, 1999; Battaglia et al, 2001) and other 
experimental models of PD (Aquirre et al, 2001). These data are also consistent with 
reports of a neuroprotective action of L-AP4 in vivo following acute treatment or single 
injections in models of diffuse brain injury (Zhou et al, 2003; Bai et al, 2004). 
Interestingly, when the degree of neuroprotection following acute treatment was 
compared to that following sub-chronic treatment with the same concentration of 
LY367385, MPEP or L-AP4 no significant differences were observed. These data indicate 
that acute treatment with these mGluR ligands provides neuroprotection of the nigrostriatal 
system against 6-OHDA toxicity that is directly comparable to that observed following sub- 
chronic treatment. This suggests that repeated intranigral injection of these compounds over 
a sub-chronic period does not result in greater neuroprotection. These data argue that the 
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neuroprotective actions of LY367385, MPEP may be limited by the biochemical alterations 
to mGluRI in response to repeated antagonist injections. This could be due to 
desensitisation of Group I mGluR in response to endogenous glutamate (see section 4.4.2) 
or more likely, the development of antagonist induced receptor supersensitivity (see section 
4.4.3). Additionally, it suggests that the neuroprotective actions of L-AP4 may be limited 
by the desensitisation of Group III mGluR in response to repeated injections of agonist (see 
section 4.4.4). 
Altematively, it may be possible that the key neurodegenerative processes that 
occur in the 6-OHDA model do so in the first few days, during the time at which the drugs 
are present following acute treatment. Hence, the biochemical alteration of receptor 
signalling by repeated exposure to direct-acting antagonists or agonists may not in fact 
affect the neuroprotective actions of these compounds in this model, although these 
possibilities are considered in full below. In support of this, the time course of cell death 
following 6-OHDA lesioning is acute, usually initiated within 24 hours of injection 
(Deumens et al, 2002). 
4.4.2 Effects of Group I mGluR desensitisation by endogenous glutamate on the 
neuroprotective action of Group I mGluR antagonists 
Group I mGluR undergo both constitutive and agonist induced desensitisation and 
internalisation following stimulation by endogenous glutamate, which leads to attenuation 
of Group I mGluR signalling (see section 1.10.5). This may have consequences for the 
neuroprotective actions of LY367385 or MPEP at postsynaptic Group I mGluR expressed 
on nigral DA neurones or on presynaptic excitatory axon terminals from the STN (or PPN 
and cortex). 
However, the role of Group I mGluR in both neuroclegeneration and 
neuroprotection remains controversial and solid evidence exists to suggest both a 
neuroprotective and a neurotoxic effect of Group I mGluR activation (see section 3.4.2.3) 
(Nicoletti et al, 1999). Interestingly, activation of Group I mGluR by the selective agonist 
(S)-3,5-dihydroxyphenylglycine ((S)-3,5-DHPG) is neuroprotective against NMDA- 
mediated toxicity in neurones of the hippocampus (Blaabjerg et al, 2001; 2003). 
Additionally, activation of Group I mGluR has been reported to be neuroprotective in 
studies of NO or ischaernia-induced cell death (Lin and Maiese, 2001a and b). In contrast, 
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several studies have shown that selective antagonism of Group I mGluR is neuroprotective 
(see section 3.5). Importantly, the mechanism which underlies the neuroprotective action of 
Group I mGluR activation appears to involve an activity-dependent switch from facilitation 
to inhibition (Nicoletti et al, 1999; Bruno et al, 2001b). Thus, in cultures of mixed cortical 
cells, application of (S)-3,5-DHPG prior to, or co-application with NMDA led to enhanced 
NMDA toxicity (Bruno et al, 2001). However in contrast, when (S)-3,5-DHPG was applied 
twice both before and during the NMDA toxic pulse, (S)-3,5-DHPG substantially protected 
against NMDA toxicity (Bruno et al, 2001). Interestingly, this effect showed a marked 
time-dependency, since neuroprotection was still observed even when the two (S)-3,5- 
DHPG applications were applied up to 45 min apart before NMDA application (Bruno et 
al, 2001). The presence of inhibitors of PKC during the first application of (S)-3,5-DHPG 
prevented the neuroprotective effect of a second (S)-3,5-DHPG application (Bruno et al, 
2001). Additionally, when either of the Group I mGluR antagonists MPEP or CPCCOEt 
were applied during the first (S)-3,5-DHPG application this abolished the protective effect 
of a second (S)-3,5-DHPG treatment, although it is noteworthy, that each of these 
antagonists was neuroprotective against NMDA toxicity when administered alone (Bruno et 
al, 2001b). Similar data were obtained in pure neuronal cultures, arguing against a possible 
complicating effect of glial Group I mGluR (Bruno et al, 2001). Importantly, it has also 
been demonstrated that the neuroprotective effect of Group I mGluR activation is 
associated with a decrease in NMDAR currents, which is consistent with data suggesting 
that Group I mGluR and NMDAR functionally interact, with a resultant enhancement of 
NMDAR activity (Awad et al, 2000; Alagarsamy et al, 1999a, b; 2002; Blaabjerg et al, 
2003; Baskys et al, 2005). 
Taken together, these data argue that Group I mGluR (both mGluRI and 5) appear 
to undergo an activity-dependent switch, based upon previous exposure to agonist 
stimulation (Nicoletti et al, 1999; Bruno et al, 2001). Initially, activation of 
pharmacologically "naYve" receptors facilitates excitotoxic death, whilst prior exposure to a 
receptor agonist (including endogenous glutamate) seems to induce neuroprotection by 
inducing desensitisation of Group I mGluR, such these receptors can no longer participate 
in pathological glutamate signalling (Nicoletti et al, 1999; Bruno et al, 2001) The 
importance of endogenous glutamatergic tone in the functional state of Group I mGluR has 
been previously suggested, based on the finding that Group I mGluR agonists inhibit 
neurotransmission at Schaffer collateral - CAI synapses in the hippocampus, but produce 
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an opposite effect when the endogenous glutamate tone is removed (Rodriquez-Moreno et 
al, 1998). The fact that this process is sensitive to PKC inhibition strongly suggests that the 
underlying mechanism of this functional switch is Group I mGluR homolgous 
desensitisation induced by PKC phosphorylation (see section 1.10.5), although a role for 
GRK-mediated desensitisation cannot be excluded (Rodriquez-Moreno et al, 1998; Bruno 
et al, 2001). It is conceivable that this effect may also involve selective desensitisation of 
differential signalling pathways, for example from P1 production to a pathway more 
compatible with neuroprotective actions such as activation of MAPK or inhibition of Ca2+ 
currents (Bruno et al, 2001; Blaabjerg et al, 2003; Baskys et al, 2005). It also conceivable 
that this is an exclusive property of presynaptic Group I mGIuR which have been 
demonstrated in vitro to facilitate glutamate release (Thomas et al, 2001; Fazal et al, 2003), 
but "switch" through desensitization in order to Prevent harmful release of glutamate 
(Bruno et al, 2001). 
Importantly, these observations have ramifications for the potential efficacy of 
Group I mGluR antagonists as neuroprotective agents against 6-OHDA toxicity following 
infusion in to the SNc. It is highly likely that the efficacy of these drugs is related to the 
functional state of Group I mGluR and the level of endogenous glutarnatergic tone these 
receptors are exposed to. In this respect, the existence of glutamate releasing nerve 
terminals has been demonstrated in the SN (Abarca et al, 1985; Fiedler and Bustos, 1991; 
Smith et al, 1996) primarily arising from the cell bodies of glutamatergic neurones arising 
in the STN and frontal cortex and PPN (Kita and Kitai, 1987; Fiedler and Bustos, 1991; 
Smith et al, 1996; Iribe et al, 1999; Breit et al, 2001). Furthermore, there is extensive 
physiological evidence to suggest that metabotropic glutamate receptors regulate neuronal 
activity in the STN (Kaatz and Albin, 1995; Abbott et al, 1997; Awad et al, 2000), SNr 
(Bradley et al, 2000; Marino et al, 2001; Wittmann et al, 2001a and b) and SNc (Fiorillo 
and Williams, 1998) leading to control of DA release in the striaturn, and SNc and the 
firing of the GABAergic output neurones of the SNr, all of which are critical in the 
maintenance of the balance of neurotransmission between the direct and indirect neuronal 
circuits in the BG and the initiation and control of smooth movement, suggesting that 
mGluR in the SN are exposed to significant glutamatergic tone under normal brain 
conditions (Rouse et al, 2000; Bustos et al, 2004). 
Thus, it is conceivable that Group I mGluR antagonists administered intranigrally 
may be effective neuroprotective agents when they blockade "ndve" Group I mGluR in the 
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initial phases of an excitotoxic event (Bruno et al, 2001), which may underlie the 
neuroprotection observed following acute treatment with either LY367385 or MPEP. In 
contrast, the same antagonists may be less effective under conditions of chronic glutarnate 
over stimulation where receptor desensitisation due to endogenous glutamate means the 
majority of Group I mGluR are no longer coupled to detrimental signalling pathways and 
are undergo desensitisation and internalisation (Bruno et al, 2001), perhaps explaining why 
sub-chronic treatment does not result in greater neuroprotection. In support of this, rodents 
unilaterally lesioned with 6-OHDA show a significant reduction in the density of Group I 
mGluR as measured by in situ hybridisation and immunocytochernical methods in the SNc 
(Messenger et al, 2002; Gu et al, 2003). Thus, it is tempting to speculate that this represents 
a functional compensation following the development of chronic glutarnate over 
stimulation of nigral DA neurones after the 6-OHDA lesion, although this may also simply 
be a reflection of nigral cell loss (Messenger et al, 2002). 
However, it is noteworthy that co-application of either MPEP (Bruno et al, 2001) or 
LY367385 (Blaabjerg et al, 2001; Baskys et al, 2005) reversed the protective effect of 
repeated (S)-3,5-DHPG stimulation. Such that Group I mGluR activation again enhanced 
NMDA toxicity, although the mechanism by which this occurs could not be delineated 
since these antagonists when administered alone were also neuroprotective (Bruno et al, 
2001). In the current study, both MPEP and LY367385 were administered one hourprior to 
the 6-OHDA neurotoxin, which suggests that activity-dependent changes as a result of 
endogenous glutarnate mediated Group I mGluR desensitisation may not completely 
account for the finding that sub-chronic treatment does not produce increased 
neuroprotection compared to acute treatment with these ligands. A second possible 
explanation is the less documented effect of Group I mGluR supersensitivity following 
prolonged antagonist application, 
4.4.3 Development of Group I mGluR receptor supersensitivity in response to sub- 
chronic antagonist exposure 
Interestingly, long-term antagonist pre-treatment has been reported to alter the functions 
and properties of a number of GPCRs (Lavreysen et al, 2005). Indeed, the phenomenon of 
DA receptor supersensitivity in the putamen is now well documented and is characterised 
by an enhancement of subsequent agonist responses due to an increase in agonist potency 
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and a decrease in antagonist potency (Jenner and Marsden, 1987; Gerfen et al, 2000; 2003; 
Kim et al, 2006). Therefore, it is important to address the potential effects of prolonged 
antagonist treatment on the signalling properties of Group I mGluR, especially in light of 
the results of the current study, which suggest these compounds may represent a useful 
novel neuroprotective therapy for the treatment of PD. 
In this respect, Lavreysen and colleagues (2002; 2005) have studied the effect of 
prolonged treatment with the non-competitive selective mGluRI antagonist CPCCOEt and 
the competitive selective mGluRI antagonist (S)-4-carboxy-3-hydroxyphenylglycine ((S)- 
4C3HPG) in vitro using both a heterologous expression system (L929sA cells) and native 
systems (cerebellar granule cells). Interestingly, in L929sA cells, 24 hr pre-treatment with 
either antagonist significantly enhanced subsequent mGluRI agonist responses, as 
demonstrated by increased [3 HJIP production and the potentiation of glutamate-induced 
increases in intracellular Ca2+ (Lavreysen et al, 2002). Furthermore, the IC50 for glutarnate 
activation of mGluR Ia was significantly lower (by approx. 3-fold) in antagonist pre-treated 
cells, and time-course studies demonstrated that this phenomenon could occur with as little 
as 30 min pre-incubation with either antagonist (Lavreysen et al, 2002). More importantly 
with respect to the current study, the potency of the Group I mGluR antagonists to inhibit 
mGluRla-mediated responses was significantly reduced following 24 hr pre-incubation 
with either antagonist (Lavreysen et al. 2002). Taken together, these data strongly argue 
that these responses are due to the development of mGluR I supersensitivity and that Group 
I mGluRI per se show increased sensitivity to glutamate following prolonged antagonist 
incubation (Lavreysen et al, 2002). In support of this, although an increase in the total 
amount of mGluRla was not observed, a significant increase in the number of mGluRIa 
receptors at the cell surface was observed (Lavreysen et al, 2002). Importantly, these 
findings were replicated subsequently in cerebellar granule cells, suggesting that this effect 
also occurs in neurones (Lavreysen et al, 2005). 
The mechanism by which this supersensitivity develops is not clear. However the 
rapid time course over which it occurs suggests that it involves fast molecular mechanisms, 
including potentially receptor resensitisation either by dephosphorylation or by decreases 
in 
the time course of receptor recycling from the endosomal compartment to the plasma 
membrane (Lavreysen et al, 2001; 2005). It is noteworthy that for human mGluR1, 
in vitro 
studies have demonstrated that agonist-mediated desensitisation parallels agonist-mediated 
stimulation of the receptor (Desai et al, 1996). Moreover, in cerebellar granule cell primary 
-233- 
cultures, mGluRI desensitises rapidly on agonist addition (Catania et al, 1991; Aronica et 
al, 1993). It is therefore conceivable that these effects observed both in heterologous 
expression systems and neurones by Lavreysen and colleagues (2002; 2005) may be due to 
constant desensitisation of rnGluRla by endogenous glutamate, which is reversed by 
antagonist blockade, leading to alteration of the biochemical properties of the receptor, 
manifest as increased agonist potency but reduced antagonist potency. Interestingly, this 
possibility is highly likely to occur in vivo as a consequence of glutarnate released during 
synaptic transmission; particularly under the pathological conditions increases in glutamate 
transmission induced by the 6-OHDA lesion (see sections 1.5 and 1.7.4). However, in vitro 
incubation of L929sA cells with glutamate pyruvate transaminase (GPT) to remove 
endogenous glutamate did not result in enhancement of glutamate-induced Caý+ 
mobilisation (Lavreysen et al, 2002). Similarly, the addition of CPCCOEt to HEK293 cells 
expressing mGluRla did not affect the constitutive internalisation of the receptor (Pula et 
al, 2004). These data suggest that the development of supersensitivity is not simply the 
reversal of agonist-mediated desensitisation and that internalisation is not due to glutarnate 
present in the culture medium, at least in HEK293 cells (Pula et al, 2004; Lavreysen et al, 
2005). 
The mechanism by which prolonged antagonist incubation appears to increase 
mGluRla number at the cell surface is not clear. One possibility may involve the enhanced 
trafficking of mGluRla from endosomal compartments (Ciruela et al, 1999). The cell 
surface receptor expression and stability of mGluR1 is known to be regulated by 
interactions with the Homer family of proteins (Brakeman et al, 1997; Kammermier and 
Ikeda, 1999). Indeed, co-expression of both Homer la and Ic have been shown to increase 
the cell surface expression of mGluRla in HEK293 cells (Ciruela et al, 1999; 2000) thus 
Homer proteins represent a likely effector protein by which antagonist binding may 
increase receptor trafficking (Lavreysen et al, 2002; 2005). However, the nature of this 
interaction or how antagonist binding affects Homer protein expression or localisation even 
in vitro has yet to be determined. 
A second possibility is the inhibition of the internalisation of mGluRla. In support 
of this, in HEK293 cells incubation with LY367385 markedly attenuates the internalisation 
of mGluRIa and appears to slightly increase the number of mGluRIa at the cell surface 
(Pula et al, 2004). Interestingly, this appears to be related to the fact that LY367385 
displays inverse agonist properties at mGluRla, which CPCCOEt does not (Litschig et al, 
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1999; Lavreysen et al, 2002; Pula et al, 2004). These data are consistent with other reports 
of pre-treatment with inverse agonists resulting in increased cell surface number and 
enhanced responsiveness of GPCRs which show constitutive activity and, as such, 
constitutive internal isation, including the 02 adrenoreceptors and importantly Group I 
mGluR (Prezeau et al, 1996; MacEwan and Milligan, 1996; Leurs et al, 1998; Dale et al, 
2001; Seifert and Wenzel-Seifert, 2002; Fourgeaud et al, 2003). This suggests an obvious 
link between constitutive activity and subsequent constitutive internalisation of GPCRs 
(Pula et al, 2004) 
Taken together, it is therefore possible that in vivo intranigral injection of 
LY367385 prior to the addition of the 6-OHDA neurotoxin may result in the development 
of a profound postsynaptic receptor supersensitivity response for mGluR1 in the SNc, 
thereby leading to a decrease in the efficacy of subsequent antagonist injections to attenuate 
the effects of increased glutamate transmission onto nigral DA neurones. This is consistent 
with the time course suggested for the development of mGluR1 supersensitivity in vitro 
(Lavreysen et al, 2002; 2005), although it is important to stress we currently do not know 
the time course at which LY367385 is cleared from the brain. Alternatively, it is possible 
that the neuroprotection observed following intranigral injection of LY367385 may result 
neuroprotection against early events in 6-OHDA toxicity, whilst subsequent antagonist 
injections have a reduced effect, which may explain why acute and sub-chronic treatment 
with this compound result in comparable neuroprotection of the nigrostriatal system. In 
support of this, significant and long-lasting neuroprotection of the nigrostriatal system 
similar to that described herein has been observed following a single i. c. v injection of the 
mGluR I antagonist AIDA prior to injections of the MPTP neurotoxin (Aquirre et al, 2001). 
It may also be hypothesised that pre-treatment with MPEP may result in a similar 
development of receptor supersensitivity as described for mGluR1 antagonists above 
Interestingly, human mGluR5 has been reported to show high constitutive activity in vitro 
(Gasparini et al, 1999; Goudet et al, 2004) and MPEP shows inverse agonist activity at 
mGluR5 (Gasparini et al, 1999; Goudet et al, 2004). Moreover, MPEP is reported to inhibit 
the constitutive activity of mGluR5, which is suggested to be due to its inverse agonist 
action (Goudet et al, 2004). Thus, it may be hypothesised that pre-treatment with MPEP 
may result in the development of receptor supersensitivity as described for antagonists of 
mGluRl. In support of this, concept, pre-incubation with MPEP led to a significant 
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increase in the agonist-stimulated response of human mGluR5 expressed in HEK293 cells, 
suggesting the possibility of a supersensitivity response (Muhlemann et al, 2005). 
However, in the normal brain, the majority of mGluR5 expressed in the rodent SNc 
has been observed to localise to discreet intracellular compartments (Hubert et al, 2001). 
Therefore, speculatively it may be expected that initial injection of MPEP prior to 6-OHDA 
would have a limited effect on the properties of mGluR5 expressed on nigral DA neurones 
since these are for the most part not accessible to the antagonist. It is noteworthy however, 
that mGluR5 under conditions of DA depletion a "degree of plasticity" exists in Group I 
mGluR pharmacology, thus in PD, both mGluR1 and 5 may regulate the excitation of SNr 
neurones (Marino et al, 2001; 2002a). If a similar effect occurs in the SNc following 6- 
OHDA lesioning, it is conceivable that repeated injections of MPEP may alter the 
signalling properties of mGluR5 and result in the generation of mGuR5 supersensitivity as 
observed in vitro (Muhlemann et al, 2005). Interestingly, in 6-OHDA lesioned rats, chronic 
MPEP treatment (2 weeks) reduces the functional effects of the selective mGluR5 agonist 
(RS)-2-chloro-5-hyroxyphenylglycine (CHPG; Domenici et al, 2005). In vivo, CHPG 
potentiates the effect of NMDAR as measured by increases in striatal extracellular field 
potentials (FPs, Domenici et al, 2005), however following chronic MPEP treatment this 
effect is reversed (Domenici et al, 2005). This effect was only observed in the ipsilateral 
(lesioned) hemisphere of the brain, but not in the contralateral side where chronic MPEP 
treatment did not impair the ability of CHPG to potentiate NMDAR responses, suggesting 
that DA depletion and chronic mGluR5 blockade are required for this effect in the 
ipsilateral striata (Domenici et al, 2005). These data would suggest that in the normal brain 
chronic MPEP treatment may indeed result in mGluR5 supersensitivity, as suggested by the 
inability of MPEP to block CHPG effects in the intact striatum following chronic treatment, 
suggesting a decreased efficacy of antagonist action following chronic treatment (Domenici 
et al, 2005). This is supported by data which suggests that MPEP results in near complete 
receptor occupancy, which persists for one hour following systemic administration 
(Anderson et al, 2002), which is consistent with the time course suggested for the 
development of mGluR I supersensitivity in vitro (Lavreysen et al, 2002; 2005). 
However, under conditions of DA depletion, it appears chronic MPEP treatment 
does not induce a supersensitivity response as chronic MPEP treatment results in marked 
inhibition of CHPG-mediated responses (Domenici et al, 2005). This is supported by the 
finding that this effect is not associated with changes in the number of striatal mGluR5 
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binding sites (B,,, .. ) or dissociation constant (KD) of [3 H]-MPEP in the DA depleted 
striaturn (Domenici et al, 2005). Interestingly, similar results were observed in the 
contralateral striaturn, suggesting that simple receptor upregulation alone may not explain 
the development of mGluR5 supersensitivity. This is supported by the finding that 
development of mGluR5 supersensitivity in the striaturn following lesioning of the 
corticostriatal pathway is not associated with increases in the expression of mGluR5 
mRNA or an increase in striatal binding sites with Group I mGluR pharmacology (Friberg 
et al, 1998), suggesting that alternative mechanisms may underlie this response such as 
reductions in the efficacy of coupling to G-proteins and thus intracellular effectors. 
Taken together, these data would argue that in DA-depleted animals, chronic 
treatment with MPEP may not result in a supersensitivity response. Thus, the finding that 
the degree of neuroprotection observed in animals treated acutely with MPEP is 
comparable to sub-chronic treatment may be that MPEP is similarly neuroprotective against 
initial toxic insults induced by 6-OHDA as discussed for LY367385. However, it is also 
possible that the neuroprotection observed following acute treatment with MPEP may 
simply reflect neurones that are already programmed to undergo cell death, but are still 
viable at the time point at which animals were sacrificed, 4 days after cessation of drug 
treatment. Thus, if longer survival time points were examined different results may be 
observed, which may warrant further investigation. Additionally, further studies are 
required to resolve the long-term impacts of chronic MPEP administration on mGluR 
function and neuroprotection. 
4.4.4 Desensitisation of Group III mGluR as a potential limiting factor in the 
neuroprotective action of L-AP4 
The finding that acute treatment with the Group III mGluR agonist L-AP4 provides 
comparable neuroprotection to that observed following sub-chronic treatment with the same 
ligand suggests that the neuroprotective potential of selective activation of Group III 
mGluR may be limited by the process of receptor desensitisation in response to prolonged 
agonist stimulation. In support of this hypothesis, in reserpine-treated rodents, a single i. c. v 
injection of a high concentration of the Group III mGluR agonist L-SOP markedly reverses 
akinesia in these animals. Interestingly, this response appears to rapidly desensitise, since 
repeated injections of L-SOP up to 12 h later did not result in any significant reversal of 
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akinesia (Broadstock and Duty, 2004). These data suggest that this behavioural response 
mediated by Group III mGluR undergoes both rapid homologous desensitisation following 
repeated agonist stimulation in vivo (Broadstock and Duty 2004). Therefore, it is reasonable 
to assume that repeated intranigral administration of L-AP4 may also result in profound 
agonist-induced homologous desensitisation, which would have implications for the 
efficacy of Group III mGluR agonists as putative neuroprotective agents for the treatment 
of PD. Although it is noteworthy that, 24 hours is the time interval between injections in 
the current study which may be important in terms of the time course of receptor 
desensitisation and resensitisation. 
Indeed, in contrast to the well-characterised mechanisms underlying Group I 
mGluR desensitisation and internalisation (see section 1.10.5) studies of the desensitisation 
and internalisation of Group III mGluR are limited (lacovelli et al, 2004). Evidence exists 
to suggest a clear role for second messenger-dependent kinases in facilitating heterologous 
desensitisation of Group III mGluR (Macek et al, 1998; Schaffbauser et al, 2000; Cai et al, 
2001). Indeed, activation of PKC has been shown block agonist-mediated responses of 
Group III mGluR at several synapses in the mammalian brain (Swartz et al, 1993; Kamiya 
and Yamamoto, 1997; Macek et a], 1998). The mechanism by which this occurs is 
predicted to be analogous to that observed for Group I mGluR, such that PKC 
phosphorylation of C-terminal tails of Group III mGluR results in the inhibition of G 
protein coupling and attenuation of downstream signalling, although the precise residues at 
which this occurs have not yet been identified (Macek et al, 1998). In support of this 
concept, PKC directly phosphorylates the C-terminus of mGluR7 at a calmodulin-binding 
site, located immediately after the seventh transmembrane domain (Nakajima et al, 1999). 
Interestingly, calmodulin binding at this site is required for normal mGluR7 signalling 
(O'Connor et al, 1999). These data suggest that phosphorylation of Group III mGluR by 
PKC may inhibit agonist-induced responses by inhibiting the association of calmodulin 
with this critical domain in the C-terminus, thereby regulating Group III mGluR activity 
(Nakajima et al, 1999; Schaffbauser et al, 2000). 
Interestingly, sequence alignment studies have revealed that the C-terminal tail of 
Group III mGluR also contain consensus sites for PKA phosphorylation, suggesting that 
PKA may also regulate the function of Group III mGluR (Schaffhauser et al, 2000; Cai et 
al, 2001). In support of this hypothesis, activation of PKA has been demonstrated to result 
in phosphorylation of mGluR4a, mGluR7a and mGluR8a in vitro, which is reversed by the 
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specific PKA inhibitor PKI (Schaffhauser et al, 2000; Cai et al, 2001). Furthermore, this 
phosphorylation is C-terminal tail specific as demonstrated by PKA-mediated 
phosphorylation of c-terminal fusion proteins of mGluR4a, 7a and 8a respectively, in an in 
vitro phosphorylation assay, Importantly, application of forskolin also attenuated the 
depression of EPSPs induced by L-AP4 at the S chaffer-co I lateral -CAI and Lateral 
Perforant Path-Dentate-Gyrus (LPP-DG) synapses in the hippocampus, which was reversed 
in the presence of PKA inhibitor Rp-cAMPs, further suggesting that PKA also plays a 
critical role in the modulation of Group III mGluR responses (Cai et al, 2001). Indeed, it is 
noteworthy that forskolin also inhibits the L-AP4 induced suppression of GABA-meidated 
inhibitory synaptic transmission in the substantia nigra (Cai et al, 2001). This finding is the 
first to demonstrate that synaptic transmission in this brain region modulated by Group III 
mGluR appears to be regulated by PKA activation, which could be a potential mechanism 
for the desensitisation of Group III mGluR responses following repeated agonist 
stimulation, which occurs rapidly following prolonged agonist application (Schaffhauser et 
al, 2000). 
Importantly however, these findings only describe the possible regulation of Group 
III mGluR as a whole, due to a lack of subtype selective agonists. Coupled with the likely 
presence of multiple Group III mGluR subtypes in native tissue preparations it is difficult 
to extract information pertaining to the regulation of responses by individual Group III 
mGluR subtypes using native tissue preparations (lacovelli et al, 2004). However, studies 
in heterologous expression systems, in which the responses mediated by a singly expressed 
receptor can be measured, have provided some useful clues to the regulation of mGIuR4 
signalling (lacovelli et al, 2004; Mathiesen and Ramirez et al, 2006). These are of particular 
importance as convincing pharmacological and electrophysiological evidence exists to 
suggest that the mGluR4 subtype is responsible for the negative modulation of glutarnate 
transmission at subthalamonigral synapses (Valenti et al, 2005). Therefore, activation of 
mGluR4 following L-AP4 administration is likely to represent one of the primary neuronal 
mechanisms of neuroprotection against glutarnate-toxicity by this agonist (Vernon et al, 
2006). 
In this respect, in vitro studies have revealed that signalling through mGluR4 is also 
regulated by homologous desensitisation mediated by GRK2, which also regulates Group I 
mGluR activity (Dale et al, 2000; Dhami et al., 2002; lacovelli et al, 2003; Mundell et al., 
2003; Sorensen and Conn, 2003). Interestingly, in vitro GRK2 does not reduce inhibition of 
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forskolin stimulated cAMP accumulation, suggesting that GRK2 does not regulate the 
classical signal transduction path of Group III mGluR that is negative coupling to adenylyl 
cyclase, which may instead be under the control of PKC or PKA as described above 
(lacovelli et al, 2004). In contrast, GRK2, but not GRK4 inhibited stimulation of MAPK 
activity following mGluR4 activation, suggesting the function of GRK2 is to drive 
signalling through mGluR4 to inhibition of cAMP formation (lacovelli et al, 2004). This 
may be important since activation of the MAPK and phosphatodylinositol-3-kinase (PI-3- 
K) pathways mediate the protective action of mGluR4 activation on cerebellar granule cells 
against trophic deprivation in vitro (lacovelli et al, 2002). 
Intriguingly, in vitro studies in HEK293 cells revealed that following either agonist 
stimulation by L-AP4 or L-glutamate, mGluR4a is not internalised (Mathiesen and 
Ramirez, 2006). For comparative purposes, mGluRla was also expressed in the same 
system and stimulation with L-quisqualic acid resulted in rapid intemalisation of mGluRla 
(Mathiesen and Ramirez et al, 2006) consistent with previous results (Dale et al, 2001; 
Mundell et al, 2001). These data suggest that mGluR4a is not intemalised following 
agonist-mediated homologous desensitisation (Mathiesen and Ramirez et al, 2006). 
Speculatively, the lack of internalisation following heterologous desensitisation of 
Group III mGluR may be thought to be consistent with the proposed function of Group III 
mGluR presynaptic autoreceptors on excitatory nerve terminals (Conn and Pin, 1997; 
Cartmell and Schoepp, 2000). Thus, presynaptic mGluR4 expressed on STN axon terminals 
that form synapses with SNc dendrites (Iribe et al, 1999; Valenti et al, 2003; 2005) act as 
66sensors" to detect the level of glutamate in the synaptic cleft. Thus, under conditions of 
pathological glutamate release, such as from hyperactive STN neurones, mGluR4 is 
activated and negatively modulates glutamate release (Mathiesen and Ramirez et al, 2006). 
Therefore, glutamate-mediated loss of mGluR4 function due to homologous desensitisation 
and internalisation would not be favourable to the function of mGluR4 (Mathisen and 
Ramirez et al, 2006). 
Taken together, these data suggest that in vivo a possible combination of 
homologous desensitisation by PKA/PKC-mediated desensitisation of the mGluR4 
inhibition of adenylyl cyclase and GRK2-mediated desensitisation of MAPK signalling in 
response to repeated L-AP4 stimulation, which does not result in receptor intemalisation, 
may limit the potential neuroprotective effects of this compound against 6-OHDA toxicity. 
This may explain the finding that acute and sub-chronic treatment with L-AP4 result in 
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comparable neuroprotection of the nigrostriatal system against 6-OHDA toxicity in this 
model. Additionally, this may also explain why a greater neuroprotective effect is not 
observed following repeated intranigral injections of L-AP4 compared to acute 
administration of this agonist. However, it is noteworthy that in the current study there is 24 
hours between each agonist injection. Furthermore, the time course of Group III mGluR 
desensitisation, internalisation and receptor recycling are unknown. Moreover, in the 
absence of data which may inform us of the rate at which L-AP4 is cleared from the brain it 
is difficult to be completely certain that these effects are a result of Group III mGluR 
desensitisation following repeated agonist exposure. Thus, alternatively, these effects could 
be due to neuroprotection against early events in 6-OHDA toxicity, although this is 
speculative in the absence of mechanistic data in vivo. 
4.4.5 Absence of neuroprotection following acute intranigral treatment with the 
Group 11 mGluR agonist 2R, 4R-APDC 
The finding that acute intranigral treatment with 10 nmol in 4 pl of the selective mGluR2/3 
agonist 2R, 4R-APDC does not replicate the neuroprotection of the nigrostriatal system 
observed following sub-chronic treatment with the same concentration of this compound 
was unexpected. Interestingly, similar results were observed with the selective Group 11 
mGluR agonist LY354740 (Behrens et al, 1999). Indeed, acute LY354740 treatment did not 
attenuate cell death induced by NMDA or hypoxic-ischaemic insults either in vitro or in 
vivo (Behrens et al, 1999). Furthermore, acute LY354740 treatment did not result in 
neuroprotection in rodent models of focal ischaemia (Behrens et al, 1999; Bond et al, 
1999). 
A possible explanation for these findings may lie in the mode of cell death involved 
in these different experimental models (Bond et al, 2000). Indeed, in vitro studies have 
suggested that selective mGluR2/3 agonists are more potent against apoptotic indices of 
neuronal death in vitro rather than necrotic indices, at concentrations that are commensurate 
with an action at Group 11 mGluR (Kingston et al, 1999). Thus, it is conceivable that 
selective Group 11 mGluR agonists may have limited neuroprotective effects in conditions 
where there is a rapid development of cell loss such as acute excitoxicity or focal 
ischaemia, but are more effective in circumstances in which neuronal death is more 
progressive, such as global ischaemia (Bond et al, 2000). This is supported by the finding 
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that acute treatment with the selective mGluR2/3 agonist LY379268 was neuroprotective in 
models of global ischaernia (Bond et al, 2000). 
However, the time-course of cell death in the 6-OHDA model does not support this 
hypothesis. Indeed, evidence suggests nigral DA cells begin to degenerate 24-48 hours 
following 6-OHDA lesion (Perese et al, 1989; Schwarting and Huston, 1996; Finklestein et 
al, 2000; Stanic et al, 2003). Additionally, this hypothesis does not reconcile with the 
observed neuroprotection following sub-chronic treatment with this compound in our 
model (Vernon et al, 2005; 2006), which is consistent with previous reports documenting 
similar neuroprotection following sub-chronic treatment with LY354740 (7 days; Murray et 
al, 2002) and LY379268 (7 days; Battaglia et al, 2003) in the 6-OHDA and MPTP 
experimental models of PD, respectively. 
Thus, an alternative explanation may be provided by the mechanisms underlying the 
neuroProtective action of 2R, 4R-APDC and other selective mGluR2/3 agonists. Primarily, 
the neuroprotective action of selective activation of Group 11 mG1uR is suggested to be due 
to the inhibition of neuronal glutamate release, thereby attenuating activation of 
postsynaptic ionotropic glutamate receptor mediated toxicity (Nicoletti et al, 1996). Indeed, 
several lines of evidence, suggest that this explanation is too simplistic and in fact the 
activation of Group 11 mGluR expressed on glial cells may account for a major portion of 
the neuroprotective actions of selective Group 11 mGluR agonists. 
In support of this hypothesis, the neuroprotective effects of the selective Group 11 
mGluR agonists DCG-IV, 4C3HPG and L-CCG-1 against NMDA and KA toxicity I mixed 
neurone / glial cultures required protein synthesis, since addition of the protein synthesis 
inhibitor cyclohexamide abolished neuroprotection, suggesting the involvement of a troPhic 
factor (Bruno et al, 1997). Subsequently, it was proven that neurotrophic factors released by 
astrocytes, including transforming growth factor P, and P2 (TGF-P, and TGF-P2), nerve 
growth factor (NGF) and SlOOP were responsible for the neuroprotection observed during 
the NMDA insult, since antibodies to these proteins also abolished neuroprotection (Bruno 
et al, 1998; 1999; Ciccarelli et al, 1999). Furthermore, pure neuronal cultures in vitro, acute 
treatment with DCG-IV, L-CCG-1, N-acetylaspartylglutarnate (NAAG) and importantly, 
2R, 4R-APDC resulted in no neuroprotection against the excitotoxins NMDA, AMPA or 
KA, oxidative stress following application of hydrogen peroxide or apoptosis following 
incubation with staurosporine (Moldrich et al, 2001b). Moreover, intrastriatal infusions of 
DCG-IV protect doparninergic nerve terminals against intrastriatal MPP+ infusion and this 
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is associated with increased production of brain derived neurotrophic factor (BDNF) 
mRNA expression in the striatum (Matarredona et al, 2002). Interestingly, the increase in 
BDNF mRNA expression was localized to activated glial cells surrounding the lesion site, 
later identified as microglia by in situ hybridization and immunohistochernical analysis 
(Venero et al, 2003). Importantly, there is strong evidence to suggest that both astroglial. 
and microglial cells express functional mGluR2/3 receptors in the mammalian CNS (see 
section 1.10.4; Petralia et al, 1996; Biber et al, 1999; Taylor et al, 2002; 2003; 2005). In 
addition to these mechanisms, stimulation of astroglial Group 11 mGluR may also result in 
neuroProtection. by stimulating increased glutamate uptake by upregulation of astroglial 
GluTs (Yao et al, 2005; Tramontina et al, 2006; Zhou et al, 2006; see section 7.3.2) Taken 
together, these data strongly suggest that activation of Group 11 mGluR expressed on glial 
cells by mGluR2/3 selective agonists, such as 2R, 4R-APDC is the primary mechanism 
underlying their neuroprotective action (Conn et al, 2005). 
These data may therefore explain the absence of neuroprotection following acute 
treatment with 2R, 4R-APDC in vivo, since it may be that more chronic treatment is required 
to elicit the neuroprotective trophic effects derived from glial mGluR2/3 -stimulation. An 
alternative and perhaps more likely explanation may be that stimulation of glial mGluR2/3 
by 2R, 4R-APDC provides trophic support sufficient to sustain doparninergic cells already 
injured in response to 6-OHDA infusion into the SNc, delaying but not abrogating neuronal 
death mechanisms, such that no obvious neuroprotection is observed 4 days after the 
cessation of 2R AR-A PDC -treatment. 
It is also noteworthy however, that strong evidence exists to suggest that stimulation 
of mGluR2 expressed on microglia results in profound neurotoxicity in vitro characterized 
by microglial activation and increased TNF-a secretion (Taylor et al, 2002; 2005). This 
effect was demonstrated to be specific to rnGluR2 activation since addition of NAAG (a 
preferential mGluR3 agonist) to the culture medium did not result in microglial activation 
or toxicity in vitro (Taylor et al, 2005). Importantly, neuronal death in the 6-OHDA model 
is documented to be accompanied by a rapid infiltration of reactive microglial cells 
(McGeer et al, 1988; Cicchetti et al, 2002; Depino et al, 2003) and astrogliosis (Kohutnicka 
et al, 1998; Vila et al, 2001). Importantly, in the current study significant 
neuroinflammation was also observed in 6-OHDA lesioned animals (see section 3.3) and 
interestingly, time course studies in our laboratory have been demonstrated that microglial 
infiltration (measured by increases in the number of OX42 and OX6-immunoreactive cells) 
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mirrors the loss of nigral TH-IR cells following 6-OHDA leisoning (M. Sadeghian, 
D. Dexter unpublished observations). Thus, it may be possible that the beneficial effects of 
glial mGluR2/3 activation following acute treatment with 2R, 4R-APDC may be 
counterbalanced by microglial toxicity as a result of 2R, 4R-APDC stimulation of microglial 
mGluR2, which may explain the absence of neuroprotection observed. 
4.5 Conclusions 
In summary the main findings of this study are that acute (3 day) intranigral treatment with 
the Group I mGluR antagonist LY367385 or MPEP and the Group III mGluR agonist L- 
AN results in significant neuroprotection of the nigrostriatal system against 6-OHDA 
toxicity in vivo which is closely comparable to that observed following sub-chronic (7 day) 
treatment with the same concentration of each of these compounds. In the case of 
LY367385 this action may be explained by the development of mGluRI supersensitivity, 
leading to a reduced efficacy of further injections of LY367385, whilst for L-AP4 this 
action may be accounted for by the homologous desensitization of mGluR4-medaited 
responses following long-term drug exposure. Interestingly, under conditions of DA 
depletion, MPEP treatment does not appear to result in the development of mGluR5 
supersensitivity, which implies that the neuroprotective effects of MPEP are not diminished 
by more chronic treatment, consistent with previous reports (Armentero et al, 2005). 
Therefore, the finding that MPEP treatment provides comparable neuroprotection at both 
the acute and sub-chronic time-points may reflect the fact that maximal neuroprotection has 
already been achieved with the concentration of MPEP used and thus subsequent injections 
do not result in enhanced neuroprotection. Unexpectedly, acute treatment with the Group 11 
mGluR agonist 2R, 4R-APDC at a clearly effective concentration following sub-chronic 
administration does not result in any significant protection of the nigrostriatal system 
against 6-OHDA toxicity in vivo, which may in part be explained by its potential trophic 
mechanism of action. Taken together, these data suggest that the use of mGluRI 
antagonists as chronic neuroprotective treatments for PD may be a severely limited strategy 
whilst, in contrast, chronic blockade of mGluR5 may reflect a better target for a 
neuroprotective therapy. Additionally, the chronic use of selective agonists of Group III 
mGluR may be limited by profound receptor desensitization, although potentially this could 
be overcome by the use of positive allosteric modulators of mGluR4a such as PHCCC (see 
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section 7.5.4). Additionally, the finding that neuroprotection is still observed 4 days after 
cessation of drug treatment in animals treated with LY367385, MPEP and L-AP4 is 
suggestive of a relatively long-lasting neuroprotective effect, although longer survival times 
need to be investigated to confirm this. 
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Chapter 5 
Investigation of potential additive or synergistic 
interactions in neuroprotection against 6-OHDA 
toxicity in vivo following co- administration of 
mGluR ligands 
-246- 
5.1 Introduction 
The substantia nigra pars compacta (SNc) receives glutarnatergic innervations from 
several brain nuclei, including the subthalamic nucleus (STN), cerebral cortex and 
peduriculopontine nucleus (PPN) (Smith et al, 1996; Kita and Kitai, 1997; Iribe et al, 
1999; Wichmann and DeLong, 2003), all of which are hyperactive in the Parkinsonian 
brain (see section 1.5). Interestingly, STN axon terminals express both mGluR2/3 and 
mGluR4 and 7 with a clear presynaptic localisation (Testa et al, 1994; 1998; Bradley et 
al, 1999). Functional studies have demonstrated that activation of these receptors by 
both selective agonists and importantly, endogenous glutamate results in decreased 
glutarnate transmission at subthalamonigral synapses (Wigmore and Lacey, 1998; 
Wittmann et al, 2002; 2003; Katayama et al, 2003; Valenti et al, 2003; Wang et al, 
2005; Valenti et al, 2005). These findings have given rise to the hypothesis that 
selective activation of these receptors may be neuroprotective in Parkinson's disease 
(PD) by reducing glutarnate transmission onto midbrain doparninergic neurones (see 
section 1.10.7.2). Consistent with this hypothesis, the data presented in Chapters 3 and 4 
of this thesis provide compelling evidence to suggest that intranigral administration of 
either 2R, 4R-APDC, a selective mGluR2/3 agonist, or L-AP4, a selective Group III 
agonist results in neuroprotection of the nigrostriatal system following infusion of 6- 
OHDA into the SNc (Vernon et al, 2005; 2006). Interestingly, the finding that both 
Group 11 and III receptor subtypes are localised on STN axon terminals raises the 
possibility that simultaneous co-activation of these receptors may lead to an enhanced 
neuroprotective effect against glutamate-mediated toxicity. 
It is also noteworthy that both doparninergic neurones in the SNc and 
glutamatergic neurones in the STN express both mGluR1 and mGluR5 (Testa et al, 
1994; 1998; Awad et al, 2000; Marino et al, 2001; Hubert et al, 2001). Previously, co- 
expression of these receptors in postsynaptic axons and dendrites has been assumed to 
represent a functional redundancy between the two receptor types, as they are coupled 
to identical effector systems through Gq type G-proteins (Valenti et al, 2002; Marino et 
al, 2002b). However, surprisingly, increasing evidence suggests that in fact mGluR1 
and mGluR5 co-expressed in the same neuronal population have distinct functional 
roles and these are clearly segregated (Valenti et al, 2002; Marino et al, 2002b). Indeed, 
in the SNr, activation of postsynaptic mGluR1 mediates the excitation of GABAergic 
neurones in this nucleus, but mGluR5 does not (Marino et al, 2001). Furthermore, 
activation of both Group I mGluR produces a profound decrease in inhibitory 
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transmission in the SNr, which results in the increased excitation of this BG output 
nucleus (Marino et al, 2001). In contrast, in the STN, neuronal depolarisation is solely 
mediated by activation of postsynaptic mGluR5, but not mGluR1 (Awad et al, 2000). A 
similar functional separation of Group I mGluR has also recently been demonstrated in 
neurones of the globus pallidus which also co-express these receptors (Poisik et al, 
2005). 
Interestingly, in the SNc, activation of postsynaptic mGluRl, but not mGluR5, 
mediates the direct depolarisation and excitability of dopaminergic (DA) neurones 
(Mercuri et al, 1993; Shen and Johnson, 1997; Fiorillo and Williams, 1998). 
Furthemore, to date, no functional evidence exists to describe a role for mGluR5 in 
nigral DA neurones (Valenti et al, 2002) although it is clearly expressed in these cells 
(Testa et al, 1994; 1998; Hubert et al, 2001; Messenger et al, 2002). These findings raise 
the possibility that the neuroprotective actions observed following intranigral injection 
of MPEP, a selective mGluR5 antagonist or LY367385 a selective mGluRl antagonist 
(see Chapters 3 and 4) may potentially be mediated through distinct mechanisms. 
Interestingly, electrophysiological studies in vitro in midbrain slices from DA depleted 
animals demonstrate that under conditions of DA depletion, the pharmacology of Group 
I mGluR is altered in both STN and SNr neurones, such that both Group I mGluR 
subtypes may regulate the excitability of these cells (Marino et al, 2002a). These data 
indicate that a "degree of plasticity" exists in the coupling of Group I mGluR to effector 
systems and suggest that these receptors may play enhanced roles in mediated glutamate 
transmission under pathological conditions (Marino et al, 2002a). If this effect also 
occurs in DA neurones in the SNc, it may be possible that simultaneous blockade of 
both mGluR1 and mGluR5 may result in an enhanced neuroprotective effect against 
glutamate-mediated toxicity in the Parkinsonian nigra. Similarly, it is also possible that 
simultaneous blockade of either postsynaptic mGluR1 or mGluR5 on nigral DA 
neurones, coupled with selective activation of either presynaptic mGluR2/3 or Group III 
mGluR on STN (or PPN / cortical) axon terminals, may also result in an enhanced 
neuroprotective effect against glutamate-mediated toxicity. 
Additionally, it is also be possible that co-application of combinations of 
selective mGluR ligands may result in enhanced neuroprotection due to stimulation or 
antagonism of mGluRs expressed on glial cells in the SNc, which may play a key role in 
the neuroprotective action of these mGluR ligands (particularly for mGluR2/3 agonists) 
as discussed in detail in Chapter 7. 
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To date, to the best of the author's knowledge, few studies have investigated 
whether combinations of selective mGluR ligands acting at different mGluR subtypes 
results in additive interactions to produce an enhanced therapeutic effect. Importantly, 
to the best of the author's knowledge no reports exist for such a study in an 1. n vi . Vo 
model of PD. Thus, the aim of the current study was to investigate if intranigral co- 
administration of combinations of selective mGluR ligands studied in the proceeding 
chapters could result in enhanced neuroprotection of the nigrostriatal system following 
6-OHDA lesioning. 
5.2 Experimental Design 
5.2.1 Neuroprotection studies with co-treatments of selective mGluR ligands 
In order to investigate if co-administration of selective mGluR ligands acting at 
different mGluR subtypes produces enhanced neuroprotection against 6-OHDA toxicity 
in vivo through synergistic or additive interactions, male Sprague-Dawley rats (250-270 
g) were cannulated I mm superior to the SNc and allowed to recover (see section 
2.1.2.2). Animals were then subsequently treated according to the experimental design 
shown graphically in Figure 5.1 below. 
Action 
Time point 
7 days 10 days 1 hour 7 days drug I hour 
or vehicle 
treatment 
Figure 5.1 Experimental design used to investigate if sub-chronic co-administration of 
combinations of different, selective mGluR ligands result in enhanced neuroprotection 
of the nigrostriatal system following 6-OHDA lesioning in vivo (CBU, Central 
Biomedical Unit). 
In the current study, drug solutions of combinations of different, selective 
mGluR ligands were made up and administered intracerebrally in the same injection 
volume (4 [tl) as previously described (see section 2.1.4). To investigate potential 
synergistic or additive interactions of selective mGluR ligand combinations, cannulated 
Animals enter Stereot@(ic 1stfocal drug 6-OHDA Final focal Animals 
CE3U facility surgery injection infusion drug injection sacrificed 
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animals were divided into treatment groups (n =8 per group) and administered a single 
unilateral intranigral injection of one of a number of different combinations of mGluR 
ligands, as outlined in Table 5.1. Control animals received an equal volume of drug 
vehicle. In all treatment groups, mGluR ligand combinations or drug vehicle was 
administered focally one hour prior to the induction of a unilateral lesion of the left SNc 
by 6-OHDA infusion as previously described (see sections 2.1.3 and 2.1.5). Treatment 
groups then received single, daily, intranigral injections of mGluR ligand combinations 
(or drug vehicle) over a sub-chronic period (7 days; see Figure 1.5). For the 
combinations of mGluR ligands, a concentration of each mGluR ligand was chosen that 
provided sub-maximal neuroprotection with minimal side-effects, based on data from 
the studies presented in Chapter 3. The selective mGluR5 antagonist MPEP was chosen 
over the selective mGluR1 antagonist LY367385 since substantial evidence exists to 
suggest that mGluR5 antagonists are antiparkinsonian, whilst this has not been 
rigorously investigated for mGluR1 antagonists (Ossowska et al, 2006). Taking this into 
account it is perhaps more clinically relevant to investigate any potential additive or 
synergistic effects using MPEP rather than LY3673 85 (see section 1.10.7.1). However, 
for the sake of completion, the effect of co -administering MPEP and LY367385 
together was also examined. 
In the current study, sub-chronic (7 day) treatment as opposed to acute (3 day) 
treatment with the combinations of mGluR ligands was chosen based on the fact that 
under conditions of DA depletion repeated MPEP treatment may not affect the efficacy 
of this drug (see section 4.4.3). Furthermore, acute treatment with 2R, 4R-APDC did not 
confer any neuroprotection against 6-OHDA toxicity in vivo, whilst in contrast sub- 
chronic treatment was significantly neuroprotective (see section 4.3.3 and 4.4.5). 
Therefore, in order to observe any potential neuroprotective effects with this compound, 
sub-chronic treatment is necessary, which for the sake of consistency was therefore also 
applied to the other treatment groups. 
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Group Treatment 
Concentration(s) 
Duration 
(nmol in 4 pl) 
Vehicle 
_ _ 
PBS / sterile saline n/a 7 days 
Group I rnGluR 
LY367385 
antagonists + 40+2 7 days MPEP 
rnGluR1 antagonist 
plus Group 11 
MPEP 
(mGluR2/3) + 2+2 7 days 
agonist 
2R, 4R-APDC 
mGluRl antagonist MPEP 
plus Group rnGluR + 2+2 7 days 
III agonist L-AP4 
Group Il 
2R 4R-APDC (rnGluR2/3) plus , 
Group III rnGluR 
+ 2+2 7 days 
L-AP4 
agonist 
Table 5.1 Treatment groups for co-administration study; each mGluR ligand was tested 
at a sub-maximal concentration (based on data from Chapter 3 of this thesis) for 7 days 
duration in vivo. 
At the defined end-point of the experiment (see Figure 5.1) animals were 
sacrificed by decapitation and the brains removed and dissected (see section 2.1.6). At 
this point the positioning of the cannula was assessed by examination of needle tracts in 
freshly dissected tissue in all experimental groups. Animals that showed tracts outside 
of the area of the SNc were not included in subsequent data analysis. To quantify the 
effects of combined mGluR ligand treatment on the integrity of the nigrostriatal system 
following 6-OHDA lesioning in these animals, immunohistochernistry for tyrosine 
hydroxylase (TH) was then performed (see section 2.2.1.3) and the numbers and 
morphology of TH-immunoreactive (TH-IR) cells in the SNc were then quantified (see 
section 2.2.2.1). To determine the effects on nigrostriatal functionality, the 
concentrations of striatal monoamines were measured by HPLC-ECD and subsequently 
analysed (see section 2.2.3). 
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5.2.2 Statistical analysis of data 
All data (except where stated) are presented as the mean ± SEM based on n independent 
observations. Individual comparisons were made using a two-tailed paired or unpaired 
Student's t-test as appropriate. Where multiple comparisons were made, one-way 
ANOVA with post-hoc Tukeys test for multiple comparisons was employed. Data for 
cell loss in vehicle and drug treated groups is presented as the mean percentage change 
± SEM, although mean cell numbers were also compared. Biochemical data for 
monoamines is expressed in the same manner, in ng/ml wet weight tissue, although 
mean values were also compared. Striatal DA turnover ratio, is expressed as the mean 
values ± SEM calculated using the equation ((DOPAC + HVA)/DA) and mean values 
for each monoamine in pmol/ml. In all figures, n values are shown in parenthesis. 
Differences were considered statistically significant at P<0.05 and all statistical data 
analysis was performed using GraphPad Prism v4.00 software (GraphPad software, San 
Diego, CA, USA). 
5.3 Results 
In all treatment groups the mean number of nigral TH-IR cells in the contralateral 
hemisphere was comparable and not significantly different (FO. 890; P=0.491). In vehicle- 
treated animals, intranigral infusion of 12 ýtg 6-OHDA produced a significant reduction 
of TH-IR cells in the ipsilateral SNc when compared to the contralateral side (67.5 ± 
2.8% [95% CI 60.87-74.13]; P<0.01) as shown in Figure 5.2A and illustrated in a 
representative photomicrograph in Figure 5.3A. One-way ANOVA analysis did not 
reveal any significant effect of SNc region in the mean percentage loss of TH-IR cells 
(Fo. 107 P=0.971; Figure 5.213) indicating a consistent lesion size in all regions of the 
SNc 
in these animals. 
In all treatment groups the mean concentrations of striatal DA in the 
contralateral (unlesioned) striata were comparable and not significantly different (Fi . 038; 
P=0.418). Consistent with the cellular data, intranigral infusion of 6-OHDA produced a 
concomitant and significant depletion of striatal doparnine (DA) (56.6 ± 4.4% [95% CI 
46.8 - 66.5]; P<0.01; Figure 5.4A), and also of DOPAC 
(56.2 ± 7.1% [95% CI 35.6 - 
78.8]; P<0.01) and HVA (52.2 ± 6.7% [95% CI 23.2 - 81.8]; P<0.01) (Figures 5.413 and 
5AC, respectively) and resulted in a significant increase in striatal DA turnover (0.144 ± 
0.009 pmol/ml vs. 0.120 ± 0.003 vs.; P<0.05; Figure 5.4D) when comparing the 
ipsilateral and contralateral striata. Importantly, when comparing mean numbers of 
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nigral TH-IR cells and the mean concentration of striatal monoarnines between the 
contralateral and ipsilateral striata significant reductions were also observed (P<0.001, 
data not shown). In both vehicle and all drug-treated groups no significant changes were 
observed in the concentrations of either 5-hydroxytryptarnine (5-HT) or its metabolite 
5-hydroxyindoleacetic acid (5-HIAA) in either the contralateral or ipsilateral striata 
(data not shown). 
5.3.1 Co-administration of LY3637385 and MPEP is neuroprotective 
Sub-chronic intranigral administration of 40 nmol in 4 ýd LY367385 or 2 nmol in 4 [d 
MPEP alone significantly attenuated the reduction of nigral TH-IR cells induced by 
infusion of 6-OHDA into the SNc as shown clearly in Figure 5.2A (see sections 3.3.2.1 
and 3.3.3.1). Similarly, sub-chronic intranigral co-administration of 40 nmol LY3673 85 
and 2 nmol MPEP in 4 ýtl also significantly attenuated the 6-OHDA induced loss of 
nigral TH-IR cells (32.7 ± 2.8% vs. 67.5 ± 2.8%; P<0.001; Figure 5.2A). The degree of 
neuroprotection observed in these animals is illustrated by a representative 
photomicrograph shown in Figure 5.3B. One-way ANOVA analysis indicated no 
significant differences in lesion size between any region of the SNc in animals treated 
with LY367385 and MPEP in combination (F2.474; P=0.105; Figure 5.2B). Furthermore, 
one-way ANOVA analysis also revealed that the lesion size was significantly reduced in 
all regions of the SNc compared to vehicle treated animals (F7.714; P<0.0001, Figure 
5.2B). These data suggest that LY367385 and MPEP in combination provide robust 
neuroprotection throughout the extent of the SNc, in contrast to the observations made 
with each compound alone at the same concentrations (see sections 3.3.2.1 and 3.3.3.1). 
However, consistent with previous observations with each compound alone, when 
comparing the mean number of nigral TH-IR cells between the contralateral and 
ipsilateral hemispheres, 6-OHDA infusion still resulted in a small but significant 
reduction of nigral TH-IR cells in these animals (P<0.01 data not shown). Interestingly, 
co-administration of LY367385 and MPEP provides significantly greater 
neuroprotection than observed with either MPEP (32.7 ± 2.8% vs. 48.6 ± 2.3%; P<0.01; 
Figure 5.2A) or LY367385 alone (32.7 ± 2.8% vs. 52.7 ± 4.9%; P<0.05; Figure 5.2A). 
Furthermore, the mean percentage loss of nigral TH-IR cells in animals treated with 
LY367385 + MPEP in combination is not significantly different from that observed in 
animals treated with either LY367385 or MPEP at concentrations producing maximal 
neuroprotection (32.7 ± 2.8% vs. 35.7 ± 4.4% and 39.9 ± 3.1% P>0.05; P>0.05 for 
LY367385 and MPEP, respectively). Taken together, these data suggest that LY367385 
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and MPEP show an additive effect, which results in significantly enhanced 
neuroprotection of the entire SNc structure compared to that observed with each 
compound alone at the same concentration which, moreover, is comparable to the 
maximal neuroprotective effect observed with either LY367385 or MPEP alone. 
In terms of nigrostriatal functionality, sub-chronic intranigral treatment with 
either LY367385 or MPEP alone significantly attenuated the depletion of DA and its 
metabolites in the corpus striatum. induced by infusion of 6-OHDA into the SNc, as 
illustrated in Figure 5.4A (see sections 3.3.2.2 and 3.3.3.2, respectively). Similarly, 
LY367385 and MPEP in combination significantly attenuated the depletion of DA in 
the corpus striaturn following 6-OHDA lesioning (19.9 ± 5.5% vs. 56.6 ± 4.4%; P<0.01; 
Figure 5.4A). Additionally, the depletion of both DOPAC and HVA were also 
significantly attenuated by LY367385 and MPEP in combination (17.8 ± 3.8% vs. 56.2 
± 7.0%; P<0.01; Figure 5.413 and 23.6 ± 5.0% vs. 52.2 ± 6.7%; P<0.05; Figure 5.4Q. 
However when comparing the mean concentrations of DA, DOPAC and HVA in these 
animals, a significant reduction was still observed for each monoamine in the ipsilateral 
striata compared to the contralateral side (P<0.05 data not shown). Importantly, 
treatment with LY367385 and MPEP completely blocked the increases in striatal DA 
turnover observed in vehicle-treated animals (Figure 5.41)). 
Interestingly, in animals treated with LY367385 and MPEP in combination, the 
depletion of striatal DA was not significantly different to that observed following sub- 
chronic treatment with either MPEP or LY367385 alone at these concentrations (19.9 ± 
5.4% vs. 19.0 ± 1.7% (MPEP) and 23.7 ± 1.7% (LY367385); P>0.05; respectively, 
Figure 5.4A). Similar results were observed for both DOPAC (17.8 ± 3.8% vs. 21.7 ± 
4.4% (MPEP) and 22.3 ± 3.7% (LY367385); P>0.05; respectively, Figure 5.413) and 
HVA (23.6 ± 5.0% vs. 23.2 ± 4.2% (MPEP) and 30.3 ± 4.9% (LY367385); P>0.05; 
respectively, Figure 5AC). It is interesting to note however, that a trend towards 
increased prevention of striatal monoamine depletion is observed in animals treated 
with LY36785 + MPEP compared to either compound alone, although this was not 
statistically significant. These data suggest that LY367385 and MPEP in combination 
do not provide enhanced protection of nigrostriatal functionality following 6-OHDA 
lesioning compared to that observed with each compound alone at the same 
concentration, in contrast to the observed greater neuroprotection of nigrostriatal 
integrity. 
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Figure 5.2 Neuroprotective effects of LY367385 and MPEP on 
nigrostriatal integrity alone and in combination 
(A) Sub-chronic (7 day) co-administration of 2 nmol MPEP and 40 nmol 
LY367385 in 4 ýtl significantly attenuates the 6-OHDA induced loss of nigral TH- 
IR cells and this is significantly enhanced compared to the neuroprotection of 
nigral TH-IR cells observed following sub-chronic treatment with each compound 
alone at the same concentration, indicating an additive interaction. *P<0.05; 
**P<0.01; ***P<0.001, drug-treated vs. vehicle-treated; IP<0.01, LY367385 or 
MPEP alone vs. LY367385 + MPEP-treated. (B) There are no regional differences 
in lesion size in any region of the SNc in animals treated sub-chronically with 
MPEP + LY367385. Additionally, the lesion size is significantly reduced in MPEP 
+ LY367385 compared to vehicle-treated animals in all stereotaxic regions of the 
SNc. indicating robust neuroprotection of the entire SNc structure. Data shown in 
(A) and (B) are mean % loss of nigral TH-IR ± SEM, n values are shown in 
parenthesis 
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Figure 5.3 Representative photomicrographs of nigral TH-IR cells in the 
SNc of 6-OHDA lesioned animals treated with combinations of selective 
mGluR ligands 
All images correspond to region B of the SNc (-5.30 mm from bregma), taken at 
x 40 magnification, scale bar = 200 ýtm. 
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Figure 5.4 Neuroprotective effects of LY367385 and MPEP on 
nigrostriatal functionality alone and in combination 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the 
corpus striaturn of animals treated sub-chronically with 40 nmol LY367385 +2 
nmol MPEP in 4 [d or LY367385 or MPEP alone at the same concentrations 
following 6-OHDA lesioning. In all drug treatment groups the 6-OHDA 
induced loss of striatal monoamines is significantly attenuated, and LY367385 
+ MPEP does not confer significantly greater protection of striatal monoamines 
than either compound alone. Data shown are mean striatal dopamine, DOPAC 
and HVA content in ng/mL wet weight tissue ± SEM, n values are shown in 
parenthesis. *P<0.05, **P<0.01 vehicle vs. drug-treated. (D) No significant 
alterations in striatal monoamine turnover were observed following sub-chronic 
treatment with either LY367385, MPEP or LY367358 + MPEP compared to 
vehicle-treated rats. *P<0.05 contralateral vs. ipsilateral striata. Data shown are 
mean striatal monoamine turnover ratio (pmol/ml) calculated using the 
expression ((DOPAC+HVA)/DA). 
-257- 
C\19 'IQ Iq I 
. 4e +1 0<,; 0x 
5.3.2 Co-administration of MPEP and 2R, 4R-APDC is neuroprotective 
Sub-chronic intranigral administration of 2 nmol in 4 ýLl MPEP or 2 nmol in 4 ýtl 2R, 4R- 
APDC alone significantly attenuated the loss of nigral TH-IR cells induced by infusion 
of 6-OHDA into the SNc as shown clearly in Figure 5.5A (see sections 3.3.3.1 and 
3.3.4.1). Similarly, sub-chronic intranigral co-administration of 2 nmol MPEP and 2 
nmol 2R, 4R-APDC in 4 ýtl also significantly attenuated the 6-OHDA induced loss of 
nigral TH-IR cells (30.5 ± 2.8% vs. 67.5 ± 2.8%; P<0.001; Figure 5.5A). The degree of 
neuroprotection observed in these animals is illustrated by a representative 
photomicrograph shown in Figure 5.3C. No significant differences in lesion size 
between any region of the SNc in animals treated with MPEP and 2R, 4R-APDC in 
combination were observed following one-way ANOVA analysis (FO. 315 ; P=0.862, 
Figure 5.5B). One-way ANOVA analysis did however reveal that the lesion size was 
significantly reduced in all regions of the SNc compared to vehicle treated animals 
(F7.240; P<0.000 1, Figure 5.5B). 
These data suggest that MPEP and 2R, 4R-APDC in combination provide 
significant neuroprotection throughout the extent of the SNc in contrast to the 
observations made with each compound alone at the same concentrations see sections 
3.3.3.1 and 3.3.4.1). However, when comparing the mean number of nigral TH-IR cells 
between the contralateral and ipsilateral hemispheres, 6-OHDA infusion still resulted in 
small but significant reduction of TH-IR cells in the SNc in animals treated with MPEP 
and 2R, 4R-APDC in combination (P<0.01 data not shown). Interestingly, co- 
administration of MPEP and 2R, 4R-APDC results in a significantly greater 
neuroprotection of nigral TH-IR cells compared to that observed in animals treated with 
either MPEP (30.5 ± 2.8% vs. 48.6 ± 2.3% P<0.01; Figure 5.5A) or 2R, 4R-APDC alone 
(30.5 ± 2.8% vs. 51.0 ± 2.3%; P<0.01; Figure 5.5A). Furthermore, the mean percentage 
loss of nigral TH-IR cells in animals treated with MPEP + 2R, 4R-APDC in combination 
is not significantly different from that observed in animals treated with either MPEP or 
2R, 4R-APDC at concentrations producing maximal neuroprotection (30.5 ± 2.8% vs. 
39.9 ± 3.1% and 36.3 ± 5.6% P>0.05; P>0.05 for MPEP and 2R, 4R-APDC, 
respectively). Taken together, these data suggest that MPEP and 2R, 4R-APDC show an 
additive effect and provide significantly increased neuroprotection of nigrostriatal 
integrity to that observed with the same concentration of either compound alone. 
In terms of nigrostriatal functionality, sub-chronic intranigral treatment with 
either MPEP or 2R, 4R-APDC alone significantly attenuated the depletion of DA and its 
metabolites in the corpus striatum induced by infusion of 6-OHDA into the SNc as 
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illustrated in Figure 5.5A (see also sections 3.3.3.2 and 3.3.4.2, respectively). Similarly, 
MPEP and 2R, 4R-APDC in combination significantly attenuated the depletion of DA in 
the corpus striatum induced by infusion of 6-OHDA into the SNc (23.4 ± 4.7% vs. 56.6 
± 4.4%; P<0.01; Figure 5.6A). Additionally, the depletion of both DOPAC and HVA 
were also significantly attenuated by MPEP and 2R, 4R-APDC in combination (21.4 ± 
2.2% vs. 56.2 ± 7.0%; P<0.01; Figure 5.613 and 12.5 ± 4.5% vs. 52.2 ± 6.7%; P<0.01; 
Figure 5.6Q. When comparing the mean concentration of DA, DOPAC and HVA in 
animals treated with MPEP and 2R, 4R-APDC, a small but significant reduction was 
observed for each monoamine in the ipsilateral striata compared to the contralateral side 
(P<0.05). Importantly however, treatment with MPEP and 2R,, 4R-APDC in combination 
completely blocked that significant increase in striatal DA turnover observed in vehicle- 
treated animals (Figure 5.61)). This is of particular interest since in animals treated with 
2 nmol in 4 [d 2R, 4R-APDC alone, a significant increase in striatal DA turnover was 
observed. Thus, co-administration of MPEP and 2R, 4R-APDC blocks this increase, 
perhaps due to the greater protection of nigral TH-IR cells observed in this treatment 
group. 
Interestingly, the attenuation of striatal DA depletion observed in animals treated 
with MPEP and 2R, 4R-APDC in combination was not significantly different to that 
observed following sub-chronic treatment with either 2R, 4R-APDC or MPEP alone at 
the same concentrations (23.4 ± 5.7% vs. 19.0 ± 1.7% (MPEP) and 17.7 ± 3.4% (2R, 4R- 
APDQ P>0.05; respectively, Figure 5.6A). Similar results were observed for both 
DOPAC (21.4 ± 2.1% vs. 21.7 ± 4.4% (MPEP) and 30.5 ± 4.5% (2R, 4R-APDC); 
P>0.05; respectively, Figure 5.6B) and HVA (12.5 ± 4.5% vs. 23.2 ± 4.2% (MPEP) and 
12.8 ± 3.0% (2R, 4R-APDC) P>0.05; respectively, Figure 5.6Q. These data suggest that 
MPEP and 2R, 4R-APDC administered in combination do not appear to show any 
additive effects to provide significantly enhanced protection of nigrostriatal 
functionality following 6-OHDA lesioning in vivo compared to that observed with each 
compound alone at the same concentration. 
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Figure 5.5 Neuroprotective effects of MPEP and 2R, 4R-APDC on 
nigrostriatal integrity alone and in combination 
(A) Sub-chronic (7 day) co-administration of 2 nmol MPEP and 2 nmol 2R, 4R- 
APDC in 4 ýtl significantly attenuates the 6-OHDA induced loss of nigral TH-IR 
cells and this is significantly enhanced compared to the neuroprotection of nigral 
TH-IR cells observed following sub-chronic treatment with each compound 
alone at the same concentration, indicating an additive interaction. **P<0.01; 
***P<0.001, drug-treated vs. vehicle-treated; IP<0.01, MPEP or 2R, 4R-APDC 
alone vs. MPEP + 2R, 4R-APDC -treated. (B) There are no regional differences 
in lesion size in any region of the SNc in animals treated sub-chronically with 
MPEP + 2R, 4R-APDC Additionally, the lesion size is significantly reduced in 
MPEP + 2R, 4R-APDC compared to vehicle-treated animals in all stereotaxic 
regions of the SNc, indicating robust neuroprotection of the entire SNc structure. 
Data shown in (A) and (B) are mean % loss of nigral TH-IR ± SEM, n values are 
shown in parenthesis 
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Figure 5.6 Neuroprotective effects of MPEP and 2R, 4R-APDC on 
nigrostriatal functionality alone and in combination 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the 
corpus striaturn of animals treated sub-chronically with 2 nmol MPEP +2 
nmol 2R, 4R-APDC in 4 ttl or MPEP or 2R, 4R-APDC alone at the same 
concentrations following 6-OHDA lesioning. In all drug treatment groups the 
6-OHDA induced loss of striatal monoamines is significantly attenuated, and 
MPEP + 2R, 4R-APDC does not confer significantly greater protection of 
striatal monoamines than either compound alone. Data shown are mean striatal 
dopamine, DOPAC and HVA content in ng/mL wet weight tissue ± SEM, n 
values are shown in parenthesis. *P<0.05, **P<0.01 vehicle vs. drug-treated. 
(D) No significant alterations in striatal monoamine turnover were observed 
following sub-chronic treatment with either MPEP, 2R, 4R-APDC or MPEP + 
2R, 4R-APDC compared to vehicle-treated rats. *P<0.05 contralateral vs. 
ipsilateral striata. Data shown are mean striatal monoamine turnover ratio 
(pmol/ml) calculated using the expression ((DOPAC+HVA)/DA). 
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5.3.3 Co-administration of MPEP and L-AP4 is neuroprotective 
Sub-chronic intranigral administration of 2 nmol in 4 ýtl MPEP or 2 nmol in 4 [d L-AP4 
alone significantly attenuated the loss of nigral TH-IR cells induced by infusion of 6- 
OHDA into the SNc as shown clearly in Figure 5.7A (see sections 3.3.3.1 and 3.3.5.1). 
Similarly, sub-chronic intranigral co-administration of 2 nmol MPEP and 2 nmol L- 
AN in 4 ýtl at these concentrations also significantly attenuated the 6-OHDA induced 
loss of nigral TH-IR cells (25.5 ± 3.0% vs. 67.5 ± 2.8%; P<0.001; Figure 5.7A). The 
degree of neuroprotection observed in these animals is illustrated by a representative 
photomicrograph shown in Figure 5.3D. One-way ANOVA analysis indicated no 
significant differences in lesion size between any region of the SNc in animals treated 
with MPEP and L-AP4 in combination (F, 
. 314; 
P=0.329, Figure 5.7B). Furthermore, one- 
way ANOVA analysis also revealed that the lesion size was significantly reduced in all 
regions of the SNc compared to vehicle treated animals (F12.43; P<0.0001, Figure 5.7B). 
These data suggest that MPEP and L-AP4 in combination provide robust 
neuroprotection of the entire SNc structure in contrast to previous observations with 
each compound alone at the same concentration (see sections 3.3.3.1 and 3.3.5.1). 
However, when comparing the mean number of nigral TH-IR cells between the 
contralateral and ipsilateral hemispheres, 6-OHDA infusion still resulted in a small but 
significant reduction of TH-IR cells in the SNc in animals treated with MPEP and L- 
AN in combination (P<0.01). Co-administration of MPEP and L-AP4 resulted in a 
significantly greater protection of nigral TH-IR cells compared to that observed 
following sub-chronic treatment with each compound alone at the same concentration 
(25.5 ± 3.0% vs. 48.9 ± 2.6% (MPEP) and 47.7 ± 3.7% (L-AP4) P<0.01, respectively, 
Figure 5.7A). Furthermore, the neuroprotection of nigral TH-IR cells was also 
significantly enhanced in animals treated with MPEP and L-AP4 in combination 
compared to that observed in animals treated MPEP alone at a concentration which 
produced maximal neuroprotection of nigral TH-IR cells (25.5 ± 3.0% vs. 39.9 ± 3.1%; 
P<0.05). A similar trend towards increased neuroprotection of nigral TH-IR cells was 
observed when comparing animals treated with MPEP + L-AP4 to those treated with L- 
AN alone at a concentration that resulted in maximal neuroprotection of nigral TH-IR 
cells, however this failed to reach statistical significance (25.5 ± 3.0% vs. 33.9 ± 4.2%; 
P>0.05). Taken together, these data suggest that MPEP and L-AP4 appear to interact 
additively to produce significantly enhanced neuroprotection of nigral TH-IR cells. 
Sub-chronic intranigral treatment with either MPEP or L-AP4 alone 
significantly attenuates the depletion of DA and its metabolites in the corpus striatum. 
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induced by infusion of 6-OHDA into the SNc as illustrated in Figure 5.8A (see sections 
3.3.3.2 and 3.3.5.2, respectively). Similarly, MPEP and L-AP4 in combination 
significantly attenuated the depletion of DA in the corpus striatum induced by infusion 
of 6-OHDA into the SNc (16.7 ± 4.8% vs. 56.6 ± 4.4%; P<0.01; Figure 5.8A). 
Additionally, the depletion of both DOPAC and HVA was also significantly attenuated 
by MPEP and L-AP4 in combination (17.5 ± 4.2% vs. 56.2 ± 7.0%; P<0.01; Figure 
5.8B and 18.6 ± 6.3% vs. 52.2 ± 6.7%; P<0.01; Figure 5.8C). Importantly, treatment 
with MPEP and L-AP4 also completely blocked the increases in striatal DA turnover 
observed in vehicle-treated animals (Figure 5.81)). However, a small but significant 
reduction was still observed for DOPAC and HVA when comparing the mean 
concentrations of each in the ipsilateral striaturn relative to the contralateral side 
(P<0.05, P<0.01; respectively data not shown) following treatment with this drug 
combination. Interestingly, the mean striatal DA concentration was not significantly 
different when comparing the ipsilateral and contralateral striaturn, suggestive of a very 
robust neuroprotective effect (P>0.05). It is noteworthy however, that the attenuation of 
striatal DA depletion observed in animals treated with MPEP and L-AP4 in 
combination was not significantly different to that observed following sub-chronic 
treatment with either L-AP4 or MPEP alone at the same concentrations (16.7 ± 2.3 % vs. 
19.0 ± 1.7% (MPEP) and 16.9 ± 3.5% (L-AP4); P>0.05; respectively, Figure 5.8A). 
Similar results were observed for both DOPAC (17.5 ± 4.2% vs. 21.7 ± 4.4% (MPEP) 
and 24.9 ± 4.6% (L-AP4); P>0.05; respectively, Figure 5.813) and HVA (18.6 ± 6.3% 
vs. 23.2 ± 4.2% (MPEP) and 10.62 ± 3.1 % (L-AP4) P>0.05; respectively, Figure 5.8Q. 
These data suggest that MPEP and L-AP4 when administered in combination provide 
significant prevention of striatal monoamine depletion, although when compared to the 
data from animals treated with each compound alone at the same concentration, any 
additive effect does not reach statistical significance. Taken together, these data suggest 
that MPEP and L-AP4 in combination do not appear to show any additive effect to 
provide enhanced neuroprotection of nigrostriatal functionality in vivo following 6- 
OHDA lesioning. 
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Figure 5.7 Neuroprotective effects of MPEP and L-AP4 on 
nigrostriatal integrity alone and in combination 
(A) Sub-chronic (7 day) co-administration of 2 nmol MPEP and 2 nmol L-AP4 in 
4 gi significantly attenuates the 6-OHDA induced loss of nigral TH-IR cells and 
this is significantly enhanced compared to the neuroprotection of nigral TH-IR 
cells observed following sub-chronic treatment with each compound alone at the 
same concentration, indicating an additive interaction. **P<0.01; ***P<0.001, 
drug-treated vs. vehicle-treated; *P<0.01, MPEP or L-AP4 alone vs. MPEP + L- 
AN -treated. (B) There are no regional differences in lesion size in any region of 
the SNc in animals treated sub-chronically with MPEP + L-AP4. Additionally, the 
lesion size is significantly reduced in MPEP + L-AP4 compared to vehicle-treated 
animals in all stereotaxic regions of the SNc, indicating robust neuroprotection of 
the entire SNc structure. Data shown in (A) and (B) are mean % loss of nigral TH- 
IR ± SEM, n values are shown in parenthesis 
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Figure 5.8 Neuroprotective effects of MPEP and L-AP4 on nigrostriatal 
functionality alone and in combination 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the 
corpus striaturn of animals treated sub-chronically with 2 nmol MPEP +2 nmol L- 
AP4 in 4 [tl or MPEP or L-AP4 alone at the same concentrations following 6-OHDA 
lesioning. In all drug treatment groups the 6-OHDA induced loss of striatal 
monoamines is significantly attenuated, and MPEP + L-AP4 does not confer 
significantly greater protection of striatal monoamines than either compound alone. 
Data shown are mean striatal dopamine, DOPAC and HVA content in ng/mL wet 
weight tissue ± SEM, n values are shown in parenthesis. *P<0.05, **P<0.01 vehicle 
vs. drug-treated. (D) No significant alterations in striatal monoamine turnover were 
observed following sub-chronic treatment with either MPEP, L-AP4 or MPEP + L- 
AP4 compared to vehicle-treated rats. *P<0.05 contralateral vs. ipsilateral striata. 
Data shown are mean striatal monoamine turnover ratio (pmol/ml) calculated using 
the expression ((DOPAC+HVA)/DA). 
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5.3.4 Co-administration of 2R, 4R-APDC and L-AP4 is neuroprotective 
In animals treated with sub-chronic intranigral injections of 2 nmol in 4 [tl 2R, 4R- 
APDC or 2 nmol in 4 ýd L-AP4 alone, the loss of nigral TH-IR cells induced by 
infusion of 6-OHDA into the SNc was significantly attenuated as shown clearly in 
Figure 5.9A (see sections 3.3.4.1 and 3.3.5.1). Similarly, sub-chronic intranigral co- 
administration of 2 nmol 2R,, 4R-APDC and 2 nmol L-AP4 in 4 [tl also significantly 
attenuated the 6-OHDA induced loss of nigral TH-IR cells (33.7 ± 1.1% vs. 67.5 ± 
2.8%; P<0.001; Figure 5.9A). The degree of neuroprotection observed in these animals 
is illustrated by a representative photomicrograph shown in Figure 5-3E. One-way 
ANOVA analysis indicated no significant differences in lesion size between any region 
of the SNc in animals treated with 2R, 4R-APDC and L-AP4 in combination (FO. 653; 
P=0.634, Figure 5.913). Furthermore, one-way ANOVA analysis also revealed that the 
lesion size was significantly reduced in all regions of the SNc compared to vehicle 
treated animals (FIO. 69P<0.0001, Figure 5.913). 
These data suggest that 2R, 4R-APDC and L-AP4 in combination provide robust 
neuroprotection of the entire SNc structure, in contrast to previous observations with 
each compound alone at the same concentration (see sections 3.3.4.1 and 3.3.5.1). 
However, when comparing the mean number of nigral TH-IR cells between the 
contralateral and ipsilateral hemispheres, 6-OHDA infusion still resulted in a small but 
significant reduction of TH-IR cells in the SNc in animals treated with 2R, 4R-APDC 
and L-AP4 in combination (P<0.01 data not shown). Interestingly, co-administration of 
2RAR-APDC and L-AP4 resulted in a significantly enhanced neuroprotection of nigral 
TH-IR cells compared to that observed following sub-chronic treatment with each 
compound alone at the same concentration (33.7 ± 1.5% vs. 51.0 ± 2.3% (2R, 4R- 
APDQ and 47.6 ± 3.7% (L-AP4) P<0.00 I, respectively, Figure 5.9A). Furthermore, the 
mean percentage loss of nigral TH-IR cells observed in animals co-administered 2R, 4R- 
APDC and L-AP4 was not significantly different from the loss of nigral TH-IR cells 
observed in animals treated with a concentration of either 2R, 4R-APDC or L-AP4 
which resulted in maximal neuroprotection of nigrostriatal integrity (33.7 ± 1.5% vs. 
36.3 ± 5.6% and 33.9 ± 4.2%; P>0.05; P>0.05 2R, 4R-APDC and L-AP4, respectively). 
Moreover, these data tend to suggest a trend towards increased neuroprotection. Taken 
together, these data suggest that 2R, 4R-APDC and L-AP4 interact in an additive fashion 
to provide significantly increased protection of nigrostriatal integrity compared to either 
compound alone at the same concentration. 
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Sub-chronic intranigral treatment with either 2 nmol in 4 ýd of 2R, 4R-APDC or 
2 nmol in 4 ýtl L-AP4 alone also significantly attenuated the depletion of DA and its 
metabolites in the corpus striatum induced by infusion of 6-OHDA into the SNc as 
illustrated in Figure 5.1 OA (see sections 3.3.4.2 and 3.3.5.2, respectively). Similarly, 2 
nmol 2R,, 4R-APDC and 2 nmol L-AP4 in 4 ýd administered in combination 
significantly attenuated the depletion of DA in the corpus striatum induced by infusion 
of 6-OHDA into the SNc (15.4 ± 3.5% vs. 56.6 ± 4.4%; P<0.01; Figure 5.10A). 
Additionally, the depletion of both DOPAC and HVA were also significantly attenuated 
by treatment with 2R, 4R-APDC and L-AP4 in combination (19.5 ± 3.8% vs. 56.2 ± 
7.0%; P<0.01; Figure 5.1013 and 15.8 ± 5.2% vs. 52.2 ± 6.7%; P<0.01; Figure 5.10Q. 
However, when comparing the mean concentration of DA in animals treated with 
2R, 4R-APDC and L-AP4 in combination, a significant difference was observed in the 
ipsilateral striata relative to the contralateral side suggesting that 6-OHDA still induces 
a small, but significant reduction in nigrostriatal functionality (P<0.05 data not shown). 
Interestingly however, no significant differences were observed when the same 
comparison was made for DOPAC and HVA (P>0.05 data not shown). This finding 
could be due to increases striatal DA turnover. However, in animals treated with 2R, 4R- 
APDC and L-AP4 in combination, although a slight increase is observed in striatal DA 
turnover in the ipsilateral striata relative to the contralateral side, this failed to reach 
statisitical significance (0.154 ± 0.02 vs. 0.129 ± 0.01; P>0.05; Figure 5.10D). 
Interestingly, in animals treated with the same concentration of 2R, 4R-APDC alone, a 
significant increase in striatal DA metabolism was observed, which is blocked following 
co-administration of L-AP4 with 2R, 4R-APDC. The attenuation of striatal DA depletion 
observed in animals treated with 2R, 4R-APDC and L-AP4 in combination is not 
significantly different to that observed following sub-chronic treatment with either 
2R, 4R-APDC or L-AP4 alone (15.4 ± 3.5% vs. 17.7 ± 3.3% (2R, 4R-APDC) and 16.9 ± 
3.5%; P>0.05; respectively, Figure 5.10A). Similar results were observed for both 
DOPAC (19.5 ± 3.8% vs. 30.5 ± 4.8% (2R, 4R-APDC) and 24.9 ± 4.5% (L-AP4); 
P>0.05; respectively, Figure 5.1013) and HVA (15.8 ± 5.2% vs. 16.7 ± 2.5% (2R, 4R- 
APDC) and 10.6 ± 3.1%; P>0.05; respectively, Figure 5.10C). However, these data 
suggest a trend towards increased protection of nigrostriatal functionality in animals co- 
administered 2R, 4R-APDC and L-AP4. Taken together, these results suggest that 
2R, 4R-APDC and L-AP4 in combination do not appear to show any significant additive 
interactions to provide enhanced neuroprotection of nigrostriatal functionality in vivo 
following 6-OHDA lesioning. 
-267- 
A 
(A 
- 
0 a---- 
Vehicle 
2R, 4R-APDC 
L-AP4 
=Vehicle =2R, 4R-APDC + L-AP4 
6 
C) 
E3 
9 20 , 10 
1 im in 1 1 11 1 1 im 
0* 0 A B c D E 
Region of SNc 
Figure 5.9 Neuroprotective effects of 2R, 4R-APDC and L-AP4 on 
nigrostriatal integrity alone and in combination 
(A) Sub-chronic (7 day) co-administration of 2 nmol 2R, 4R-APDC and 2 nmol L-AP4 
in 4 ýd significantly attenuates the 6-OHDA induced loss of nigral TH-IR cells and this 
is significantly enhanced compared to the neuroprotection of nigral TH-IR cells 
observed following sub-chronic treatment with each compound alone at the same 
concentration, indicating an additive interaction. **P<0.01; ***P<0.001, drug-treated 
vs. vehicle-treated; -+'P<0.05,2R, 4R-APDC or L-AP4 alone vs. 2R, 4R-APDC + L-AP4 
-treated. (B) There are no regional differences in lesion size in any region of the SNc in 
animals treated sub-chronically with 2R, 4R-APDC + L-AP4. Additionally, the lesion 
size is significantly reduced in 2R, 4R-APDC + L-AP4 compared to vehicle-treated 
animals in all stereotaxic regions of the SNc, indicating robust neuroprotection of the 
entire SNc structure. Data shown in (A) and (B) are mean % loss of nigral TH-IR 
SEM, n values are shown in parenthesis. 
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Figure 5.10 Neuroprotective effects of 2R, 4R-APDC and L-AP4 on 
nigrostriatal functionality alone and in combination 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the corpus 
striaturn of animals treated sub-chronically with either 10 nmol /4 V1 2R, 4R-APDC, 10 
nmol /4 [d L-AP4 alone or 2R, 4R-APDC + L-AP4 in combination at the same 
concentrations. In all drug treatment groups the 6-OHDA induced loss of striatal 
monoamines is significantly attenuated, although 2R, 4R-APDC + L-AP4 does not confer 
greater protection of striatal monoamines than each compound alone. Data shown are mean 
striatal dopamine, DOPAC and HVA content in ng/ml ± SEM, n values are shown in 
parenthesis. *P<0.05, **P<0.01 vehicle vs. drug-treated. (D) A significant increase in 
striatal monoamine turnover was observed following sub-chronic treatment with 2R, 4R- 
APDC but not L-AP4. Interestingly, co-application of 2R, 4R-APDC + L-AP4 also resulted 
in no significant alterations in striatal dopamine metabolism compared to vehicle-treated 
rats. *P<0.05 contralateral vs. ipsilateral striata. Data shown are mean striatal monoamine 
turnover ratio (pmol/ml) calculated using the expression ((DOPAC+HVA)/DA). 
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5.4 Discussion 
5.4.1 Summary offindings 
In line with the aims of this study, the main findings of the current study were that sub- 
chronic intranigral administration of the following mGluR ligand combinations (1) the 
LY367385 and MPEP (2) MPEP and 2R, 4R-APDC, (3) MPEP and L-AP4 and (4) 
2R, 4R-APDC and L-AP4, all at sub-maximal concentrations which are neuroprotective 
for each compound alone (see Chapter 3 in this thesis), showed clear additive 
interactions that resulted in enhanced neuroprotection of nigral DA cells, quantified by 
increased survival of TH-IR cells in the ipsilateral SNc. Indeed, the level of 
neuroprotection achieved for all combinations tested was comparable to that observed 
following sub-chronic treatment with the concentration of each mGluR ligand alone 
which resulted in maximal neuroprotection of nigrostriatal integrity, as shown from 
previous concentration response studies (see Chapter 3 of this thesis). Interestingly, in 
animals treated with MPEP and L-AP4, the degree of neuroprotection was significantly 
higher than the effects of MPEP alone at a concentration which produced maximal 
neuroprotection. 
Theoretically, the observed decrease in nigral TH-IR cells and the 
neuroprotective effects of selective mGluR ligand combinations could be due to 
transient atrophy of cells and downregulation of TH expression rather than true cell 
death and neuroprotection (Sherman and Moody, 1995; Yuan et al, 2005; Meuer et al, 
2006). This possibility has been previously addressed (see Chapter 3 section 3.4) . 
However, in all the drug treatment groups, intranigral infusion of 6-OHDA still 
induced a smaller but significant loss of nigral DA cells when comparing mean cell 
numbers in the ipsilateral and contralateral SNc. This is consistent with previous 
observations following sub-chronic administration of mGluR ligands alone following 6- 
OHDA lesioning (see Chapters 3 and 4 in this thesis). This probably reflects the fact an 
initial amount of 6-OHDA-mediated cell death must occur in the SNc to initiate the 
hypofunction of the indirect pathway and secondary increases in glutamate transmission 
on to midbrain DA neurones (see section 1.5) or that there are some toxic mechanisms 
of 6-OHDA which mGluR ligands do not protect against. Thus, small but significant 
lesions are generated in the nigrostriatal system in drug-treated animals. Importantly, 
the 6-OHDA lesion size is dramatically reduced compared to vehicle-treated animals, 
indicative of neuroprotection following mGluR ligand treatment. 
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Surprisingly, co-administration of combinations of selective mGluR ligands did 
not result in enhanced preservation of nigrostriatal functionality, as measured by the 
concentrations of DA and its metabolites in the corpus striaturn, when compared to that 
observed for each compound alone at the same concentration. However, despite the lack 
of statistically significant differences, it is noteworthy that there appeared to be a trend 
towards increased prevention of striatal monoamine depletion following 6-OHDA 
lesioning in animals treated with the mGluR ligand combinations, suggesting that weak, 
but not statistically significant additive effects may occur. Importantly, in all drug 
treated groups, the 6-OHDA induced increases in striatal DA turnover were blocked. 
Furthermore, co-administration of MPEP or L-AP4 with 2R, 4R-APDC blocked the 
increases in striatal DA turnover observed in animals treated with the same 
concentration of 2R, 4R-APDC alone, suggestive of an additive interaction between 
these compounds to produce a greater neuroprotective effect that corrects the increased 
striatal DA metabolism in these animals. 
Importantly, the attenuation of the 6-OHDA-induced depletion of striatal DA 
and its metabolites in animals treated with selective mGluR ligand combinations 
indicates preservation of axonal projections. The observation that treatment with these 
drug combinations also blocks 6-OHDA-induced increases in striatal DA turnover 
suggests that the prevention of DA depletion by following treatment with these 
compounds is due to neuroprotection of striatal DA terminals, rather than increased 
compensatory DA metabolism by the surviving nigral TH-IR cells. Furthermore, 
because of the relatively short time between 6-OHDA lesioning and HPLC 
measurements (7 days post-6-OHDA lesion) it is unlikely that the preservation of 
striatal DA could be explained by sprouting of the remaining axonal projections, which 
has only been seen to occur 4 weeks after 6-OHDA lesioning (Finklestein et al, 2000; 
Stanic et al. 2003). 
Taken together, these data suggest that sub-chronic intranigral co-administration 
of selected combinations of mGluR ligands at sub-maximal concentrations appear to 
result in enhanced neuroprotection of nigrostriatal integrity, but not functionality in 
unilaterally 6-OHDA lesioned animals. 
5.4.2 Methodological considerations 
These interesting observations are preliminary in nature and the data must be interpreted 
cautiously. Importantly, none of the combinations of selective mGluR ligands tested 
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produced significantly enhanced preservation of nigrostriatal functionality, although 
there was a generalised trend towards increased protection. A possible explanation for 
this may be that when administered alone all of the mGluR ligands tested very robustly 
prevented striatal monoamine depletion, even at the sub-maximal concentrations 
employed in this study, although this effect was concentration dependent (see sections 
3.3 and 4.3, respectively). Additionally, in the current study, a partial 6-OHDA lesion 
model was employed, thus, the degree of monoamine depletion in the corpus striaturn 
was relatively mild following 6-OHDA lesioning. Taking these data into consideration, 
it is perhaps not surprising that no significant additive benefit of administering mGluR 
ligands in combination was observed for nigrostriatal functionality, since a combination 
of the robust neuroprotection observed for each compound alone and the mild degree of 
striatal monoamine depletion, may make it impossible to discern any significant benefit 
of administering selected mGluR ligands together. 
It is noteworthy however, that a slight trend towards increased neuroprotection 
of nigrostriatal functionality was observed in most treatment groups, suggesting the 
possibility of additive interactions. Interestingly, in vehicle-treated animals sacrificed 14 
days post-6-OHDA lesion, the degree of striatal monoamine depletion was considerably 
greater as the lesion progresses (see section 6.3). Therefore, it would be interesting to 
examine the effect of mGluR combination on nigrostriatal functionality at this time- 
point where it may be possible to discern significant additive neuroprotective effects 
due to the greater lesion size. An alternative possibility may be that these combinations 
of drugs alter the balance of dopamine: glutamate interactions in the basal ganglia, 
leading to increased synthesis and release of DA in the striatum. Therefore an 
alternative approach to investigate this would be to use a dual-probe microdialysis 
technique to investigate the real-time changes in the levels of extracellular DA in the 
striaturn in response to both 6-OHDA lesioning and intranigral administration of mGluR 
ligands alone or in combination. 
Additionally, the possibility exists that the neuroprotective effects of mGluR 
ligand combinations observed in the current study could be solely due to the initial pre- 
treatment injection prior to 6-OHDA infusion. As a result, in order to demonstrate a true 
neuroprotective action, it will be important in future studies to investigate the 
neuroprotective effects of administering these mGluR ligand combinations to animals 
already undergoing nigrostriatal degeneration. 
Furthermore, the finding that co-administration of combinations of mGluR 
ligands resulted in enhanced survival of nigral TH-IR cells could potentially 
be due to 
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over estimation of nigral TH-IR cell numbers due to the counting methology employed. 
In the current study, the numbers of nigral TH-IR cells were quantified manually in a 
blind fashion throughout the rostral to caudal extent of the SNc (see section 2.2.2.1). As 
the cell counting was not performed at pre-determined distance intervals as is the case in 
unbiased stereological methods (Hedreen JC, 1999; Baddely A, 2001) coupled with the 
thickness of the tissue sections on which TH - immuno staining and cell counting was 
performed (20 ýM-thick, (see section 2.2.1.2) the possibility exists that the same TH-IR 
cell may be present in two sections, leading to possible over estimation of cell numbers. 
Therefore, whilst the current data suggests an additive interaction resulting in increased 
survival of nigral DA cells, in order to definitively confirm these findings, these 
experiments should be repeated and TH-IR cell numbers rigorously assessed using 
unbiased stereological methods of cell counting as described by others (Aquirre et al, 
2001; 2005). Indeed, this limitation applies to all the studies in this thesis. However, it is 
important to note that this approach to cell counting has been employed in previously 
published studies to ensure that comparable rostral to caudal levels of the SNc are 
sampled between animals and importantly, provides robust and accurate quantification 
of nigral cell loss (Iravani et al, 2002; 2004) and neuroprotection (Datla et al, 2001 a, b; 
2003; 2004; 2006; Vernon et al, 2005; 2006; Zbarsky et al, 2006). 
It is also important to remember that these findings are the result of sub-chronic 
intranigral drug treatment. The results of the studies discussed in Chapter 4 suggest that 
the neuroprotective effects of LY367385 and L-AP4 may be affected by the 
development of mGluRI supersensitivity and agonist-induced desensitisation of 
mGluR4, respectively (see sections 4.4.4 and 4.4.4). Therefore it will also be important 
in future studies to address the effect of different treatment regimens and also whether 
similar results may be observed following intracerebroventricular (i. c. v) 
drug 
administration or from a clinical standpoint, systemic administration. 
Taking these limitations into account, these data provide exciting preliminary 
evidence to suggest that mGluR ligands may show additive interactions 
leading to an 
enhanced protection of the nigrostriatal system in vivo against 6-OHDA toxicity. 
This 
may be important as it suggests that mGluR ligands could be co-administered to provide 
an enhanced degree of neuroprotection over that observed for mGluR 
ligands alone but 
at lower concentrations, which potentially may be associated with a 
lower incidence of 
detrimental side-effects. In this respect it would also be extremely 
interesting to 
investigate whether similar additive interactions may influence the 
documented anti- 
parkinsonian actions of selective mGluR ligands which to 
date have not been rigorously 
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investigated. The potential mechanisms by which co-administration of selective mGluR 
ligands may result in enhanced neuroprotection are discussed below. 
5.4.2 LY367385 and MPEP co-administration 
The finding that the mGluR1 antagonist LY367385 and the mGluR5 antagonist MPEP 
show additive interactions is consistent with previously published data. Indeed the 
results of several studies indicate that both LY367385 and MPEP applied alone 
significantly reduce the size of epileptiform discharges in hippocampal slice 
preparations, and when applied together the effect is additive (Lee et al, 2002; Thuault 
et al, 2002; Merlin et al, 2002; Lanneau et al. 2002). Similarly, the mGluRl antagonist, 
3,4-dihydro-2H-pyrano[2,3]beta-quinolin-7-yl(cis-4-methoxycyclohexyl)methanone 
(JNJ16259685) and MPEP when applied alone produce significant anxiolytic effects in 
a number of behavioural tests in rodents, effects that are additive when these 
compounds are co-applied (Steckler et al, 2005). Importantly, addition of sub-maximal 
concentrations of both LY367385 and MPEP in vitro resulted in enhanced 
neuroprotection against NMDA toxicity in mixed cortical cultures compared that 
observed with either compound alone, suggesting an additive interaction, (Battaglia et 
al, 2001) consistent with the in vivo data presented herein. 
These data suggest that mGluR1 and mGluR5 play different roles in the 
induction and progression of neuronal death of nigral DA cells induced by glutamate 
excitotoxicity. This is relevant since it has been previously assumed that because these 
receptors are identically coupled through Gq G-proteins, co-expression of these 
receptors in the same neurone simply reflected a redundancy of function (Valenti et al, 
2002). However, the findings described above and the data presented herein using 
subtype selective antagonists of Group I mGluR suggest the opposite, in that there is a 
clear separation of function between mGluRI and mGluR5 when expressed in the same 
neuronal populations (Valenti et al, 2002), as previously discussed (see sections 3.5 and 
4.5). Thus, given this apparent segregation of function, how does co-administration of 
MPEP and LY367385 lead to enhanced neuroprotection of nigral DA neurones? 
In this respect, it is noteworthy that all of the Group I mGluR-mediated 
responses described above for various basal ganglia (BG) nuclei were measured in what 
corresponded to the normal brain state. Thus, it is important to consider if functional 
changes occur in Group I mGluR-mediated functions in the BG under Parkinsonian 
conditions. Interestingly, following DA-depletion a "degree of plasticity" exists in the 
coupling of Group I mGluR to effector systems and suggest that these receptors may 
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play enhanced roles in mediated glutamate transmission under pathological conditions 
(Marino et al, 2002a) (see sections 3.5 and 4.5). Thus, it is conceivable that both 
mGluR1 and mGluR5 may contribute to the depolarisation of nigral DA neurones under 
parkinsonian conditions, which may provide one explanation for the additive 
neuroprotective effect of LY367385 and MPEP following 6-OHDA lesioning, or indeed 
the neuroprotective effects of MPEP alone (see section 3.4.2.2). 
It is noteworthy, however, that no functional data exist to describe a role for 
mGluR5 in nigral DA neurones under in either the normal or Parkinsonian brain 
(Valenti et al, 2002). Interestingly, mGluR5 has been demonstrated to potentiate the 
activity of NMDAR-mediated responses in vitro (Alagarsamy et al, 2002; 2005; Collett 
et al, 2004), a functional interaction which has also been demonstrated in vivo in the 
corpus striatum. (Tebano et al, 2005; Pietraszek et al, 2005; Choe et al, 2006) and in 
experimental models of Parkinsonism (Turle-Lorenzo et al, 2005). Furthermore, this has 
been suggested to account for some the neuroprotective actions of MPEP against 
glutamate-mediated toxicity (Popoli et al, 2004; Armentero et al, 2005). Thus if such an 
effect occurs in the SNc, it is possible that blockade of mGluR5 may prevent 
potentiation of NMDAR responses, thus uncoupling deleterious downstream NMDAR 
signal transduction and preventing activation of an apoptotic cascade leading to 
neuroprotection (see section 1.7.3. and Figures 1.4 and 1.9) (Battaglia et al, 2005). 
However, how this alteration of Group I mGluR pharmacology occurs under 
conditions of DA depletion remains unresolved (see section 3.5). 
Alternatively, the additive neuroprotection observed following LY367385 and 
MPEP co-administration may not be the result of an interaction in the same neurone. 
Indeed, it is possible that this could be due to antagonism of mGluR5 facilitatory 
autoreceptors on STN efferent terminals. Complementary in vitro and in vivo evidence 
suggests such receptors exist in the cortex (Thomas et al, 2000; 2001; Fazal et al, 2003). 
Should facilitatory presynaptic mGluR5 exist on STN axon terminals, the antagonism of 
these receptors would be predicted to result in reduced glutamate release onto midbrain 
doparninergic neurones, which combined with an inhibition of SNc neurone 
depolarisation by LY367385, may result in enhanced neuroprotection. 
A final possibility which cannot be excluded may be the effects of antagonising 
responses mediated through mGluR5 expressed on astrocytes and microglia, which may 
directly contribute to neuroprotection (see section 7.3.3) which may combine with the 
antagonism of neuronal Group I mGluR on SNc neurones, resulting in enhanced 
neuroprotection. A summary diagram to illustrate the potential mechanisms by which 
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LY367385 and MPEP may show additive interactions to produce enhanced 
neuroprotection is illustrated in Figure 5.11 below. 
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Figure 5.11 Possible interactions leading to enhanced neuroprotection of nigral 
cloparninergic neurones following co-administration of the mGluR5 antagonist MPEP 
and the mGluRl antagonist LY367385 into the substantia nigra pars compacta. 
5.4.3 MPEP and 2R, 4R-APDC co-administration 
To the best of the author's knowledge, to date, no studies have investigated if co- 
administration of selective mGluR5 antagonists and a selective mGluR2/3 agonist 
results in enhanced neuroprotection against glutamate-mediated toxicity in vitro or in 
vivo. Thus, the finding that co-administration of MPEP and 2R, 4R-APDC results in 
enhanced neuroprotection of the nigrostriatal system following 6-OHDA lesioning in 
vivo is novel. These data are consistent with the predicted role and expression patterns 
of mGluR5 and mGluR2/3 in the BG, particularly at striatonigral and subthalamonigral 
synapses, where these compounds would be predicted to exert an effect following 
intranigral administration (Rouse et al, 2000). Based on this evidence, the increased 
neuroprotection observed in the current study could result from the interaction of a 
number of different pathways, which are outlined in Figure 5.12. 
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Figure 5.12 Possible interactions leading to enhanced neuroprotection of nigral 
doparninergic neurones following co-administration of the mGluR5 antagonist MPEP 
and the mGluR2/3 agonist 2R, 4R-APDC into the substantia nigra pars compacta. 
Indeed, speculatively, blockade of postsynaptic mGluR5 on STN axon tenninals 
by NIPEP may inhibit the depolarisation of STN neurones (Awad et al, 2000) and 
additionally, prevent the facilitation of glutamate release from STN nerve terminals, 
should presynaptic mGluR5 facilitatory autoreceptors exits in this brain region as 
discussed above. Alternatively, antagonism of mGluR5-mediated responses in nigral 
DA neurones themselves may account for the neuroprotective action (see section 5.4.2), 
but confirmation of this awaits a demonstration of a physiological role for mGluR5 in 
nigral DA neurones (Valenti et al, 2002). As discussed above, a neuroprotective action 
following antagonism of mGluR5-mediated responses in astroglia or microglia must 
also be considered (see section 5.4.2; Nicoletti et al, 1999) 
The additive effect of co-administration of 2R, 4R-APDC may be due to 
inhibition of glutamate release from STN axon terminals by this agonist, which has been 
previously demonstrated at subthalamonigral synapses (Bradley et al, 2000), consistent 
with studies demonstrating the expression of both mRNA and receptor protein for 
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mGluR2/3 in axon terminals of STN neurones, with a clear presynaptic localisation 
(Petralia et al, 1996; Bradley et al, 1999; 2000). This hypothesis is also supported by 
electrophysiological studies which demonstrate that application of 2R, 4R-APDC 
depresses excitatory post synaptic potentials (EPSPs) in vitro at subthalamonigral 
synapses recorded from DA neurones in the SNc (Wigmore and Lacey, 1998; Katayama 
et al, 2003). Importantly, a physiological role for this action of mGluR2/3 is supported 
by the finding that activation of these receptors by endogenous glutamate results in an 
inhibition of glutamate release from STN axon terminals and a decrease in excitatory 
postsynaptic currents (EPSCs) recorded from DA neurones of the SNc, with a clear 
presynaptic mechanism of action (Wang et al, 2005). These data are consistent with the 
proposed role of Group II mGluR as glutamate autoreceptors at these synapses, which 
function to "sense" the extracellular concentration of glutamate in the synaptic cleft and 
modulate glutamate release accordingly. (Wang et al, 2005). 
Importantly however, there is substantial evidence to suggest that the 
neuroprotective actions of mGluR2/3 agonists are mediated through glial cells (see 
section 4.4.5) by secretion of trophic factors (Bruno et al, 1997; 1998; 1999; Ciccarelli 
et al, 1999; Matarredona et al, 2002) or the regulation of glutamate transporters and 
glutamate uptake in astrocytes (Yao et al, 2005; Tramontina et al, 2006). Additionally, it 
is noteworthy that under conditions of DA depletion, the activity of Group 11 mGluR is 
reduced as previously discussed (see sections 3.5 and 4.4.5). Indeed a tonic level of DA 
stimulation, possibly mediated through presynaptic DA D2 receptors may be required to 
maintain mGluR2/3 in an active state (Wittmann et al, 2002). In support of this concept, 
anatomical studies have demonstrated a reciprocal connection between DA neurones in 
the SNc and glutamatergic neurones in the STN (see section 1.5). Furthermore, 
somatodendritically released DA from SNc neurones has been demonstrated to inhibit 
glutamate release from STN axon terminals by activation of DA D2 receptors 
(Hatzipetros and Yamamoto, 2006). These data suggest that presynaptic mGluR2/3 
autoreceptors on STN axon terminals may be under the heterologous control of 
presynaptic DA D2 heteroreceptors. Thus, if a similar relationship exists for the 
regulation of excitatory projections from the STN to the SNc, it may be predicted that 
activation of presynaptic mGluR2/3 would not lead to sustained decreases in glutamate 
transmission from the STN due to loss of function caused by DA depletion. These data 
would suggest that major contribution of 2R, 4R-APDC to the neuroprotective effects of 
MPEP is through an action at glial cells (see section 4.4.5 and Figure 5.12) resulting in 
the enhanced neuroprotection of the nigrostriatal system observed in the current study. 
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5.4.4 MPEP and L-AP4 co-administration 
The finding that co-administration of sub-maximal concentrations MPEP and L-AP4 act 
in an additive fashion to produce enhanced neuroprotection of the nigrostriatal system 
following 6-OHDA lesioning in vivo is also a novel finding of this study. These data are 
consistent with the predicted role and expression patterns of mGluR5 and Group III 
mGluR in the BG, particularly at striatonigral and subthalamonigral synapses, where 
these compounds would be expected to exert an effect following intranigral 
administration (Rouse et al, 2000). The potential mechanisms by which these two 
compounds could interact to produce enhanced neuroprotection are illustrated in Figure 
5.13 below. 
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Figure 5.13 Possible interactions leading to enhanced neuroprotection of nigral 
dopaminergic neurones following co-administration of the mGluR5 antagonist MPEP 
and the broad spectrum Group III mG1uR agonist L-AP4 into the substantia nigra pars 
compacta. Red outlined boxes indicate alternative speculative mechanisms that may 
also contribute to the additive neuroprotective effect of these compounds. 
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Interestingly, in vitro studies suggest MPEP may be a weak positive allosteric 
modulator (PAM) of mGluR4 (Mathiesen et al, 2003). This is relevant since mGluR4 is 
is predicted to account for the Group III mGluR mediated inhibition of glutamate 
neurotransmission onto midbrain dopaminergic neurones from STN axon terminals 
(Valenti et al, 2003; 2005). Furthermore, this may be one of the primary mechanism by 
which selective activation of Group III mGluR may be neuroprotective against 
secondary glutamate excitotoxicity under parkinsonian conditions (Nicoletti et al, 1996; 
Bruno et al, 2000a; Valenti et al, 2003; 2005). Indeed, in the presence of L-AP4, MPEP 
significantly increases GTP7S binding in vitro to human mGluR4 and weakly 
potentiated the ability of L-AP4 to inhibit cAMP formation in vitro in a concentration- 
dependent manner (Mathiesen et al, 2003). Furthermore, MPEP also produced a 
significant leftward shift in the concentration response curve for GTP-JS binding in the 
presence of L-AP4, suggesting that MPEP can enhance both the potency and efficacy of 
L-AP4 at human mGluR4 (Mathiesen et al, 2003). Taken together, these data suggest 
that MPEP may act as a weak PAM of L-AP4-induced responses mediated through 
mGluR4 (Mathiesen et al, 2003). Thus, the additive neuroprotective effect of MPEP and 
L-AP4 may be explained in part by positive allosteric effect of MPEP to enhance the 
action of L-AP4 activation of mGluR4 in vivo at subthalamonigral synapses. It is 
noteworthy however, that a significant allosteric effect of MPEP on mGluR4 was only 
observed at concentrations of >50 ýtM in vitro (Mathiesen et al, 2003). In the current 
study, a sub-maximal concentration of MPEP was employed (2 nmol in 4 ýfl), thus, it is 
reasonable to assume that following diffusion into the tissue, the concentration of MPEP 
utilised in the current study may not be high enough to potentiate responses mediated by 
mGluR4. However, since we cannot accurately quantify the concentration of MPEP 
present at the receptor, this possibility cannot be definitively excluded. 
Alternatively, this additive interaction may be explained by the regulation of 
mGluR4 activity. Indeed, in vitro evidence suggests that the activity of mGluR4- 
mediated responses is not only regulated by homologous desensitisation through PKC/A 
and/or GRK2 (see section 4.4.4) but also through heterologous desensitisation, since 
activation of either a Neurokinin-3 (NK-3) or GABAB receptor co-expressed with 
mGluR resulted in desensitisation of mGluR4-agonist stimulated responses, through a 
PKC dependent mechanism (Mathisen and Ramirez, 2006). Thus, potential candidates 
for this receptor include the GABABand NK-3 receptors both of which are known to be 
expressed in the nerve terminals of glutarnatergic neurones (Boyes and Bolarn 2003; 
Lessard and Pickel, 2005; Mathisen and Ramirez, 2006). Interestingly, activation of 
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mGluR5 also couples to signal transduction through activation of PKC via the inositol 
triphosphate / diacylglycerol (IP3/DAG) pathway (Pin et al, 1999; Hermans and Challis, 
2001). Thus, it is tempting to speculate that activation of presynaptic mGluR5, should 
these receptors exist on STN axon terminals in a presynaptic localisation, may regulate 
the activity of mGluR4 via PKC-mediated phosphorylation. If this occurs in vivo, it is 
tempting to speculate that MPEP could enhance the neuroprotective action of L-AP4 by 
antagonising the mGluR5-mediated desensitisation of mGluR4, thus facilitating 
mGIuR4 activity and inhibiting glutamate release (Mathisen and Ramirez, 2006). 
Interestingly, the combination of MPEP and L-AP4 resulted in the greatest 
neuroprotective effect observed following 6-OHDA lesioning, further suggesting a 
critical role for mGluR5 and Group III mGluR in glutamate-mediated toxicity in PD. 
The development of an mGluR4 subtype selective agonist is eagerly awaited to 
rigorously test this combination in vivo. Interestingly, the compound PHCCC is a PAM 
which displays a unique selectivity for mGluR4 in vitro and in vivo (Maj et al, 2003). 
Furthermore, this compound mimics both the documented anxiolytic (Stachowitz et al, 
2004; Klak et al, 2006) and anti-akinetic effects of L-AP4 (Marino et al, 2003b) when 
administered alone, suggesting these responses are mediated partly through mGluR4 
and that PHCCC can pharmacologically mimic the actions of L-AP4. Importantly, 
selective activation of mGluR4 by PHCCC also results in significant neuroprotection 
against MPTP toxicity in mice (Battaglia et al, 2006), suggesting that the 
neuroprotective actions of selective Group III mGluR activation on the nigrostriatal 
system induced by L-AP4 (Vernon et al, 2005; 2006) may be mediated primarily 
through mGluR4 (Valenti et al, 2005; Battaglia et al, 2006). Thus, it would be very 
interesting to investigate the effect of co-administering PHCCC with MPEP on the 
nigrostriatal. system following 6-OHDA lesioning, since one might predict this would be 
similarly neuroprotective to L-AP4 + MPEP. In support of this hypothesis, it has been 
demonstrated that co-administration of PHCCC is neuroprotective against both NMDA 
and P-amyloid toxicity in vitro in cultures of murine mixed cortical cells (Maj et al, 
2003). Furthermore, this neuroprotection was additive to that shown by the to selective 
mGluRI antagonist CPCCOEt, and was reversed by application of the Group III mGluR 
antagonist MSOP, confirming the specificity of PHCCC action at Group III mGluR 
(Maj et al, 2003). Furthermore, these data are consistent with the findings of the present 
study which suggest that that co-application of a Group I mGluR antagonist and a 
Group III mGluR agonist results in enhanced neuroprotection. 
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Additionally', it is noteworthy that the additive neuroprotective effects observed 
following MPEP and L-AP4 co-administration may also result from an action at either 
mGluR5 or Group III mGluR expressed on astrocytes and microglia, (see section 7.3.2) 
and Figure 5.13), which may add to the neuroprotective effects described above 
following antagonism of neuronal mGluR5 and stimulation of neuronal mGluR4. 
5.4.5 2R, 4R-APDC and L-AP4 co-administration 
The finding that co-administration of sub-maximal concentrations of 2R, 4R-APDC and 
L-AP4 act in an additive fashion to produce enhanced neuroprotection of the 
nigrostriatal system following 6-OHDA lesioning is also a novel finding of this study. 
These data are also consistent with the predicted role and expression patterns of Group 
11 and Group III mGluR in the BG, particularly at striatonigral and subthalamonigral 
synapses, where these agonists would be expected to exert an effect following 
intranigral. administration, as described above for Group II mGluR (see section 5.4.2 
and Figure 5.12) and Group III mGluR (see section 5.4.4 and Figure 5.13). The possible 
mechanisms by which these compounds could combine to produce enhanced 
neuroprotection of the nigrostriatal system are illustrated in Figure 5.14 below. 
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Figure 5.14 Possible interactions leading to enhanced neuroprotection of nigral 
dopaminergic neurones following co-administration of the mGluR2/3 agonist 2R, 4R- 
APDC and the Group III mGluR agonist L-AP4 into the substantia nigra. pars 
compacta. 
Interestingly, there is evidence to suggest that both Group 11 and Group III 
mGluR may function as presynaptic autoreceptors to inhibit glutamate release on STN 
axon terminals at excitatory synapses onto GABAergic neurones in the SNr (Bradley et 
al, 1999; 2000; Wittmann et al, 2002) and the DA neurones in SNc (Wigmore and 
Lacey, 1998; Katayama et al, 2003; Valenti et al, 2003; 2005; Wang et al, 2005). These 
data are consistent with the finding that STN neurones express mRNA and receptor 
protein for both mGluR2/3 and mGluR4 and 7 (Testa et al, 1994; 1998; Bradley et al, 
1999; Kosinski et al, 1999; Messenger et al, 2002). As discussed above, Group 11 
mGluR appear to require an endogenous doparninergic tone to maintain their activity at 
subthalamonigral synapses (Wittmann et al, 2002, see section 5.4.3). Thus, if a similar 
situation occurs at STN: SNc synapses, under conditions of nigral DA depletion, this 
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tonic influence will be reduced, which may affect the function of mGluR2/3 
autoreceptors. Therefore, the finding that L-AP4 and 2R, 4R-APDC appear to show 
additive effects may reflect a functional compensation for the reduced effectiveness of 
mGluR2/3 by the selective activation of Group III mGluR, (particularly mGluR4) to 
inhibit glutarnate release onto midbrain DA neurones, leading to enhanced 
neuroprotection. Importantly, in the SNr, DA depletion does not appear to affect the 
inhibition of excitatory transmission following Group III mGluR activation with L-AP4 
(Wittmann et al, 200 1; 2002). Alternatively, this may also reflect a combination of both 
neuronal effects as described above, and the stimulation of mGluR2/3 or Group III 
mGluR expressed on astroglial and microglia cells as illustrated in Figure 5.14 (see also 
sections 3.4,4.4 and 7.3.3) 
5.5 Conclusions 
In conclusion, the results of these studies demonstrate for the first time in an in vivo 
model of Pl) that sub-chronic intranigral co-administration of combinations of selective 
mGluR ligands at sub-maximal concentrations, in this case the Group I antagonists 
LY367385 and MPEP, or MPEP and either the selective Group 11 mGluR agonist 
2R, 4R-APDC or the broad spectrum Group III mGluR agonist L-AP4, or finally, 2R, 4R- 
APDC and L-AP4 produces an enhanced neuroprotection of the nigrostriatal system 
following 6-OHDA lesioning. Interestingly, the most significantly enhanced 
neuroprotective effect was observed in animals treated sub-chronically with MPEP and 
L-AP4. The neuroprotective effect observed following sub-chronic treatment with these 
mGluR ligand combinations is greater than that observed for the individual mGluR 
ligands alone at the same concentration, but not greater than the maximal 
neuroprotective effect observed with each mGluR ligand alone. These data suggest that 
these compounds when administered in combination interact in an additive, but not 
synergistic fashion, resulting in a greater neuroprotection of the nigrostriatal system 
against 6-OHDA toxicity in vivo. These data also therefore suggest that mGluR ligands 
may modulate the induction and progression of excitotoxic damage through different 
mechanisms, thus when added in combination an additive, enhanced neuroprotective 
effect is observed. Furthermore, these data provide evidence to suggest that 
combinations of selected mGluR ligands, in particular antagonists of mGluR5 such as 
MPEP and agonists or perhaps, positive allosteric modulators of Group III mGluR may 
represent useful options for the treatment of PD. This is relevant, since the additive 
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nature of the neuroprotective actions of these compounds mean that lower doses could 
be administered to patients, thereby minimising the potential side-effects. Collectively, 
these findings may have important implications for the future treatment of PD. 
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6.1 Introduction 
In the preceding chapters, a clear neuroprotective action of the following selective 
mGluR ligands, the mGluR1 antagonist LY367385, the mGluR5 antagonist MPEP, the 
mGluR2/3 agonist 2R, 4R-APDC and the Group III mGluR agonist L-AP4 against 6- 
OHDA toxicity in a rodent experimental model of PD was demonstrated. Importantly 
however, in all of these studies, the compounds were administered initially as a pre- 
treatment, one hour prior to 6-OHDA infusion into the left SNc. Thus, the possibility 
exists that this pre-treatment may account for a significant proportion of the 
neuroprotective effects of these compounds. 
Parkinsonian symptoms in man are known to manifest when a critical threshold 
of degeneration is reached, prior to which inbuilt compensatory mechanisms appear to 
compensate for the underlying nigrostriatal degeneration, described as the 
"presymptomatic phase" of PD (Zigmond et al, 2002; Berzard et al, 2001; 2003; Pifl et 
al, 2006; see section 1.4.1). Thus, when patients who may have PD first arrive at the 
clinic this is typically assumed to be the level of neurodegeneration that they will 
present with, that is to say, approximately 50-60% loss of nigral dopaminergic neurones 
and a 70-80% depletion of dopamine (DA) in the putamen (see section 1.4.1). 
Importantly, therefore, putative neuroprotective interventions, defined as "any 
intervention which favourably influences the disease process or underlying pathogenesis 
to produce an enduring benefit for the patient" should ideally be tested in animal models 
which mimic this level of early stage degeneration (Meissner et al, 2004). 
Thus, the primary aim of the work reported in this chapter is an attempt to 
address this issue by investigating the potential neuroprotective effects of the same 
selective mGluR ligands which provide effective neuroprotection when given as a pre- 
treatment, using a more "clinically-driven design" (Meissner et al, 2004). This is 
defined as a design which mimics more accurately the clinical setting, where the drugs 
are administered to animals already undergoing nigrostriatal degeneration, preferably at 
a time point where the degree of nigrostriatal neuronal degeneration approximates to 
that observed in early-stage PD patients, who are likely to receive such neuroprotective 
treatments and not as previously, administered prophylactically prior to the 6-OHDA 
neurotoxin. 
Interestingly, in the previous experiments, it is observed that the degree of 
nigrostriatal degeneration following intranigral infusion of 6-OHDA in animals 
sacrificed 7 days post-6-OHDA lesion is remarkably similar to the critical threshold for 
PD symptom manifestation in humans, with a 60-65% degeneration of nigral DA 
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neurones, coupled with an approximate 60% depletion of striatal DA, values consistent 
with a partial lesion of the nigrostriatal tract (Vernon et al, 2005; 2006). Furthermore, 
small but significant increases in striatal DA turnover ratio were observed, suggesting 
the presence of endogenous compensatory mechanisms (Zigmond et al, 1984; 1989; 
1998; 2002). Importantly, whilst the depletion of DA in the striatum is perhaps lower 
than suggested threshold values, the degeneration of nigral DA neurones is closely 
similar to the critical threshold value suggested for the appearance of PD symptoms in 
humans (Bernheimer et al, 1973). Furthermore, previous studies have shown that 
following an initial acute phase of nigrostriatal degeneration following intranigral 
lesioning, the remaining nigral DA neurones and striatal DA terminals degenerate in a 
more progressive manner over a period of 2-3 weeks until 90% depletion is achieved 
(Deumens et al, 2002; Stanic et al, 2003). Interestingly, it is also noteworthy that studies 
in 6-OHDA lesioned animals have suggested that the hyperactivity of the STN reaches a 
maximal level 7 days post-6-OHDA lesion (Vila et al, 2000). Therefore, it may be 
argued that 7 days post-6-OHDA lesion, in our 6-OHDA experimental model, may 
represent a time point at which the nigrostriatal degeneration is robustly equivalent to 
early stage PD. Thus, the aim of the current study was to investigate if sub-chronic 
intranigral treatment with each of the mGluR ligands tested in the preceding chapters 
could protect the remaining nigral DA cells, prevent further depletion of striatal 
monoamines and attenuate further increases in striatal DA turnover when intranigral 
treatment is delayed until 7 days post-6-OHDA lesion. 
6.2 Experimental Design 
6.2.1 Neuroprotection studies with selective mGluR ligands in animals already 
undergoing nigrostriatal degeneration 
To investigate whether treatment with mGluR ligands are neuroprotective post 6-OHDA 
lesioning, male Sprague-Dawley rats (250-270 g) were cannulated I mm superior to the 
left SNc and allowed to recover as previously described (see section 2.1.2.1). 
Subsequently, these animals were treated according to the experimental design shown 
graphically in Figure 6.1 below. 
-288- 
Animals enter Stereotaxic 6-OHDA lstfocal drug Final focal Animals A cti on CE)U facility surgery infusion injection drug injection sacrificed 
Time point ob Ob -1p. 
7 days 10 days 7 days no 7 days drug 1 hour 
treatm ent or vehicle 
treatm ent 
Figure 6.1 Experimental design used to investigate if sub-chronic treatment with 
mGluR ligands can rescue the nigrostriatal system following a 6-OHDA lesion in vivo. 
(CBU, Central Biomedical Unit) 
To assess the effect of post-6-OHDA lesion treatment with mGluR ligands on 
the nigrostriatal system, cannulated animals were divided into treatment groups (n =8 
per group) as illustrated in Table 6.1. A unilateral lesion of the left SNc was induced by 
6-OHDA infusion as previously described (see section 2.1.3) and left to develop for 7 
days, at which point drug treatment commenced (see Figure 6.1). Drug treatment groups 
then received single, daily, unilateral intranigral injections of mGluR ligand sub- 
chronically (7 days) as previously described (see section 2.1.5). Control groups received 
an equal volume of drug vehicle. All mGluR ligands (and 6-OHDA) were made up and 
administered intracerebrally as previously described (see section 2.1.3 and 2.1.4). Each 
mGluR ligand was administered at the concentration that provided maximal 
neuroprotection with minimal side-effects, based on the data from the studies presented 
in Chapter 3 (see section 3.5). Details of each individual treatment group are shown in 
Table 6.1. A sub-chronic treatment regimen was chosen based on the fact that 2R, 4R- 
APDC did not show any neuroprotective activity following acute treatment compared to 
that observed following sub-chronic treatment. Therefore, for consistency all drug 
treatment groups were treated sub-chronically. Moreover, this is in line with previous 
studies which have assessed the delayed treatment of neuroprotective drugs (including 
mGluR ligands) where more chronic rather than acute treatment regimens have been 
employed (Murray et al, 2003; Battaglia et al, 2005; Armentero et al, 2005). 
Additionally, to quantify the size of the 6-OHDA lesion after 7 days, at the start 
of drug (or vehicle) treatment, a second group of male Sprague-Dawley rats (250-270g) 
were cannulated and allowed to recover as per the timescale shown in Table 6.1 and 
Figure 6.1. These animals were then unilaterally lesioned by infusion of 12 ýtg 6-OHDA 
into the left SNc as described in above, which was allowed to develop for 7 days, after 
which the animals were sacrificed and the brain tissue collected as described below. 
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Group Treatment Coneentration(s) Duration (nmol in 4 pl) 
7 days, starting one 
Vehicle I PBS / sterile saline n/a hour post-6-OHDA 
lesion 
7 days, starting 7 
Vehicle 2 PBS / sterile saline n/a days post-6-OHDA 
lesion 
7 days, starting 7 
mGluRl antagonist LY367385 200 days post-6-OHDA 
lesion 
7 days, starting 7 
mGluR5 antagonist MPEP 10 days post-6-OHDA 
lesion 
7 days, starting 7 
mGluR2/3 agonist 2R, 4R-APDC 10 days post-6-OHDA 
lesion 
Group III mGluR 
7 days, starting 7 
L-AP4 10 days post-6-OHDA 
agonist lesion 
Table 6.1 Treatment groups for post-lesion treatment study. Each mGluR ligand was 
tested in vivo at the optimal concentration as determined from Chapter 3, for 7 days 
duration, starting 7 days after the induction of 6-OHDA lesions in vivo. 
As before, at the defined end point of the experiment (see Figure 6.1) animals 
were sacrificed by decapitation and the brains removed and dissected (see section 
2.1.6). To quantify the effects of post-lesion mGluR treatment on the integrity of the 
nigrostriatal. system following 6-OHDA lesioning in these animals, 
immunohistochernistry for tyrosine hydroxylase (TH) was then performed and the 
numbers and morphology of TH-immunoreactive (TH-IR) cells in the SNc were 
quantified as previously described (see sections 2.2-1.3 and 2.2.2.1). Additionally, 
sections from vehicle-treated animals sacrificed 14 days post-6-OHDA lesion were 
processed and stained for NeuN immunoreactivity (NeuN-IR), and the numbers of 
NeuN-IR cells in the SNc quantified as previously described (see sections 2.2.1.4 and 
2.2.2.2). This was done to confirm if the loss of nigral TH-IR cells at 14 days post 6- 
OHDA lesion is mirrored by a loss of NeuN-IR cells, thus confirming neuronal death 
(see section 3.5). To determine the effects on nigrostriatal functionality, concentrations 
of striatal monoamines were measured by HPLC-ECD and subsequently analysed (see 
section 2.2-3). In all experimental groups the positioning of the cannula was assessed 
by 
examination of needle tracts in freshly dissected tissue and CFV-stained sections 
(see 
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section 2.1.2.4). Animals that showed cannulae implantation outside the SNc were not 
included in subsequent data analysis. 
6.2.2 Statistical analysis 
All data (except where stated) are presented as the mean ± SEM based on n independent 
observations. Individual comparisons were made using a two-tailed paired or unpaired 
Student's t-test as appropriate. Where multiple comparisons were made, one-way 
ANOVA with post-hoc Tukeys test for multiple comparisons was employed. Data for 
cell loss in vehicle and drug treated groups is presented as the mean percentage change 
± SEM. Biochemical data for monoamines is expressed in the same manner in ng/ml 
wet weight tissue, except striatal DA turnover, which is expressed as the mean values ± 
SEM in pmol/ml. Mean values were also compared for nigral cell numbers and striatal 
monoamine content. In all figures, n values are shown in parenthesis. Differences were 
considered statistically significant at P<0.05 and all statistical data analysis was 
performed using GraphPad Prism v4-00 software (GraphPad software, San Diego, CA, 
USA). 
6.3 Results 
In vehicle-treated 6-OHDA lesioned animals sacrificed 7 days post-lesion, the number 
of nigral TH-IR cells was significantly reduced by 68.8 ± 1.9% (95% Cl: 61.2 - 70.1 %); 
P<0.001) as shown in Figure 6.2A. The degree of nigral cell loss is illustrated in a 
representative photomicrograph in Figure 6.3A. Concomitant with this loss of nigral 
TH-IR cells was a significant depletion of striatal dopamine (DA) (59.3 ± 6.1%; (95% 
CI: 46.4 - 72.1%; P<0.01) and also DOPAC (55.6 ± 6.3% (95% Cl: 48.2 - 68.9%; 
P<0.01) and HVA (48.9 ± 4.6% (95% Cl: 39.5 - 58.5%; P<0.01) as illustrated in 
Figures 6AA, B and C, respectively. Moreover a small, but significant increase in 
striatal DA metabolism was also observed when comparing the ipsilateral and 
contralateral striata (0.161 ± 0.02 vs. 0.102 ± 0.006 pmol/ml; P<0.05; Figure 6.41)). 
These data are consistent with previous observations at this time point (see sections 3.3, 
4.3 and 5.3). 
Interestingly, in animals treated with drug vehicle starting 7 days after the 
infusion of 6-OHDA into the SNc, there is a significantly increased loss of nigral TH-IR 
cells compared to that seen in vehicle-treated animals sacrificed seven 
days post-6- 
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OHDA lesioning (77.20 ± 1.55% vs. 68.75 ± 1.95%; P<0.01, Figure 6.2A), which is 
illustrated by a representative photomicrograph in Figure 6.313. Importantly this was 
mirrored by a significantly increased loss of NeuN-IR cells in the SNc (81.7 ± 1.7%; 
P<0.01 data not shown) which is illustrated by a representative photornicrograph in 
Figure 6.31). Concomitant with this is an enhanced depletion of striatal DA (84.71 ± 
6.2% vs. 59.3 ± 6.1 %; P<0.05; Figure 6.4A) as well as DOPAC (81.7 ± 7.3% vs. 55.6 ± 
6.3%; P<0.05; Figure 6.413) and HVA (75.7 ± 5.4% vs. 48.9 ± 4.6%; P<0.05, Figure 
6.4Q. Furthermore, the degree of striatal DA turnover is significantly enhanced in these 
animals (0.730 ± 0.05 vs. 0.397 ± 0.07 pmol/ml; P<0.01; Figure 6.41)), which is 
consistent with significant increases in DA turnover reported elsewhere, due to the 
greater degree of DA depletion in the corpus striaturn (Agid et al., 1973; Sherman and 
Moody, 1995; Yuan et al., 2005). Interestingly, there is also an increase in DA turnover 
in the contralateral hemisphere of the brain, which may reflect intrinsic compensatory 
mechanisms (Bezard et al, 2003; Pifl et al, 2006). These data suggest the presence of a 
continued progressive lesion of the nigrostriatal system after the initial insult, consistent 
with previous observations following lesioning with 6-OHDA (Jeon et al, 1995; Ben et 
al, 1999; Finklestein et al, 2000; Stanic et al, 2003). 
6.3.1 Neuroprotection of the nigrostriatal system following sub-chronic post-6- 
OHDA lesion treatment with LY367385 
In animals treated sub-chronically with intranigral injections of 200 nmol in 4 ýil 
LY367385,7 days post 6-OHDA, the loss of nigral TH-IR cells appeared to be reduced 
compared to vehicle-treated animals, but this just failed to reach statistical significance 
(62.6 ± 6.1% vs. 77.20 ± 1.55%; P=0.0621; Figure 6.2A). However, the trend would 
suggest a reduced loss of nigral TH-IR cells. No significant differences in lesion size 
across the SNc were observed in LY367385-treated animals (FO. 820; P=0.5346; Figure 
6.213). Interestingly, in regions A, B and C (but not D or E) of the SNc, the mean 
percentage loss of nigral TH-IR cells was significantly reduced when compared to 
vehicle-treated animals (P<0.05; Figure 6.213), suggesting a mild preservation of nigral 
TH-IR cells post-6-OHDA lesion. It is worth noting that in animals pre-treated with 
LY367385 at this concentration the loss of nigral TH-IR cells was significantly reduced 
in all regions of the SNc compared to vehicle-treated animals (see section 3.3.2.1). 
Importantly, the neuroprotection of nigral TH-IR cells is significantly reduced 
compared to that observed when LY367385 is injected prior to 6-OHDA (62.6 ± 6.1% 
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vs. 37.3 ± 4.4%; P<0.01; Figure 6.2A) Interestingly, the loss of nigral TH-IR cells in 
LY3 673 85 -treated animals is very similar to, and indeed, not significantly different 
from, that observed in animals sacrificed 7 days post 6-OHDA-lesion, the time point at 
which drug or vehicle-treatment started (62.6 ± 6.1% vs. 68.8 ± 1.9%; P>0.05, Figure 
6.2A). These data are illustrated in representative photornicrographs shown in Figure 
6.3E. However, consistent with previous observations, when comparing the mean 
number of TH-IR cells between the ipsilateral and contralateral hemispheres of the brain 
a significant reduction in nigral TH-IR cell number is observed (P<0.01, data not 
shown). 
In terms of nigrostriatal functionality, post-lesion treatment with LY367385 
significantly attenuated the depletion of striatal DA compared to vehicle-treated animals 
(44.5 ± 6.4% vs. 84.71 ± 6.2%; P<0.01; Figure 6.4A) as well as DOPAC (43.06 ± 3.8% 
vs. 81.7 ± 7.3%; P<0.01; Figure 6.413) and HVA (40.45 ± 1.9% vs. 75.7 ± 5.4%, 
P<0.01; Figure 6.4Q. Interestingly, the depletion of striatal DA in LY3 673 85 -treated 
animals is not significantly different from that observed in animals sacrificed 7 days 
post 6-OHDA-lesion, the time point at which drug or vehicle-treatment started (44.5 ± 
6.4% vs. 59.3 ± 6.1%; P>0.05, Figure 6.4A). Similar observations were also recorded 
for DOPAC (43.06 ± 3.8% vs. 55.6 ± 6.3%; P>0.05; Figure 6.413) and HVA (40.45 ± 
1.9% vs. 48.9 ± 4.6%; P>0.05; Figure 6.4Q. A slight increase in striatal DA turnover 
was observed in LY367385-treated animals as shown in Figure 6AD, but this failed to 
reach statistical significance when comparing the ipsilateral and contralateral striata. 
Furthermore, this increase was significantly lower than that observed in vehicle-treated 
animals (0.115 ± 0.004 vs. 0.730 ± 0.05, P<0.000 1; Figure 6.41)). It is also noteworthy 
that the DA turnover ratio in LY367385-treated animals is not significantly different 
from that observed in vehicle-treated animals at the time drug treatment was initiated 
(0.115 ± 0.004 vs. 0.161 ± 0.0 1, P>0.05; Figure 6.41)). However, when comparing the 
mean concentrations of each monoamine between the ipsilateral and contralateral 
striata, a significant reduction is still observed in animals treated with LY367385 
(P<0.05, data not shown). These data are in marked contrast to the very significant 
preservation of striatal monoamine levels observed when LY367385 is administered 
prior to the 6-OHDA neurotoxin (Figure 6AA-D). Thus, the protection of both the 
integrity and functionality of the nigrostriatal tract is markedly and significantly reduced 
in post-lesion treated animals compared to that observed when LY367385 is injected 
prior to 6-OHDA (Figures 6.2A and 6AA-D). 
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Taken together, these data indicate that sub-chronic intranigral treatment with 
LY367385 post-6-OHDA lesioning provides mild but not significant protection of 
nigrostriatal tract integrity, but significantly prevents further depletion of striatal 
monoamines and increases in striatal DA turnover compared to vehicle-treated animals. 
These data suggest that LY367385 treatment may slow the degeneration of the 
nigrostriatal system in vivo induced by 6-OHDA. 
6.3.2 Neuroprotection of the nigrostriatal system following post-6-OHDA lesion 
treatment with MPEP 
In animals treated sub-chronically with intranigral injections of 10 nmol in 4 ýtl MPEP 7 
days after 6-OHDA administration, the mean percentage loss of nigral TH-IR cells was 
significantly reduced compared to that observed in vehicle-treated animals (54.4 ± 5.4% 
vs. 77.2 ± 1.5%; P<0.01; Figure 6.5A). No significant differences in lesion size were 
observed between any regions of the SNc in MPEP-treated animals (F, . 944; 
P=0.2079; 
Figure 6.513). Interestingly however, the mean percentage loss of nigral TH-IR cells 
was only significantly reduced when compared to vehicle-treated animals in regions A, 
B and C (but not D or E) of the SNc as shown in Figure 6.513. These data are consistent 
with previous observations with MPEP when administered as a pre-treatment (see 
section 3.3.3.1). The mean percentage loss of nigral TH-IR cells in MPEP-treated 
animals was found to be not significantly different from that observed in animals 
sacrificed 7 days post 6-OHDA-lesion, the time point at which drug or vehicle- 
treatment started (54.4 ± 5.4% vs. 68.8 ± 1.9%; P=0.064; Figure 6.5A). These data are 
illustrated in a representative photomicrograph shown in Figure 6.3F. It is noteworthy 
however, that the neuroprotection of nigral TH-IR cells is significantly reduced 
compared to that observed when MPEP is injected prior to 6-OHDA (54.4 ± 5.4% vs. 
39.9 ± 3.1%; P<0.05 Figure 6.5A). It is noteworthy however that when comparing the 
mean number of nigral TH-IR cells between the ipsilateral and contralateral 
hemispheres, a significant reduction in the number of nigral TH-IR cells is still observed 
in MPEP-treated animals (P<0.01, data not shown), consistent with previous 
observations with this compound (see section 3.3.3.1). 
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Figure 6.2 Effect of post-lesion LY367385 treatment on nigrostriatal 
integrity 
(A) Sub-chronic (7 day) treatment with LY367385 administered prior to 6-OHDA 
significantly reduced the 6-OHDA induced loss of nigral TH-IR cells. In contrast, sub-chronic 
(7 day) post-lesion treatment with LY367395 appeared to reduce the 6-OHDA induced loss of 
nigral TH-IR cells, but this just failed to reach statistical significance. (B) There are no 
regional differences in lesion size in any region of the SNc in animals treated post-lesion with 
LY367385. Interestingly, the lesion size is significantly reduced in LY367385 compared to 
vehicle-treated animals in regions A, B and C indicating some protection of nigral TH-IR 
cells. Data shown in (A) and (B) are mean % loss of nigral TH-IR ± SEM, n values are shown 
in parenthesis, *P<0.05; **P<0.01; LY367385 vs. vehicle-treated; tP<0.01 7 days post-6- 
OHDA vehicle-treated vs. 14 days (14d) post-6-OHDA vehicle treated. 
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Figure 6.3 Representative photomicrographs of nigral TH-IR and 
NeuN-IR cells following 6-OHDA lesion and post-lesion treatment 
with selective mGluR ligands 
Panels A and B show representative photomicrographs of nigral TH-IR cells in animals 
sacrificed at 7 and 14 days post-6-OHDA lesion respectively. Panels C and D show 
representative photomicrographs of NeuN-IR cells in the SNc from animals sacrificed at 
the same time point. Panels E-H shown representative photomicrographs of nigral TH- 
IR cells from animals treated sub-chronically (7 days) with selective mGluR ligands, 
starting 7 days post-6-OHDA lesion, (E) LY367385, (F) MPEP, (G) 2R, 4R-APDC, (H) 
L-AP4. All Images correspond to region B of the SNc (-5.30 mm from bregma), taken at 
x 40 magnification, scale bar = 200 gm. 
-296- 
R 
A (7) (6) (6) (4) B 
t 
E 
C 
4I 
(I, 
U, 
U, 
0 
E 
C) 
0 
0 
0 
4-. 
4-. 
U) 
0 
U) 
U) 
0 
C 
CF) 
D 
E 
0 
cn 
t 
Contralateral IMM I p§ lateral 
Figure 6.4 Effects of post-lesion LY367385 treatment on nigrostriatal 
tract functionality following 6-OHDA leisoning 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the corpus 
striatum of vehicle and LY3 673 85 -treated male rats. LY367385 when given prior to 6- 
OHDA significantly reduced the 6-OHDA induced depletion of striatal monoamines. 
Interestingly, post-lesion treatment with LY367385 also significantly reduced the further 
depletion of striatal monoamines compared to vehicle-treated animals in animals already 
undergoing nigrostriatal degeneration. Data shown in (A), (B) and (C) are mean striatal 
dopamine, DOPAC and HVA content in ng/ml wet weight tissue ± SEM, n values are 
shown in parenthesis. TP<0.01 7-day post-6-OHDA vehicle-treated vs. 14 day (14d) post- 
6-OHDA vehicle-treated; **P<0.01 LY367385 (sub-chronic and post-lesion) vs. vehicle- 
treated. (D) No significant alterations in striatal monoamine turnover were observed 
following treatment with LY367385 compared to vehicle-treated animals. *P<0.05; 
**P<0.01 contralateral vs. ipsilateral striata. Data shown are mean striatal monoamine 
turnover ratio calculated using the expression ((DOPAC+HVA)/DA) (pmol/ml). 
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In terms of nigrostriatal functionality, post-lesion treatment with MPEP 
significantly attenuated the depletion of striatal DA compared to vehicle treated animals 
(40.9 ± 4.7% vs. 84.71 ± 6.2%; P<0.01; Figure 6.6A) as well as DOPAC (22.1 ± 4.8% 
vs. 81.7 ± 7.3%; P<0.01; Figure 6.6B) and HVA (22.5 ± 4.9% vs. 75.7 ± 5.4%, P<0.01; 
Figure 6.6C). The depletion of striatal DA in MPEP-treated animals is not significantly 
different from that observed in animals sacrificed 7 days post 6-OHDA-lesion, the time 
point at which drug or vehicle-treatment started (40.9 ± 4.7% vs. 59.3 ± 6.1%; P>0.05, 
Figure 6.6A). However, it is noteworthy that the mean percentage loss of striatal 
monoamines is significantly increased compared to that observed when MPEP is 
injected prior to 6-OHDA (Figure 6.6A). Interestingly, the depletion of striatal DOPAC 
was found to be significantly different from that observed in animals sacrificed 7 days 
post 6-OHDA-lesion, the time point at which drug or vehicle-treatment started (22.1 %± 
4.8% vs. 55.6 ± 6.3%; P<0.05; Figure 6.6B) and a similar result was observed for HVA 
(22.5 ± 4.9% vs. 48.9 ± 4.6%; P<0.05; Figure 6.6Q. Furthermore these values were not 
significantly different from those observed when MPEP was administered sub- 
chronically prior to 6-OHDA for both DOPAC (22.1 4.8% vs. 22.45 ± 6.4%; P>0.05; 
Figure 6.613) and HVA (22.5 ± 4.9% vs. 10.14 3.6%; P>0.05; Figure 6.6Q. 
Importantly, however, a significant increase in striatal DA turnover was observed in 
MPEP-treated animals when comparing the ipsilateral and contralateral striata (0.15 0± 
0.005 vs. 0.100 ± 0.004; P<0.01; Figure 6.6D). This increase is significantly smaller 
than that observed in vehicle-treated animals (0.150 ± 0.005 vs. 0.730 ± 0.04; P<0.0001; 
Figure 6.61)). However, the DA turnover ratio in MPEP-treated animals was not 
significantly different from that observed in vehicle-treated animals at the time drug 
treatment was initiated (0.150 ± 0.005 vs. 0.161 ± 0.01, P>0.05; Figure 6.6D). 
Nevertheless, when comparing the mean concentrations of striatal monoamines between 
the ipsilateral and contralateral striata a significant reduction was still observed in 
MPEP-treated animals (P<0.05, data not shown), a finding consistent with previous 
observations with this compound in this model (see section 3.3.3.2). 
Taken together, these data suggest that sub-chronic intranigral treatment with 
MPEP post-6-OHDA lesioning significantly attenuates the further progressive loss of 
both nigral TH-IR cells and striatal DA in vivo and prevents further increases in striatal 
DA metabolism. These data suggest that MPEP may slow nigrostriatal degeneration in 
vivo following a 6-OHDA lesion. 
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Figure 6.5 Effect of post-lesion MPEP treatment on nigrostriatal 
integrity 
(A) Sub-chronic (7 day) treatment with MPEP administered prior to 6-OHDA significantly 
reduced the 6-OHDA induced loss of nigral TH-IR cells. Similarly, sub-chronic post-lesion 
treatment with MPEP significantly attenuated further loss of nigral TH-IR cells in animals 
already undergoing nigrostriatal degeneration. (B) There are no regional differences in 
lesion size in any region of the SNc in animals treated post-lesion with MPEP. Interestingly, 
the lesion size is only significantly reduced in MPEP compared to vehicle-treated animals 
in regions A, B and C. Data shown in (A) and (B) are mean % loss of nigral TH-IR ± SEM, 
n values are shown in parenthesis; **P<0.01 MPEP vs. vehicle-treated, tP<0.01 7 days 
post-6-OHDA vehicle-treated vs. 14 days (14d) post-6-OHDA vehicle treated. 
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Figure 6.6 Effects of post-lesion MPEP treatment on nigrostriatal 
tract functionality following 6-OHDA leisoning 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the corpus 
striaturn of vehicle and MPEP-treated male rats. MPEP when given prior to 6-OHDA 
significantly reduced the 6-OHDA induced depletion of striatal monoamines. 
Interestingly, post-lesion treatment with MPEP also significantly reduced the further 
depletion of striatal monoamines compared to vehicle-treated animals in animals 
already undergoing nigrostriatal degeneration. Data shown in (A), (B) and (C) are 
mean striatal dopamine, DOPAC and HVA content in ng/ml wet weight tissue ± SEM, 
n values are shown in parenthesis. *P<0.05; **P<0.01 MPEP vs. vehicle-treated; 
tP<0.01 7-day post-6-OHDA vehicle-treated vs. 14 day (14d) post-6-OHDA vehicle- 
treated; JP<0.05 MPEP post-lesion vs. vehicle post-lesion (D) A significant increase in 
striatal monoamine turnover was observed following post-lesion treatment with MPEP 
although this was markedly reduced compared to that observed in vehicle-treated 
animals. *P<0.05, **P<0.01 contralateral vs. ipsilateral striata. Data shown are mean 
striatal monoamine turnover ratio calculated using the expression 
((DOPAC+HVA)/DA) (pmol/ml). 
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6.3.3 Neuroprotection of the nigrostriatal system following post-6-OHDA lesion 
treatment with 2R, 4R-APDC 
In animals treated sub-chronically with intranigral injections of 10 Mol in 4 ýtl 2R, 4R- 
APDC 7 days after 6-OHDA administration, the loss of nigral TH-IR cells was 
significantly reduced compared to that observed in vehicle-treated animals (53.9 ± 3.0% 
vs. 77.2 ± 1.5%; P<0.01; Figure 6.7A). No significant differences in lesion size were 
observed between any region of the SNc in 2R, 4R-APDC -treated animals (F1 . 588; 
P=0.267). Additionally, the mean percentage loss of nigral TH-IR cells was only 
significantly reduced when compared to vehicle-treated animals in regions A, B and C 
(but not D or E) of the SNc as shown in Figure 6.713. This is in contrast to previous 
observations with this compound at the same concentration in this model, in which 
significant neuroprotection of nigral TH-IR cells was observed in all regions except 
region E of the SNc (see section 3.3.4.1). Importantly, the mean percentage loss of 
nigral TH-IR cells in 2R, 4R-APDC -treated animals was found to be not significantly 
different from that observed in animals sacrificed 7 days post 6-OHDA-lesion, the time 
point at which drug or vehicle-treatment started (53.9% ± 3.0 vs. 68.9 ± 6.1%; P=0.06; 
Figure 6.7A). The degree of neuroprotection following 2R, 4R-APDC treatment is 
illustrated in a representative photomicrograph shown in Figure 63G. It is noteworthy 
however, that the neuroprotection of nigral TH-IR cells is significantly reduced 
compared to that observed when 2R, 4R-APDC is injected prior to 6-OHDA (54.4 ± 
5.4% vs. 36.26 ± 5.5%; P<0.05 Figure 6.7A). Furthermore, when comparing the mean 
number of nigral TH-IR cells between the ipsilateral and contralateral hemispheres of 
the brain, 6-OHDA still induces a significant loss of nigral TH-IR cells in 2R, 4R- 
APDC-treated animals, (P<0.01, data not shown) consistent with previous observations 
with this compound (see section 3.3.4.1). 
In terrns of nigrostriatal functionality, post-lesion treatment with 2R, 4R-APDC 
significantly attenuated the depletion of striatal DA compared to vehicle treated animals 
(53.3 ± 6.0% vs. 84.71 ± 6.2%; P<0.01; Figure 6.8A) as well as DOPAC (49.5 ± 8.9% 
vs. 81.7 ± 7.3%; P<0.05; Figure 6.813) and HVA (47.2 ± 9.8% vs. 75.7 ± 5.4%, P<0.05; 
Figure 6.8Q. The depletion of striatal DA in 2R, 4R-APDC-treated animals is not 
significantly different from that observed in animals sacrificed 7 days post 6-OHDA- 
lesion, the time point at which drug or vehicle-treatment started (53.3 ± 6.0% vs. 59.3 ± 
6.1 %; P>0.05, Figure 6.8A). Similar results were observed for DOPAC (49.5 ± 8.9% vs. 
55.6 ± 6.3%; P>0.05; Figure 6.813) and HVA (47.2 ± 9.8% vs. 48.9 ± 4.6%; P>0.05; 
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Figure 6.8Q. However, it is noteworthy that the mean percentage loss of striatal DA is 
significantly increased compared to that observed when 2R, 4R-APDC is injected prior 
to 6-OHDA (Figure 6.8A) and similar results were observed for DOPAC and HVA 
(Figure 6.813 and Q. Importantly, a significant increase in striatal DA turnover was also 
observed in 2R, 4R-APDC -treated animals when comparing the ipsilateral and 
contralateral striata (0.159 ± 0.02 vs. 0.107 ± 0.005; P<0.05; Figure 6.81)), although, 
this was significantly reduced compared to that observed in vehicle-treated animals 
(0.159 ± 0.02 vs. 0.730 ± 0.05, P<0.0001; Figure 6.81)). However, it is noteworthy that 
when comparing the mean concentrations of striatal monoamines between the ipsilateral 
and contralateral. striata, 6-OHDA still induces a significant depletion of DA and its 
metabolites (P<0.05, data not shown), consistent with previous observations (see 
section 3.3.4.2). 
Taken together, these data suggest that sub-chronic intranigral treatment with 
2R, 4R-APDC post-6-OHDA lesioning significantly attenuates the further progressive 
loss of both nigral TH-IR cells and striatal DA and its metabolites in vivo. Furthermore, 
post-lesion treatment with 2R, 4R-APDC also prevents further increases in striatal DA 
metabolism. These data suggest that this compound may be able to slow nigrostriatal 
degeneration in vivo following a 6-OHDA lesion 
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Figure 6.7 Effect of post-lesion 2R, 4R-APDC treatment on 
nigrostriatal integrity 
(A) Sub-chronic (7 day) treatment with 2R, 4R-APDC administered prior to 6-OHDA 
significantly reduced the 6-OHDA induced loss of nigral TH-IR cells. Similarly, post- 
lesion treatment with 2R, 4R-APDC significantly attenuated further loss of nigral TH-IR 
cells in animals already undergoing nigrostriatal degeneration (B) There are no regional 
differences in lesion size in any region of the SNc in animals treated post-lesion with 
2R, 4R-APDC. Interestingly, the lesion size is significantly reduced in 2R, 4R-APDC 
compared to vehicle-treated animals in regions A, B and C. Data shown in (A) and (B) 
are mean % loss of nigral TH-IR ± SEM, n values are shown in parenthesis; **P<0.01 
2R, 4R-APDC vs. vehicle-treated; tP<0.01 7 days post-6-OHDA vehicle-treated vs. 14 
days (14d) post-6-OHDA vehicle treated. 
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Figure 6.8 Effects of post-lesion 2R, 4R-APDC treatment on 
nigrostriatal tract functionality following 6-OHDA leisoning 
Mean percentage reduction of dopamine (A), DOPAC (B) and FIVA (C) in the corpus 
striaturn, of vehicle and 2R, 4R-APDC-treated male rats. 2R, 4R-APDC when given 
prior to 6-OHDA significantly reduced the 6-OHDA induced depletion of striatal 
monoamines. Similarly, post-lesion treatment with 2R, 4R-APDC significantly 
reduced further depletion of striatal monoamines compared to vehicle-treated animals 
in animals already undergoing nigrostriatal degeneration. Data shown in (A), (B) and 
(C) are mean striatal dopamine, DOPAC and HVA content in ng/ml wet weight tissue 
± SEM, n values are shown in parenthesis. *P<0.05; **P<0.01 2R, 4R-APDC (Sub- 
chronic and post-lesion) vs. vehicle-treated tP<0.01 7-day post-6-OHDA vehicle- 
treated vs. 14 day (14d) post-6-OHDA vehicle-treated. (D) A significant increase in 
striatal monoamine turnover was observed following post-lesion treatment with 
2R, 4R-APDC. *P<0.05, **P<0.01 contralateral vs. ipsilateral striata. Data shown are 
mean striatal monoamine turnover ratio calculated using the expression 
((DOPAC+HVA)/DA) (pmol/ml). 
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6.3.4 Neuroprotection of the nigrostriatal system following post-6-OHDA lesion 
treatment with L-AP4 
In animals treated sub-chronically with intranigral injections of 10 nmol in 4 ýtl L-AP4 
7 days after 6-OHDA administration, the mean percentage loss of nigral TH-IR cells 
was not significantly different from that observed in vehicle-treated animals (71.57 ± 
9.10% vs. 77.20 ± 1.55%; P>0.05; Figure 6.9A), although there appeared to be a trend 
towards a reduction in nigral TH-IR cell loss (Figure 6.9A). However, in all regions of 
the SNc the mean percentage loss of nigral TH-IR cells was not significantly different to 
vehicle-treated animals (F1 
. 649; 
P=O. 15 1) as shown in Figure 6.913 and nor were any 
significant differences observed between regions of the SNc (FI. 230; P=0.349; Figure 
6.9B). This is in marked contrast to the very significant neuroprotection observed at all 
stereotaxic levels of the SNc when L-AP4 is administered as a pre-treatment, prior to 6- 
OHDA at the same concentration (see section 3.3.5.1 and Figure 6.9A). Moreover, 
when comparing the mean number of nigral TH-IR cells between the ipsilateral and 
contralateral hemispheres of the brain, 6-OHDA induces a significant loss of nigral TH- 
IR cells in post-lesion L-AP4-treated animals (P<0.01, data not shown), although this 
was also observed when L-AP4 is administered prior to the 6-OHDA neurotoxin (see 
section 3.3.5.1). Interestingly however, the mean percentage loss of nigral TH-IR in L- 
AP4-treated animals is also not significantly different from that observed in animals 
sacrificed 7 days post 6-OHDA-lesion, the time point at which drug or vehicle- 
treatment started (71.57 ± 9.10% vs. 68.8 ± 1.9%; P>0.05, Figure 6.9A) which may 
suggest a very mild degree of neuroprotection. Indeed, a representative 
photomicrograph shown in Figure 6.3H illustrates a greater number surviving nigral 
TH-IR cells in these animals than is apparent in vehicle-treated groups. 
In contrast, the depletion of striatal DA in the ipsilateral striatum was 
significantly reduced in L-AN-treated animals compared to vehicle-treated controls 
(44.5 ± 6.5% vs. 84.71 6.2%; P<0.01; Figure 6.10A). Similar results were observed 
for both DOPAC (38.6 5.6% vs. 81.7 ± 7.3%; P<0.05; Figure 6.1013) and HVA (39.6 
± 5.9% vs. 75.7 ± 5.4%; P<0.01; Figure 6.1 OC). The depletion of DA in L-AN-treated 
animals was not significantly different from that observed in vehicle-treated animals 
sacrificed 7 days post 6-OHDA-lesion (44.5 ± 6.5% vs. 59.3 ± 6.1%; P>0.05, Fig 
6.10A). Similar results were observed for both DOPAC (38.6 ± 5.6% vs. 55.6 ± 6.3%; 
P>0.05; Figure 6.1 OB) and HVA (39.6 ± 5.9% vs. 48.9 ± 4.6%; P>0.05; Figure 6.1 OC). 
However, it is noteworthy that the mean percentage loss of striatal DA is significantly 
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increased compared to that observed when L-AP4 is injected prior to 6-OHDA (Figure 
6.1 OA) and similar results were observed for DOPAC and HVA (Figure 6.1 OB and C). 
Importantly, a significant increase in striatal DA turnover in the L-AP4-treated animals 
was also observed when comparing the ipsilateral and contralateral striata (0.141 ± 
0.008 vs. 0.107 ± 0.004; P<0.05; Figure 6.1 OD), although this was significantly reduced 
compared to that observed in vehicle-treated animals (0.141 ± 0.008 vs. 0.730 ± 0.05, 
P<0.0001; Figure 6.10D). It is also noteworthy that when comparing the mean 
concentrations of striatal monoamines between the ipsilateral and contralateral 
hemispheres in this group, 6-OHDA induces a significant depletion of both DA and its 
metabolites (P<0.05, data not shown). Indeed, this is in marked contrast to the very 
significant neuroprotection observed when comparing the same values in animals pre- 
treated with L-AP4 at the same concentration (see section 3.3.5.2). 
Taken together, these data indicate that sub-chronic intranigral treatment with L- 
AN post-6-OHDA lesioning does not provide significant neuroprotection of the 
integrity of the nigrostriatal system against continued neurodegeneration, although there 
may be a trend towards some protection of nigral TH-IR cells. In marked contrast, post- 
lesion treatment with L-AP4 significantly attenuates further depletion of striatal 
monoamines induced by 6-OHDA, and prevents further increases in striatal DA 
metabolism. These data suggest that L-AP4 may be able to slow nigrostriatal 
degeneration in vivo following 6-OHDA lesioning. 
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Figure 6.9 Effect of post-lesion L-AP4 treatment on nigrostriatal 
integrity 
(A) Sub-chronic (7 day) treatment with L-AP4 administered prior to 6-OHDA 
significantly reduced the 6-OHDA induced loss of nigral TH-IR cells. In contrast, post- 
lesion treatment with L-AP4 does not significantly attenuate further loss of nigral TH-IR 
cells in animals already undergoing nigrostriatal degeneration, although there is a trend 
towards a neuroprotective effect. (B) There are no regional differences in lesion size in 
any region of the SNc in animals treated post-lesion with L-AP4 . The lesion size is not 
significantly different from vehicle-treated animals in any region of the SNc in post-lesion 
L-AP4-treated animals. Data shown in (A) and (B) are mean % loss of nigral TH-IR ± 
SEM, n values are shown in parenthesis; * *P<0.0 I L-AP4 sub-chronic vs. vehicle-treated, 
tP<0.01 7 days post-6-OHDA vehicle-treated vs. 14 days (14d) post-6-OHDA vehicle 
treated. 
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Figure 6.10 Effects of post-lesion L-AP4 treatment on nigrostriatal 
tract functionality following 6-OHDA leisoning 
Mean percentage reduction of dopamine (A), DOPAC (B) and HVA (C) in the corpus 
striaturn of vehicle and L-AP4-treated male rats. L-AP4 when given prior to 6-OHDA 
significantly reduced the 6-OHDA induced depletion of striatal monoamines. Similarly, 
post-lesion treatment with L-AP4 significantly reduced the further depletion of striatal 
monoamines compared to vehicle-treated animals in animals already undergoing 
nigrostriatal degeneration. Data shown are mean striatal dopamine, DOPAC and HVA 
content in ng/ml wet weight tissue ± SEM, *P<0.05; **P<0.01 L-AP4 vs. vehicle-treated 
tP<0.01 7-day post-6-OHDA vehicle-treated vs. 14 day (14d) post-6-OHDA vehicle- 
treated. (D) A significant increase in striatal monoamine turnover was observed following 
post-lesion treatment with L-AP4, *P<0.05, P<0.01 contralateral vs. ipsilateral striata. 
Data shown are mean striatal monoamme turnover ratio calculated using the expression 
((DOPAC+HVA)/DA) (pmol/mi). 
(6) 
+ 
-308- 
r 
t' 
Ne 
e 
NG oe 
Nel 
e 
Ob jq 
NO 
Z oe oe x§ 
6.4 Discussion 
6.4.1 Summary of mainfindings 
The main findings of the current study are that in animals already undergoing 
nigrostriatal degeneration, sub-chronic intranigral treatment with the mGluR1 
antagonist LY367385 or the Group III mGluR agonist L-AP4 appeared to provide mild 
but importantly, not significant neuroprotection against the further degeneration of 
nigral TH-IR cells. Interestingly, both LY367385 and L-AP4 treatment did significantly 
attenuate further depletion of striatal monoamines and prevented further increases in 
striatal DA turnover. In contrast, sub-chronic treatment with MPEP significantly 
attenuated further degeneration of both nigrostriatal integrity and functionality and 
prevented further increases in striatal DA metabolism when treatment is initiated post-6- 
OHDA lesioning. Similar results were also observed following post-60HDA lesion sub- 
chronic intranigral treatment with the Group Il mGluR agonist 2R, 4R-APDC. 
Interestingly, in each drug treatment group both the mean numbers and the mean 
percentage loss of nigral TH-IR cells was closely similar and indeed, not significantly 
different from, that observed in animals sacrificed at 7 days post-6-OHDA lesion, the 
timepoint at which drug treatment was initiated. Consistent with this, similar findings 
were observed when comparing the mean concentrations or mean percentage loss of 
striatal DA and its metabolites and when comparing the increase in striatal DA 
metabolism in the ipsilateral striatum. 
Few previous studies have examined the neuroprotective effects of mGluR 
ligands in vivo in animals already undergoing nigrostriatal degeneration. Interestingly, 
these data presented herein are consistent with previous findings in a transgenic mouse 
model of Huntington's Disease (HD) a neurological disease in which chronic glutamate 
toxicity is implicated, in which both MPEP and the mGluR2/3 agonist (-)-2-oxa-4- 
aminobicyclo[3.1. O]hexane-4,6-dicarboxylate (LY379268) significantly retard disease 
progression (Schiefer et al, 2004). Additionally, these data are consistent with a report 
published during the course of the present work, in which chronic MPEP treatment was 
demonstrated to significantly protect the nigrostriatal system following intrastriatal 
infusion of 6-OHDA (Armentero et al, 2005). Interestingly, in this study MPEP also 
normalised increases in STN and SNr/EPN metabolic activity suggesting that 
modulation of STN activity may be critical to MPEP neuroprotective mechanisms 
(Armentero et al, 2005). The finding that normalisation of STN activity correlates with 
neuroprotection further implicates increased excitatory drive from this structure in PD 
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pathogenesis. Importantly, to the best of the author's knowledge, no in vivo studies 
exist which have investigated the neuroprotective effects of mGluRl antagonists such as 
LY367385 or Group III mGluR agonists in animals already undergoing nigrostriatal 
degeneration, thus these data presented herein are novel findings and have been 
previously published in part (Vernon et al, 2006). 
In contrast, the neuroprotective action of another mGluR2/3 agonist, LY379268, 
has been previously reported in vivo in a rodent 6-OHDA model (Murray et al, 2002). 
Interestingly, in these studies chronic systemic administration of LY379268 resulted in 
significant neuroprotection of DA axon terminals in the striatum. and moderate but not 
significant neuroprotection of nigral TH-IR cell bodies in the SNc following intrastriatal 
infusion of 6-OHDA (Murray et al, 2002). In contrast, in the current study post 6- 
OHDA lesion treatment with the selective Group 11 mGluR agonist 2R, 4R-APDC 
resulted in significant neuroprotection of nigral TH-IR cell bodies. These differences in 
efficacy may be explained by conflicting effects of LY379268 at different sites within 
the basal ganglia following systemic administration, which may have important clinical 
implications (Murray et al, 2002). Thus, it will be important to confirm the 
neuroprotective effects of post-lesion 2R, 4R-APDC treatment either by i. c. v or systemic 
administration. Alternatively, in the study by Murray and colleagues (2002) it is not 
clear whether the entire rostral to caudal extent of the SNc was sampled for TH-IR cell 
counting as it was in the current study. This may be important since data presented 
herein demonstrate that in animals treated post-lesion with 2R, 4R-APDC there is only 
significant neuroprotection in certain stereotaxic regions A, B and C but not D or E (see 
section 663). Thus, the discrepancy in apparent neuroprotective efficacy in these two 
studies may be explained by differences in the cell counting methodology employed. 
As previously discussed, theoretically, the observed further decrease in nigral 
TH-IR cells and the neuroprotective effects of each mGluR ligand on the remaining 
nigral TH-IR cells could be due to transient atrophy of cells and downregulation of TH 
expression rather than true cell death and neuroprotection (Sherman and Moody, 1995; 
Yuan et al, 2005; Meuer et al, 2006). This possibility has been previously addressed 
(see section 3.4) where it was described that infusion of 6-OHDA into the SNc produces 
a comparable reduction of NeuN-IR cells as well as TH-IR cells (65.62 ± 1.61% vs. 
73.31 ± 4.63%). Importantly, 14 days post-6-OHDA lesion, the further reduction in 
nigral TH-IR cells is mirrored by a further decrease in NeuN cells (62.8 ± 4.3% vs. 81.9 
± 1.6%; P<0.05, data not shown), suggesting a process of continued and progressive 
neuronal death. 
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Interestingly, post-lesion treatment with all the mGluR ligands tested 
significantly attenuated the 6-OHDA-induced depletion of striatal DA and its 
metabolites, which indicates preservation of axonal Projections. However, it is 
noteworthy that in animals treated with MPEP, 2R, 4R-APDC and L-AP4 a small but 
significant increase in DA turnover was observed in the ipsilateral striatum. Importantly 
however, post-lesion treatment with these compounds prevented the development of 
further increases in the 6-OHDA-induced elevation of striatal DA turnover as was 
observed in vehicle-treated animals. Taken together, these data suggest that the 
preservation of striatal monoamine levels may be due to a combination of 
neuroprotection and intrinsic compensatory mechanisms, such as increases in DA 
metabolism by the surviving nigral TH-IR cells (Zigmond et al, 2002). Importantly, 
these data are consistent with the previous findings of Murray and colleagues (2002) in 
that sub-chronic post-lesion treatment with LY379268 reduced, but did not completely 
block 6-OHDA induced increases in striatal DA turnover. Due to the short time between 
6-OHDA lesioning and HPLC measurements (7 and 14 days post-6-OHDA lesion, 
respectively) it is unlikely however, that the preservation of striatal DA observed in the 
current study could be explained by sprouting of the remaining axonal projections, 
which has been suggested to occur a minimum of 4 weeks after 6-OHDA lesioning 
(Finkelstein et al, 2000; Stanic et al, 2003). 
Taking all these findings together, these data suggest that delayed sub-chronic 
intranigral. treatment with selective mGluR ligands appears to slow the continued 
degeneration of the nigrostriatal system following 6-OHDA lesioning in vivo, such that 
the state of the system is similar to that observed at the timepoint at which drug 
treatment was started. However, this action does not appear to be not associated with 
any functional regeneration of the integrity of nigrostriatal system, implying a 
neuroprotection of remaining nigral TH-IR cells and striatal monoamines, but not a 
"neurorescue" effect as has been observed following delayed treatment with growth 
factors such as Glial derived neurotrophic factor or Neurturin (GDNF and NTN; 
Bjorklund et al, 1997; Rosenblad et al, 1999; 2000; Kirik et al, 2000a, b; 2001) and 
with vascular endothelial growth factor (VEGF; Yasuhara et al, 2005). 
6 2.4 Methodological considerations 
When comparing previous studies of delayed treatment with putative neuroprotective 
agents to those described herein, some important methodological differences must also 
be considered. In the studies by both Armentero and colleagues (2005) and Murray and 
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co-workers (2002) and indeed, numerous others (Rosenblad et al, 1999; 2000; Kirik et 
al, 2000a, b; 2001) the 6-OHDA neurotoxin was administered into the corpus striaturn 
to produce partial lesions of the nigrostriatal system (see section 2.1.1). This method has 
been suggested to mimic more closely the progressive nature of the disease course in 
humans, producing degeneration more comparable to that observed in early stage PD 
patients when symptoms initially manifest (Sauer and Oertel, 1994; Kirik et al, 1998; 
Deumens et al, 2002). This is known to occur when approximately 80% of striatal DA 
terminals and 50% of nigral DA neurones have degenerated (Bernheimer et al, 1973; 
Riederer and Wuketich, 1976; Fearnly and Lees, 1991), coupled with an approximate 
80% loss of striatal dopamine (Foley and Riederer, 1999). In contrast, intranigral 
injection of 6-OHDA as utilised in the current study produces an acute and rapid 
degeneration of nigral DA neurones within 24-48 hours, followed by striatal DA 
depletion and loss of nigrostriatal DA axon terminals within 3-4 days (Ungerstedt U, 
1968; Agid et al, 1973; Perse et al, 1989; Blanchard et al, 1996; Deumens et al, 2002). 
Importantly, following this initial rapid phase of cell death, the remaining nigral DA 
neurones then degenerate in an apparently progressive manner until typically as many as 
90% of nigral DA neurones are destroyed and 90% depletion of striatal DA is achieved, 
following 6-OHDA infusion into the SNc as measured 2-3 weeks after lesioning 
(Deumens et al, 2002). Thus, it has been suggested that this method of 6-OHDA 
lesioning may reflect a more advanced disease state than the more progressive, 
intrastriatal lesion model (Betarbet et al, 2002; Cenci et al, 2002; Meissner et al, 2004). 
In the current study, however, it is demonstrated that one week following 
intranigral infusion of 6-OHDA, the loss of nigral DA neurones is -65%, which is 
approximately equivalent to the suggested level of degeneration seen in early stage PD, 
although the level of DA depletion is not as great (60% vs. 80%). However, if the lesion 
is allowed to develop for a further 7 days, an enhanced degeneration of nigral DA 
neurones is observed with concomitant increases in the depletion of striatal monoamines 
and further increases in striatal DA turnover as the system attempts to compensate for 
the further degeneration of the nigrostriatal system, suggesting a progressive lesion 
development. Thus, this protocol may also represent a relevant model that mimics the 
degeneration of the nigrostriatal system which is observed in early stage PD patients, 
thus representing a valid and clinically relevant experimental model in which to initially 
screen compounds for their neuroprotective or neurorescue actions with treatment 
delayed until after the 6-OHDA infusion. Furthermore, in all the other studies we have 
performed with these compounds, including the concentration-response studies, which 
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provided the optimum concentrations of each compound to use, a single intranigral 
lesion has been utilised. Thus, for the sake of consistency and time, intranigral lesioning 
was also employed in the post-lesion studies. 
However, whilst the data presented herein remain valid and interesting findings, 
which are broadly consistent with previous findings, particularly in the case of MPEP 
(Armentero et al, 2005), it will perhaps be more relevant and indeed, interesting in 
future studies to repeat the studies described herein utilising the intrastriatal lesioning 
model, in order to investigate the neuroprotective effect of mGluR ligands in a model 
which may more closely mimic the progressive nature of the degeneration seen in PD. 
Furthermore, previous studies have employed more chronic dosing regimens (Murray et 
al. 2002; Armentero et al, 2005). Partly this reflects the slower time course of the 
degeneration produced by intrastriatal administration of 6-OHDA, but is also more 
clinically relevant, particularly since systemic administration was employed in both of 
these studies. Thus, it will also be important to adopt these approaches to test more 
chronic dosing regimens with these compounds, which may result in a greater 
neuroprotective effect than observed in the current study, utilising a systemic method of 
administration in future studies, which will be more clinically relevant. 
6 4.3 MPEP and 2R, 4R-APDC appear to be more efficacious at preventing continued 
nigrostriatal degeneration following 6-OHDA lesioning than either LY367385 or L-AP4 
Interestingly, in the current study, the greatest attenuation of continued nigrostriatal 
degeneration resulted after treatment with either MPEP or 2R, 4R-APDC, whereas 
treatment with either LY367385 or L-AP4 produced less pronounced effects. 
This may be explained by experimental difficulties, including post-operative loss 
of animals following 6-OHDA lesioning, animals having to be culled following 
displacement of cannulae, and animals which did not show correct cannulae placement. 
These factors conspired such that in the L-AP4-treated group there was a smaller n 
value compared to the other groups (n=4 vs. typically n=6/7). Thus, it is possible that 
the lack of statistically significant neuroprotection of nigral TH-IR cells in this group 
may be explained by large variation due this smaller sample size. In support of this, the 
SEM of both the mean percentage loss of nigral TH-IR cells and the mean number of 
nigral TH-IR cells was relatively high in this group (Figures 6.9 and 6.10) compared to 
other groups where the n value is higher (Figures 6.2 - 6.8). Interestingly 
however, the 
trend shown in Figure 6.9 would tend to suggest neuroprotection post-lesion 
following 
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L-AP4 treatment, but the large error bar means this does not reach statistical 
significance when compared to vehicle-treated animals. Thus, it will be important to 
repeat this experiment in additional animals to increase the sample size, which may lead 
to the observation of a statistically significant effect. 
Additionally, these findings may be related to regulation of the expression of 
individual mGluR subtypes within the basal ganglia (13G). Given the important role that 
mGluR play in modulating glutamate neurotransmission within the BG, it is likely that 
any changes in the expression of these receptors under the pathological conditions of 
PD may lead to an exacerbation of already aberrant glutamate neurotransmission in the 
BG, particularly at subthalamonigral synapses (Messenger et al, 2002; Gu et al, 2003). 
A further alternative possibility is that elevated levels of glutamate in the SNc released 
from STN terminals may lead to plasticity of mGluR expression as a compensatory 
mechanism. In support of these receptor-mediated concepts, numerous studies have 
identified changes in the expression levels of specific mGluR subtypes under 
parkinsonian conditions in the BG using experimental models of PD in vivo. Indeed, a 
specific -50% downregulation of mGluRl immunoreactivity was observed in the SNc 
of rodents bearing a unilateral 6-OHDA lesion of the nigrostriatal tract (Kosinski et al, 
1998). Recently, Messenger and colleagues (2002) have conducted a systematic 
evaluation of the expression of all mGluR subtypes in the BG nuclei and other brain 
regions in animals bearing a unilateral lesion of the nigrostriatal tract. Consistent with 
previous observations, Messenger and colleagues (2002) reported a significant decrease 
in mGluR1 mRNA signal in the SNc of approximately 51%, indicating that changes at 
the receptor mRNA level are translated into changes at the receptor protein level 
(Kosinski et al, 1998; Messenger et al, 2002). Interestingly, a modest reduction in 
mGluR3 mRNA in the striaturn and globus pallidus and small but significant reductions 
in mGluR4 in the motor cortex and striaturn were also observed (Messenger et al, 2002). 
These findings have been confirmed by subsequent immuocytochernical studies of 
mGluR expression in unilateral 6-OHDA lesioned rodents (Gu et al, 2003) and 
importantly, a similar significant decrease in mGluRl immunoreactivity has also been 
described in the pallidal complex and the substantia nigra of non-human primates 
rendered parkinsonian by MPTP intoxication (Kaneda et al, 2005). 
Importantly, in the rodent studies, amphetamine rotational screening tests 
suggested these animals had an 80-90% lesion of the nigrostriatal system (see section 
2.1.1.4). These findings raise the possibility that the remaining mGluRl mRNA and 
receptor protein may reside on non-doparninergic neurones in the SNc, which may be of 
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GABA phenotype (Kosinski et al, 1998; Messenger et al, 2002). More importantly, 
these findings suggest that at least 50% of mGluR1 receptors in the SNc are expressed 
in vulnerable DA neurones (Messenger et al, 2002). Since activation of Group I mGluR 
regulates excitability of nigral neurones (Meltzer et al, 1993; Shen and Johnson, 1997; 
Fiorillo and Williams 1998; Wigmore and Lacey, 1998), it is possible that the 
downregulation of mGluR1 observed may reflect a functional compensation in response 
to increased glutamate transmission onto midbrain DA neurones under parkinsonian 
conditions (Messenger et al, 2002). Of course, it could also be argued that these findings 
are simply the result of neuronal death induced by the 6-OHDA neurotoxin (Kosinski et 
al, 1998; Messenger et al, 2002). Importantly, these changes in mGluR1 were observed 
between 3 and 4 weeks post 6-OHDA lesioning, whereas the longest timepoint studied 
in the current study was 2 weeks post 6-OHDA lesion. Therefore, until the spatio- 
temporal nature of these changes is elucidated in response to 6-OHDA lesioning, it is 
difficult to say with certainty whether this does indeed represent functional 
compensation or is merely a reflection of DA neuronal loss in the SNc (Messenger et al, 
2002). 
In this respect, in MPTP-treated non-human primates, a downregulation of 
mGluR1 a immunoreactivity has been reported, beginning within I week of the start of 
MPTP treatment, suggesting that mGluRl a downregulation occurs quickly in response 
to the generation of a nigrostriatal lesion (Kaneda et al, 2005). However, whether this 
occurs with a similar time course in 6-OHDA lesioned rodents requires future 
confirmation. It is also noteworthy, that no other changes were observed in the 
expression of any other mGluR subtype in non-human primates as a result of MPTP 
treatment, in particular, no change was observed in the expression of nigral mGluR5 
(Kaneda et al, 2005). Interestingly, this finding was replicated in 6-OHDA lesioned 
rodents, where no downregulation of mGluR5 mRNA was observed either despite the 
detection of moderate expression of mGluR5 in the rodent SNc (Hubert et al, 2001; 
Messenger et al, 2002). These findings therefore tend to argue against the suggestion 
that decreased mGluR1 expression in the primate (or rodent) is due to neuronal 
degeneration (Kaneda et al. 2005) but may support the suggestion that mGluR1 is 
specifically down-regulated as a compensatory mechanism in response to increased 
glutamate transmission. However, it must also be considered that the mGlu5 receptors 
may also be on non-dopaminergic neurones in the SNc that do not degenerate in PD, 
this explaining the lack of changes in mGlu5 receptor protein and mRNA. 
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It is however noteworthy that under parkinsonian conditions, the pharmacology 
of Group I mGluR is altered such that mGluR5 may also regulate nigral neurone 
excitability (Marino et al, 2001 see section 5.3.1). Furthermore, in the rodent and 
primate SNc, mGluRl and mGluR5 have been demonstrated to show differential 
subcellular localisation, with mGluRI mainly found associated with the plasma 
membrane, whilst mGluR5 is mainly located in discreet intracellular compartments 
(Hanson and Smith, 1999; Hubert et al, 2001). Moreover,, increasing evidence suggests 
that Group I mGluR when expressed in the same neuronal population show distinct 
functional segregation (Valenti et al, 2002). Thus, it is conceivable that mGluR5 may 
also regulate nigral cell excitability under parkinsonian conditions (see section 5.3.1), 
perhaps in response to mGluR1 down-regulation. These data may therefore explain why 
expression of mGluR5 is unaltered following DA denervation, which may in turn 
account for the increased neuroprotective effect of MPEP, an mGluR5 antagonist. 
However, until the spatiotemporal relationship of these changes in response to 6-OHDA 
lesioning in rodents is determined more accurately, this must remain a speculative 
conclusion. 
Alternatively, one could simply argue that the greater action of MPEP in animals 
already undergoing nigrostriatal degeneration may be due to an action of this compound 
on activated or dysfunctional glial cells in the SNc, since astroglia and microglia both 
express functional mGluR5 (Biber et al, 1999). In support of this we have observed in 
our 6-OHDA model a progressive inflammatory response initiated following 6-OHDA 
lesioning, which was characterised by increased infiltration of reactive microglia and 
astroglia into the ipsilateral SNc that was still persisting at 14 days post-6-OHDA 
lesion, the time point at which the experiment ended (M. Sadeghian and D. T. Dexter, 
unpublished observations). Thus, it is conceivable that the greater neuroprotective 
action of MPEP may be mediated through actions at mGluR5 expressed on the 
increasing numbers of activated glia cells infiltrating the SNc in response to the lesion, 
whilst in contrast; neuronal mGluRl is possibly down-regulated as described above. 
Similarly, this may also explain the finding that 2R, 4R-APDC appears to show greater 
neuroprotective actions than either LY367385 or L-AP4. Indeed, DA depletion is 
reported to lower the ability of Group 11 mGluR to function as presynaptic autoreceptors 
(Wittmann et al, 200 1; 2002) thus, one would predict Group II mGluR to be less 
efficacious against potential glutamate toxicity following delayed treatment. However, 
increasing evidence suggests that in fact, the majority of the neuroprotective actions 
resulting from Group II mGluR stimulation is due to increased trophic support from 
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glial cells (see section 4.4.5), which are increased in the SNc in response to the 6- 
OHDA lesion. Taken together, these suggestions may account for the greater 
neuroprotective effects observed following delayed MPEP or 2R, 4R-APDC treatment in 
this rodent model of parkinsonism. Importantly, if MPEP and 2R, 4R-APDC are 
demonstrated to be neuroprotective through a mechanism involving modulation of glial 
cell function, this may explain the apparent disease slowing effects of these compounds 
observed in the current study. This may be relevant as it has been suggested that 
reactive microgliosis may contribute to the progression of PD. Indeed, reactive 
microgliosis has been observed to persist over a long time period in MPTP-treated 
primates and this may correlate with disease progression in these animals (Barcia et al, 
2003; McGeer and McGeer, 2004; Jenner and Olanow, 2006). 
Interestingly, previous studies have also suggested that the hyperactivity of the 
STN in response to a 6-OHDA lesion reaches maximal levels at 7 days post-6-OHDA 
lesion, although it is noteworthy that increased STN activity is observed as early as a 24 
hours following 6-OHDA lesion, which persists up to 14 days post-lesion (Villa et al, 
2000). Thus, at the time-point at which drug treatment is initiated, theoretically the 
glutarnatergic output onto nigral neurones from the STN is already maximal (Villa et al, 
2000). Therefore, speculatively, plastic changes in Group I mGIuR may already have 
occurred in Group I mGluR, specifically the possible downregulation of mGluRl, 
thereby limiting the neuroprotective efficacy of mGluRl antagonists such as LY367385. 
Additionally, recent evidence suggests that in fact, Group III mGIuR do not 
greatly contribute to the regulation of glutamate transmission at subthalamonigral 
synapses in response to stimulation by endogenous glutamate (Wang et al, 2005), in 
contrast to the marked effects seen following agonist stimulation in vitro (Valenti et al, 
2005). Thus, it may be that agonists of Group III mGluR are less effective in animals 
already undergoing nigrostriatal degeneration since they do not greatly contribute to the 
regulation of glutamate transmission onto SNc neurones. 
Taken together, these data may also explain why L-AP4 and LY367385 are less 
efficacious when administered post-6-OHDA at this time-point (Vernon et al, 2006). 
However, it is noteworthy that whilst no significant neuroprotection is observed with 
these compounds, there is a generalised trend towards protection. 
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6.4.4 Absence of functional regeneration of the nigrostriatal system following post- 
lesion treatment with mGluR ligands 
In all the drug-treatment groups treated in the present study, neither the numbers of 
nigral TH-IR cells nor the concentrations of striatal DA and its metabolites were 
significantly restored above the levels observed in animals sacrificed 7 days post-6- 
OHDA lesioning, the timepoint at which drug treatment was initiated. One exception to 
this was observed in animals treated with MPEP, in which the levels of DOPAC and 
HVA were significantly different from vehicle-treated animals sacrificed at 7 days post- 
6-OHDA lesioning, although is likely to be due to the larger increases in striatal DA 
metabolism observed in these animals. Interestingly, in animals treated with 2R, 4R- 
APDC there appeared to be a trend suggesting increased survival of nigral DA neurones 
compared to the level observed when drug treatment was started, although this failed 
reach statistical significance. Taken together, these findings argue that the drug effects 
observed reflect a neuroprotection of the remaining nigral DA neurones and striatal 
monoamines, and argue against any functional regeneration. This is perhaps not 
surprising given the short survival time assessed (2 weeks post 6-OHDA lesion). 
Therefore the possibility that longer treatment with mGluR ligands may lead to the 
functional regeneration of the nigrostriatal system cannot be excluded. 
This is an interesting possibility, although the idea that regeneration of the 
nigrostriatal system may occur by de novo neurogenesis is very controversial. 
Neuroprogenitor cells (NPCs) are a relatively undifferentiated population of cells, 
which are capable of giving rise to neurones and glia of the CNS (Gritti et al, 1996; 
Gage FH, 1999; Pagano et al, 2000; Di Giorgi-Gerevini et al, 2005). Within the adult 
mammalian CNS the presence of NPCs and continued neurogenesis has been 
demonstrated to occur in two discreet brain regions, the subependymal zone of the 
lateral ventricle (SVZ) and the dentate gyrus (DG) of the hippocampus (Zhao et al, 
2003; Sanai et al, 2004). Interestingly, the SVZ has been demonstrated to produce DA 
neurones and intriguingly this process appears to be regulated by DA through an action 
on D2-like DA receptors, from doparninergic innervations projecting from the SNc 
(Hoglinger et al, 2004; Hack et al, 2005). Furthermore it has been demonstrated that DA 
prevents proliferation by arresting cells at the GUS phase cell cycle checkpoint, by 
inhibition of ribonucleotide reductase A, further suggesting DA plays a key role in the 
control of neurogenesis (Woldman et al, 2005). Interestingly, under conditions of DA 
depletion induced by 6-OHDA there is a reduction in total cell proliferation in the SVZ, 
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but an increase in the number of DA neurones as measured by the increased expression 
of TH and neuronal markers, such as NeuN in the SVZ and olfactory bulb (Hoglinger et 
al, 2004; Yamada et al, 2004; Winner et al, 2006). Thus, loss of dopaminergic 
innervation of the SVZ appears to lead to a distinct cell fate decision towards the 
stimulation of doparninergic neurogenesis, at least in the olfactory bulb (Winner et al, 
2006). Interestingly, recent evidence also suggests that activation of DA D3-like 
receptors regulates neurogenesis in the adult substantia nigra, further implicating tonic 
DA levels in the control of this process (Van Kampen and Robertson, 2005). 
Evidence also exists to suggest that in mice a slow physiological turnover of 
neurones occurs in the SN and the source of these cells has been delineated as the SVZ, 
suggesting a functional role for NPCs in the midbrain (Anglade et al, 1997; Dunnett and 
Bjorklund, 1999; Zhao et al. 2003). Interestingly, in mice treated with MPTP there is a 
significant increase in the proliferation and number of NPCs in the SN as measured by 
increases in the number of cells stained positive for the thymidine analogue 
BromoUridine (BrdU), a common marker for proliferating cells (Zhao et al, 2003), 
which was associated with small increases in neurogenesis thought to represent new DA 
neurones (Yoshimi et al, 2005; Shan et al, 2006). In contrast, in rodents treated with 6- 
OHDA this was not observed, although this may potentially reflect the larger lesion size 
generated, thereby precluding any regeneration (Lie et al, 2002; Zhao et al, 2003). In 
support of this it has been demonstrated that functional sprouting of remaining 
doparninergic axons does not occur in rodents bearing an SN lesion exceeding 70% 
(Finklestein et al, 2000; Stanic et al, 2003). However, many other studies have shown 
no evidence of neural proliferation, instead the vast majority of newborn cells were of 
astroglial lineage as measured by GFAP staining (Cooper and Isacson, 2004; Mohapel 
et al, 2005; Chen Y et al, 2005; Rierners et al, 2006). Furthermore, studies in aged, 
MPTP-treated primates have suggested that the appearance of new neurones in the 
striaturn in these animals reflects a phenotypic shift of existing neurones, from small 
GABAergic interneurons to those with a dopaminergic phenotype, expressing both TH 
and DAT, suggesting that de novo neurogenesis may not occur in this model (Tande et 
al, 2006). 
Despite these controversial findings, the idea that control of NPC proliferation 
could form the basis of novel cell replacement therapies for the treatment of PD is an 
interesting one (Di Giorgi-Gerevini et al, 2005). Thus, it has recently been demonstrated 
that endogenous activation of mGluR5 and potentially, mGluR3 appears to control and 
support the proliferation and survival of NPCs in vitro and in vivo (Di Giorgi-Gerevini 
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et al, 2005). It is noteworthy therefore that MPEP, appeared to reduce the survival and 
proliferation of these cells both in vitro and in vivo, whereas the effects of the 
mGluR2/3 agonist LY379268 appeared to induce survival and limited proliferation of 
these cells in vitro, although in vivo a single injection of LY379268 did not show any 
effect on SVZ NPCs (Di Giorgi-Gerevini et al, 2005). Thus, further studies are required 
to elucidate the role of mGluR3 in the control of NPC proliferation. 
Taken together, speculatively, these data raise the possibility that NPCs from the 
SVZ may be implicated in de novo neurogenesis in the SNc. Thus, it is possible that 
reduced proliferation of these cells may impair endogenous repair mechanisms 
following nigrostriatal damage, particularly when antagonists of mGluR5, such as 
MPEP as used as neuroprotective agents, as described herein and in other studies (Di 
Giorgi-Gerevini et al, 2005; Battaglia et al, 2005; Armentero et al, 2005). Interestingly, 
LY367385 has also been reported to reduce the number of cells expressing the protein 
Turned On After Division, 64 kDa (TOAD-64) in vitro in hippocampal explants, a 
marker of immature neuronal cells, suggesting that activation of mGluR1 may facilitate 
neurogenesis (Baskys et al, 2005). Thus, speculatively antagonism of mGluR1 may also 
impair endogenous repair systems (Baskys et al, 2005). On the other hand, it is possible 
that prolonged treatment with mGluR3 agonists may favour the increased survival and 
proliferation of NPCs, thus Group 11 mGluR agonists (such as 2R, 4R-APDC) may show 
greater neuroprotection by enhancing endogenous repair mechanisms (Di Giorgi- 
Gerevini et al, 2005), thereby possibly supporting increased gliogeneisis in the SN, 
which may provide neuroprotection through the subsequent release of trophic factors 
(Chen LW et al, 2005). Interestingly, it also recently been demonstrated that NPCs in 
vitro down-regulate mGluR5 as they differentiate and begin to express mGluR4 at both 
the mRNA and protein level (Cappuccio et al, 2006). Subsequently these cells when 
plated in medium containing specific growth factors differentiated towards a neural 
lineage, as shown by expression of the intermediate filament protein nestin and the 
homeobox protein Dlx-2 (Cappuccio et al, 2006). Activation of mGluR4 by L-AP4 
increased the expression of both of these markers, suggesting that this receptor may 
affect stem cell differentiation (Cappuccio et al, 2006), although clearly much future 
work is required to properly characterise these effects, particularly in vivo. 
Taken together however, these preliminary data suggest that mGluR ligands may 
play a role in the regulation of NPC proliferation, survival and possibly differentiation 
(Di Giorgi-Gerevini et al, 2005; Cappuccio et al, 2006). Therefore, one could speculate 
that prolonged treatment with MPEP would perhaps not be expected to result in 
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functional regeneration of the nigrostriatal system due to its inhibitory actions on NPCs, 
should this endogenous repair mechanism be present in the rodent brain, whilst 
activation of mGluR3 may act in an opposite fashion to facilitate repair, and potentially 
mGluR4 activation could influence the differentiation of NPCs towards a neuronal 
lineage. Clearly, this represents an interesting avenue for future research and it will be 
important in future studies to study the neuroprotective effects of mGluR ligands on the 
nigrostriatal system at longer survival times, and perhaps also to investigate the effect of 
mGluR ligand treatment on cell proliferation and neuro/gliogenesis in vivo in 
experimental models of PD. 
6.5 Conclusions 
In summary, the current study provides evidence to suggest that post-lesion treatment 
with the mGluR5 antagonist MPEP or the rnGluR2/3 agonist 2R, 4R-APDC results in 
significant attenuation of the further degeneration of both the integrity and functionality 
of the nigrostriatal tract, following sub-chronic intranigral treatment starting 7 days post 
infusion of 6-OHDA into the SNc. In contrast, post-lesion treatment with either the 
mGluR1 antagonist LY367385 or the Group III mGluR agonist L-AP4 provides mild 
but not significant protection of nigrostriatal integrity, but does prevent further depletion 
of striatal. monoamines following sub-chronic intranigral treatment with these 
compounds following the same treatment regime. In all drug treatment groups although 
increases in striatal dopamine turnover were measured, indicative of compensatory 
processes (Zigmond et al, 1984; 1989; 1998; 2002), these were significantly reduced 
compared to those observed in vehicle-treated animals. Furthermore, in all drug 
treatment groups, the mean numbers of nigral TH-IR cells and levels of striatal 
monoamines and DA turnover were directly comparable to, and not significantly 
different from, those observed in animals sacrificed 7 days post-6-OHDA infusion into 
the left SNc, the time point at which drug treatment was started. Taken together, these 
data suggest that delayed treatment with ligands acting at mGluRs expressed 
intranigrally may be able to slow the progression of nigrostriatal degeneration induced 
by 6-OHDA in vivo. Furthermore, these data suggest that antagonism of mGluR5 or 
stimulation of mGluR2/3 may lead to a greater neuroprotective effect than antagonism 
of mGluR1 or stimulation of Group III mGluR, although this requires further 
investigation to confirm, particularly with respect to Group III mGluR. It is noteworthy 
however, that the neuroprotective effects are markedly reduced compared to those 
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observed when mGluR ligands are administered prior to the 6-OHDA neurotoxin, as 
shown in previous studies in this thesis (see Chapters 3,4 and 5). 
It will also be important to confirm these preliminary findings in future studies 
using an intrastriatal method of 6-OHDA lesioning, which produces a retrograde, 
progressive loss of nigrostriatal DA cells (Sauer and Oertel, 1994; Kirik et al, 1998; 
Deumens et al, 2002). Indeed, this may be a more appropriate model, since it mimics 
the progressive disease course observed in humans, in contrast to the more acute 
degeneration produced by intranigral lesioning (Kirik et al, 1998; Deumens et al, 2002). 
Furthermore, it will be important to assess if the neuroprotective effects observed herein 
following intracerebral administration can be replicated following systemic application 
of these compounds, providing a more clinically relevant assessment (Meissner et al, 
2004). It will also be interesting to examine the effect of more chronic treatment 
regimens with these compounds to see if this results in greater neuroprotection or 
functional regeneration of the nigrostriatal system. In the latter case, in light of findings 
that specific mGluR subtypes may regulate the proliferation, survival and differentiation 
of NPCs, it will also be very interesting to assess the effect of chronic mGluR treatment 
on de novo neurogenesis and cell proliferation in vivo in normal rodents and 
experimental models of PD. 
In conclusion, these preliminary data suggest that mGluR ligands appear to 
prevent continued degeneration of the nigrostriatal system in vivo, suggesting that the 
targeting of specific mGluR subtypes in the BG may represent a valid non- 
doparninergic neuroprotective treatment strategy for early-stage PD patients, which may 
slow disease progression and delay the need to start L-DOPA pharmacotherapy and 
postponing the inevitable development of the motor complications associated with this 
treatment. 
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Chapter 7 
Discussion and Future Work 
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7.1 Summary of main findings 
The principal findings of the work presented in this thesis are as follows. Firstly, sub- 
chronic intranigral treatment with the Group I mGluR antagonists LY367385 and 
MPEP, the Group 11 mGluR agonist 2R, 4R-APDC or the Group III mGluR agonist L- 
AN results in robust neuroprotective effects of the integrity and functionality of the 
nigrostriatal tract following 6-OHDA lesioning in a rodent model of parkinsonism. 
These effects show clear concentration dependence and in the case of the Group 11 and 
III mGluR agonists, these effects were blocked by subtype selective Group 11 or III 
mGluR antagonists, indicating a receptor-mediated mechanism of action. Importantly, it 
is also demonstrated that these compounds when administered sub-chronically in sham- 
lesioned animals at concentrations that impart significant neuroprotection in 6-OHDA- 
lesioned animals have no significant effects on either the integrity or functionality of the 
nigrostriatal tract. 
Secondly, acute intranigral treatment with LY367385, MPEP or L-AP4 provides 
robust neuroprotection of both nigrostriatal integrity and functionality following 6- 
OHDA lesioning which is directly comparable to that observed following sub-chronic 
treatment. However, in contrast, acute treatment with 2R, 4R-APDC, does not result in 
any significant neuroprotection. 
Thirdly, sub-chronic intranigral treatment with combinations of selective mGluR 
ligands at sub-maximal concentrations produces enhanced neuroprotection of the 
integrity and functionality of the nigrostriatal tract compared to that observed for each 
compound alone at the same concentration, suggesting an additive interaction, which to 
date, to the best of our knowledge has not been demonstrated in an in vivo experimental 
model of parkinsonism. 
Finally, sub-chronic intranigral treatment post-6-OHDA lesion with selective 
mGluR ligands significantly attenuated further degeneration of the nigrostriatal tract, 
suggesting that these compounds may be able to slow the progression of 
neurodegeneration in our rodent model of parkinsonism. In all cases, the most 
consistently efficacious compounds were the mGluR5 antagonist MPEP and the broad- 
spectrum Group III mGluR agonist L-AP4. These data provide compelling evidence for 
a neuroprotective action of selective mGluR ligands against 6-OHDA toxicity in vivo. 
To the best of the author's knowledge these data are reported for the first time for these 
compounds in this experimental model of PD. These data have also been published in 
part (Vernon et al, 2005; 2006). 
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7.2 Methodological considerations related to the choice of experimental 
model of PD for investigations of the putative neuroprotective effects 
of mGluR ligands 
Whilst the findings presented herein may be of significant interest, especially since they 
are in vivo, it is noteworthy that these data are preliminary in nature and must be 
interpreted in the context of some methodological considerations related to the 
experimental model of PD employed in the current study, which are discussed in the 
following sections. 
Experimental models in vivo of human idiopathic PD provide useful tools for the 
study of the aetiology of PD and for testing novel therapeutic strategies (Betarbet et al, 
2002). In the current study, a rodent model of parkinsonism was created by a unilateral 
intracerebral. injection of 6-OHDA into the SNc. This decision was based on several 
factors. Firstly, from the outset of the current study it was desired to investigate the 
effects of the selected mGluR ligands following intranigral administration. This 
decision was based on the premise that increased glutamate release from STN efferents 
projecting to the SNc exacerbates the nigrostriatal degeneration observed in PD 
(Blandini and Greenamyre, 1998; Rodriquez et al, 1998; Blandini et al, 2000). 
Furthermore, there is extensive immunocytochernical and in situ hybridisation data 
which demonstrates that all of the mGluR subtypes targeted are expressed either on SNc 
neurones or on STN axon terminals (see section 1.10.6). Moreover, extensive functional 
evidence exists to demonstrate these receptors play a critical modulatory role in 
glutamatergic neurotransmission onto midbrain doparninergic neurones at 
subthalamonigral synapses (see section 1.7.4). Additionally, in previous studies 
investigating the neuroprotective action of mGluR ligands in vivo, compounds were 
administered either systemically (Murray et al, 2002; Battaglia et al. 2003; 2005) or 
intracerebroventricularly (i. c. v) (Aquirre et al, 2001; 2005; Murray et al, 2002), thus the 
precise site of action of these compounds within the basal ganglia could not be 
delineated. For these reasons it was decided to investigate intranigral administration of 
mGluR ligands. Additionally, one may speculate that injection of mGluR ligands into 
the SNc, where they may act selectively on mGluR expressed at subthalamonigral 
synapses may result in a greater neuroprotective effect. 
Secondly, the time-course at which the mGluR ligands could have a 
neuroprotective effect is currently unknown, thus, in these initial preliminary studies it 
was desired to administer an initial pre-treatment injection of each mGluR ligand one 
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hour prior to the infusion of 6-OHDA,, via chronically implanted indwelling guide 
cannulae into the SNc. Taking this into account, it is apparent that once the cannulae are 
implanted, further surgical interventions become impossible as the cranium is covered 
in dental cement. Thus, no option is left but to administer the neurotoxin also via the 
cannulae implanted above the SNc. 
Thirdly, injections of 6-OHDA into the lateral portion of the SNc produce 
moderate sparing of dopaminergic neurones (Carmen et al, 1991), generating a lesion 
size of between 60-80% as measured by decreased in the number of TH-IR cells (Perese 
et al, 1989; Carmen et al. 1991; Dentresangle et al, 2001; Stanic et al, 2003). 
Additionally, following injection of 6-OHDA into the lateral portion of the SNc there is 
a relative sparing of dopaminergic cells in the medial portion of the SNc, which is 
similar to the pattern of neuronal loss observed in human PD (German et al, 1989; Goto 
et al, 1989). In the current study, use of the noradrenaline uptake inhibitor desipramine 
was not employed, since this produces almost total destruction of nigrostriatal axons 
and cell bodies by preventing uptake and sequestration of 6-OHDA into noradrenergic 
neurones. This was done in order to ensure a partial lesion of the nigrostriatal system 
was generated such that the lesion size may be closer in scale to that observed in early 
stage PD. This is important, since clearly it would be preferable to investigate the 
potential neuroprotective effects of putative neuroprotective agents in a model system 
which mimics this clinical situation, in which some of the nigrostriatal system is still 
preserved, which may serve as a substrate for functional regeneration or neuroprotection 
(Miessner et al, 2004). 
Additionally, intranigral lesions also produce greater dopamine (DA) depletion 
in the lateral portions of the striatum, which again is comparable to observations made 
in human PD tissue in which DA depletion is also more pronounced in the lateral 
striaturn (German et al, 1989; Goto et al, 1989; Carmen et al, 1991). Thus, when 
investigating the potential neuroprotective effects of mGluR ligands, injections of 6- 
OHDA into the SNc were chosen based on the premise that this model appears to more 
closely replicate the pattern of nigral cell loss and striatal DA depletion observed in 
idiopathic PD, and also taking account of the experimental factors discussed above. 
However, whilst the 6-OHDA model closely mimics a number of features of the 
human disease process, there are some limitations to this model which must be taken 
into account when interpreting these data generated in this model. Primarily, whilst 
human PD is characterized by a progressive degeneration of the nigrostriatal system 
(Braak et al, 2003a, b; 2004), the degeneration in the intranigral 6-OHDA model is 
-326- 
relatively acute (Deumens et al, 2002). This is important since ideally it would be 
perhaps more relevant to investigate the neuroprotective effects of putative 
neuroprotective agents in a model system that preferably mimics the progressive nature 
of neuronal degeneration observed in PD (Kirik et al, 1998; Deumens et al, 2002; 
Miessner et al, 2004). 
This could be overcome by utilizing injection(s) of 6-OHDA into the caudate- 
putamen (CPu) complex of the rodent striaturn. This method produces partial lesions of 
the nigrostriatal system, characterized by acute, selective and circumscribed destruction 
of dopaminergic axons and terminals in the striaturn but importantly, delayed and 
protracted degeneration of DA neurones in the substantia nigra, which is suggested to 
more closely model the progressive nature of neurodegeneration in PD (SN; Sauer and 
Oertel, 1994; Kirik et al, 1998; Deumens et al, 2002; see section 62.4). Thus, it may be 
relevant in future studies relating to the neuroprotective effects of mGluR ligands to 
carry out these experiments using this lesioning protocol to confirm our results. 
In contrast, injection of 6-OHDA into the SNc as utilized in the current study 
produces an acute and rapid degeneration of nigral DA neurones within 24 hours, 
followed by striatal DA depletion and loss of striatal DA axon terminals within 3-4 days 
(Ungerstedt, 1968; Faull and Laverty, 1969; Agid et al, 1973; Perse et al, 1989; 
Blanchard et al, 1996). Thus, it has been suggested that this method of 6-OHDA 
lesioning may reflect a more advanced disease state than the more progressive, 
intrastriatal lesion model (Deumens et al, 2002; Meissner et al, 2004). Importantly, 
however, in the current study we have demonstrated that between 7 and 14 days post-6- 
OHDA lesion there is an apparent progressive loss of the remaining nigral DA neurones 
and striatal monoamine content (see section 6.2.4; Vernon et al, 2006). These data are 
also consistent with similar findings in previously published reports (Jeon et al, 1995; 
Stanic et al. 2003). Thus, for the purposes of initial neuroprotective screening as 
described herein for selective mGluR ligands, testing compounds in animals with 
intranigral 6-OHDA lesions may be appropriate. 
Another limitation of the 6-OHDA model is that in general 6-OHDA lesioning 
does not induce neuronal loss in other brain regions affected in PD (see section 1.2.1), 
nor does it result in proteinaceous cytoplasmic inclusion bodies reminiscent of Lewy 
bodies observed in Pl) (Schwarting and Huston, 1996; Del Tredici et al, 2002; Betarbet 
et al, 2002; Schober et al, 2004), although it is interesting to note that evidence exists to 
suggest that 6-OHDA-induced neuronal death may be associated with proteolytic stress 
(see section 2.1.1.3). This is important since whilst the consequences of these 
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neuropathological changes in PD are relatively unknown, a greater understanding of 
these changes may provide important clues about the development of both the motor 
and non-motor symptoms observed in PD, thus aiding development of novel treatments 
for PD (Jenner and Olanow, 2006). This is important since these additional 
neuropathological changes are often ignored and indeed have not been widely 
investigated with respect to PD pathogenesis and aetiology (Jenner and Olanow, 2006). 
Therefore, in future studies it may be informative to carry out neuroprotection 
experiments with mGluR ligands in more recently developed experimental models of 
Parkinsonism, For example, chronic treatment of rodents with the pesticide Rotenone 
(Betarbet et al, 2000a) or the proteasome inhibitors such as lactacystin and MG-132 
(McKnaught et al, 2002; 2004) or Z-Ile-Glu(OtBu)-Ala-Leu-al (PSI) (Zeng et al, 2006), 
both of which appear to replicate the classical neuropathology of PD, but importantly 
are associated neuropathological changes in other brain nuclei affected in PD and with 
the formation of Lewy body-like inclusions in vivo. 
However it should be noted that there is currently no "perfect" experimental 
model of PD, thus, if these data are interpreted within the limitations of the 6-OHDA 
model as discussed above, the data presented herein provides solid and robust 
experimental evidence that mGluR ligands are neuroprotective against 6-OHDA 
toxicity in vivo. 
An additional criticism of the current study may be related to the cell counting 
methodology employed. Indeed, this methodology may potentially lead to over 
estimation of nigral TH-IR cell numbers. In the current study, the numbers of nigral TH- 
IR cells were quantified manually in a blind fashion throughout the rostral to caudal 
extent of the SNc (see section 2.2.2.1). As the cell counting was not performed at pre- 
determined distance intervals as is the case in unbiased stereological methods (Hedreen 
JC, 1999; Baddely A, 2001) coupled with the thickness of the tissue sections on which 
TH-immunostaining and cell counting was performed (20 [tM-thick, see section 2.2.1.2) 
the possibility exists that the same TH-IR cell may be present in two sections, leading to 
possible over estimation of cell numbers. Therefore, in future studies TH-IR and indeed, 
NeuN-IR cell numbers, since these were counted in the same manner (see section 
2.2.2.2) should be rigorously assessed using unbiased stereological methods of cell 
counting as described by others (Aquirre et al, 2001; 2005). However, it is important to 
note that this approach to cell counting has been employed in previously published 
studies to ensure that comparable rostral to caudal levels of the SNc are sampled 
between animals and importantly, provides robust and accurate quantification of nigral 
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cell loss (Iravani et al, 2002; 2004; 2005a; 2006b) and neuroprotection (Datla et al, 
2001a, b; 2003; 2004; 2006; Vernon et al, 2005; 2006; Zbarsky et al, 2006). Moreover, 
the counting was performed blind to the treatment group and verified by a second 
operator, also blind to the treatment group. 
7.3 Putative models to explain the neuroprotective actions of 
metabotropic glutamate receptor ligands in vivo against 6-OHDA 
toxicity 
7.3.1 A reappraisal of glutamate excitotoxicity and the pathogenesis of Parkinson's 
disease 
The rationale for anti-glutamatergic drugs as putative neuroprotective agents is based on 
the prediction that in response to DA depletion in the striaturn, significant downstream 
alterations occur in the activity of basal ganglia nuclei that send excitatory projections 
to the SNc (see section 1.5). Primarily, these changes are characterized by a 
hyperactivity of glutarnatergic neurones in the subthalamic nucleus (STN) which is 
suggested to result in pathological increases in glutamate neurotransmission onto 
midbrain DA neurones, thereby contributing to nigral degeneration through the process 
of secondary excitotoxicity either directly by "fast" excitotoxicity, or indirectly by 
44slow" excitotoxic mechanisms, or through glial cell dysfunction (see section 1.8.3). 
Furthermore, this process results in the generation of a vicious feed-forward loop in 
which nigral degeneration and STN hyperactivity is self-sustaining (see section 1.5.4.6). 
In support of this concept, substantial laboratory evidence demonstrates that 
unilateral DA depletion caused by 6-OHDA lesioning results in hyperactivity of STN 
neurones and output pathways (see sections 1.5 and 1.8.4). Additionally, an increasing 
body of indirect evidence suggests that pathological increases in glutamate 
neurotransmission onto nigral DA neurones from the STN may contribute to the demise 
of these cells in I'D and importantly, that interruption of increased excitatory drive from 
the STN by anti -glutarnatergic drugs is neuroprotective and may retard this process (see 
sections 1.8.4 and 1.9.2). Thus, the rationale for the use of selective mGluR ligands as 
putative neuroprotective agents is thus largely based on these predictions and the 
numerous studies which have shown that members of each of the three-mGluR subtypes 
play important roles in regulating the activity through the parallel neuronal circuits and 
different synapses in the BG (see section 1.10.6). Importantly, mGluR appear to 
modulate rather than mediate glutamate transmission, thus it was predicted that mGluR 
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ligands may represent a more effective anti - glutarnatergic drug target with fewer side 
effects than ligands acting at Ionotropic glutamate receptors (iGluR) (see section 
LI 0.7). The evidence presented in the studies described in this thesis provides 
compelling evidence to support this concept, but it is important to address the question, 
"what are the potential mechanisms that underlie this neuroprotective effect? " 
In this respect, it is noteworthy, that no direct evidence exists to support a role 
for glutamate excitotoxicity in PD and to date, no publications exist which robustly 
support its occurrence in sporadic parkinsonism (Jenner and Olanow, 2006). 
Furthermore, the evidence to suggest a role for this process in DA neuronal death in the 
SNc, particularly with respect to the activity of STN neurones is derived essentially 
from studies in experimental models of PD (Luquin et al, 2006; Jenner and Olanow, 
2006) (see section 1.8.4). This has led to the suggestion that this process may in fact be 
an artefactual mechanism of cell death particular to experimental models, which may 
not be relevant to the pathogenesis of idiopathic PD (Jenner and Olanow, 2006). 
In support of this suggestion, Luquin and colleagues (2006) have demonstrated 
that nigral degeneration induced by MPTP in non-human primates is neither reduced, 
nor prevented by prior surgical removal of the excitatory drive from the STN on to 
nigral DA neurones. Additionally, in a separate experiment, the animals were allowed to 
develop a stable asymmetric Parkinsonism following MPTP treatment, at which point 
the STN was surgically destroyed by subthalamotomy (Luquin et al, 2006). Importantly, 
subthalamotomy produced a beneficial effect on the parkinsonian symptoms in these 
animals, but quantification of the numbers of nigral TH-IR cells revealed no significant 
differences between MPTP-only treated animals and MPTP-treated animals which 
received subthalamotomy, suggesting that blockade of STN inputs to the SNc does not 
modify cell loss during the ongoing neurodegeneration caused by MPTP (Luquin et al, 
2006). 
Additionally, in rodent experimental models of PD, it has been demonstrated 
that high frequency stimulation of the STN using DBS results in significant recovery of 
motor functions, which appears to correlate with reduced degeneration of the 
nigrostriatal system, suggesting this procedure may be neuroprotective by blocking 
glutamate excitotoxicity (Darbaky et al, 2003; Maesawa et al, 2004). However, this idea 
that STN-DBS is associated with neuroprotection is controversial and unproven, and 
recent evidence from I'D patients suggests this is not the case. Indeed, Hilker and 
colleagues (2005b) have recently demonstrated in sporadic PD patients with clinically 
effective bilateral DBS that DBS is not associated with a slowing of disease 
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progression, as measured by 18 F-DOPA positron emission topography (PET) imaging in 
the corpus striaturn over a 16 month follow up period post-surgery. However, it is 
noteworthy that this was measured in advanced PD patients and therefore this study 
does not preclude a potential beneficial effect of pharmacological treatments that mimic 
this process in early-stage PD. Moreover, the short nature of the follow-up period may 
not have been long enough to detect a neuroprotective effect of DBS. However, it raises 
questions over the hypothesis that neutralisation of STN hyperactivity is associated with 
neuroprotection and slowing of PD progression, which may support the findings of 
Luquin and colleagues (2006) in non-human primates. Therefore, these data argue that 
glutarnate excitotoxicity as a result of STN neurone hyperactivity may not contribute to 
the progression of nigral cell loss, although future studies are required to definitely 
prove this hypothesis. 
It is therefore, noteworthy, that the SNc also receives extensive glutamatergic 
innervation from brain stem nuclei including the PPN and also the amygdala and 
cerebral cortex and the output pathways of these structures are all hyperactive in PD 
(see section 1.5.4.4 and 1.5.4.6). Thus, it may be hypothesised that in fact, glutamate 
input from these structures, may provide a greater contribution to the progression of 
nigral cell loss through glutamate excitotoxicity that increased STN output (Obeso et al, 
2000; Breit et al, 2005; Luquin et al, 2006). In support of this concept, lesions of the 
PPN are neuroprotective in MPTP-treated primates (Takada et al, 2000). 
Taken together, these data suggest that in the current study the neuroprotective 
effects of mGluR ligands may be in part due to reductions in glutarnate transmission 
from hyperactive PPN as well as perhaps other excitatory projections such as the cortex 
and the amygdala. However, in contrast to the amygdala and cerebral cortex in which 
substantial evidence exists to suggest a role for mGluR in modulating glutamate 
transmission in these structures (Keele et al, 1997; Attuci et al, 2001; Cho and Bashir, 
2002), to date to the best of the author's knowledge, no studies have demonstrated 
whether mGluR are localised on PPN axon terminals or demonstrated a functional role 
for mGluR in the regulation of glutamate transmission at synapses between PPN axon 
terminals and nigral DA neurones in the SNc. Functional evidence does exist however, 
to demonstrate that stimulation of the PPN induces excitation of nigral DA neurones, 
mediated through postsynaptic iGluR on nigral DA neurones (Di Loreto et al, 1992; 
Meltzer et al. 1997b; Forster and Blaha, 2003), suggesting that increased glutamate 
transmission from the PPN may result in nigral excitotoxicity under conditions of DA 
depletion. 
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Alternatively, the neuroprotective effect of mGluR ligands may reflect an action 
at mGluR expressed on either infiltrating reactive microglia or damaged and 
dysfunctional astroglia in the SNc as a result of 6-OHDA lesioning (see section 7.3.2). 
Indeed, an almost universal theme in mGluR ligand neuroprotection studies is the 
required presence of glial cells, which when absent lead to remarkable reductions in the 
neuroprotective actions of these compounds (Spillson and Russell, 2003) (see section 
4.4.5). Furthermore, direct evidence exists for an inflammatory glial cell response in 
both experimental models and post-mortern brain tissue from idiopathic PD cases 
(McGeer and McGeer, 1997; 1998; Akiyama and McGeer, 1999; Hirsch et al, 2003; 
Tiesmann et al. 2003). Moreover, laboratory evidence exists to suggest that activation of 
glial cells and subsequent inflammation results in nigral DA neuronal death (see section 
1.8; Figure 1.8) (Iravani et al, 2002; 2005a; Vijitruth et al, 2006; Ferrari et al, 2006). 
Additionally, glial cells may also contribute to nigral cell death by indirect 
excitotoxicity (see section 1.8-3.3). Importantly, both populations of glial cells express 
functional mGlu receptors (see section 1.10.4) and significant evidence suggests 
activation of these receptors by endogenous glutamate and selective mGluR ligands 
critically regulates the functions of these cells (see section 1.10.6). Moreover, in the 
current study it is demonstrated that neuronal death in the SNc is accompanied by a 
rapid and prolonged infiltration of reactive microglial cells and astrogliosis (see section 
3.3.1). 
Therefore, it is tempting to speculate that the neuroprotective actions of selective 
mGluR ligands may results from two distinct mechanisms, firstly by an action at pre- 
and postsynaptic mGluR on neurones of the SNc, STN or PPN and secondly through an 
action at mGluR expressed on glial cells in the SNc. These possibilities are discussed in 
more detail below. 
7.3.2 Putative model to explain the neuroprotective effects of selective mGluR 
ligands against 6-OHDA toxicity through actions at neuronal mGluR following 
intranigral administration 
As discussed previously, induction of nigrostriatal damage by 6-OHDA may lead to 
increased glutamate release in the SNc from multiple sources including, dysfunctional 
astrocytes, infiltrating reactive microglia, or from hyperactive STN / PPN axon 
terminals as discussed above. This may lead to over-activation of postsynaptic Group I 
mGluR on nigral DA neurones, which due to mitochondrial dysfunction induced by 6- 
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OHDA are potentially rendered supersensitive to glutamate, (see section 1.8.3). 
Therefore, pharmacological antagonism of postsynaptic Group I mGluR on nigral DA 
neurones by LY367385, or MPEP may be neuroprotective, either by direct blockade of 
neuronal depolarisation by relieving Group I mGluR -mediated inhibition of K+- 
conductances and preventing Group I mGluR-mediated activation of voltage-dependent 
Na+ and Ca 2+ channels (see section LI 0.1). Additionally, antagonism of Group I mGluR 
may block the Group I mGluR-mediated potentiation of NMDAR responses. In support 
of this concept, Group I mGluR and NMDAR have been demonstrated to be 
functionally coupled and display reciprocal interactions by virtue of connections 
through post synaptic density (PSD) molecular scaffold proteins, including Homerlb/c, 
2 and 3 Shank, guanylate kinase associated protein (GKAP) and PSD-95 as depicted in 
Figure 7AA and B (Naisbitt et al, 1999; Kim and Sheng, 2004; Kammermeier et al, 
2006). These interactions act as a "molecular bridge" and promote functional clustering 
of NMDAR and mGluR at excitatory synapses and furthermore allow biochemical 
coupling of these receptors to each other and to downstream signalling effectors 
including neuronal nitric oxide synthase (nNOS), to form excitatory signalling 
complexes on neuronal dendrites (Sattler et al, 1999; Kim and Sheng, 2004). Thus, in 
nigral neurones sustained NMDAR activation and Ca 2+-influx could lead to numerous 
deleterious signal transduction events resulting in cell death (see section 1.8.3). In 
support of this concept, electrophysiological evidence demonstrates that both mGluR1 
and mGluR5 can markedly potentiate NMDAR activity in neurones in numerous brain 
regions (see section 1.10.6 and 5.4.2). Thus, if a similar relationship exists between 
Group I mGluR and NMDAR in nigral DA neurones it is conceivable that Group I 
mGluR antagonists may block excitotoxic cell death of SNc neurones by functional 
antagonism of the potentiation of NMDAR activity mediated by Group I mGluR with 
resultant uncoupling of NMDAR activation from deleterious signal transduction events, 
thereby preventing cell death. Consistent with this hypothesis, in vitro studies have 
shown that direct activation of Group I mGluR induced a rapid and transient 
phosphorylation of the c-Jun N-terminal kinase (JNK or Stress Activated Protein 
Kinase, SAPK) pathway, which correlates with phosphorylation of the transcriptional 
activators c-Jun and API (Yang et al, 2006) and is critically involved in the regulation 
of responses to cellular insults and stressors, including 6-OHDA (Brecht et al, 2005; 
Ouyang and Shen, 2006). Additionally, numerous studies have detected significant 
increases in both c-Jun and phosphorylated c-Jun in dopaminergic neurones in the SNc 
in 6-OHDA lesioned rats, suggesting an ongoing process of apoptotic cell death 
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(Vaudano et al, 2001; Kramer and Mytilineou, 2004; 2004; Paul et al, 2004; Winter et 
al, 2006). The possible signal transduction pathways which may be involved are 
outlined schematically in Figure 7.2. 
In contrast, activation of pre-synaptic Group II or Group III mGluR on either 
STN or PPN axon terminals would be predicted to result in the inhibition of glutamate 
release, leading to neuroprotection by preventing pathological increases in extracellular 
glutamate and thereby preventing subsequent over excitation of nigral DA neurones (see 
section 1.10.2 and 1.10.3). 
-334- 
Gl, u 
mGluR 1/5 NMDAR 
TVT 
Pyk2 
T 
PP2A ?? Jý 
Glu 
N 
Fyn Src 
PKC 
M GKAP 
Shank 
NMDAR 
Gl, u 
' DAG IP3 
Ca2' 
J 
C92, stores 
PER 
mGluR. 
Calmodulhijý 
Ca2+ k-C a Ici"eurin P 
CaMKII 
0 GKAP 
Shank 
Homer 
0 PSD-95 
DAG IP3 
COOH 
Ca2+ 
PKC C82- sto s 
(EM 
MAPK / ERK1/2 signal 
cascades 
Figure 7.1 Molecular scaffold proteins functionally cluster NMDAR 
and Group I mGluR at the postsynaptic membrane as signalling 
complexes, such that these receptors display reciprocal interactions to 
regulate their activity. 
(A) Activation of postsynaptic Group I mGluR potentiates NMDAR responses to 
glutamate by activation of a PKC-dependent kinase cascade involving Src / Fyn and Pyk2 
tyrosine kinases which leads to phosphorylation of tyrosine residues on the carboxyl-tail of 
NMDAR N_R2A/B subunits which is predicted to enhance NMDAR channel properties or 
negatively regulate NMDAR trafficking. (B) Activation of NMDAR can potentiate 
signalling through postsynaptic Group I mGluR by activation of the calcium-dependent 
protein phosphatase Calcineurin, which reverses PKC-mediated phosphorylation of Ser / 
Thr residues in the carboxyl terminal sequence of Group I mGluR thereby preventing 
uncoupling of the receptor from its G-protein and signal transduction mechanisms through 
PKC-mediated desensitisation of the receptor. 
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Figure 7.2 Excitotoxicity resulting from activation of NMDAR and 
Group I mGluR signal transduction systems leading to gene 
transcription and activation of cellular death pathways under conditions 
of oxidative stress or mitochondrial impairment in nigral DA neurones. 
Under conditions of mitochondrial impairment such as induced by 6-OHDA, 
increases in glutamate release can sensitise DA neurones to activation of 
postsynaptic NMDAR through the process of "slow" excitotoxicity. 
Activation of both NMDAR and Group I mGluR result in excess Ca 2+ influx 
and release from intracellular stores leading to activation of protein kinase C 
(PKQ and Ca2+/Calmodulin dependent kinase 11 signalling and neuronal 
Nitric oxide synthase activation, resulting in oxidative stress and other 
deleterious process (see Figure 1.4, Chapter 1), potentially leading to 
activation of gene transcription and cellular death pathways by one of three 
potential signalling cascades A: Potentiation of NMDAR and Group I 
mGluR-mediated ERKI/2 signalling as a result of peroxynitrite-mediated 
oxidative modification of ERKI/2 protein phosphatases leading to loss of 
phosphatase activity B: Activation of c-JNK/p38 kinase via NMDAR and 
Group I mGluR dependent on Ca2+ influx and PKC activation, C: Direct 
activation of c-JNK/p38 kinase by Group I mGluR via a Ca 2+_independent 
pathway and transactivation of EGF receptor 5. 
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7.3.2 Putative model to explain the neuroprotective effects of selective mGluR 
ligands against 6-OHDA toxicity through actions at glial mGluR following 
intranigral administration 
In addition to the neuronal mechanisms discussed in the proceeding section, the 
neuroprotective effects of selective mGluR ligands may be due to an action at mGluR 
expressed on glial cells in the SNc as shown in Figure 7.3. This may occur through a 
plethora of potential mechanisms based on the critical roles mGluR appear to play in the 
regulation of glial cell function and glial-neuronal interactions (see section 1.10.6). 
Firstly, pharmacological antagonism of mGluR5 by MPEP (and potentially mGluR1 by 
LY367385) on reactive microglial cells in the SNc may block the activation of signal 
transduction pathways leading to NOS activation or secretion of inflammatory 
mediators, thereby reducing toxicity to DA nigral neurones. Alternatively, antagonism 
of mGluR5 by MPEP may reverse downregulation of astroglial GLAST and GLT- I due 
to stimulation of mGluR5 on astrocytes by endogenous glutamate, thereby leading to a 
recovery of astroglial. glutamate uptake, thereby attenuating neurotoxicity (Aronica et al, 
2003; 2005). This would also be predicted to occur following activation of astroglia 
mGluR3 by 2R, 4R-APDC (Aronica et al, 2003). In support of this concept, evidence 
suggests that neuroprotection against both MPP+ and LPS toxicity in vitro is mediated at 
least in part by increased glutamate uptake following selective activation of astroglial 
mGluR3 by 2R, 4R-APDC or antagonism of astroglial mGluR5 by MPEP (Yao et al, 
2005; Zhou et al, 2006). Interestingly, selective activation of Group III glial mGluR by 
L-AP4 is also neuroprotective against LPS toxicity, in part due to increased glutamate 
uptake, suggesting that Group III mGluR may also be involved in this process (Zhou et 
al. 2006). Interestingly this recovery of function was associated with a recovery of 
astroglial glutathione levels that had been previously depleted (Zhou et al, 2006). These 
data suggest that Group II and III mGluR agonists may also have anti-oxidant 
capabilities and prevent astroglial dysfunction caused by oxidative stress induced by 6- 
OHDA (Spillson and Russell, 2003; Zhou et al, 2006). 
Additionally, selective activation of astroglial Group II or III mGluR may lead 
to increased secretion of trophic factors thus supporting damaged neurones (Conn et al, 
2005). In support of this, selective activation of these receptors in vitro using subtype 
selective agonists leads to increased TGF-P (Bruno et al, 1998); NGF and SlOOP 
(Ciccarelli et al, 1999) or BDNF synthesis and release (Materredona et al, 2002; 
Venereo et al, 2003), which was shown to be mediated by activation of the P13K or 
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MAPK signal transduction pathways in these cells (D'Onofrio et al, 2001; lacovelli et 
al, 2002; 2004). Importantly, BDNF is suggested to have trophic activity towards nigral 
neurones (Altar et al, 1994) and in the SN, BDNF mRNA is localised to both astroglia 
and DA neurones, whilst BDNF receptors (trkB and Q are also expressed in DA 
neurones (Altar et al, 1994). Furthermore, downregulation of BDNF expression in vivo 
results in nigrostriatal degeneration (Porrit et al. 2005). Increased production of TGF-P 
is demonstrated to correlate with neuroprotection of mixed cortical cultures against 
NMDA toxicity in vitro (Bruno et al, 1997; 1998; 1999) whilst increased BDNF 
production was suggested to account for neuroprotection against MPP+ toxicity in vivo 
(Materradona et al, 2002) and against 6-OHDA and MPTP toxicity in vitro (Spina et al, 
1992) by Group 11 mGluR agonists. Interestingly, SlOOP has also recently been 
demonstrated to increase astroglial glutamate uptake in vitro (Tramontina et al, 2006), 
suggesting increased trophic support may act in an autocrine fashion to repair altered 
glial cell function, thereby leading to neuroprotection. 
Finally, an action of selective mGluR ligands at glial mGluR may prevent 
neurotoxicity by altering secretion of inflammatory mediators. Indeed, the levels of both 
TNF-cc and IL- IP are known to be upregulated in the SN and CSF of PD patients (Boka 
et al, 1994; Mogi et al, 1994; McNaught and Jenner, 2000a). Thus, modulation of 
chemokine or interleukin secretion from reactive astrocytes or microglia to reduce 
potentially deleterious inflammatory responses may also partly explain the 
neuroprotective action of Group III mGluR ligands. In support of this hypothesis, L- 
AN is neuroprotective against LPS or chromogranin A (CGA) toxicity in vitro (Taylor 
et al, 2003). Importantly, stimulation of microglial Group III mGluR by L-AP4 did not 
appear to induce proliferation or activation of microglia (Taylor et al., 2003). Moreover, 
in vitro, microglial toxicity was rescued by application of medium from microglial 
cultures treated with L-AP4 (Taylor et al, 2005). This would suggest that selective 
activation of Group III mGluR on microglia might induce the release of a positive factor 
that prevents neuronal death or inhibit the release of a neurotoxic factor. 
In support of this, pharmacological activation of Group III mGluR by L-AP4, 
RS-PPG and L-SOP strongly inhibits release of the P-chemokine RANTES (regulated 
upon activation of normal T-cell expressed and secreted) induced by TNF-a and IFNy, 
cultured cortical mouse and rat astrocytes (Besong et al, 2002). Chemokines show cell- 
type selective chemotactic activity and play a vital role in defining the site and cellular 
composition of inflammatory responses at sites of tissue damage, such as neuronal cell 
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death (Mennicken et al, 1999). Chemokines are constitutively expressed at low levels in 
astrocytes, microglia and neurones and are markedly upregulated in response to pro- 
inflammatory stimuli such as TNF-a (Barnes et al, 1996; Mennicken et al, 1999). Thus, 
inhibition of chemokine secretion by selective activation of glial Group III mGluR may 
reduce the inflammatory response, which could be neuroprotective. 
In addition, selective activation of mGluR3 on astroglia in the presence of IL- IP 
leads to increased IL-6 secretion from astrocytes in vitro (Aronica et al, 2005), a 
cytokine with pleiotropic biological functions (Van Snick, 1990). Elevated levels of IL- 
6 are detected in other neurode generative disorders such as AD as well as in stroke and 
epilepsy (Zhao and Schwartz, 1998). Interestingly, some reports suggest that IL-6 may 
have a beneficial role, indeed intracerebral injection of IL-6 is neuroprotective against 
ischaernia in rodents (Loddick et al, 1998) and has been shown to promote neuronal 
survival and differentiation in vitro (Hama et al, 1991; Kushima et al, 1992; Marz et al, 
1998), thus perhaps mGluR3-mediated increases in IL-6 may also account for some of 
the neuroprotection observed in the current studies. 
In summary therefore, intranigral administration of mGluR ligands may 
potentially induce neuroprotection against 6-OHDA toxicity by the following 
mechanisms: (1) An action on postsynaptic Group I mGluR to prevent excitotoxic 
damage to nigral DA neurones (2) Induce recovery of dysfunctional astroglia leading to 
recovery of glutarnate uptake (3) Increased trophic support from reactive astrocytes (4) 
modulation of reactive microglial activity and finally (5) blockade of inflammatory 
mediator secretion, leading to modulation of neuroinflammation. These possibilities are 
illustrated in a schematic in Figure 7.4 
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Figure 7.3 Mechanisms of impaired glial cell function leading to 
neurodegeneration induced by 6-OHDA infusion into the SNc. 
Infusion of 6-OHDA into the SNc leads to oxidative stress, GSH depletion and 
mitochondrial dysfunction in both neurones and astrocytes, leading to impaired 
astroglial function characterised by a loss of trophic support to neurones and 
glutamate efflux due to impaired glutamate uptake capacity. Mitochondrial 
dysfunction in DA neurones sensitises these cells to glutamate, leading to 
excitotoxicity and cell death (see section 1.7.3) which may also be caused by loss 
of trophic signals from dysfunctional astrocytes. Additionally, neuronal 
degeneration induces reactive microgliosis and infiltrating activated microglia 
release cytokines including TNF-cc, leading to further inflammation and 
potentially neuronal apoptosis of DA neurones. Cytokines may also act in an 
autocrine fashion to potentiate microglia activation. Activated microglia also 
release NO and hydrogen peroxide, which may synergise with 6-OHDA induced 
oxidative stress leading to peroxynitrite formation and neurotoxicity. Microglia 
also release glutamate, possibly leading to excitotoxicity. Thus, NO production, 
inflammation, glutamate release and mitochondrial dysfunction may forrn a 
destructive cycle which combines to produce neurodegeneration in this model of 
PD. 
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Figure 7.4 Schematic to illustrate putative mechanisms of neuroprotection 
against 6-OHDA toxicity in vivo following pharmacological antagonism of 
Group I mGluR by LY367385 or MPEP, or pharmacological stimulation of 
Group 11 or IH mGluR by 2R, 4R-APDC or L-AP4 expressed on either 
neurones, astrocytes or microglia in the substantia nigra pars compacta 
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7.4 Evaluation of selective metabotropic glutamate receptor ligands as 
a potential non-dopaminergic treatment for Parkinson's disease 
Current pharmacological treatment of PD is highly successful at managing the early 
stages of this disease (see section 1.7.1) but is associated with a number of severe 
complications following long-term use (see section 1.7.1) and thus, current management 
of parkinsonism is associated with a number of unmet clinical needs (see section 1.7.4). 
Thus, clearly there is a need for novel pharmacological agents to meet these needs, but 
importantly, if a novel drug treatment is to be considered an improvement on the current 
treatment options, such drugs should ideally meet the following criteria: "(1) 
demonstrate a robust anti -parkinsonian activity without long-term decreases in efficacy, 
(2) do not result in the development of debilitating dsykinesias, (3) provide some relief 
of PD non-motor symptoms and (4) modify disease progression" (Jenner, 2003; 2004). 
Therefore, if one is to suggest that selective ligands acting at central mGluR in the basal 
ganglia are to be an effective novel pharmacological treatment for PD, they must be 
evaluated as per the criteria described above. 
Thus, in response to point (1), a significant body of pre-clinical evidence exists 
to suggest that pharmacological antagonism of central Group I mGluR, or selective 
activation of Group 11 and III mGluR in the BG motor loop results in robust anti- 
parkinsonian activity (see section 1.10.7.1). Importantly, this includes a recovery of 
postural abnormalities, which are generally insensitive to dopamimetic therapy (see 
section 1.7.4). Additionally, it has been demonstrated that L-AP4 is as efficacious as L- 
DOPA in reversing forelimb akinesia (Valenti et al, 2003; MacInnes et al, 2004). 
Secondly, in response to point (2), it is hypothesized that Group I mGluR 
antagonists may prevent dsykinesia by modulating glutarnatergic neurotransmission at 
the level of the striaturn, by inhibition of the potentiation of NMDAR-mediated 
responses (Bonsi et al, 2005; 2006). In support of this, MPEP treatment alleviates L- 
DOPA induced dsykinesia (LID) in 6-OHDA lesioned rodents (Dekundy et al, 2006). 
However, few or no studies have investigated whether this is also true for ligands acting 
selectively at Group II or Group III mGluR. Thus, this should form an important part of 
further pre-clinical testing in vivo. 
Thirdly, in response to point (3) there is a vast quantity of literature which 
documents that Group 1,11 and III mGluR modulate excitatory transmission in 
numerous brain regions implicated in anxiety and depression disorders, such as the 
amygdala and nucleus accumbens (Swanson et al, 2005). Furthermore, several studies 
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have demonstrated that selective mGluR ligands acting at mGluRl, 5,2/3 and Group III 
mGluR have potential anxiolytic and anti-depressant actions in experimental models of 
these conditions in vivo (Schoepp et al, 2003; Linden et al, 2003; 2004; Wieronska et al. 
2005; Porter et al, 2005; Steckler et al, 2005) Furthermore, selective mGluR2/3 agonists 
are currently under evaluation for similar effects in humans (Grillon et al, 2003; Kellner 
et al, 2005) Additionally, evidence exists to suggest that selective mGluR1 and 5 
antagonists and mGluR2/3 agonists may also be effective at ameliorating chronic pain 
(Varney and Gereau, 2002; Fisher et al, 2002; Zhu et al, 2004; Varty et al, 2005). Thus, 
it is tempting to speculate that selective mGluR ligands, in particular mGluR5 
antagonists and mGluR2/3 agonists may also counter depression and anxiety symptoms, 
as well as attenuating chronic "off' period pain in PD patients, thereby providing some 
relief of non-motor symptoms in addition to the documented anti-parkinsonian and 
neuroprotective effects of these ligands. 
Lastly, in response to point (4), the evidence presented in this thesis, suggests 
that pharmacological manipulation of mGluR in the BG motor loop results in significant 
neuroprotection of the nigrostriatal system in an experimental model of PD (Vernon et 
al. 2005; 2006), consistent with other previously published studies in other experimental 
models of PD (Aquirre et al, 2001; Battaglia et al, 2003; 2005). 
Taken together, these findings suggest that mGluR ligands satisfy to some extent 
each of the criteria for a novel non-dopaminergic therapy for PD and therefore warrant 
further investigation in this respect. In further support of this, a large body of preclinical 
studies now suggests that ligands for specific mGluR subtypes have potential as 
treatment for a wide variety of neurological and psychiatric disorders, including 
depression (Palucha and Pilc, 2002), anxiety disorders (Chojnacka-Wojcik et al, 2001) 
schizophrenia (Chavez-Noriega et al, 2002) chronic pain (Varney and Gereau, 2002) 
epilepsy (Doherty and Dingledine, 2002), Alzheimer's disease (Tsai et al, 2005; Lee et 
al. 2004) as well as Parkinson's disease (Marino et al, 2003a; Marino and Conn, 2006). 
However, three of the mGluR ligands used in the current study (LY367385, 
2R, 4R-APDC, and L-AP4, respectively) are confon-nationally constrained or substituted 
amino acid analogues, which are designed to bind at the N-terminal ligand binding site 
of mGluR (Schoepp et al, 1999). Although this approach to ligand design has produced 
valuable pharmacological tools for the study of mGluR functions in the brain, the 
chemical tractability of these compounds is poor, which makes development of subtype 
specific ligands difficult, although partly this is also due to the highly conserved nature 
of the glutamate binding site (Kew et al, 2004). This lack of subtype selectivity is 
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particularly relevant for selective Group III mGluR agonists such as L-AP4 (Conn et al, 
2005). Indeed, the antiparkinsonian action of L-AP4 is attributed to a central action at 
mGluR4 expressed on striatopallidal synapses or subthalamonigral synapses of the 
indirect pathway (Valenti et al, 2003; 2005; MacInness et al, 2004; Conn et al, 2005). 
However, following systemic administration, L-AP4 would also be predicted to exert an 
effect at mGluR7 expressed on striatonigral synapses of the direct pathway, thereby 
inhibiting GABAergic transmission in SNr neurones and counteracting the benefit of 
mGluR4 activation in the indirect pathway (Marino et al, 2003b). This may also have 
implications for the neuroprotective effects of this compound as previously discussed 
(see section 3.4.2.2). Importantly, therefore the neuroprotective and anti -parkinsonian 
effect of L-AP4 may be compromised following systemic administration. This 
limitation is compounded by poor central bioavailability and CNS penetration of these 
compounds, due to low BBB permeability following systemic administration (Marino 
and Conn, 2006). 
Additionally, a further complication is that the use of direct acting antagonists or 
agonists results in profound biochemical alterations to the receptor (Niswender et al, 
2005). These include profound receptor desensitisation following prolonged exposure to 
agonists such as 2R, 4R-APDC or L-AP4 or the generation of receptor supersentivity in 
the case of repeated exposure to antagonists such as LY367385 (see section 4-4). 
Importantly, this could lead to adverse effects due to excessive activation of the receptor 
(in the case of agonists) and furthermore, continuous agonist stimulation may result in 
the loss of the neuronal basis of receptor activation due to pulsatile release of 
neurotransmitter as previously discussed (see section 4.4). Additionally, receptor 
supersensitivity will result in reduced efficacy of antagonists over time, plus significant 
withdrawal effects when the drugs are removed from the system of the patients 
(Lavreysen et al, 2001; 2005), as previously discussed (see section 4.4). Moreover, as a 
result of these factors such ligands are likely to induce significant side-effects following 
an action at central mGluR in healthy brain areas, particularly with respect to cognition, 
learning and memory as described for NMDAR antagonists (Lee et al, 1999; Chen and 
Lipton, 2006). Indeed, antagonism of Group I mGluR following i. c. v injection of either 
LY379368 or MPEP resulted in significant impairment of LTP in the rodent 
hippocampus, which was associated with deficits in working and reference memory 
(Naie and Manahan-Vaughan, 2005). Furthermore, i. c. v administration of L-AP4 results 
in spatial learning impairments in rodents (Holscher et al, 1996; Gerlai et al, 1998). 
However, this does not detract from the relevance of the current study, in which these 
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compounds are useful pharmacological tools to provide proof-of-concept that targeting 
these subtypes of mGluR is neuroprotective in an experimental model of PD in vivo. 
Interestingly, recent developments in Group 11 mGluR pharmacology have led to 
the development of numerous systemically active mGluR2/3 agonists, including 
LY379268 and LY354740, which show good central bioavailability (Monn et al, 1999). 
Interestingly, LY354740 has entered human clinical trials for the treatment of anxiety, 
after demonstrating good efficacy with minimal side effects in animal models (Schoepp 
et al, 2003) and appears to be safely tolerated in humans with minimal side-effects and 
to date, no evidence of cognitive or memory deficits (Levine et al, 2001; Grillion et al, 
2003). Importantly, LY379268 has also been demonstrated to be neuroprotective and 
anti -parkinsoni an in experimental models of I'D (Murray et al, 2002; Battaglia et al, 
2003). These findings argue that potentially, mGluR2/3 agonists could represent useful 
I'D therapeutics in humans, without significantly detrimental side-effects, although 
these are only preliminary data and clearly, further investigation is required. 
Additionally, the non-competitive mGluR5 inhibitor MPEP binds at a distinct 
site within the transmembrane domain of mGluR5 (Pagano et al, 2000; Malherbe et al, 
2005). Whilst there is evolutionary pressure to maintain the structure of the glutamate 
binding site (Parmentier et al, 2000), this would be expected to be less likely for 
allosteric sites. Thus, small molecules such as MPEP which act as either positive or 
negative allosteric modulators offer the potential for improved selectivity for individual 
mGluR family members compared to competitive agonists and antagonists at the 
glutamate binding site as well as scope for enhanced chemical tractability (Kew et al, 
2004). Indeed, these small molecules do not activate mGluR directly, but act at the 
allosteric site on the receptor to potentiate or inhibit receptor activity in response to 
endogenous glutamate (Marino and Conn, 2006). Thus, allosteric compounds in 
addition to producing unprecedented selectivity may be associated with greatly reduced 
side effects compared to direct-acting orthosteric mGluR agonists and antagonists 
(Marino and Conn, 2006) (see section 4.4). Importantly, MPEP is also systemically 
active, with good CNS penetrance and bioavailability following systemic administration 
(Gasparini et al, 1999; Spooren et al, 2000; Anderson et al, 2002). Furthermore, MPEP 
is both an efficient anti-parkinsonian agent and also neuroprotective (Vernon et al, 
2005; Armentero et al, 2005; Aquirre et al, 2005). 
Taking all these data into account, it therefore seems unlikely that compounds 
such as LY367385, or L-AP4 would be likely to enter the clinic as potential 
neuroprotective and antiparkinsonian drugs, whereas mGluR2/3 agonists and allosteric 
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modulators such as MPEP may represent clinically useful drugs for the treatment of PD. 
This is unfortunate since evidence from the studies presented in this thesis demonstrate 
that selective activation of Group III mGluR by L-AP4 produced consistently 
neuroprotective effects (Vernon et al, 2006) as well as a previously documented anti- 
parkinsonian action (see section ]. 10.7.1). Importantly, recent evidence suggests that 
both the anti-parkinsonian action and the neuroprotective action of L-AP4 is replicated 
in vivo by the systemically active and mGluR4 selective positive allosteric modulator 
PHCCC, (Maj et al, 2003; Marino et al, 2003b; Battaglia et al, 2006). Interestingly, the 
magnitude of the anti -parkinsonian and neuroprotective actions of PHCCC is directly 
comparable to that observed with L-AP4 observed in previous studies (Vernon et al, 
2005; 2006; MacIness et al, 2004). This is relevant since it suggests that allosteric 
compounds can exert similar effects to orthosteric agonists in vivo under pathological 
conditions of glutamate release and provides validation of the proof-of-concept studies 
reported herein, which suggest targeting Group III mGluR may be neuroprotective. In 
further support of this we have also demonstrated a neuroprotective action of PHCCC 
following intranigral administration in 6-OHDA lesioned rodents (H. Chan, A. C. 
Vernon and D. T. Dexter,, unpublished observations). 
7.4.5 Could mGluR ligands be a useful therapeutic treatment for idiopathic PD on 
the basis of observations in experimental models of PD? 
Despite all this encouraging evidence, it is noteworthy that despite exhaustive research, 
almost all putative neuroprotective drugs which have shown demonstrable 
neuroprotection in vitro and in vivo experimental models of PD have failed to show 
neuroprotective or disease modifying actions in humans, which may reflect limitations 
of current experimental models of this disease (Schapira, 2004; Miessner et al, 2004; 
Linazoro et al, 2004; Jankovic, 2006). Thus, when considering the putative 
neuroprotective actions of mGluR ligands in a rodent 6-OHDA model of PD as 
described herein, one must consider the question, why should these compounds work 
where others have failed? This begs a second question, which is why do most 
neuroprotective strategies not translate effectively into humans? Part of the answer to 
these questions probably lies in the fact that despite evidence to suggest that 
excitoxicity, oxidative stress, UPS defects, and inflammation may all be potential 
pathogenic mechanisms in PD, we still do not know what triggers neurodegeneration in 
the SNc or indeed, any of the other brain regions affected in PD (Jenner and Olanow, 
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2006). Additionally, increasing evidence suggests that PD is not simply a single illness, 
but may in fact be a syndrome associated with different aetiologies, that may vary in 
complexity between individuals (Jenner and Olanow, 2006; Langston, 2006; Carvey et 
al, 2006). It is apparent that different signs and symptoms of PD manifest at different 
time points in individual patients, suggesting that the involvement of pathogenic factors 
may also vary between individual patients (Jenner and Olanow, 2006). This argues that 
individual patients could "enter the pathogenic sequence at different time points" 
suggesting a distinct heterogeneity of PD aetiology (Jenner and Olanow, 2006). Taking 
together the possibility that PD is a syndrome, in which different patients may be 
undergoing different pathogenic mechanisms at different times and in different brain 
regions, it is perhaps not surprising that many neuroprotective strategies which are 
aimed at a specific pathogenic event or pathway implicated in PD may fail (Jenner and 
Olanow, 2006). Additionally, compounding symptomatic effects and problems with the 
design of neuroprotective clinical trials, coupled with the difficulty of titrating the 
correct dose of an agent which demonstrates a bell-shaped neuroprotective profile (as 
observed for both MPEP and L-AP4 in the current study) from an experimental model 
into an effective dose in humans may all hinder the identification of disease modifying 
agents (Schapira AH, 2004; Marras and Lang, 2004; Hauser and Zesiewicz, 2006). 
Thus, until these issues are resolved or we are able to identify specific subsets of 
PD patients with specific aetiologies and treat them accordingly to the pathogenic 
cascade underlying their disease, a possible useful approach to PD treatment may be the 
use of multi-functional, so-called "dirty" drugs which are able to protect neurones 
against multiple toxic insults (Jenner and Olanow, 2006). Indeed, support for this idea 
comes from the development of novel iron chelators which are also monoamine oxidase 
B inhibitors and sequester free radicals. These compounds result in significantly greater 
neuroprotection in experimental models of PD than compounds with these individual 
activities alone (Zheng et al, 2005; Gal et al, 2005) These data suggest that a drug with 
at least two mechanisms of action targeted at multiple pathogenic mechanisms of the 
same disease may offer more therapeutic benefit compared with a drug that only targets 
one disease aetiology (Van der Schyf et al, 2006). Therefore, the observations that 
mGluR ligands may be neuroProtective by two distinct mechanisms in vivo, one 
mediated by neuronal mGluR due to the modulation of glutamate neurotransmission and 
a second through the action of glial cell mGluR leading to modulation of altered glial 
cell function or neuroinflarnmation strengthen the case for selective ligands acting at 
mGluR as potentially useful treatments for PD. This is particularly relevant for the 
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putative actions of these compounds on glial cells, since altered glial cell function and 
reactive microgliosis appears to be a common pathology of PD (Barcia et al, 2003; 
McGeer and McGeer, 2003; Jenner and Olanow, 2006) 
Alternatively, one may consider using these mGluR ligands as a combination 
therapy with other non-doparninergic interventions, which may synergise to produce 
greater anti -parkinsonian activity or neuroprotection (Van der Schyf et al, 2006). In this 
respect it is intriguing to note recent evidence which suggests that Adenosine A2A 
receptors, another putative non-dopaminergic therapy (Jenner, 2003c; Fuxe et al, 2003) 
(see section 1.7.2) appear to synergise with mGlu5 receptors in the striaturn to counter 
the effects of DA on the indirect pathway (see section 1.10.6). It is not surprising 
therefore, that co-administration of MPEP with the A2A antagonist KW-6002 interact 
synergistically to produce a greater anti-parkinsonian action in bilaterally 6-OHDA 
lesioned rodents (Coccurello et al, 2004) and MPTP-intoxicated mice (Kachroo et al, 
2005) than either compound alone, suggesting a functional interdependence of these 
receptors, which may hold promise as a future combinatorial drug-treatment strategy for 
the treatment of PD. 
7.5 Future studies 
Among the most interesting results of the studies described in this thesis are the findings 
that selective mGluR ligands administered in combination at sub-maximal concentration 
demonstrate an additive interaction to produce enhanced neuroprotection of the 
nigrostriatal system (see Chapter 5). Additionally, the finding that delayed treatment 
with these ligands may slow disease progression in animals already undergoing 
nigrostriatal degeneration (see Chapter 6). Furthermore, in the studies described in this 
thesis, the mGluR5 antagonist MPEP, the mGluR2/3 agonist 2R, 4R-APDC and the 
Group III mGluR agonist L-AP4 were consistently the most efficacious compounds 
within the limitations of this experimental model, providing clear proof-of-concept that 
targeting these particular mGluR subtypes may of benefit as a novel I'D treatment (see 
sections 5.4,6 4 and 7.2). 
Therefore, future studies should perhaps focus on ligands acting at mGluR5, 
mGluR2/3 and Group III mGluR, particularly mGluR4 (see section 7.4). Importantly, in 
order to obviate potential clinical issues resulting from the use of orthosteric direct 
acting agonists or antagonists (see section 7.4), future studies should focus on 
compounds which are either negative allosteric modulators at mGluR5, such as MPEP 
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(Gasparini et al, 1999) or positive allosteric modulators of mGluR2/3 such as N-(4-(2- 
methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine 
(LY487379) (Johnson et al, 2003), or mGluR4 such as PHCCC (Maj et al, 2003). 
Therefore, future studies should focus on providing pre-clinical evidence to support the 
proof-of-concept studies described in this thesis with allosteric mGluR ligands. Initially, 
it will be important to evaluate the potential neuroprotective and anti-parkinsonian 
actions of these compounds, which importantly has yet to be described for positive 
allosteric modulators of mGluR2/3, despite the accumulating evidence that mGluR2/3 
agonists are neuroprotective and anti-parkinsonian in experimental models of PD 
(Murray et al, 2002; Battaglia et al, 2003; Vernon et al, 2005). Additionally, to date no 
studies have investigated whether co-administration of allosteric ligands results in 
additive or synergistic interactions to produce either enhanced neuroprotective or anti- 
parkinsonian effects in vivo, furthermore, in vivo evidence for the mechanisms 
underlying the neuroprotective effects of selective mGluR agonists is lacking, thus both 
of these may form important parts of subsequent future studies with these compounds. 
In order to achieve this, selective negative allosteric modulators of mGluR5 or 
positive allosteric modulators of mGluR2/3 or mGluR4 should be tested at a range of 
concentrations in experimental models of PD which ideally bear closer similarity to the 
human disease state, with respect to both the progressive nature of the 
neurodegeneration and the pathology (see section 7.2) (Meissner et al, 2004). 
Additionally the lesions should be partial in nature, as more severe nigrostriatal lesions 
may preclude examination of neuroprotective actions. Thus, initial pre-clinical 
screening of these compounds should perhaps be carried out in rodents using either the 
intrastriatal 6-OHDA lesion model (Kirik et al, 1998) or the newly developed 
proteasome inhibitor models (McNaught et al, 2002b; 2004a; Zeng et al, 2006). Ideally 
also, a "clinically-driven design" should be employed in which these drugs are 
administered in animals already undergoing nigrostriatal degeneration or at a defined 
level of neuronal loss to more accurately mimic the clinical setting. Moreover, having 
provided proof-of-concept from focal injection studies, such drugs should be 
administered systemically or into the ventricular system such that whole-brain effects 
may be examined, preferably over a chronic period, again to more accurately mimic the 
clinical setting. The easiest way to achieve this would be the use of subcutaneously 
implanted osmotic minipumps as previously described (Battaglia et al, 2003) which 
allow the delivery of a constant dose of drug over a chronic period without the need for 
repeated intraperitoneal injections which may cause discomfort to animals. 
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In order to investigate the potential anti-parkinsonian actions of these 
compounds in our rodent 6-OHDA model, it will be important to decide the correct type 
of behavioral tests to employ. Interestingly, the relevance of contraversive circling 
behavior to the pathophysiology of PD has also been questioned by recent findings 
(Lane et al, 2005; 2006). In this studies the effect of the monoamine reuptake inhibitor 
(I -[I -(3,4-dichlorophenyl)cyclobutyl]-2-(3-diaminethylaminopropylethio)ethanone 
monocitrate (BTS 74 398) and L-DOPA on rotational behavior was investigated in 
rodents bearing a unilateral 6-OHDA lesion (Lane et al, 2005; 2006). When 
administered alone,, BTS 74 398 produced ipsiversive rotation, whilst L-DOPA induced 
contraversive rotation (Lane et al, 2005). However, when these agents were 
administered in combination, this produced a contralateral. response, similar to that 
induced by L-DOPA alone (Lane et al, 2006). This finding suggests that stimulation of 
the lesioned,, dennervated striatum predominates over stimulation of the intact striatum 
(Lane et al, 2006). This finding raises doubts as to whether contraversive-circling 
behavior in 6-OHDA lesioned rats is indicative of anti-parkinsonian efficacy (Lane et 
al, 2006). Indeed, contraversive-circling behavior may not simply represent just anti- 
parkinsonian activity but possibly also indicates the ability of a compound to prime for 
the appearance of dsykinesia (Lane et al, 2006; Marin et al, 2006). This is supported by 
the finding that in contrast to L-DOPA, BTS 74 398 does not sensitise rotational 
behavior in rodents nor does it induce dsykinesia in MPTP-treated primates previously 
primed with L-DOPA and exhibiting stable dsykinesia (Hansard et al, 2004; Lane et al, 
2005; 2006). Furthermore, other studies have also found no correlation between 
contraversive rotation and improvement of motor disability following treatment with 
anti-parkinsonian drugs (Lundblad et al, 2002; Metz and Wishaw, 2002). Indeed, 
treatment with these agents produced excessive contraversive rotation in rodents and 
more importantly, the same treatments produced no or only partial restoration of limb 
use in weight-shifting tests (Lundblad et al, 2002) or in skilled paw-reaching tests (Metz 
and Wishaw, 2002). Moreover, the drug induced contraversive rotation does not result 
from a significant relief of akinesia on the parkinsonian side of the body, but as gait 
analysis suggests, appears to be initiated by non-affected limbs, whilst the impaired 
limbs perform "catch-up" steps whilst the non-impaired limb shifts the weight of the 
animal (Schallert et al, 2000; Cenci et al, 2002). Taken together, these findings suggest 
that whilst quantitative rotometry is indicative of dopaminergic activity and the size of 
nigrostriatal lesions, it is not suitable to be used in isolation as an adequate test to 
evaluate compounds with potential anti-parkinsonian activity, since it appears it may 
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lead to the development of drugs which have the potential to induce dsykinesia (Lane et 
al, 2005b; Marin et al, 2006). Furthermore, focus on rotometry alone overshadows the 
use of more subtle motor impairments observed in unilaterally lesioned 6-OHDA rats 
such as gait and postural deficits, sensorimotor deficits and forelimb akinesia (Cenci et 
al, 2002). Therefore in order to provide a balanced assessment of the anti-parkinsonian 
action of selective mGluR ligands in future studies it may be appropriate to employ a 
battery of behavioral tests measuring several of these motor impairments, for example 
measuring sensorimotor deficits using the "disengage task" (Schallert et al, 1989; 
Henderson et al, 1999) or akinesia using a stepping test (Olsson et al, 1995) or reaction 
time tasks (Breyesse et al, 2002). Importantly such tests have been demonstrated to 
reveal significant motor deficits in animals with more moderate SNc lesions which are 
likely to be employed in neuroprotection studies. 
In order to quantify the neuroprotective effects of selective mGluR ligands, 
similar approaches to those described herein may be employed, such as TH 
immunohistochernistry and quantitative cell counting, and the analysis of striatal 
concentrations of DA, its metabolites and the amount of DA turnover. Importantly, it 
may be appropriate to also quantify that drug treatment preserves nigral neurones by 
staining sections from drug as well as vehicle-treated animals for specific neuronal 
markers such as NeuN. Alternatively, assays to investigate either TH mRNA levels or 
activity in surviving DA neurones may yield interesting data. 
Finally, as an approach to investigate the potential mechanisms of mGluR ligand 
neuroprotection it may be interesting to carry out in vivo microdialylsis experiments to 
measure real-time changes in neurotransmitter levels (particularly for dopamine in the 
striaturn and glutamate in the nigra) in response to nigrostriatal lesions, but also 
following drug treatment which may provide interesting information on the effects of 
selective mGluR ligands on glutamate and dopamine release in vivo, which may then be 
correlated to any neuroprotective effect. Additionally, it may be interesting to examine 
the metabolic activity of nuclei other than the STN which send glutamatergic 
projections to the SNc, particularly the PPN using cytochrome Oxidase-I 
immunoreactivity as previously described (Armentero et al, 2005; Oueslati et al, 2005) 
to examine if treatment with mGluR ligands normalises activity in these neurones and if 
this correlates with a neuroprotective effect, may indirectly implicate PPN projections 
as mediators of glutamate excitotoxicity onto nigral neurones. Lastly, it would also be 
extremely interesting to attempt to unravel the potential neuroprotective effects resulting 
from an action of selective mGluR ligands on glial cells. This could be investigated in 
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several ways, firstly by investigation if treatment with selective mGluR ligands in 
lesioned animals' results in any change in the number and morphology of reactive 
microglial cells in the SNc using quantitative cell counting methods as previously 
described (Iravani et al, 2005b). Additionally, it may be investigated if mGluR ligands 
result in upregulation of trophic factors, such as BDNF in the SNc using either RT-PCR 
or western blotting coupled with double-label immunocytochernical studies to attempt 
to determine if the increase is from astroglia or microglia. Similar investigations could 
also be performed to measure if mGluR ligand treatment results in downregulation of 
detrimental cytokines such as TNF-a and chemokines such as RANTES in vivo in the 
SNc. Finally, it may also be interesting to investigate the effects of selective mGluR 
ligands on glial glutamate transporter protein expression by use of in situ hybridisation, 
immunocytochernistry or molecular biology methods in nigral tissue. 
In addition, as a final step in pre-clinical testing such compounds should be 
tested in the MPTP non-human primate model of PD (Jenner and Marsden, 1986). 
Indeed, this model replicates all the major human motor symptoms of PD and these 
animals respond to all currently used symptomatic treatments for PD, rapidly develop 
dyskinesia in response to L-DOPA and thus are suggested to be highly predictive of 
drug actions in humans (Jenner, 2003b). In support of this, evidence of the anti- 
parkinsonian efficacy of adenosine A2Aantagonists such as Istradefylline (KW-6002) as 
anti-parkinsonian agents has been demonstrated from such pre-clinical studies in 
MPTP-treated primates (Chase et al, 2003; Jenner, 2003c; 2005), which has prompted 
the investigation of these drugs in human clinical trials (Knutsen and Weiss, 2001; 
Hauser et al. 2003; Bara-Jiminez et al, 2003) 
Indeed, testing in this experimental model will provide important pre-clinical 
evidence on the efficacy of mGluR ligands as anti-parkinsonian agents, and importantly 
whether these compounds prime for dyskinesia (Jenner, 2003b). Interestingly, to date no 
publications exist which have investigated these possibilities. Additionally, 
neuroprotection studies with allosteric mGluR ligands should be carried out to confirm 
the preliminary data described herein in rodents, since it is likely that complex cell 
death mechanisms may differ between rodents and primates (Meissner et al, 2004). 
Importantly, in the classical MPTP primate model, extensive nigrostriatal damage is 
induced, thus there may not be sufficient remaining dopaminergic neurons in the SNc 
for neuroprotective or neurorestorative agents to exert any significant effect (Iravani et 
al, 2005a). Therefore, such studies should be carried out in the recently described partial 
MPTP lesion model in marmosets, which may be more appropriate for neuroprotective 
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investigations, where some SNc neurones remains to act as a functional substrate for 
neuroprotection and/or neurorestoration (Messiner et al, 2004; Iravani et al, 2005a). 
Importantly, to date, such studies have not been published. 
7.6 Conclusions 
In conclusion, the current thesis provides evidence to suggest that pharmacological 
antagonism of Group I mGluR by LY367385 or MPEP and stimulation of Group 11 and 
Group III mGluR by 2R, 4R-APDC or L-AP4 results in significant neuroprotection in an 
experimental model of PD. However, the current commercially available receptor 
ligands including the compounds used in the current study, but with the possible 
exception of MPEP, are unlikely to be clinically successful due to low bioavai lability, 
poor CNS penetration, off-target effects and profound alterations in receptor function as 
discussed in detail earlier (see section 7.4). Therefore, whilst these data provide proof-of 
-concept that pharmacological targeting of these mGluR subtypes, in particular 
mGluR5, mGluR2/3 and mGluR4 in the BG may lead to neuroProtection, it is likely 
that the future investigation of allosteric modulators, which are associated with fewer 
off-target effects and show greater selectivity, particularly where Group III mGluR are 
concerned, may hold the key to developing clinically effective mGluR ligands for the 
treatment of PD. but also other neurological disorders such as AD, stroke, epilepsy, 
schizophrenia, chronic pain and anxiety disorders. Taken together, however, the data 
herein provide compelling evidence to support the concept that ligands acting at mGluR 
in the BG motor loop may represent a novel non-dopaminergic treatment for sporadic 
PD. 
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